Original Article
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
N Engl J Med 2002; 347:975-982September 26, 2002
- Abstract
Background
Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C.
Methods
A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 μg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks.
Results
A significantly higher proportion of patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a alone (56 percent vs. 29 percent, P<0.001). The proportions of patients with HCV genotype 1 who had sustained virologic responses were 46 percent, 36 percent, and 21 percent, respectively, for the three regimens. Among patients with HCV genotype 1 and high base-line levels of HCV RNA, the proportions of those with sustained virologic responses were 41 percent, 33 percent, and 13 percent, respectively. The overall safety profiles of the three treatment regimens were similar; the incidence of influenza-like symptoms and depression was lower in the groups receiving peginterferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin.
Conclusions
In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.
Media in This Article
Figure 2
Predictability of Sustained Virologic Response.Figure 1
End-of-Treatment Virologic Response (Panel A) and Sustained Virologic Response (Panel B), According to Intention-to-Treat Analysis.Article Activity
- Article
Although the mechanism of action of ribavirin remains speculative,1 the current standard of care for patients with chronic hepatitis C is the addition of ribavirin to interferon-based therapies.2-7 Unfortunately, some patients, particularly those with more resistant hepatitis C virus (HCV) genotypes, do not respond to these agents.
Two types of pegylated interferon, which differ in their pharmacokinetic and chemical properties, have been developed. Both have demonstrated significantly superior efficacy to non-pegylated interferons in several controlled clinical trials.8-12 Peginterferon alfa-2b (a 12-kD linear polyethylene glycol moiety) plus ribavirin produced significantly improved sustained virologic responses as compared with interferon alfa-2b plus ribavirin.13 Peginterferon alfa-2a (a 40-kD branched polyethylene glycol moiety) has an extended serum half-life that provides constant viral suppression for seven days, thus allowing once-weekly dosing and enhanced clinical efficacy.8-10,14-17 We undertook the present study to determine whether peginterferon alfa-2a plus ribavirin is more effective than interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone for the treatment of chronic hepatitis C.
Methods
Patient Selection
The study was conducted by the Pegasys International Study Group. Eligible subjects were adult patients who had never received interferon and who had at least 2000 copies of HCV RNA per milliliter of serum according to a polymerase-chain-reaction (PCR) assay (Cobas Amplicor HCV Monitor Test, version 2.0; Roche Diagnostics), serum alanine aminotransferase activity above the upper limit of normal within six months before entry into the study, and a liver-biopsy result consistent with the diagnosis of chronic hepatitis C. Serum HCV RNA levels above the linear range of the PCR (more than 1 million copies per milliliter) were diluted to within the linear range. Patients were excluded from participation if they had neutropenia (fewer than 1500 neutrophils per cubic millimeter), thrombocytopenia (fewer than 90,000 platelets per cubic millimeter), anemia (less than 12 g of hemoglobin per deciliter in women and less than 13 g of hemoglobin per deciliter in men), human immunodeficiency virus (HIV) infection, decompensated liver disease, a serum creatinine level more than 1.5 times the upper limit of normal, poorly controlled psychiatric disease, alcohol or drug dependence within one year before entry into the study, or substantial coexisting medical conditions.
Study Design
This randomized, controlled clinical trial was conducted at 81 centers worldwide from February 1999 to April 2001. Patients were randomly assigned in a 2:1:2 ratio (with a block size of five) to receive subcutaneous, once-weekly injections of 180 μg of peginterferon alfa-2a (Pegasys, Hoffmann–LaRoche) plus daily ribavirin (Hoffmann–LaRoche) or placebo, or subcutaneous, thrice-weekly injections of 3 million units of interferon alfa-2b plus ribavirin (Rebetron, Schering-Plough) for 48 weeks. Ribavirin was given orally at a dose of 1000 mg per day for patients weighing 75 kg or less and 1200 mg per day for those weighing more than 75 kg. Randomization was stratified according to country and HCV genotype (HCV genotype 1 vs. other genotypes). Genotyping was performed by sequence analysis of a portion of the 5' untranslated region of the HCV genome.18 Participants were followed for 24 weeks after cessation of therapy. The sponsor, investigators, and patients who received peginterferon alfa-2a were unaware of who received ribavirin or placebo.
The institutional review boards of the participating centers approved the protocol, and all patients provided written informed consent. The study was designed by the sponsor in collaboration with expert hepatologists. Data were collected by the Pegasys International Study Group. Data analysis was performed by the sponsor and the authors of this report; the authors had full access to the data, and the decision to publish was not limited by the sponsor. The study was conducted according to the guidelines of the Declaration of Helsinki, the applicable provisions of Good Clinical Practices, or both.
Assessment of Efficacy
The primary efficacy end point was sustained virologic response, defined as the absence of detectable HCV RNA at the end of follow-up according to a PCR assay (Cobas Amplicor HCV Test, version 2.0; lower limit of detection, 100 copies [50 IU] per milliliter). For patients with at least 20 weeks of follow-up, the last observed HCV RNA level was used in assessments of efficacy. All patients with follow-up of less than 20 weeks were considered to have had no response to treatment.
Assessment of Safety
Safety was assessed by laboratory tests and evaluation of adverse events at weeks 1, 2, 4, 6, and 8; monthly thereafter during treatment; and at weeks 52, 60, and 72. Patients who discontinued therapy prematurely because of intolerance were encouraged to remain in the study. Stepwise reductions in the peginterferon alfa-2a dosages to 135, 90, or 45 μg per week and reductions in ribavirin dosages to 800 or 600 mg per day were allowed to manage adverse events or laboratory abnormalities that had reached predetermined thresholds of severity. If the adverse event resolved or improved, a return to initial dosing levels was permitted unless the patient had received the reduced dose for more than four weeks. Patients were withdrawn from treatment if they continued to have viremia at week 24, if they missed four consecutive doses, or at the discretion of the investigator.
Statistical Analysis
For the primary efficacy end point, a closed testing procedure was planned to allow for all possible pairwise comparisons among the three treatment groups.19,20 The global hypothesis of no differences among the three treatment groups was tested at a significance level of 0.05; if there was a significant difference among the three treatment groups, each treatment comparison was then tested at a significance level of 0.05. The Cochran–Mantel–Haenszel test was used for both types of analysis and was stratified according to the combination of country and HCV genotype (HCV genotype 1 vs. other genotypes).21 Because the simulated error rate (with the use of the Cochran–Mantel–Haenszel test for a single stratum) for each pairwise treatment comparison under this closed testing procedure was approximately 0.025, a two-sided 97.5 percent confidence interval for the odds ratios was reported for each pairwise treatment comparison. Stepwise, backward, and multiple logistic-regression models were used to explore base-line factors predicting a sustained virologic response. All patients who received at least one dose of study medication were included in all efficacy analyses, and if they had undergone at least one safety assessment after base line, they were included in the safety analysis.
Results
Patient Demographics
Of the 1459 patients screened, 1149 were randomly assigned to treatment and 1121 were randomly assigned to treatment and received at least one dose of study medication. The patients who were excluded from the study did not have elevated alanine aminotransferase levels, refused to participate, or failed to meet other inclusion criteria. Twenty-eight patients were randomly assigned to treatment but did not receive at least one dose of study medication because they refused or did not come for treatment, because they did not meet inclusion criteria, or for other reasons, including administrative reasons that were identified after randomization. The pretreatment characteristics of patients in the treatment groups were similar (Table 1Table 1
Characteristics of the Patients at Base Line.).Virologic Response
Significantly more patients treated with peginterferon alfa-2a plus ribavirin had end-of-treatment virologic responses than patients treated with interferon alfa-2b plus ribavirin (69 percent vs. 52 percent, P<0.001) or peginterferon alfa-2a plus placebo (69 percent vs. 59 percent, P=0.01) (Figure 1Figure 1
End-of-Treatment Virologic Response (Panel A) and Sustained Virologic Response (Panel B), According to Intention-to-Treat Analysis.). Significantly more patients treated with peginterferon alfa-2a plus ribavirin had a sustained virologic response (i.e., no detectable HCV RNA 24 weeks after cessation of therapy) than those treated with interferon alfa-2b plus ribavirin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a plus placebo (56 percent vs. 29 percent, P<0.001) (Figure 1).Forty-six percent of patients with HCV genotype 1 who received peginterferon alfa-2a plus ribavirin had a sustained virologic response, as compared with 36 percent of those who received interferon alfa-2b plus ribavirin (P=0.01) and 21 percent of those who received peginterferon alfa-2a plus placebo (P<0.001) (Table 2Table 2
Proportion of Patients with a Sustained Virologic Response as a Function of HCV Genotype and HCV Genotype plus Base-Line HCV RNA.). Among the patients with HCV genotype 2 or 3, significantly more of those treated with peginterferon alfa-2a plus ribavirin had a sustained virologic response than of those treated with interferon alfa-2b plus ribavirin (76 percent vs. 61 percent, P=0.005) (Table 2). Among patients with HCV genotype 1 and high base-line viral RNA levels (more than 2 million copies per milliliter), 41 percent of those receiving peginterferon alfa-2a plus ribavirin had a sustained virologic response, as compared with 33 percent of those receiving interferon alfa-2b plus ribavirin (Table 2). Among patients with cirrhosis, 43 percent of those treated with peginterferon alfa-2a plus ribavirin and 33 percent of those treated with interferon alfa-2b plus ribavirin had a sustained virologic response (Table 2).Independent Factors Associated with a Sustained Virologic Response
In multivariable analyses to identify predictors of sustained virologic response among patients who received peginterferon alfa-2a plus ribavirin, our final multiple logistic-regression model, including the following factors, was entered in the final stepwise regression analysis: sex, race (white vs. nonwhite), age (≤40 years vs. >40 years), body weight (≤75 kg vs. >75 kg), pretreatment viral load (≤2 million copies per milliliter vs. >2 million copies per milliliter), pretreatment alanine aminotransferase quotient (>3 vs. ≤3), pretreatment histologic diagnosis (cirrhosis vs. noncirrhosis), and HCV genotype (1 vs. non-1). Three factors independently and significantly increased the odds of achieving a sustained virologic response: an HCV genotype other than 1 (odds ratio, 3.25; 95 percent confidence interval, 2.09 to 5.12; P<0.001), an age of 40 years or less (odds ratio, 2.60; 95 percent confidence interval, 1.72 to 3.95; P<0.001), and a body weight of 75 kg or less (odds ratio, 1.91; 95 percent confidence interval, 1.27 to 2.89; P=0.002).
Predictive Value of Early Virologic Response
By week 12, 86 percent of patients (390 of 453) treated with peginterferon alfa-2a plus ribavirin had had a virologic response, defined as a 2-log decrease from base-line HCV RNA levels (97 patients) or no detectable serum HCV RNA (293 patients) (Figure 2Figure 2
Predictability of Sustained Virologic Response.). The absence of an early virologic response was not associated with early treatment discontinuation (before week 12) or dose modification (data not shown). Of those with early virologic responses, 65 percent subsequently had a sustained virologic response. Those with no detectable HCV RNA by week 12 were more likely to have a sustained virologic response than those who had only a 2-log decrease in HCV RNA (221 of 293 vs. 32 of 97). In contrast, among the 63 patients who did not have an early virologic response, 61 (97 percent) did not have a sustained virologic response.Safety
The proportions of patients withdrawn from treatment because of laboratory abnormalities or other adverse events were similar in the groups receiving peginterferon alfa-2a plus ribavirin (3 percent for laboratory abnormalities and 7 percent for other adverse events), peginterferon alfa-2a plus placebo (1 percent and 6 percent, respectively), and interferon alfa-2b plus ribavirin (1 percent and 10 percent) (Table 3Table 3
Incidence of Discontinuation, Dose Modification, and Adverse Events.). The most common types of events leading to discontinuation were psychiatric disorders (mainly depression-related events). The frequency and major causes of dose modifications are detailed in Table 3. Among patients who had an early virologic response with peginterferon alfa-2a plus ribavirin, the proportion with a sustained virologic response was similar among those who had a substantial dose reduction (to <80 percent of both study medications) and those who maintained the full dosing schedule (67 percent and 75 percent, respectively).22 In contrast, discontinuation despite an early virologic response was associated with a decrease in efficacy in this treatment group (rate of sustained response, 12 percent).22 The median hemoglobin values decreased between weeks 1 and 8 in all treatment groups, then stabilized, and then returned to near base-line values after treatment was completed. The maximal decrease was greater in patients treated with peginterferon alfa-2a plus ribavirin (3.7 g per deciliter) or interferon alfa-2b plus ribavirin (3.6 g per deciliter) than in patients treated with peginterferon alfa-2a plus placebo (2.2 g per deciliter). There was no association between the incidence of serious cardiovascular events and the incidence of anemia.
The median neutrophil counts decreased from base line in all treatment groups, particularly during the first two weeks of treatment, and then stabilized for the remainder of the treatment period, increasing rapidly to base-line values after the completion of treatment. Four patients (three receiving peginterferon alfa-2a plus ribavirin and one receiving interferon alfa-2b plus ribavirin) discontinued treatment because the neutrophil count was below 500 per cubic millimeter. The median platelet counts remained close to base-line values throughout treatment with interferon alfa-2b plus ribavirin but decreased progressively during the first eight weeks of treatment with peginterferon alfa-2a plus ribavirin or placebo, before stabilizing. After treatment was completed, the median platelet counts returned to normal within four weeks. Two patients with thrombocytopenia (one receiving peginterferon alfa-2a plus placebo and the other receiving interferon alfa-2b plus ribavirin) had serious bleeding. Five patients (four receiving peginterferon alfa-2a plus ribavirin and one receiving peginterferon alfa-2a plus placebo) discontinued treatment because of thrombocytopenia.
Most adverse events in all study groups were those commonly associated with interferon-based treatment (Table 3). Patients treated with peginterferon alfa-2a plus ribavirin or placebo had a lower incidence of influenza-like symptoms, such as pyrexia, myalgia, and rigors, than those treated with interferon alfa-2b plus ribavirin. Although few patients had a history of depression or active depression at base line (1 to 2 percent and 3 to 5 percent, respectively), a substantial minority reported depression during the study. Patients treated with peginterferon alfa-2a plus ribavirin or placebo had a lower incidence of depression than those treated with interferon alfa-2b plus ribavirin (22 percent and 20 percent vs. 30 percent). Three patients died after the end of treatment. One patient who had received interferon alfa-2b plus ribavirin died of hypertensive heart disease, and two who had received peginterferon alfa-2a plus placebo died, one from drowning and the other from liver cancer. None of the deaths were considered related to treatment.
Discussion
Peginterferon alfa-2a plus ribavirin was significantly more effective than interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone for the treatment of chronic hepatitis C. Overall, the rate of sustained virologic response was similar to that reported with peginterferon alfa-2b plus ribavirin.13 In the current study, improved efficacy was seen in subgroups of patients with disease generally considered to have treatment-resistant characteristics.13 In particular, patients with all HCV genotypes and those with high base-line levels of HCV RNA (more than 2 million copies per milliliter) were more likely to have a sustained virologic response when treated with peginterferon alfa-2a plus ribavirin than when treated with interferon alfa-2b plus ribavirin. Among patients considered to have the most treatment-resistant disease — that is, those with both HCV genotype 1 and high base-line viral levels — a substantially higher proportion of those treated with peginterferon alfa-2a plus ribavirin had a sustained virologic response than of those treated with interferon alfa-2b plus ribavirin.
Early prediction of virologic response to interferon-based therapy can help identify patients who are unlikely to have a sustained response and allow clinicians the option to discontinue treatment, saving patients the side effects and cost of additional therapy. In the current study, 97 percent of patients who did not have an early virologic response to peginterferon alfa-2a plus ribavirin by week 12 never had a sustained virologic response. The incremental benefit of continuing therapy beyond 12 weeks for patients who have not had an early virologic response must be considered for each patient individually.
This study was designed to treat patients for 48 weeks, regardless of HCV genotype. Therefore, we cannot comment on shorter treatment periods.
Several adverse events typically associated with the use of interferon (including influenza-like symptoms and depression) occurred less frequently with peginterferon alfa-2a, alone or in combination with ribavirin, than with interferon alfa-2b plus ribavirin. Monotherapy with peginterferon alfa-2a was generally better tolerated than the ribavirin-containing regimens. As is usual with interferon-based therapy, there were reductions in neutrophil and platelet counts with all treatments. Although these decreases were greater in patients treated with peginterferon alfa-2a plus ribavirin than in those treated with interferon alfa-2b plus ribavirin, they did not appear to be associated with serious sequelae and were effectively managed by dose modifications. Interestingly, for patients treated with peginterferon alfa-2a plus ribavirin who had an early virologic response, completion of therapy with dose reduction was not associated with a substantial decrease in efficacy.
Peginterferon alfa-2a offers significantly enhanced sustained virologic responses in all patients, regardless of HCV genotype and viral load, and a once-weekly dosing schedule. We think that the ability to predict the absence of sustained virologic response from HCV RNA levels at week 12 will be a useful clinical tool. The results of this study show that combination therapy with peginterferon alfa-2a plus ribavirin provides a considerable clinical advantage over therapy with interferon alfa-2b plus ribavirin.
Supported by grants from Hoffmann–LaRoche, Basel, Switzerland, and the University of North Carolina General Clinical Research Centers program, Division of Research Resources, National Institutes of Health (RR00046).
Ms. Lin, Dr. Hoffman, and Dr. Yu are employees of Hoffmann–LaRoche. Drs. Fried, Shiffman, Reddy, and Craxi served as consultants for Hoffmann–LaRoche. Drs. Fried, Shiffman, Reddy, and Craxi served as lecturers for Hoffmann–LaRoche. Dr. Reddy served as a consultant for Schering-Plough. Drs. Fried, Shiffman, Reddy, and Craxi served as lecturers for Schering-Plough. Drs. Fried, Shiffman, and Craxi received grant support from Hoffmann–LaRoche. Drs. Fried, Shiffman, Reddy, and Craxi received grant support from Schering-Plough.
We are indebted to Dr. Sugantha Govindarajan of Rancho Los Amigos Medical Center, Downey, California, for her work as the central pathologist in this study and to Farhad Sedarati, Ph.D., for critical review during the preparation of the manuscript.
Source Information
From the University of North Carolina, Chapel Hill (M.W.F.); the Medical College of Virginia, Richmond (M.L.S.); the University of Miami, Miami (K.R.R.); Minnesota Clinical Research Center, St. Paul (C.S.); Prince of Wales Hospital, Randwick, N.S.W., Australia (G.M.); Cidade Universitária Zeferino Vaz, Campinas, Brazil (F.L.G.); Heinrich-Heine-Universität, Düsseldorf, Germany (D.H.); General Universitario, Valencia, Spain (M.D.); Università degli Studi Brescia, Brescia, Italy (G.C.); Hôpital Henri Mondor, Creteil, France (D.D.); University of Palermo, Palermo, Italy (A.C.); and Hoffmann–LaRoche, Nutley, N.J. (J.H., A.L., J.Y.).
Address reprint requests to Dr. Fried at the University of North Carolina, CB# 7080, Rm. 708, Burnett Womack Bldg., Chapel Hill, NC 27599.
Other participants in the study are listed in the Appendix.
Appendix
In addition to the authors, the following members of the Pegasys International Study Group participated in this study: A. Abergel, Hôtel-Dieu Hospital, Clermont-Ferrand, France; A. Alberti, Università degli Studi di Padova, Padua, Italy; J. Areias, Hospital de Santo Antonio, Porto, Portugal; B.R. Bacon, Bethesda General Hospital, St. Louis; C. Berg, University of Virginia Health Systems, Charlottesville; F. Bianchi, Università degli Studi di Bologna, Bologna, Italy; M.-A. Bigard, Hôpitaux de Brabois, Vandoevre-les-Nancy, France; F. Bonino, Azienda Ospedaliera Pisana, Pisa, Italy; H. Bonkovsky, University of Massachusetts Medical Center, Worcester; F. Bosques, Hospital Universitario Jose E. Gonzalez, Monterrey, Mexico; M. Bourlière, St. Joseph Hospital, Marseilles, France; J.P. Bronowicki, Centre Hospitalier Universitaire, Nancy, France; J.T. Brouwer, Academic Hospital Rotterdam, Rotterdam, the Netherlands; R. Brown, Columbia University College of Physicians and Surgeons, New York; M. Buhl, Marselisborg Hospital, Aarhus, Denmark; G. Cadeo, Università degli Studi di Brescia, Brescia, Italy; P. Cales, Hôpital Hôtel-Dieu, Angers, France; O. Campollo, Hospital Civil de Guadalajara, Guadalajara, Mexico; R. Carithers, University of Washington, Seattle; A. Carvalho, Hospitais da Universidade de Coimbra, Coimbra, Portugal; W.G.E. Cooksley, Royal Brisbane Hospital, Herston, Queensland, Australia; P. Couzigou, Haut-Leveque Hospital, Bordeaux, France; A. Craxì, University of Palermo, Palermo, Italy; P. Desmond, St. Vincent's Hospital, Fitzroy, Victoria, Australia; D. Dieterich, Cabrini Medical Center, New York; M. Farkkila, Helsinki University Central Hospital, Helsinki, Finland; K. Fawaz, New England Medical Center, Boston; P. Ferenci, Allgemeines Krankenhaus Wien, Vienna, Austria; J. Franco, Medical College of Wisconsin at Froedtert Hospital, Milwaukee; A. Gibas, Regional Gastroenterology Associates, Lancaster, Pa.; R. Gish, California Pacific Medical Center, San Francisco; E. Godofsky, Bach and Godofsky, Bradenton, Fla.; S. Hadziyannis, Evgenidion Hospital, Athens, Greece; T. Hassanein, University of California, San Diego; K.B. Hellum, Akershus Central Hospital, Nordbyhagen, Norway; Y. Horsmans, Cliniques Universitaires St. Luc, Brussels, Belgium; A. Horta E Vale, Clínica Diagnostics Medico Integral, Vila Nova de Gaia, Portugal; D. Jensen, Rush–Presbyterian–St. Luke's Medical Center, Chicago; M.-Y. Lai, National Taiwan University, Taipei, Taiwan; D. Larrey, Hôpital St.-Eloi, Montpellier, France; S.-D. Lee, Veterans General Hospital, Taipei, Taiwan; A.S. Lok, University of Michigan Medical Center, Ann Arbor; P. Marcellin, Hôpital Beaujon, Clichy, France; P. Martin, University of California, Los Angeles; D.K. Moonka, Henry Ford Health System, Detroit; R. Moreno, Hospital Universitario de la Princesa, Madrid; A. Mouro, Hospital Pulido Valente, Lisbon, Portugal; F. Nevens, University Hospital Gasthuisberg, Leuven, Belgium; G. Pastore, Policlinico di Bari, Bari, Italy; G.R. Piexe, Hospital Egas Moniz, Lisbon, Portugal; R. Poupon, Hôpital St.-Antoine, Paris; T. Poynard, Hôpital de la Salpétrière, Paris; F. Ramalho, Hospital Santa Maria, Lisbon, Portugal; H.W. Reesink, Academic Medical Center, Amsterdam; J. Reichen, Universität, Bern, Switzerland; S. Roberts, Alfred Hospital, Prahran, Victoria, Australia; J. Rodes, Clinico y Provincial, Barcelona, Spain; F.J. Salmeron, Hospital Clinico San Cecilio de Granada, Granada, Spain; D. Schulman, Digestive Health Consultants, Burbank, Calif.; H. Sette, Jr., Instituto de Infectologia Emílio Ribas, São Paulo, Brazil; S. Shedlofsky, University of Kentucky Medical Center, Lexington; K.E. Sherman, University of Cincinnati Medical Center, Cincinnati; F. Siddiqui, Harper Hospital, Detroit; M. Sulkowski, Johns Hopkins University, Baltimore; M.J. Tong, Huntington Medical Research Institutes, Pasadena, Calif.; R. Trejo, Centro Medico Nacional S. XXI, Mexico City, Mexico; C. Trepo, Hôpital Hôtel-Dieu, Lyons, France; D.J. van Leeuwen, University of Alabama, Birmingham; D. Vetter, Hôpital Civil, Strasbourg, France; T.L. Wright, University of California, San Francisco; J.-P. Zarski, Hôpital de la Tronche, Grenoble, France; S. Zeuzem, Klinikum der J.W. Goethe-Universität, Frankfurt, Germany. Safety Review Board: E. Krawitt, University of Vermont Medical Center, Burlington; V. Feinman, Mount Sinai Hospital, Toronto; V. Rustgi, Metropolitan Research, Fairfax, Va.
- References
References
1
Thomas HC ,Torok ME ,Forton DM ,Taylor-Robinson SD . Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999;31:Suppl 1:152-159
CrossRef | Web of Science | Medline2
EASL International Consensus Conference on hepatitis C: Paris, 26-28, February 1999: consensus statement. J Hepatol 1999;30:956-961
CrossRef | Medline3
Booth JC ,O'Grady J ,Neuberger J . Clinical guidelines on the management of hepatitis C. Gut 2001;49:Suppl 1:I-1
CrossRef | Web of Science4
Canadian Association for the Study of the Liver
Medline5
Lai MY ,Kao JH ,Yang PM , et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312
CrossRef | Web of Science | Medline6
Poynard T ,Marcellin P ,Lee SS , et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432
CrossRef | Web of Science | Medline7
McHutchison JG ,Gordon SC ,Schiff ER , et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
Full Text | Web of Science | Medline8
Reddy KR ,Wright TL ,Pockros PJ , et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438
CrossRef | Web of Science | Medline9
Zeuzem S ,Feinman SV ,Rasenack J , et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672
Full Text | Web of Science | Medline10
Heathcote EJ ,Shiffman ML ,Cooksley WG , et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680
Full Text | Web of Science | Medline11
Lindsay KL ,Trepo C ,Heintges T , et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
CrossRef | Web of Science | Medline12
Pockros PJ, Carithers R, Desmond P, et al. Evaluation of two doses of peginterferon alfa-2a for the treatment of chronic hepatitis C (CHC). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2002:285. abstract.
13
Manns MP ,McHutchison JG ,Gordon SC , et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
CrossRef | Web of Science | Medline14
Xu Z-X ,Hoffman J ,Patel I ,Joubert P . Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects. Hepatology 1998;28:Suppl:702A-702A abstract.
CrossRef | Web of Science15
Nieforth KA ,Nadeau R ,Patel IH ,Mould D . Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59:636-646
CrossRef | Web of Science | Medline16
Wills RJ . Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390-399
CrossRef | Web of Science | Medline17
Algranati NE ,Sy S ,Modi M . A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999;30:Suppl:190A-190A abstract.
Web of Science18
Germer JJ ,Rys PN ,Thorvilson JN ,Persing DH . Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999;37:2625-2630
Web of Science | Medline19
Marcus R ,Peritz E ,Gabriel KR . On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-660
CrossRef | Web of Science20
Bauer P . Multiple testing in clinical trials. Stat Med 1991;10:871-890
CrossRef | Web of Science | Medline21
Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyons, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
22
Ferenci P ,Shiffman ML ,Fried MW , et al. Early prediction of response to 40 kDa peginterferon alfa-2a (Pegasys) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001;34:351A-351A abstract.
CrossRef | Web of Science
- Citing Articles (2254)
Citing Articles
1
Hubert J. Metzner, Thomas Weimer, Stefan Schulte. 2012. Half-Life Extension by Fusion to Recombinant Albumin. , 223-247.
CrossRef2
Yasunori Yamaguchi, Akihiro Tamori, Yasuhito Tanaka, Shuji Iwai, Sawako Kobayashi, Hideki Fujii, Hiroyasu Morikawa, Atsushi Hagihara, Masaru Enomoto, Norifumi Kawada. (2012) Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatology Researchno-no
CrossRef3
Philippe Halfon, Christoph Sarrazin. (2012) Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?. Liver International 32, 79-87
CrossRef4
Vincenza Calvaruso, Antonio Craxì. (2012) 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver International 32, 2-8
CrossRef5
Christophe Hézode. (2012) Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver International 32, 32-38
CrossRef6
Mitchell L. Shiffman, Rafael Esteban. (2012) Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?. Liver International 32, 54-60
CrossRef7
K. Rajender Reddy, Frederick Lin, Fabien Zoulim. (2012) Response-guided and -unguided treatment of chronic hepatitis C. Liver International 32, 64-73
CrossRef8
Christopher E. McGowan, Michael W. Fried. (2012) Barriers to hepatitis C treatment. Liver International 32, 151-156
CrossRef9
P. Ramachandran, A. Fraser, K. Agarwal, A. Austin, A. Brown, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, P. R. Mills, D. J. Mutimer, S. D. Ryder, J. F. Dillon. (2012) UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology & Therapeuticsn/a-n/a
CrossRef10
Jennifer R. Kramer, Fasiha Kanwal, Peter Richardson, Minghua Mei, Hashem B. El-Serag. (2012) Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Journal of Hepatology 56:2, 320-325
CrossRef11
Alexander J. Thompson, Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mingfu Zhu, Qianqian Zhu, Thomas J. Urban, Keyur Patel, Hans L. Tillmann, Susanna Naggie, Nezam H. Afdhal, Ira M. Jacobson, Rafael Esteban, Fred Poordad, Eric J. Lawitz, Jonathan McCone, Mitchell L. Shiffman, Greg W. Galler, John W. King, Paul Y. Kwo, Kevin V. Shianna, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, Mark S. Sulkowski, David B. Goldstein, John G. McHutchison, Andrew J. Muir. (2012) Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. Journal of Hepatology 56:2, 313-319
CrossRef12
C. Kondo, M. Atsukawa, A. Tsubota, N. Itokawa, T. Fukuda, Y. Matsushita, H. Kidokoro, T. Kobayashi, Y. Narahara, K. Nakatsuka, H. Kanazawa, C. Sakamoto. (2012) An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. Journal of Viral Hepatitisno-no
CrossRef13
S. Raghuraman, H. Park, W. O. Osburn, E. Winkelstein, B. R. Edlin, B. Rehermann. (2012) Spontaneous Clearance of Chronic Hepatitis C Virus Infection Is Associated With Appearance of Neutralizing Antibodies and Reversal of T-Cell Exhaustion. Journal of Infectious Diseases
CrossRef14
Ching-Chih Hu, Cheng-Hao Weng, Chih-Lang Lin, Hui-Ching Tien, Yen-Lin Kuo, Cheng-Hung Chien, Cho-Li Yen, Chun-Yen Lin, Rong-Nan Chien. (2012) Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α. Renal Failure1-6
CrossRef15
Lok, Anna S., Gardiner, David F., Lawitz, Eric, Martorell, Claudia, Everson, Gregory T., Ghalib, Reem, Reindollar, Robert, Rustgi, Vinod, McPhee, Fiona, Wind-Rotolo, Megan, Persson, Anna, Zhu, Kurt, Dimitrova, Dessislava I., Eley, Timothy, Guo, Tong, Grasela, Dennis M., Pasquinelli, Claudio, . (2012) Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine 366:3, 216-224
Full Text16
Chung, Raymond T., . (2012) A Watershed Moment in the Treatment of Hepatitis C. New England Journal of Medicine 366:3, 273-275
Full Text17
Pierre-Alain Rubbo, Philippe Van de Perre, Edouard Tuaillon. (2012) The long way toward understanding host and viral determinants of therapeutic success in HCV infection. Hepatology International
CrossRef18
Masood Mansour, Paul J. Pockros. (2012) HCV Therapy in 2011: Development of New Treatment Paradigms for Naïve and Non-Responder Patients. Current Hepatitis Reports
CrossRef19
Kevin X. Chen, Bancha Vibulbhan, Weiying Yang, Mousumi Sannigrahi, Francisco Velazquez, Tin-Yau Chan, Srikanth Venkatraman, Gopinadhan N. Anilkumar, Qingbei Zeng, Frank Bennet, Yueheng Jiang, Charles A. Lesburg, Jose Duca, Patrick Pinto, Stephen Gavalas, Yuhua Huang, Wanli Wu, Oleg Selyutin, Sony Agrawal, Boris Feld, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A. Kozlowski, Stuart B. Rosenblum, F. George Njoroge. (2012) Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase. Journal of Medicinal Chemistry120106152720008
CrossRef20
Anthony D. Martinez, Robert G. Gish. (2012) HCV In At Risk Populations: Who Can be Treated and How?. Current Hepatitis Reports
CrossRef21
Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Kazuhiko Hayashi, Takashi Honda, Yoshiaki Katano, Hidemi Goto, Takahisa Kawaguchi, Yoshiki Murakami, Fumihiko Matsuda. (2012) Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. Journal of Medical Virology 84:1, 61-70
CrossRef22
Ahmed El-Shamy, Soo-Ryang Kim, Yoshi-Hiro Ide, Noriko Sasase, Susumu Imoto, Lin Deng, Ikuo Shoji, Hak Hotta. (2012) Polymorphisms of Hepatitis C Virus Non-Structural Protein 5A and Core Protein and Clinical Outcome of Pegylated-Interferon/Ribavirin Combination Therapy. Intervirology 55:1, 1-11
CrossRef23
A. Amanzada, S. Schneider, F. Moriconi, S. Mihm, D. H. van Thiel, G. Ramadori. (2012) Enhancing predictive ability of IL28B-SNPs for SVR in HCV. Alimentary Pharmacology & Therapeutics 35:2, 317-318
CrossRef24
Hideyuki Nomura, Yuugou Miyagi, Hironori Tanimoto, Nobuyuki Yamashita, Seiji Oohashi, Saburo Nishiura. (2012) Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin. Hepatology Researchno-no
CrossRef25
Francesco Azzaroli, Laura Turco, Andrea Lisotti, Paolo Cecinato, Claudio Calvanese, Federica Buonfiglioli, Monica Cevenini, Marco Montagnani, Giuseppe Mazzella. (2012) Alisporivir for the treatment of chronic HCV. Future Virology 7:1, 9-18
CrossRef26
Jing Tong, You-wei Wang, Yuan-an Lu. (2012) New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. Journal of Zhejiang University SCIENCE B 13:1, 56-82
CrossRef27
P. Ferenci. (2012) Optimal treatment duration for patients with HCV genotype 1 infection. Journal of Viral Hepatitis 19, 7-13
CrossRef28
M. Simón-Talero, M. Buti, R. Esteban. (2012) Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?. Journal of Viral Hepatitis 19, 14-17
CrossRef29
M. Rumi, A. Aghemo, G. M. Prati. (2012) Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C. Journal of Viral Hepatitis 19, 37-41
CrossRef30
Diane S. Morse, Miriam Schiff, Shabtay Levit, Rinat Cohen-Moreno, Geoffrey C. Williams, Yehuda Neumark. (2012) A Pilot Training Program for a Motivational Enhancement Approach to Hepatitis C Virus Treatment Among Individuals in Israeli Methadone Treatment Centers. Substance Use & Misuse 47:1, 56-66
CrossRef31
Sang Hoon Park, Choong Kee Park, Jin Woo Lee, Young Seok Kim, Sook-Hyang Jeong, Yun Soo Kim, Ju Hyun Kim, Seong Gyu Hwang, Kyu Sung Rim, Hyung Joon Yim, Jae Youn Cheong, Sung Won Cho, June Sung Lee, Young Min Park, Jeong Won Jang, Chun Kyon Lee, Joo Hyun Shon, Jin Mo Yang, Young Soo Ju. (2012) Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study. Gut and Liver 6:1, 98
CrossRef32
Christoph Sarrazin, Christophe Hézode, Stefan Zeuzem, Jean-Michel Pawlotsky. (2012) Antiviral strategies in hepatitis C virus infection. Journal of Hepatology 56, S88-S100
CrossRef33
Jinah Choi. (2012) Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: Pathogenic interactions and therapeutic considerations. Free Radical Biology and Medicine
CrossRef34
Keizo Kato, Takeshi Yonezawa, Chizuko Tachibana, Hiroyuki Tachibana, Satoshi Watanabe, Yasushi Mandai, Rei Kashima, Kazushi Fukuda. (2012) Response-guided therapy based on reaction to the initial dose using administration of peginterferon α-2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads. Kanzo 53:1, 18-27
CrossRef35
Sandra Beinhardt, Albert F. Staettermayer, Karoline Rutter, Judith Maresch, Thomas M. Scherzer, Petra Steindl-Munda, Harald Hofer, Peter Ferenci. (2012) Treatment of chronic hepatitis C genotype 1 patients at an academic center in europe involved in prospective, controlled trials: Is there a selection bias?. Hepatology 55:1, 30-38
CrossRef36
F. Jover-Díaz, J.M. Cuadrado-Pastor, C.R. Gallardo-Quesada. (2012) Pulpitis seca y fisuras en los dedos de las manos en pacientes que reciben tratamiento combinado para hepatitis C. Revista Clínica Española
CrossRef37
Milos Opravil, Maribel Rodriguez-Torres, Jürgen Rockstroh, Eric Snoeck, Raymond T. Chung, Andreas Tietz, Francesca J. Torriani. (2012) The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV. HIV Clinical Trials 13:1, 33-45
CrossRef38
Ming-Yen Hsieh, Chia-Yen Dai, Li-Po Lee, Jee-Fu Huang, Wan-Long Chuang, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Ming-Lung Yu. (2012) Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. The Kaohsiung Journal of Medical Sciences
CrossRef39
Kung-Hung Lin, Ping-I Hsu, Hsien-Chung Yu, Chun-Ku Lin, Wei-Lun Tsai, Wen-Chi Chen, Hoi-Hung Chan, Kwok-Hung Lai. (2012) Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. BMC Gastroenterology 12:1, 7
CrossRef40
Anita Arora, Natalia Mendoza, Stephen K. Tyring. 2011. Antiviral Market Overview. .
CrossRef41
Michael J Sofia, Wonsuk Chang, Phillip A. Furman, Ralph T Mosley, Bruce Saxby Ross. (2011) Nucleoside, Nucleotide and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. Journal of Medicinal Chemistry111216133615000
CrossRef42
N. I. Rallon, J. Morello, P. Labarga, J. M. Benito, S. Rodriguez-Novoa, E. Vispo, P. Barreiro, M. A. Castro, K. Aguirrebengoa, J. A. Pineda, P. Miralles, M. J. Tellez, J. Portu, C. Miralles, A. Ocampo, V. Soriano, . (2011) Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. Clinical Infectious Diseases 53:12, 1291-1295
CrossRef43
Sanja Glisic, Nevena Veljkovic, Snezana Jovanovic Cupic, Nada Vasiljevic, Jelena Prljic, Branislava Gemovic, Vladimir Perovic, Veljko Veljkovic. (2011) Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. The Protein Journal
CrossRef44
A. A. Butt, F. Kanwal. (2011) Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients. Clinical Infectious Diseases
CrossRef45
Ariel Basulto Perdomo, Fabiola Ciccosanti, Oreste Lo Iacono, Claudio Angeletti, Marco Corazzari, Nicola Daniele, Angela Testa, Roberto Pisa, Giuseppe Ippolito, Giorgio Antonucci, Gian Maria Fimia, Mauro Piacentini. (2011) Liver Protein Profiling in Chronic Hepatitis C: Identification of Potential Predictive Markers for Interferon Therapy Outcome. Journal of Proteome Research111207120234002
CrossRef46
John Carl Hoefs, Vikramjit S. Aulakh, Bernard Joseph Ilagan. (2011) Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C. Digestive Diseases and Sciences
CrossRef47
T. Ghillemijn, W. Laleman, J. Flamaing. (2011) Leverlijden bij oudere personen. Tijdschrift voor Gerontologie en Geriatrie
CrossRef48
B. L. Cullen, S. J. Hutchinson, S. O. Cameron, E. Anderson, S. Ahmed, E. Spence, P. R. Mills, R. Mandeville, E. Forrest, M. Washington, R. Wong, R. Fox, D. J. Goldberg. (2011) Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention. Journal of Public Health
CrossRef49
Eiji Kajiwara, Aritune Ooho, Naoki Yamashita. (2011) Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels. Hepatology Researchno-no
CrossRef50
I. M. Jacobson, F. Poordad, R. S. Brown Jr, P. Y. Kwo, K. R. Reddy, E. Schiff. (2011) Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. Journal of Viral Hepatitisno-no
CrossRef51
Carla Venturi, Javier Bueno, Lluís Castells, Jesus Quintero, Isabel Casas, Helena Allende, Vicente Martinez-Ibañez, Ramón Charco. (2011) Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation. Liver Transplantation 17:12, 1474-1480
CrossRef52
Jörn Lötsch, Wolf Peter Hofmann, Christina Schlecker, Stefan Zeuzem, Gerd Geisslinger, Alfred Ultsch, Alexandra Doehring. (2011) Single and combined IL28B , ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Pharmacogenomics 12:12, 1729-1740
CrossRef53
Raquel S Cuchacovich, Ignacio Garcia-Valladares, Luis R Espinoza. (2011) Cutaneous lesions from IFN-α-induced sarcoidosis: how do we reverse the effects?. Expert Review of Dermatology 6:6, 551-553
CrossRef54
Omer Khalid, Bruce R Bacon. (2011) Boceprevir in the treatment of hepatitis C infection: rationale and clinical data. Clinical Investigation 1:12, 1717-1729
CrossRef55
Béla Hunyady, Balázs Kovács, Zita Battyáni. (2011) A krónikus hepatitis C-vírus-fertőzés hagyományos pegilált interferon+ribavirin és proteázgátló direkt antivirális hatású szerekkel kiegészített kezelésének mellékhatásai. Orvosi Hetilap 152:50, 1997-2009
CrossRef56
J. Berenguer, M. A. von Wichmann, C. Quereda, P. Miralles, J. Mallolas, J. Lopez-Aldeguer, J. Alvarez-Pellicer, J. De Miguel, M. Crespo, J. M. Guardiola, M. J. Tellez, M. J. Galindo, S. Arponen, E. Barquilla, J. M. Bellon, J. Gonzalez-Garcia, , P. Miralles, J. Cosin, J. C. Lopez, B. Padilla, M. Sanchez Conde, J. M. Bellon, I. Gutierrez, M. Ramirez, S. Carretero, T. Aldamiz-Echevarria, F. Tejerina, J. Berenguer, J. Alvarez-Pellicer, E. Rodriguez, J. R. Arribas, M. L. Montes, I. Bernardino, J. F. Pascual, F. Zamora, J. M. Pena, F. Arnalich, J. Gonzalez-Garcia, M. J. Bustinduy, J. A. Iribarren, F. Rodriguez-Arrondo, M. A. Von-Wichmann, M. Blanes, S. Cuellar, J. Lacruz, M. Montero, M. Salavert, J. Lopez-Aldeguer, P. Callau, J. M. Miro, J. M. Gatell, J. Mallolas, A. Ferrer, M. J. Galindo, E. Van den Eynde, M. Perez, E. Ribera, M. Crespo, J. Vergas, M. J. Tellez, J. L. Casado, F. Dronda, A. Moreno, M. J. Perez-Elias, M. A. Sanfrutos, S. Moreno, C. Quereda, A. Jou, C. Tural, A. Arranz, E. Casas, J. de Miguel, S. Schroeder, J. Sanz, E. Condes, C. Barros, J. Sanz, I. Santos, A. Hernando, V. Rodriguez, R. Rubio, F. Pulido, P. Domingo, J. M. Guardiola, L. Ortiz, E. Ortega, L. : R. Torres, M. Cervero, J. J. Jusdado, M. L. Montes, G. Perez, G. Gaspar, E. Barquilla, B. Mahillo, B. Moyano, M. Cotarelo, E. Aznar, H. Esteban. (2011) Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. Journal of Antimicrobial Chemotherapy 66:12, 2843-2849
CrossRef57
Jorge-Shmuel Delgado, Yael Baumfeld, Victor Novack, Shulamit Monitin, Alan Jotkowitz, Ohad Etzion, Alexander Fich. (2011) Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. Hepatology International 5:4, 985-990
CrossRef58
Alla Kachko, Galina Kochneva, Galina Sivolobova, Antonina Grazhdantseva, Tatyana Lupan, Iryna Zubkova, Frances Wells, Michael Merchlinsky, Ollie Williams, Hisayoshi Watanabe, Alla Ivanova, Aleksander Shvalov, Valeriy Loktev, Sergei Netesov, Marian E. Major. (2011) New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. Vaccine 30:1, 69-77
CrossRef59
Mosaburo Kainuma, Norihiro Furusyo, Koichi Azuma, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, . (2011) Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. Hepatology Researchno-no
CrossRef60
M. H. Powdrill, E. P. Tchesnokov, R. A. Kozak, R. S. Russell, R. Martin, E. S. Svarovskaia, H. Mo, R. D. Kouyos, M. Gotte. (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proceedings of the National Academy of Sciences
CrossRef61
H. Guedj, J. Guedj, F. Negro, M. Lagging, J. Westin, P.-Y. Bochud, S. Bibert, A. U. Neumann, . (2011) The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. Journal of Viral Hepatitisno-no
CrossRef62
Milena Fioravante, Sarah Monte Alegre, Daniela Miguel Marin, Sonia Leticia Silva Lorena, Tiago Sevá Pereira, Elza Cotrim Soares. (2011) Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition
CrossRef63
Anthony F. Porto, Lauren Tormey, Joseph K. Lim. (2011) Management of chronic hepatitis C infection in children. Current Opinion in Pediatrics1
CrossRef64
Stéphane Chevaliez. (2011) Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance. Clinics and Research in Hepatology and Gastroenterology 35, S46-S51
CrossRef65
Isabelle Rosa. (2011) Management of side-effects. Clinics and Research in Hepatology and Gastroenterology 35, S69-S74
CrossRef66
Christoph Welsch, Tetsuro Shimakami, Christoph Hartmann, Yan Yang, Francisco S. Domingues, Thomas Lengauer, Stefan Zeuzem, Stanley M. Lemon. (2011) Peptidomimetic Escape Mechanisms Arise via Genetic Diversity in the Ligand-Binding Site of the Hepatitis C Virus NS3/4A Serine Protease. Gastroenterology
CrossRef67
Akihito Tsubota, Noritomo Shimada, Kai Yoshizawa, Tomomi Furihata, Rie Agata, Yoko Yumoto, Hiroshi Abe, Makiko Ika, Yoshihisa Namiki, Kan Chiba, Kiyotaka Fujise, Norio Tada, Yoshio Aizawa. (2011) Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Internationaln/a-n/a
CrossRef68
José A. Mira, Juan Macías. (2011) ¿Podemos adelantar el diagnóstico de la respuesta virológica sostenida a las 12 semanas tras finalizar el tratamiento frente al VHC?. Enfermedades Infecciosas y Microbiología Clínica
CrossRef69
Chung-Feng Huang, Ming-Lun Yeh, Jee-Fu Huang, Jeng-Fu Yang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Edward Hsi, Suh-Hang Hank Juo, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. (2011) Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Research
CrossRef70
Xiaopan Wu, Zhenhui Xin, Xilin Zhu, Liping Pan, Zhuo Li, Hui Li, Ying Liu. (2011) Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese. Antiviral Research
CrossRef71
Verónica Saludes Montoro, Vicente Ausina Ruiz, Elisa Martró Català. (2011) Posibilidades actuales para predecir la respuesta a la terapia en pacientes con hepatitis C crónica por el genotipo 1 del virus de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 29, 51-58
CrossRef72
H. E. HARRIS, A. COSTELLA, G. AMIRTHALINGAM, G. ALEXANDER, M. E. B. RAMSAY, N. ANDREWS, . (2011) Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study. Epidemiology and Infection1-8
CrossRef73
Scott A. Read, Mark W. Douglas. 2011. Hepatitis C Virus Genotypes. , 12-16.
CrossRef74
Johannes Wiegand, Thomas Berg. 2011. Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients. , 74-83.
CrossRef75
Alessandra Mangia, Leonardo Mottola. (2011) Treatment of Non-Genotype 1 Hepatitis C Virus Patients. Current Gastroenterology Reports
CrossRef76
Xavier Hanoulle, Isabelle Huvent, Arnaud Leroy, Hong Ye, Cong Bao Kang, Yu Liang, Claire Rosnoblet, Jean-Michel Wieruszeski, Ho Sup Yoon, Guy Lippens. 2011. The NS5A Domain II of HCV: Conservation of Intrinsic Disorder in Several Genotypes. , 409-424.
CrossRef77
Tsugiko Oze, Naoki Hiramatsu, Changho Song, Takayuki Yakushijin, Sadaharu Iio, Yoshinobu Doi, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Masanori Miyazaki, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara. (2011) Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. Journal of Gastroenterology
CrossRef78
Fred Poordad, Grace M. Chee. (2011) Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. Current Gastroenterology Reports
CrossRef79
Andrew V. Stachulski, Chandrakala Pidathala, Eleanor C. Row, Raman Sharma, Neil G. Berry, Alexandre S. Lawrenson, Shelley L. Moores, Mazhar Iqbal, Joanne Bentley, Sarah A. Allman, Geoffrey Edwards, Alison Helm, Jennifer Hellier, Brent E. Korba, J. Edward Semple, Jean-Francois Rossignol. (2011) Thiazolides as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus Replication. Journal of Medicinal Chemistry111121131258005
CrossRef80
M. Milan, S. Boninsegna, L. Scribano, S. Lobello, S. Fagiuoli, P. Fabris, A. Buda, D. Martines. (2011) Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?. Infection
CrossRef81
Ann D Kwong, Robert S Kauffman, Patricia Hurter, Peter Mueller. (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nature Biotechnology 29:11, 993-1003
CrossRef82
Jeong-A. Yang, Kitae Park, Hyuntae Jung, Hyemin Kim, Sung Woo Hong, Seung Kew Yoon, Sei Kwang Hahn. (2011) Target specific hyaluronic acid–interferon alpha conjugate for the treatment of hepatitis C virus infection. Biomaterials 32:33, 8722-8729
CrossRef83
Mohammed T.A. Salim, Hiroshi Aoyama, Kazuyuki Sugita, Kouichi Watashi, Takaji Wakita, Takayuki Hamasaki, Mika Okamoto, Yasuo Urata, Yuichi Hashimoto, Masanori Baba. (2011) Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives. Biochemical and Biophysical Research Communications
CrossRef84
Christian M. Lange, Simone Susser, Eva Herrmann, Ursula Karey, Tara L. Kieffer, Ann D. Kwong, Janke Schinkel, Henk W. Reesink, Stefan Zeuzem, Christoph Sarrazin. (2011) HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. Scandinavian Journal of Gastroenterology 46:11, 1362-1368
CrossRef85
Daisuke Takaya, Atsuya Yamashita, Kazue Kamijo, Junko Gomi, Masahiko Ito, Shinya Maekawa, Nobuyuki Enomoto, Naoya Sakamoto, Yoshiaki Watanabe, Ryoichi Arai, Hideaki Umeyama, Teruki Honma, Takehisa Matsumoto, Shigeyuki Yokoyama. (2011) A new method for induced fit docking (genius) and its application to virtual screening of novel HCV NS3-4A protease inhibitors. Bioorganic & Medicinal Chemistry 19:22, 6892-6905
CrossRef86
Ingi Lee, Russell Localio, Colleen M. Brensinger, Emily A. Blumberg, Ebbing Lautenbach, Leanne Gasink, Valerianna K. Amorosa, Vincent Lo Re. (2011) Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. The Journal of Heart and Lung Transplantation 30:11, 1266-1274
CrossRef87
Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Nektarios Dikopoulos, Peter Buggisch, Jens Encke, Gerlinde Teuber, Tobias Goeser, Robert Thimme, Hartwig Klinker, Wulf O. Boecher, Ewert Schulte–Frohlinde, Renate Prinzing, Eva Herrmann, Stefan Zeuzem, Thomas Berg. (2011) Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks. Gastroenterology 141:5, 1656-1664
CrossRef88
Donna M. Evon, Denise A. Esserman, Darmendra Ramcharran, Jason E. Bonner, Michael W. Fried. (2011) Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. Journal of Psychosomatic Research 71:5, 349-356
CrossRef89
J. E. Bonner, D. Esserman, D. M. Evon. (2011) Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. Journal of Viral Hepatitisno-no
CrossRef90
Sarah Maylin, Cédric Laouénan, Michelle Martinot-Peignoux, Xavière Panhard, Martine Lapalus, Marie Hélène Nicolas-Chanoine, Pierre Bedossa, Tarik Asselah, Patrick Marcellin. (2011) Role of hepatic HCV–RNA level on the severity of chronic hepatitis C and response to antiviral therapy. Journal of Clinical Virology
CrossRef91
Antonio Salvio, Maria Varriale, Tito d’Errico, Gennaro De Siena, Mario Visconti. (2011) HBsAg loss with HBsAg/anti-HBs seroconversion and non-detectable HCV-RNA in a patient with chronic HBV e-minus/HCV hepatitis treated with two cycles of antiviral therapy. Italian Journal of Medicine
CrossRef92
Yonghong Zhang, Dandan Guo, Yan Zhao, Xiaoyun Chen, Lina Ma, Yi Jin, Huiping Yan, Hao Wu, Lai Wei, Tao Dong, Xinyue Chen. (2011) The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection. Antiviral Research 92:2, 247-254
CrossRef93
Vicente Soriano, Luz Martin-Carbonero, Eugenia Vispo, Pablo Labarga, Pablo Barreiro. (2011) Infección por virus de la inmunodeficiencia humana y hepatitis víricas. Enfermedades Infecciosas y Microbiología Clínica 29:9, 691-701
CrossRef94
Kar Neng Lai. (2011) Hepatitis-related renal disease. Future Virology 6:11, 1361-1376
CrossRef95
Ahmad Amanzada, Armin Goralczyk, Federico Moriconi, Martina Blaschke, Inga-Marie Schaefer, David Thiel, Sabine Mihm, Giuliano Ramadori. (2011) Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy. Digestive Diseases and Sciences 56:11, 3296-3304
CrossRef96
SM Hosseini-Moghaddam, E. Iran-Pour, C. Rotstein, S. Husain, L. Lilly, E. Renner, T. Mazzulli. (2011) Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?. Reviews in Medical Virologyn/a-n/a
CrossRef97
D. E. FRANSEN van de PUTTE, K. FISCHER, R. J. De KNEGT, D. POSTHOUWER, K. J. Van ERPECUM, D. H. BIESMA, E. P. MAUSER-BUNSCHOTEN. (2011) Beneficial effect of successful HCV treatment in patients with inherited bleeding disorders, assessed by liver stiffness measurements. Haemophiliano-no
CrossRef98
Andrew H. Talal, Ruei-Chi Liu, Marija Zeremski, Rositsa Dimova, Lorna Dove, Daniel Pearce, Tarek Hassanein, Leleka Doonquah, David Aboulafia, Jorge Rodriguez, Hector Bonilla, Jeffrey Galpin, Judy A. Aberg, Barbara Johnston, Marshall J. Glesby, Ira M. Jacobson. (2011) Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, 261-268
CrossRef99
Vivian Ng, Sammy Saab. (2011) Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 9:11, 923-930
CrossRef100
Véronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, Marianne Maynard, Gérard Babany, Sophie Alain, Christian Trépo, Victor De Ledinghen, Marc Bourlière, Stanislas Pol, Vincent Di Martino, Jean-Pierre Zarski, Alexandrina Pinta, Denis Sautereau, Pierre Marquet. (2011) Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Digestive and Liver Disease 43:11, 850-855
CrossRef101
Tatsuo Kanda, Fumio Imazeki, Ryosaku Azemoto, Yutaka Yonemitsu, Shigeru Mikami, Kazuhiko Kita, Motohide Takashi, Masahiko Sunaga, Shuang Wu, Shingo Nakamoto, Akinobu Tawada, Makoto Arai, Keizo Kato, Yu Yoshida, Yoshihiro Koma, Keiichi Fujiwara, Kenichi Fukai, Noriaki Suzuki, Osamu Yokosuka. (2011) Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2. Digestive Diseases and Sciences 56:11, 3335-3342
CrossRef102
E. W. Hwang, I.-C. Thomas, R. Cheung, L. I. Backus. (2011) Implications of rapid virological response in hepatitis C therapy in the US veteran population. Alimentary Pharmacology & Therapeuticsno-no
CrossRef103
Yasser M. Fouad, Hanaa Khalaf, Hala Ibraheem, Heba Rady, Amal K. Helmy. (2011) Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin. International Journal of Infectious Diseases
CrossRef104
Jan Paeshuyse, Kai Dallmeier, Johan Neyts. (2011) Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology
CrossRef105
N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama, H. Kumada. (2011) Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitisno-no
CrossRef106
C. V. Almario, M. Vega, S. B. Trooskin, V. J. Navarro. (2011) Examining hepatitis c virus testing practices in primary care clinics. Journal of Viral Hepatitisno-no
CrossRef107
S. Sarwar, E. J. Ryan, M. Iqbal, P. A. McCormick, C. O’Farrelly, J. Hegarty. (2011) Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection. Irish Journal of Medical Science
CrossRef108
Marc G. Ghany, David R. Nelson, Doris B. Strader, David L. Thomas, Leonard B. Seeff. (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:4, 1433-1444
CrossRef109
Antonio Carta, Irene Briguglio, Sandra Piras, Paola Corona, Giampiero Boatto, Maria Nieddu, Paolo Giunchedi, Maria Elena Marongiu, Gabriele Giliberti, Filippo Iuliano, Sylvain Blois, Cristina Ibba, Bernardetta Busonera, Paolo La Colla. (2011) Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. Bioorganic & Medicinal Chemistry
CrossRef110
Lourianne Nascimento Cavalcante, Kiyoko Abe-Sandes, Ana Luiza Dias Angelo, Taisa Manuela B. Machado, Denise C. Lemaire, Carlos Maurício Cardeal Mendes, João Renato Pinho, Fernanda Malta, Luiz G.C. Lyra, André Castro Lyra. (2011) IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Internationaln/a-n/a
CrossRef111
Olga M Klibanov, Shannon H Williams, Lisa S Smith, Jacqueline L Olin, Stephen B Vickery. (2011) Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. Pharmacotherapy 31:10, 951-974
CrossRef112
Akihiro Tamori, Kiyohide Kioka, Osamu Kurai, Hiroki Sakaguchi, Masaru Enomoto, Hideki Fujii, Sawako Kobayashi, Shuji Iwai, Hiroyasu Morikawa, Seiko Yamaguchi, Yasuko Kawasaki, Hiroko Oka, Yasuhito Tanaka, Norifumi Kawada. (2011) Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. Hepatology Researchno-no
CrossRef113
R. J. de Knegt, G. Bezemer, A. R. Van Gool, J. P. H. Drenth, B. E. Hansen, H. A. Droogleever Fortuyn, C. J. Weegink, M. W. Hengeveld, H. L. A. Janssen. (2011) Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeuticsno-no
CrossRef114
Johannes Vermehren, Ming-Lung Yu, Alexander Monto, Joseph D. Yao, Christopher Anderson, Rasa Bertuzis, George Schneider, Christoph Sarrazin. (2011) Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. Journal of Clinical Virology 52:2, 133-137
CrossRef115
Hideyuki Tamai, Naoki Shingaki, Tatsuya Shiraki, Hiroshi Tukuda, Yoshiyuki Mori, Kosaku Moribata, Shotaro Enomoto, Hisanobu Deguchi, Kazuki Ueda, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Kimihiko Yanaoka, Masashi Oka, Masao Ichinose. (2011) Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatology Researchno-no
CrossRef116
Philippe Halfon, Marc Bourliere, Denis Ouzan, Yaakov Maor, Christophe Renou, Claire Wartelle, Guillaume Pénaranda, Albert Tran, Danielle Botta, Valérie Oules, Paul Castellani, Isabelle Portal, Laurent Argiro, Alain Dessein. (2011) A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. European Journal of Gastroenterology & Hepatology 23:10, 931-935
CrossRef117
Jeffrey W. Koehler, Lesley C. Dupuy, Aura R. Garrison, Brett F. Beitzel, Michelle J. Richards, Daniel R. Ripoll, Anders Wallqvist, Shia-Yen Teh, Andrew A. Vaewhongs, Fakhrieh S. Vojdani, Hal S. Padgett, Connie S. Schmaljohn. (2011) Novel plant-derived recombinant human interferons with broad spectrum antiviral activity. Antiviral Research
CrossRef118
Yoshito Itoh, Takeshi Nishimura, Kanji Yamaguchi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Yasuyuki Nagao, Yoshio Sumida, Hiroaki Hashimoto, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Toshikazu Yoshikawa. (2011) Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy. Hepatology Researchno-no
CrossRef119
T. Kawaoka, H. Aikata, S. Takaki, A. Hiramatsu, K. Waki, N. Hiraga, D. Miki, M. Tsuge, M. Imamura, Y. Kawakami, S. Takahashi, H. Ochi, H. Tashiro, H. Ohdan, K. Chayama. (2011) IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 18:10, e550-e560
CrossRef120
Kazuhiko Hayashi, Yoshiaki Katano, Takashi Honda, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Tetsuya Ishikawa, Isao Nakano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto. (2011) Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver International 31:9, 1359-1365
CrossRef121
Tingting Li, Zixuan Chen, Jinfeng Zeng, Jingang Zhang, Wenjing Wang, Ling Zhang, Xin Zheng, Lifang Shuai, Paul Klenerman, Jean-Pierre Allain, Chengyao Li. (2011) Impact of host responses on control of hepatitis C virus infection in Chinese blood donors. Biochemical and Biophysical Research Communications
CrossRef122
Christopher M. Moore, Magdalena George, David H. Thiel. (2011) Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin. Digestive Diseases and Sciences 56:10, 3032-3037
CrossRef123
Jian-Wu Yu, Li-Jie Sun, Yong-Hua Zhao, Peng Kang, Bing-Zhu Yan. (2011) The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C. European Journal of Gastroenterology & Hepatology1
CrossRef124
Andrew J. Skabelund, Timothy R. Hauser, Kevin J. Goist. (2011) Pure red cell aplasia caused by ribavirin and interferon treatment. Clinical Journal of Gastroenterology 4:5, 313-317
CrossRef125
Charles D. Howell, Alexis Gorden, Kathleen A. Ryan, Alexander J. Thompson, Chadi Ibrahim, Michael Fried, Nezam H. Afdhal, John G. McHutchison, Kevin V. Shianna, David B. Goldstein, Alan R. Shuldiner, Braxton D. Mitchell. (2011) Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. Journal of Hepatology
CrossRef126
Marina M. May, Heike Lorengel, Joerg Kreuter, Holger Zimmermann, Helga Ruebsamen-Schaeff, Andreas Urban. (2011) RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1814:10, 1325-1332
CrossRef127
Javier Velasco, Silvia González. (2011) Adenitis tuberculosa tras tratamiento con éxito de hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 29:8, 631
CrossRef128
Sasijit Vejbaesya, Yuwatida Nonnoi, Tawesak Tanwandee, Duangporn Srinak. (2011) Killer cell immunoglobulin-like receptors and response to antiviral treatment in Thai patients with chronic hepatitis C virus genotype 3a. Journal of Medical Virology 83:10, 1733-1737
CrossRef129
R. R. Razonable. (2011) Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. Mayo Clinic Proceedings 86:10, 1009-1026
CrossRef130
Bruno Cópio Fábregas, Flávia Domingues Vitorino, Débora Millard Rocha, Alexandre Sampaio Moura, Ricardo Andrade Carmo, Antônio Lúcio Teixeira. (2011) Screening inventories to detect depression in chronic hepatitis C patients. General Hospital Psychiatry
CrossRef131
Felix Stickel, Beat Helbling, Markus Heim, Andreas Geier, Claudia Hirschi, Benedetta Terziroli, Klaus Wehr, Andrea De Gottardi, Francesco Negro, Tilman Gerlach. (2011) Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. Journal of Viral Hepatitisno-no
CrossRef132
Pratima Sharma, Anna S. Lok. (2011) Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?. Gastroenterology
CrossRef133
B. D. Smith, J. Drobeniuc, A. Jewett, B. M. Branson, R. S. Garfein, E. Teshale, S. Kamili, C. M. Weinbaum. (2011) Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus. Journal of Infectious Diseases 204:6, 825-831
CrossRef134
Sherman, Kenneth E., Flamm, Steven L., Afdhal, Nezam H., Nelson, David R., Sulkowski, Mark S., Everson, Gregory T., Fried, Michael W., Adler, Michael, Reesink, Hendrik W., Martin, Marie, Sankoh, Abdul J., Adda, Nathalie, Kauffman, Robert S., George, Shelley, Wright, Christopher I., Poordad, Fred, . (2011) Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. New England Journal of Medicine 365:11, 1014-1024
Full Text135
Hirotoshi Ebinuma, Hidetsugu Saito, Shinichiro Tada, Nobuhiro Nakamoto, Tazuko Ohishi, Satoshi Tsunematsu, Naoki Kumagai, Kanji Tsuchimoto, Nobuhiro Tsukada, Yasutaka Inagaki, Yoshinori Horie, Masahiko Takahashi, Kazuhiro Atsukawa, Yukishige Okamura, Takanori Kanai, Toshifumi Hibi. (2011) Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. Hepatology International
CrossRef136
Nobuhiko Hiraga, Michio Imamura, Hiromi Abe, C. Nelson Hayes, Tomohiko Kono, Mayu Onishi, Masataka Tsuge, Shoichi Takahashi, Hidenori Ochi, Eiji Iwao, Naohiro Kamiya, Ichimaro Yamada, Chise Tateno, Katsutoshi Yoshizato, Hirotaka Matsui, Akinori Kanai, Toshiya Inaba, Shinji Tanaka, Kazuaki Chayama. (2011) Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 54:3, 781-788
CrossRef137
Nobuhiko Hiraga, Hiromi Abe, Michio Imamura, Masataka Tsuge, Shoichi Takahashi, C. Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama. (2011) Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 54:3, 764-771
CrossRef138
Vincent Di Martino, Carine Richou, Jean-Paul Cervoni, Jose M. Sanchez-Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot. (2011) Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. Hepatology 54:3, 789-800
CrossRef139
Alessandra Mangia, Alexander J. Thompson, Rosanna Santoro, Valeria Piazzolla, Massimiliano Copetti, Nicola Minerva, Daniela Petruzzellis, Leonardo Mottola, Donato Bacca, John G. McHutchison. (2011) Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 54:3, 772-780
CrossRef140
Chalermrat Bunchorntavakul, K. Rajender Reddy. (2011) Ribavirin: How Does it Work and is it Still Needed?. Current Hepatitis Reports 10:3, 168-178
CrossRef141
Adeel A. Butt, Kathleen McGinnis, Melissa Skanderson, Amy C. Justice. (2011) A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Research and Human Retroviruses 27:9, 973-979
CrossRef142
Dania Shoeb, Ian A. Rowe, Dennis Freshwater, David Mutimer, Ashley Brown, Sulleman Moreea, Ruchit Sood, Richard Marley, Caroline A. Sabin, Graham R. Foster. (2011) Response to antiviral therapy in patients with genotype 3 chronic hepatitis C. European Journal of Gastroenterology & Hepatology 23:9, 747-753
CrossRef143
Naoki Hiramatsu, Masayuki Kurosaki, Naoya Sakamoto, Manabu Iwasaki, Minoru Sakamoto, Yoshiyuki Suzuki, Fuminaka Sugauchi, Akihiro Tamori, Sei Kakinnuma, Kentaro Matsuura, Namiki Izumi. (2011) Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. Journal of Gastroenterology 46:9, 1111-1119
CrossRef144
Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Chung-Feng Huang, Ching-I Huang, Ming-Lun Yeh, Jeng-Fu Yang, Nei-Jen Hou, Pi-Jung Hsiao, Zu-Yau Lin, Shinn-Chern Chen, Shyi-Jang Shin, Wan-Long Chuang. (2011) Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients. Liver International 31:8, 1155-1162
CrossRef145
Hiromi Abe, C. Nelson Hayes, Hidenori Ochi, Masataka Tsuge, Daiki Miki, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Michiaki Kubo, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama. (2011) Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. Journal of Medical Virology 83:9, 1597-1607
CrossRef146
Y. Tanaka, M. Kurosaki, N. Nishida, M. Sugiyama, K. Matsuura, N. Sakamoto, N. Enomoto, H. Yatsuhashi, S. Nishiguchi, K. Hino, S. Hige, Y. Itoh, E. Tanaka, S. Mochida, M. Honda, Y. Hiasa, A. Koike, F. Sugauchi, S. Kaneko, N. Izumi, K. Tokunaga, M. Mizokami. (2011) Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Human Molecular Genetics 20:17, 3507-3516
CrossRef147
Maya Gambarin-Gelwan, Ira M. Jacobson. (2011) Chronic hepatitis C genotype 2 and 3: Are we ready for personalized medicine?. Journal of Hepatology 55:3, 505-506
CrossRef148
Yuki Ichikawa-Yamada, Satoru Joshita, Yoshinori Tsukahara, Takefumi Kimura, Susumu Morita, Atsushi Kamijo, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Eiji Tanaka. (2011) Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy. Hepatology Research 41:9, 904-909
CrossRef149
Aimee Truesdale, Gregory Everson. (2011) Treatment of Chronic Hepatitis C in the Age of Direct-Acting Antivirals with Emphasis on First Generation Inhibitors of HCV NS3/4A Protease. Current Hepatitis Reports 10:3, 204-213
CrossRef150
Dominique Larrey, Annie Salse, Didier Ribard, Olivier Boutet, Valérie Hyrailles–Blanc, Birame Niang, Georges Philippe Pageaux, Emmanuel Vaucher, Jean Pierre Arpurt, Guy Boulay, Natalia Karlova, Jean Pierre Daures. (2011) Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-α2a and Ribavirin. Clinical Gastroenterology and Hepatology 9:9, 781-785
CrossRef151
Aarthi Chary, Mark Holodniy. (2011) Interferon combination therapy for HIV/hepatitis C virus coinfection. Immunotherapy 3:9, 1087-1102
CrossRef152
Jeffrey S. McCombs, Yong Yuan, Janet Shin, Sammy Saab. (2011) Economic Burden Associated With Patients Diagnosed With Hepatitis C. Clinical Therapeutics 33:9, 1268-1280
CrossRef153
Michael Manns, Stefan Zeuzem, Ajit Sood, Yoav Lurie, Markus Cornberg, Hartwig Klinker, Peter Buggisch, Martin Rössle, Holger Hinrichsen, Ismail Merican, Yaron Ilan, Stefan Mauss, Saif Abu-Mouch, Andryes Horban, Thomas H. Müller, Christoph Welsch, Rongdean Chen, Rab Faruqi, Lisa D. Pedicone, Heiner Wedemeyer. (2011) Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. Journal of Hepatology 55:3, 554-563
CrossRef154
Kay Seden, David Back. (2011) Directly acting antivirals for hepatitis C and antiretrovirals. Current Opinion in HIV and AIDS1
CrossRef155
KwangSoo Lyoo, Myeong Jun Song, Wonhee Hur, Jung Eun Choi, Sung Woo Hong, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Sang Wook Choi, Eui-Cheol Shin, Seung Kew Yoon. (2011) Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. Journal of Clinical Virology
CrossRef156
C. Hézode, L. Castéra, F. Roudot-Thoraval, M. Bouvier-Alias, I. Rosa, D. Roulot, V. Leroy, A. Mallat, J.-M. Pawlotsky. (2011) Liver stiffness diminishes with antiviral response in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 34:6, 656-663
CrossRef157
B. E. Pickett, R. Striker, E. J. Lefkowitz. (2011) Evidence for separation of HCV subtype 1a into two distinct clades. Journal of Viral Hepatitis 18:9, 608-618
CrossRef158
Michele Malaguarnera, Marco Vacante, Gaetano Bertino, Sergio Neri, Mariano Malaguarnera, Maria Pia Gargante, Massimo Motta, Lorenzo Lupo, Giuseppe Chisari, Cosimo Marcello Bruno, Giovanni Pennisi, Rita Bella. (2011) The Supplementation of Acetyl-
l -Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-α 2b Plus Ribavirin. Journal of Interferon & Cytokine Research 31:9, 653-659
CrossRef159
Coral Lever, Kathryn L. Nash. (2011) Hepatitis C. Medicine 39:9, 550-555
CrossRef160
Harel Dahari, Jeremie Guedj, Alan S. Perelson, Thomas J. Layden. (2011) Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and Interleukin-28B. Current Hepatitis Reports 10:3, 214-227
CrossRef161
Chuan-Hai Zhang, Ge-Liang Xu, Wei-Dong Jia, Jian-Sheng Li, Jin-Liang Ma, Yong-Sheng Ge. (2011) Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta-analysis of randomized controlled trials. International Journal of Cancer 129:5, 1254-1264
CrossRef162
Tarik Asselah, Simon De Muynck, Philippe Broët, Julien Masliah-Planchon, Maud Blanluet, Ivan Bièche, Martine Lapalus, Michelle Martinot-Peignoux, Olivier Lada, Emilie Estrabaud, Qian Zhang, Ahmed El Ray, Dominique Vidaud, Marie-Pierre Ripault, Nathalie Boyer, Pierre Bedossa, Dominique Valla, Michel Vidaud, Patrick Marcellin. (2011) IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of Hepatology
CrossRef163
Magdeleine Hung, Ruth Wang, Xiaohong Liu. 2011. Preparation of HCV NS3 and NS5B Proteins to Support Small-Molecule Drug Discovery. .
CrossRef164
Maria Ripoli, Valerio Pazienza. (2011) Impact of HCV genetic differences on pathobiology of disease. Expert Review of Anti-infective Therapy 9:9, 747-759
CrossRef165
Raymond P. Donnelly, Harold Dickensheets, Thomas R. O’Brien. (2011) Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends in Immunology 32:9, 443-450
CrossRef166
Yonghong Zhang, Yali Liu, Yan Zhao, Lingxian Shi, Lina Ma, Huiping Yan, Hao Wu, Lai Wei, Tao Dong, Xinyue Chen. (2011) Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients. Liver Internationaln/a-n/a
CrossRef167
I. Yamada, F. Suzuki, N. Kamiya, K. Aoki, Y. Sakurai, M. Kano, H. Matsui, H. Kumada. (2011) Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. Journal of Viral Hepatitisno-no
CrossRef168
Naoki Hiramatsu, Yuko Inoue, Tsugiko Oze, Nao Kurashige, Takayuki Yakushijin, Kiyoshi Mochizuki, Takuya Miyagi, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Masahide Oshita, Eiji Mita, Hideki Hagiwara, Yoshiaki Inui, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Norio Hayashi. (2011) Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case–control study. Journal of Gastroenterology
CrossRef169
Hisham R. El Khayat, Yasser M. Fouad, Ezzat Ali Ahmad, Hussein El Amin, Faten Ismael, Amal Rizk. (2011) Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment. Hepatology International
CrossRef170
H. JAFFERBHOY, M. H. MILLER, P. McINTYRE, J. F. DILLON. (2011) The effectiveness of outreach testing for hepatitis C in an immigrant Pakistani population. Epidemiology and Infection1-6
CrossRef171
N. Forestier, D. Larrey, P. Marcellin, D. Guyader, A. Patat, R. Rouzier, P. F. Smith, X. Qin, S. Lim, W. Bradford, S. Porter, S. D. Seiwert, S. Zeuzem. (2011) Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon -2a and Ribavirin in Patients With Hepatitis C. Journal of Infectious Diseases 204:4, 601-608
CrossRef172
Klaus Klumpp, David B. Smith. 2011. Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection. , 287-304.
CrossRef173
Pierre Raboisson, Gregory Fanning, Herman de Kock, Åsa Rosenquist, René Verloes, Kenneth Simmen. 2011. Discovery and Development of the HCV Protease Inhibitor TMC435. , 273-286.
CrossRef174
Anne-Laure Grillot, Luc J. Farmer, B. Govinda Rao, William P. Taylor, Ilan S. Weisberg, Ira M. Jacobson, Robert B. Perni, Ann D. Kwong. 2011. Discovery and Development of Telaprevir. , 207-224.
CrossRef175
Scott D. Seiwert, Karl Kossen, Lin Pan, Jyanwei Liu, Brad O. Buckman. 2011. Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227). , 257-271.
CrossRef176
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Hiroyuki Fukui, Taizo Hijioka, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Atsushi Hosui, Takuya Miyagi, Hisashi Ishida, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi. (2011) Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Journal of Gastroenterology 46:8, 1031-1037
CrossRef177
Takao Watanabe, Ichiro Konishi, Shuichiro Shigematsu, Kazuhiro Uesugi, Kouji Joko, Hirotaka Seike, Shinichi Okada, Hiroaki Miyaoka, Seiji Nakanishi, Masanori Abe, Bunzo Matsuura, Kojiro Michitaka, Norio Horiike, Yoichi Hiasa, Morikazu Onji. (2011) Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance. Hepatology Research 41:8, 722-730
CrossRef178
Jacinta A Holmes, William Sievert, Alexander J Thompson. (2011) IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. Biomarkers in Medicine 5:4, 461-478
CrossRef179
Maria Buti, Rafael Esteban. (2011) 1990–2010: Two Decades of Interferon-Based Therapy. Clinics in Liver Disease 15:3, 473-482
CrossRef180
Robert G. Gish, Nicholas A. Meanwell. (2011) The NS5A Replication Complex Inhibitors: Difference Makers?. Clinics in Liver Disease 15:3, 627-639
CrossRef181
Elisabetta Cariani, Erica Villa, Cristina Rota, Rosina Critelli, Tommaso Trenti. (2011) Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. Clinical Chemistry and Laboratory Medicine 49:8, 1247-1256
CrossRef182
Andres Duarte-Rojo, Elizabeth Jenny Heathcote, Jordan Jay Feld. (2011) ‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?. Journal of Hepatology 55:2, 466-473
CrossRef183
S. K. Tohra, S. Taneja, S. Ghosh, B. K. Sharma, A. Duseja, R. K. Dhiman, A. Das, Y. K. Chawla. (2011) Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C. Digestive Diseases and Sciences 56:8, 2449-2455
CrossRef184
Lisa Franceschini, Stefano Realdon, Moira Marcolongo, Silvia Mirandola, Gladis Bortoletto, Alfredo Alberti. (2011) Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: A vicious circle of clinical significance?. Hepatology 54:2, 484-494
CrossRef185
Jawad A. Ilyas, John M. Vierling. (2011) An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. Clinics in Liver Disease 15:3, 515-536
CrossRef186
Paul Y. Kwo, Rong Zhao. (2011) Boceprevir: A User’s Guide. Clinics in Liver Disease 15:3, 537-553
CrossRef187
Ashwani K. Singal, Sarat C. Jampana, Bhupinderjit S. Anand. (2011) Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials. Digestive Diseases and Sciences 56:8, 2221-2226
CrossRef188
J. F. Bergmann, J. de Bruijne, D. M. Hotho, R. J. de Knegt, A. Boonstra, C. J. Weegink, A. A. van Vliet, J. van de Wetering, S. P. Fletcher, L. A. Bauman, M. Rahimy, J. R. Appleman, J. L. Freddo, H. L. A. Janssen, H. W. Reesink. (2011) Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alimentary Pharmacology & Therapeutics 34:4, 443-453
CrossRef189
Christian M. Lange, Darius Moradpour, Alexandra Doehring, Hans-Anton Lehr, Beat Müllhaupt, Stephanie Bibert, Pierre-Yves Bochud, Anca T. Antonino, Manuel Pascual, Harald Farnik, Ying Shi, Wolf Otto Bechstein, Christian Moench, Martin-Leo Hansmann, Christoph Sarrazin, Jörn Lötsch, Stefan Zeuzem, Wolf-Peter Hofmann. (2011) Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology 55:2, 322-327
CrossRef190
L. Martín-Carbonero, P. Tuma, E. Vispo, J. Medrano, P. Labarga, J. González-Lahoz, P. Barreiro, V. Soriano. (2011) Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. Journal of Viral Hepatitis 18:8, 542-548
CrossRef191
J. Scott, S. Holte, T. Urban, C. Burgess, E. Coppel, C. Wang, L. Corey, J. McHutchison, D. Goldstein. (2011) IL28B Genotype Effects During Early Treatment with Peginterferon and Ribavirin in Difficult-to-Treat Hepatitis C Virus Infection. Journal of Infectious Diseases 204:3, 419-425
CrossRef192
Mitchell L. Shiffman. (2011) Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. Clinics in Liver Disease 15:3, 665-675
CrossRef193
P. Deltenre, C. Moreno, A. Tran, I. Ollivier, F. Provôt, F. Stanke, M. Lazrek, H. Castel, V. Canva, A. Louvet, M. Colin, F. Glowacki, S. Dharancy, J. Henrion, M. Hazzan, C. Noel, P. Mathurin. (2011) Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Alimentary Pharmacology & Therapeutics 34:4, 454-461
CrossRef194
Hisashi Ishida, Tomohide Tatsumi, Atsushi Hosui, Takatoshi Nawa, Takahiro Kodama, Satoshi Shimizu, Hayato Hikita, Naoki Hiramatsu, Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara. (2011) Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochemical and Biophysical Research Communications 412:1, 92-97
CrossRef195
Helen S. Yee, Sue L. Currie, Kathryn Tortorice, Myrna Cozen, Hui Shen, Summer Chapman, Fran Cunningham, Alexander Monto. (2011) Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study. Digestive Diseases and Sciences 56:8, 2439-2448
CrossRef196
(2011) EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 55:2, 245-264
CrossRef197
Archita P. Desai, Nancy Reau. (2011) Naives, Nonresponders, Relapsers: Who Is There Left to Treat?. Clinics in Liver Disease 15:3, 483-495
CrossRef198
Takuya Miyagi, Satoshi Shimizu, Tomohide Tatsumi, Kumiko Nishio, Naoki Hiramatsu, Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara. (2011) Differential alteration of CD56bright and CD56dim natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection. Journal of Gastroenterology 46:8, 1020-1030
CrossRef199
M. Masia, C. Robledano, N. Lopez, C. Escolano, F. Gutierrez. (2011) Treatment for hepatitis C virus with pegylated interferon- plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. Journal of Antimicrobial Chemotherapy 66:8, 1861-1868
CrossRef200
Sandra Ciesek, Thomas von Hahn, Michael P. Manns. (2011) Second-wave Protease Inhibitors: Choosing an Heir. Clinics in Liver Disease 15:3, 597-609
CrossRef201
Omer Khalid, Bruce R. Bacon. (2011) Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations. Clinics in Liver Disease 15:3, 573-583
CrossRef202
Mary Olson, Ira M. Jacobson. (2011) Role of the nurse practitioner in the management of patients with chronic hepatitis C. Journal of the American Academy of Nurse Practitioners 23:8, 410-420
CrossRef203
Satoshi Shakado, Yuko Akehi, Kaoru Yotsumoto, Atsushi Fukunaga, Shizuka Kuno, Takashi Tanaka, Kunitoshi Sakurai, Hideyuki Iwashita, Shuichi Ueda, Genryu Hirano, Keiji Yokoyama, Daisuke Morihara, Shinya Nishizawa, Masaharu Sakamoto, Akira Anan, Yasuaki Takeyama, Makoto Irie, Kaoru Iwata, Tetsuro Sohda, Shotaro Sakisaka. (2011) A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin. Clinical Journal of Gastroenterology 4:4, 255-261
CrossRef204
Jacinta A. Holmes, Paul V. Desmond, Alexander J. Thompson. (2011) Redefining Baseline Demographics: The Role of Genetic Testing in Hepatitis C Virus Infection. Clinics in Liver Disease 15:3, 497-513
CrossRef205
Hiromitsu Kumada, Joji Toyota, Takeshi Okanoue, Kazuaki Chayama, Hirohito Tsubouchi, Norio Hayashi. (2011) Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. Journal of Hepatology
CrossRef206
Shahriar Tavakoli-Tabasi, Ameena Bagree. (2011) A Longitudinal Cohort Study of Mucocutaneous Drug Eruptions During Interferon and Ribavirin Treatment of Hepatitis C. Journal of Clinical Gastroenterology1
CrossRef207
Manuel Ramos-Casals, John H Stone, Maria C Cid, Xavier Bosch. (2011) The cryoglobulinaemias. The Lancet
CrossRef208
P. Tandon, K. Doucette, K. Fassbender, B. Vandermeer, T. Durec, D. M. Dryden. (2011) Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. Journal of Viral Hepatitis 18:7, e381-e393
CrossRef209
Masao Honda, Kenji Takehana, Akito Sakai, Yusuke Tagata, Takayoshi Shirasaki, Shinobu Nishitani, Takahiko Muramatsu, Tatsuya Yamashita, Yasunari Nakamoto, Eishiro Mizukoshi, Yoshio Sakai, Taro Yamashita, Mikiko Nakamura, Tetsuro Shimakami, MinKyung Yi, Stanley M. Lemon, Tetsuo Suzuki, Takaji Wakita, Shuichi Kaneko. (2011) Malnutrition Impairs Interferon Signaling Through mTOR and FoxO Pathways in Patients With Chronic Hepatitis C. Gastroenterology 141:1, 128-140.e2
CrossRef210
W. N. Southern, M.-L. Drainoni, B. D. Smith, C. L. Christiansen, D. McKee, A. L. Gifford, C. M. Weinbaum, D. Thompson, E. Koppelman, S. Maher, A. H. Litwin. (2011) Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. Journal of Viral Hepatitis 18:7, 474-481
CrossRef211
H. Hofer, I. Aydin, S. Neumueller-Guber, C. Mueller, T.-M. Scherzer, K. Staufer, P. Steindl-Munda, F. Wrba, P. Ferenci. (2011) Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy. Journal of Viral Hepatitis 18:7, 513-517
CrossRef212
M. Corouge, S. Pol. (2011) New treatments for chronic hepatitis C virus infection. Médecine et Maladies Infectieuses
CrossRef213
Hiroshi Kohno, Hirotaka Kouno, Shiomi Aimitsu, Yasuyuki Aisaka, Mikiya Kitamoto, Hiroiku Kawakami, Kazuaki Chayama. (2011) Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads. Hepatology Research 41:7, 626-634
CrossRef214
Michael W. Fried, Stephanos J. Hadziyannis, Mitchell L. Shiffman, Diethelm Messinger, Stefan Zeuzem. (2011) Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology 55:1, 69-75
CrossRef215
Varun Garg, Rolf van Heeswijk, Jee Eun Lee, Katia Alves, Priya Nadkarni, Xia Luo. (2011) Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54:1, 20-27
CrossRef216
D.-G. Ahn, S.-B. Shim, J.-E. Moon, J.-H. Kim, S.-J. Kim, J.-W. Oh. (2011) Interference of hepatitis C virus replication in cell culture by antisense peptide nucleic acids targeting the X-RNA. Journal of Viral Hepatitis 18:7, e298-e306
CrossRef217
Martin-Walter Welker, Wolf Peter Hofmann, Christian Markus Lange, Eva Herrmann, Christoph Sarrazin, Stefan Zeuzem, Bernd Kronenberger. (2011) CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology 46:7-8, 973-980
CrossRef218
Jason Grebely, Gail V. Matthews, Margaret Hellard, David Shaw, Ingrid van Beek, Kathy Petoumenos, Maryam Alavi, Barbara Yeung, Paul S. Haber, Andrew R. Lloyd, John M. Kaldor, Gregory J. Dore. (2011) Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology 55:1, 76-85
CrossRef219
Cheng-Chao Liang, Chen-Hua Liu, Yu-Li Lin, Chun-Jen Liu, Bor-Luen Chiang, Jia-Horng Kao. (2011) Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. Journal of Medical Virology 83:7, 1212-1220
CrossRef220
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Toshihiko Nagase, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Eijiro Hayashi, Yasuharu Imai, Michio Kato, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Hisashi Ishida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi. (2011) The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. Journal of Gastroenterology 46:7, 944-952
CrossRef221
Hiromi Abe, Michio Imamura, Nobuhiko Hiraga, Masataka Tsuge, Fukiko Mitsui, Tomokazu Kawaoka, Shoichi Takahashi, Hidenori Ochi, Toshiro Maekawa, C. Nelson Hayes, Chise Tateno, Katsutoshi Yoshizato, Shoichi Murakami, Nobuyuki Yamashita, Takashi Matsuhira, Kenji Asai, Kazuaki Chayama. (2011) ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. Journal of Hepatology 55:1, 11-18
CrossRef222
J. MØSS, A. ROSHOLM, A. LAURÉN. (2011) Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. Journal of Thrombosis and Haemostasis 9:7, 1368-1374
CrossRef223
C. Krueger, K. Hawkins, S. Wong, M. W. Enns, G. Minuk, J. D. Rempel. (2011) Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. Journal of Viral Hepatitis 18:7, e284-e291
CrossRef224
Peter Ferenci. (2011) Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opinion on Drug Safety 10:4, 529-544
CrossRef225
M. Lindh, M. Lagging, B. Arnholm, A. Eilard, S. Nilsson, G. Norkrans, J. Söderholm, T. Wahlberg, R. Wejstål, J. Westin, K. Hellstrand. (2011) IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Journal of Viral Hepatitis 18:7, e325-e331
CrossRef226
Jian-Wu Yu, Li-Jie Sun, Yong-Hua Zhao, Peng Kang, Bing-Zhu Yan. (2011) Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment. International Journal of Infectious Diseases
CrossRef227
Thomas Reiberger, Karoline Rutter, Arnulf Ferlitsch, Berit Anna Payer, Harald Hofer, Sandra Beinhardt, Michael Kundi, Peter Ferenci, Alfred Gangl, Michael Trauner, Markus Peck–Radosavljevic. (2011) Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 9:7, 602-608.e1
CrossRef228
Norman D. Grace. (2011) Patients With Clinically Significant Portal Hypertension Caused by Hepatitis C Virus Cirrhosis Respond Poorly to Antiviral Therapy. Clinical Gastroenterology and Hepatology 9:7, 536-538
CrossRef229
Magdalena Ydreborg, Ann Söderström, Agneta Håkanson, Åsa Alsiö, Birgitta Arnholm, Petter Malmström, Kristoffer Hellstrand, Johan Westin, Martin Lagging. (2011) Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scandinavian Journal of Infectious Diseases 43:6-7, 522-527
CrossRef230
Frank Wagner, Robert Thompson, Constantino Kantaridis, Paul Simpson, Philip J. F. Troke, Shyla Jagannatha, Srividya Neelakantan, Vivek S. Purohit, Jennifer L. Hammond. (2011) Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54:1, 50-59
CrossRef231
Renato Bonardi, Marco Tabone, Aldo Manca, Rinaldo Pellicano, Alessia Ciancio, Mario Rizzetto. (2011) Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomedicine & Pharmacotherapy 65:4, 303-306
CrossRef232
Ajit Kumar. (2011) MicroRNA in HCV infection and liver cancer. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
CrossRef233
Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier, Bruno Costes, Magali Bouvier–Alias, Stéphanie Rouanet, Juliette Foucher, Jean–Pierre Bronowicki, Albert Tran, Isabelle Rosa, Philippe Mathurin, Laurent Alric, Vincent Leroy, Patrice Couzigou, Ariane Mallat, Mariem Charaf–Eddine, Gérard Babany, Jean–Michel Pawlotsky. (2011) High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial). Gastroenterology 141:1, 119-127
CrossRef234
Sumio Watanabe, Nobuyuki Enomoto, Kazuhiko Koike, Namiki Izumi, Hajime Takikawa, Etsuko Hashimoto, Fuminori Moriyasu, Hiromitsu Kumada, Michio Imawari, . (2011) Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. Hepatology Researchno-no
CrossRef235
Itaru Ozeki, Jun Akaike, Yoshiyasu Karino, Tomohiro Arakawa, Yasuaki Kuwata, Takumi Ohmura, Takahiro Sato, Naohiro Kamiya, Ichimaro Yamada, Kazuaki Chayama, Hiromitsu Kumada, Joji Toyota. (2011) Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. Journal of Gastroenterology 46:7, 929-937
CrossRef236
Yoshisato Tanimoto, Hirotaka Tashiro, Hiroshi Aikata, Hironobu Amano, Akihiko Oshita, Tsuyoshi Kobayashi, Shintaro Kuroda, Hirofumi Tazawa, Shoichi Takahashi, Toshiyuki Itamoto, Kazuaki Chayama, Hideki Ohdan. (2011) Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. Annals of Surgical Oncology
CrossRef237
Jacobson, Ira M., McHutchison, John G., Dusheiko, Geoffrey, Di Bisceglie, Adrian M., Reddy, K. Rajender, Bzowej, Natalie H., Marcellin, Patrick, Muir, Andrew J., Ferenci, Peter, Flisiak, Robert, George, Jacob, Rizzetto, Mario, Shouval, Daniel, Sola, Ricard, Terg, Ruben A., Yoshida, Eric M., Adda, Nathalie, Bengtsson, Leif, Sankoh, Abdul J., Kieffer, Tara L., George, Shelley, Kauffman, Robert S., M.D., Stefan Zeuzem. (2011) Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine 364:25, 2405-2416
Full Text238
Rosen, Hugo R., . (2011) Chronic Hepatitis C Infection. New England Journal of Medicine 364:25, 2429-2438
Full Text239
Teerapol Srichana, Tan Suwandecha. 2011. Polyethylene Glycol in Clinical Application and PEGylated Drugs. , 451-493.
CrossRef240
Kristiana Nikolova, Shahira Ahmed Afifi, Naglaa Zayed, Tahany Awad, Shereen Hunter, Ayman Amer, Christian Gluud, Mahasen Mabrouk, Christian Gluud. 2011. Nitazoxanide for chronic hepatitis C virus infection. .
CrossRef241
Velimir Kostić, Aleksandar Petrović, Jelena Radović, Jovana Kostić, Stevan Vujić, Branislav Jovanović, Lidija Popović. (2011) FATE OF PATIENTS WITH LATE-DETECTED HEPATITIS C INFECTION - CASE REPORTS. Acta medica medianae49-52
CrossRef242
Arora, Sanjeev, Thornton, Karla, Murata, Glen, Deming, Paulina, Kalishman, Summers, Dion, Denise, Parish, Brooke, Burke, Thomas, Pak, Wesley, Dunkelberg, Jeffrey, Kistin, Martin, Brown, John, Jenkusky, Steven, Komaromy, Miriam, Qualls, Clifford, . (2011) Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers. New England Journal of Medicine 364:23, 2199-2207
Full Text243
Yuan-Hung Kuo, Tang-Wei Chuang, Chao-Hung Hung, Chien-Hung Chen, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chuan-Mo Lee. (2011) Reversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral Therapy. Journal of the Formosan Medical Association 110:6, 363-371
CrossRef244
Alison A Murphy, Eva Herrmann, Anu O Osinusi, Lynn Wu, William Sachau, Richard A Lempicki, Jun Yang, Tei L Chung, Brad J Wood, Bart L Haagmans, Shyam Kottilil, Michael A Polis. (2011) Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 25:9, 1179-1187
CrossRef245
Elena Vezali, Alessio Aghemo, Pietro Lampertico, Massimo Colombo. (2011) Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. Clinics and Research in Hepatology and Gastroenterology 35:6-7, 455-464
CrossRef246
Stefano Brillanti, Giuseppe Mazzella, Enrico Roda. (2011) Ribavirin for chronic hepatitis C: And the mystery goes on. Digestive and Liver Disease 43:6, 425-430
CrossRef247
Suguru Yoneda, Takeji Umemura, Satoru Joshita, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Yoshihiko Katsuyama, Masao Ota, Eiji Tanaka, . (2011) Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatology Research 41:6, 587-593
CrossRef248
Stephane Chevaliez, Tarik Asselah. (2011) Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology 35, S31-S41
CrossRef249
Nicole Forestier, Dominique Larrey, Dominique Guyader, Patrick Marcellin, Régine Rouzier, Alain Patat, Patrick Smith, Williamson Bradford, Steven Porter, Lawrence Blatt, Scott D. Seiwert, Stefan Zeuzem. (2011) Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. Journal of Hepatology 54:6, 1130-1136
CrossRef250
Mahmoud A. Khattab, Peter Ferenci, Stephanos J. Hadziyannis, Massimo Colombo, Michael P. Manns, Piero L. Almasio, Rafael Esteban, Ayman A. Abdo, Stephen A. Harrison, Nazir Ibrahim, Patrice Cacoub, Mohammed Eslam, Samuel S. Lee. (2011) Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. Journal of Hepatology 54:6, 1250-1262
CrossRef251
Yoshinao Kobayashi, Kohta Nishihama, Hidehiro Miyachi, Hideaki Tanaka, Norihiko Yamamoto, Mohoh Iwasa, Toshio Fukutome, Taizo Shiraishi, Yoshiyuki Takei. (2011) Acute septic shock during pegylated-interferon and ribavirin therapy in a patient with chronic hepatitis C who underwent aortic graft replacement. Clinical Journal of Gastroenterology 4:3, 179-183
CrossRef252
D. E. FRANSEN VAN DE PUTTE, K. FISCHER, D. POSTHOUWER, E. P. MAUSER-BUNSCHOTEN. (2011) The burden of HCV treatment in patients with inherited bleeding disorders. Haemophiliano-no
CrossRef253
Gary Deng, Robert C. Kurtz, Andrew Vickers, Nancy Lau, K. Simon Yeung, Jinru Shia, Barrie Cassileth. (2011) A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. Journal of Ethnopharmacology 136:1, 83-87
CrossRef254
María Ángeles Jiménez-Sousa, Raquel Almansa, Concha de la Fuente, Agustín Caro-Patón, Lourdes Ruiz, Gloria Sánchez-Antolín, José Manuel González, Rocío Aller, Noelia Alcaide, Pilar Largo, Raúl Ortiz de Lejarazu, Jesús F. Bermejo-Martín. (2011) Perfiles de expresión génica en las primeras doce semanas de tratamiento en pacientes con hepatitis C crónica. Enfermedades Infecciosas y Microbiología Clínica
CrossRef255
Neal D. Freedman, Teresa M. Curto, Karen L. Lindsay, Elizabeth C. Wright, Rashmi Sinha, James E. Everhart. (2011) Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C. Gastroenterology 140:7, 1961-1969
CrossRef256
Col Pankaj Puri. (2011) Interleukin 28B Polymorphisms and Hepatitis C—Translating the Association into Clinical Decision Making. Journal of Clinical and Experimental Hepatology 1:1, 27-33
CrossRef257
Hiromi Abe, C. Nelson Hayes, Hidenori Ochi, Toshiro Maekawa, Masataka Tsuge, Daiki Miki, Fukiko Mitsui, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Michiaki Kubo, Yusuke Nakamura, Kazuaki Chayama. (2011) IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. Journal of Hepatology 54:6, 1094-1101
CrossRef258
Michael P. Manns, Marc Bourlière, Yves Benhamou, Stanislas Pol, Maurizio Bonacini, Christian Trepo, David Wright, Thomas Berg, José L. Calleja, Peter W. White, Jerry O. Stern, Gerhard Steinmann, Chan-Loi Yong, George Kukolj, Joe Scherer, Wulf O. Boecher. (2011) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. Journal of Hepatology 54:6, 1114-1122
CrossRef259
S. Obeid, S. S. Printsevskaya, E. N. Olsufyeva, K. Dallmeier, D. Durantel, F. Zoulim, M. N. Preobrazhenskaya, J. Neyts, J. Paeshuyse. (2011) Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. Journal of Antimicrobial Chemotherapy 66:6, 1287-1294
CrossRef260
M. Lindh, B. Arnholm, A. Eilard, M. Färkkilä, K. Hellstrand, M. Lagging, N. Langeland, K. Mørch, S. Nilsson, C. Pedersen, M. R. Buhl, T. Wahlberg, R. Wejstål, J. Westin, G. Norkrans. (2011) Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of Viral Hepatitis 18:6, 400-407
CrossRef261
Ahmed El-Shamy, Ikuo Shoji, Takafumi Saito, Hisayoshi Watanabe, Yoshi-Hiro Ide, Lin Deng, Sumio Kawata, Hak Hotta. (2011) Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. Microbiology and Immunology 55:6, 418-426
CrossRef262
Yoshimasa Hashimoto, Hidenori Ochi, Hiromi Abe, Yasufumi Hayashida, Masataka Tsuge, Fukiko Mitsui, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, C. Nelson Hayes, Waka Ohishi, Michaki Kubo, Tatsuhiko Tsunoda, Naoyuki Kamatani, Yusuke Nakamura, Kazuaki Chayama. (2011) Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. Journal of Medical Virology 83:6, 981-988
CrossRef263
Joseph Torresi, Doug Johnson, Heiner Wedemeyer. (2011) Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. Journal of Hepatology 54:6, 1273-1285
CrossRef264
Alexander R. Moschen, Teresa Fritz, Andrew D. Clouston, Ilka Rebhan, Oliver Bauhofer, Helen D. Barrie, Elizabeth E. Powell, Soo-Hyun Kim, Charles A. Dinarello, Ralf Bartenschlager, Julie R. Jonsson, Herbert Tilg. (2011) Interleukin-32: A new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 53:6, 1819-1829
CrossRef265
Maurizio Pietrogrande, Salvatore De Vita, Anna Linda Zignego, Pietro Pioltelli, Domenico Sansonno, Salvatore Sollima, Fabiola Atzeni, Francesco Saccardo, Luca Quartuccio, Savino Bruno, Raffaele Bruno, Mauro Campanini, Marco Candela, Laura Castelnovo, Armando Gabrielli, Giovan Battista Gaeta, Piero Marson, Maria Teresa Mascia, Cesare Mazzaro, Francesco Mazzotta, Pierluigi Meroni, Carlomaurizio Montecucco, Elena Ossi, Felice Piccinino, Daniele Prati, Massimo Puoti, Piersandro Riboldi, Agostino Riva, Dario Roccatello, Evangelista Sagnelli, Patrizia Scaini, Salvatore Scarpato, Renato Sinico, Gloria Taliani, Antonio Tavoni, Eleonora Bonacci, Piero Renoldi, Davide Filippini, Piercarlo Sarzi-Puttini, Clodoveo Ferri, Giuseppe Monti, Massimo Galli. (2011) Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews 10:8, 444-454
CrossRef266
Femke AE Lambers, Kees Brinkman, Janke Schinkel, Ingrid JB Spijkerman, Richard Molenkamp, Roel A Coutinho, Maria Prins, Jan TM van der Meer. (2011) Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 25:10, 1333-1336
CrossRef267
Riham Salah El Dine, Azza R. Abdel Monem, Ali M. El-Halawany, Masao Hattori, Essam Abdel-Sattar. (2011) HCV-NS3/4A Protease Inhibitory Iridoid Glucosides and Dimeric Foliamenthoic Acid Derivatives from Anarrhinum orientale. Journal of Natural Products 74:5, 943-948
CrossRef268
P. Ganapati Reddy, Byoung-Kwon Chun, Hai-Ren Zhang, Suguna Rachakonda, Bruce S. Ross, Michael J. Sofia. (2011) Stereoselective Synthesis of PSI-352938: A β-
d -2′-Deoxy-2′-α-fluoro-2′-β- C- methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV. The Journal of Organic Chemistry 76:10, 3782-3790
CrossRef269
Chao-Hung Hung, Chuan-Mo Lee, Jing-Houng Wang, Tsung-Hui Hu, Chien-Hung Chen, Chih-Yun Lin, Sheng-Nan Lu. (2011) Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. International Journal of Cancer 128:10, 2344-2352
CrossRef270
Mostafa K El Awady, Mohamed A Anany, Gamal Esmat, Naglaa Zayed, Ashraf A Tabll, Amr Helmy, Abdel Rahman El Zayady, Mohga S Abdalla, Hayat M Sharada, Maissa El Raziky, Wafaa El Akel, Shadia Abdalla, Noha G Bader El Din. (2011) Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. Journal of Gastroenterology and Hepatology 26:5, 843-850
CrossRef271
Eiji Ohara, Nobuhiko Hiraga, Michio Imamura, Eiji Iwao, Naohiro Kamiya, Ichimaro Yamada, Tomohiko Kono, Mayu Onishi, Daizaburo Hirata, Fukiko Mitsui, Tomokazu Kawaoka, Masataka Tsuge, Shoichi Takahashi, Hiromi Abe, C. Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Shinji Tanaka, Kazuaki Chayama. (2011) Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. Journal of Hepatology 54:5, 872-878
CrossRef272
Joseph John Sasadeusz, Gregory Dore, Ian Kronborg, David Barton, Motoko Yoshihara, Martin Weltman. (2011) Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 106:5, 977-984
CrossRef273
Vincenza Calvaruso, Marta Mazza, Piero L Almasio. (2011) Pegylated-interferon-α 2a in clinical practice: how to manage patients suffering from side effects. Expert Opinion on Drug Safety 10:3, 429-435
CrossRef274
Yasuji Arase. (2011) Viral hepatitis: Impact of adherence to combination therapy for hepatitis C. Nature Reviews Gastroenterology & Hepatology 8:5, 248-249
CrossRef275
Andres F. Carrion, Fabrizio Fabrizi, Paul Martin. (2011) Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?. Seminars in Dialysis 24:3, 272-274
CrossRef276
Tomoyuki Tsunoda, Ayano Inui, Yuri Etani, Yuki Kiyohara, Tokio Sugiura, Koichi Ito, Reiko Miyazawa, Ikuo Nagata, Shinobu Ida, Tomoo Fujisawa, . (2011) Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C. Hepatology Research 41:5, 399-404
CrossRef277
Chao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu. (2011) Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Review of Anti-infective Therapy 9:5, 525-533
CrossRef278
Scott A. Fink, Ira M. Jacobson. (2011) Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. Nature Reviews Gastroenterology & Hepatology 8:5, 285-295
CrossRef279
Paul J. Gaglio, Noah Moss, Camille McGaw, John Reinus. (2011) Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use. Digestive Diseases and Sciences 56:5, 1509-1515
CrossRef280
Mario Masarone, Marcello Persico. (2011) Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. Expert Review of Anti-infective Therapy 9:5, 535-543
CrossRef281
Naoya Sakamoto, Mina Nakagawa, Yasuhito Tanaka, Yuko Sekine-Osajima, Mayumi Ueyama, Masayuki Kurosaki, Nao Nishida, Akihiro Tamori, Nishimura-Sakurai Yuki, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Shuhei Hige, Yoshito Itoh, Eiji Tanaka, Yoichi Hiasa, Namiki Izumi, Katsushi Tokunaga, Masashi Mizokami, Mamoru Watanabe, . (2011) Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. Journal of Medical Virology 83:5, 871-878
CrossRef282
Andreas J. Kesel. (2011) Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. European Journal of Medicinal Chemistry 46:5, 1656-1664
CrossRef283
E. J. Groessl, K. R. Weingart, C. J. Stepnowsky, A. L. Gifford, S. M. Asch, S. B. Ho. (2011) The hepatitis C self-management programme: a randomized controlled trial. Journal of Viral Hepatitis 18:5, 358-368
CrossRef284
Christian Markus Lange, Jörg Bojunga, Elizabeth Ramos-Lopez, Michael von Wagner, Angela Hassler, Johannes Vermehren, Eva Herrmann, Klaus Badenhoop, Stefan Zeuzem, Christoph Sarrazin. (2011) Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of Hepatology 54:5, 887-893
CrossRef285
P. Halfon, P. Cacoub. (2011) Polymorphisme de l’IL-28B et infection par le virus de l’hépatite C : impact sur la clairance virale prolongée, spontanée et après traitement antiviral. La Revue de Médecine Interne 32:5, 271-274
CrossRef286
Erik J. Groessl, Kimberly R. Weingart, Allen L. Gifford, Steven M. Asch, Samuel B. Ho. (2011) Development of the Hepatitis C Self-Management Program. Patient Education and Counseling 83:2, 252-255
CrossRef287
Hao Jiang, Jianing Zeng, Yuzhong Deng, Yuan-Qin Xia, Zheng Ouyang, Mohammed Jemal, Theodora W. Salcedo, Mark E. Arnold. (2011) A rugged and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. Journal of Chromatography B
CrossRef288
F. Cao, M. J. Donlin, K. Turner, X. Cheng, J. E. Tavis. (2011) Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy. Journal of Viral Hepatitis 18:5, 349-357
CrossRef289
François D'Heygere, Christophe George, Hans Van Vlierberghe, Jochen Decaestecker, Antoine Nakad, Michael Adler, Jean Delwaide, Annick Laureys, Frederik Nevens. (2011) Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials. Journal of Medical Virology 83:5, 815-819
CrossRef290
H. Jafferbhoy, M.H. Miller, J.K. Dunbar, J. Tait, S. Mcleod, J.F. Dillon. (2011) Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. Journal of Viral Hepatitisno-no
CrossRef291
Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Kazuhiro Toyoda, Hiroaki Taniai, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi. (2011) Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Journal of Infection and Chemotherapy
CrossRef292
Hong-ming Nie. (2011) Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol. Journal of Chinese Integrative Medicine 9:4, 365-373
CrossRef293
S. Yoneda, T. Umemura, Y. Katsuyama, A. Kamijo, S. Joshita, M. Komatsu, T. Ichijo, A. Matsumoto, K. Yoshizawa, M. Ota, E. Tanaka, . (2011) Association of Serum Cytokine Levels With Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C Patients. Journal of Infectious Diseases 203:8, 1087-1095
CrossRef294
Wolf Peter Hofmann, Stefan Zeuzem. (2011) A new standard of care for the treatment of chronic HCV infection. Nature Reviews Gastroenterology & Hepatology
CrossRef295
Albert Friedrich Stättermayer, Rudolf Stauber, Harald Hofer, Karoline Rutter, Sandra Beinhardt, Thomas Matthias Scherzer, Kerstin Zinober, Christian Datz, Andreas Maieron, Emina Dulic–Lakovic, Harald H. Kessler, Petra Steindl–Munda, Michael Strasser, Christoph Krall, Peter Ferenci. (2011) Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 9:4, 344-350.e2
CrossRef296
Adrian M. Di Bisceglie, Anne M. Stoddard, Jules L. Dienstag, Mitchell L. Shiffman, Leonard B. Seeff, Herbert L. Bonkovsky, Chihiro Morishima, Elizabeth C. Wright, Kristin K. Snow, William M. Lee, Robert J. Fontana, Timothy R. Morgan, Marc G. Ghany, . (2011) Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 53:4, 1100-1108
CrossRef297
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Kaytayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi. (2011) Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. Journal of Hepatology 54:4, 604-611
CrossRef298
E. S. A. Araújo, H. Dahari, A. U. Neumann, N. de Paula Cavalheiro, C. E. Melo, E. S. de Melo, T. J. Layden, S. J. Cotler, A. A. Barone. (2011) Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. Journal of Viral Hepatitis 18:4, e52-e60
CrossRef299
Davide Bitetto, Giovanna Fattovich, Carlo Fabris, Elisa Ceriani, Edmondo Falleti, Ezio Fornasiere, Michela Pasino, Donatella Ieluzzi, Annarosa Cussigh, Sara Cmet, Mario Pirisi, Pierluigi Toniutto. (2011) Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53:4, 1118-1126
CrossRef300
Mark S. Sulkowski, Curtis Cooper, Bela Hunyady, Jidong Jia, Pavel Ogurtsov, Markus Peck-Radosavljevic, Mitchell L. Shiffman, Cihan Yurdaydin, Olav Dalgard. (2011) Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature Reviews Gastroenterology & Hepatology 8:4, 212-223
CrossRef301
Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Takahiro Arakawa, Masashi Fujimori, Takuro Niinomi, Naoto Ando, Satoshi Yasuda, Keisuke Sakai, Jun Kimura. (2011) High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. Journal of Gastroenterology 46:4, 501-509
CrossRef302
H. L. Tillmann, M. Wiese, Y. Braun, J. Wiegand, S. Tenckhoff, J. Mössner, M. P. Manns, K. Weissenborn. (2011) Quality of life in patients with various liver diseases. Journal of Viral Hepatitis 18:4, 252-261
CrossRef303
Saba Khaliq, Shah Jahan, Asim Pervaiz. (2011) Sequence variability of HCV Core region: Important predictors of HCV induced pathogenesis and viral production. Infection, Genetics and Evolution 11:3, 543-556
CrossRef304
Kazuaki Chayama, C. Nelson Hayes, Kentaro Yoshioka, Hisataka Moriwaki, Takashi Okanoue, Shotaro Sakisaka, Tetsuo Takehara, Makoto Oketani, Joji Toyota, Namiki Izumi, Yoichi Hiasa, Akihiro Matsumoto, Hideyuki Nomura, Masataka Seike, Yoshiyuki Ueno, Hiroshi Yotsuyanagi, Hiromitsu Kumada. (2011) Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. Journal of Gastroenterology 46:4, 545-555
CrossRef305
Patrick Marcellin, Michel Chousterman, Thierry Fontanges, Denis Ouzan, Michel Rotily, Marina Varastet, Jean-Philippe Lang, Pascal Melin, Patrice Cacoub, . (2011) Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver International 31:4, 516-524
CrossRef306
V. D. Hope, M. Hickman, S. L. Ngui, S. Jones, M. Telfer, M. Bizzarri, F. Ncube, J. V. Parry. (2011) Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Journal of Viral Hepatitis 18:4, 262-270
CrossRef307
M. Parikh, A. Singh, G. Sood. (2011) Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin. Journal of Viral Hepatitis 18:4, e99-e103
CrossRef308
Hafsa Aziz, Muzaffar Latif Gil, Yasir Waheed, Uzama Adeeb, Abida Raza, Iram Bilal, Muhammad Amin Athar. (2011) Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infection, Genetics and Evolution 11:3, 640-645
CrossRef309
Yoshifumi Fujimoto, Hidenori Ochi, Toshiro Maekawa, Hiromi Abe, C. Nelson Hayes, Hiromitsu Kumada, Yusuke Nakamura, Kazuaki Chayama. (2011) A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. Journal of Hepatology 54:4, 629-639
CrossRef310
B. L. Pearlman, N. Traub. (2011) Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clinical Infectious Diseases 52:7, 889-900
CrossRef311
J. Grebely, J. Bryant, P. Hull, M. Hopwood, Y. Lavis, G. J. Dore, C. Treloar. (2011) Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. Journal of Viral Hepatitis 18:4, e104-e116
CrossRef312
I. Dzyublyk, T. Yegorova, L. Moroz, O. Popovych, I. Zaytsev, V. Miroshnichenko, A. Kromminga, M. M. Wilkes, E. J. van Hoogdalem, J. E. Humphries. (2011) Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial. Journal of Viral Hepatitis 18:4, 271-279
CrossRef313
A. J. Muir, K. -Q. Hu, S. C. Gordon, K. Koury, N. Boparai, S. Noviello, J. K. Albrecht, M. S. Sulkowski, J. McCone. (2011) Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Journal of Viral Hepatitis 18:4, e134-e143
CrossRef314
Sirio Fiorino, Fabio Conti, Annagiulia Gramenzi, Elisabetta Loggi, Carmela Cursaro, Roberto Di Donato, Lorenzo Micco, Stefano Gitto, Andrea Cuppini, Mauro Bernardi, Pietro Andreone. (2011) Vitamins in the treatment of chronic viral hepatitis. British Journal of Nutrition 105:07, 982-989
CrossRef315
C. Pedersen, Å. Alsiö, M. Lagging, N. Langeland, M. Färkkilä, M. Rauning Buhl, K. Mørch, J. Westin, P. Sangfelt, G. Norkrans, P. Brehm Christensen, . (2011) Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. Journal of Viral Hepatitis 18:4, 245-251
CrossRef316
S. Mauss, D. Hueppe, C. John, J Goelz, R. Heyne, B. Moeller, R. Link, G. Teuber, A. Herrmann, M. Spelter, S. Wollschlaeger, A. Baumgarten, K.-G. Simon, N. Dikopoulos, T. Witthoeft. (2011) Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. Journal of Viral Hepatitis 18:4, e81-e90
CrossRef317
Masaaki Korenaga, Isao Hidaka, Sohji Nishina, Aya Sakai, Akane Shinozaki, Toshikazu Gondo, Takakazu Furutani, Hiroo Kawano, Isao Sakaida, Keisuke Hino. (2011) A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice. Liver International 31:4, 552-560
CrossRef318
Poordad, Fred, McCone, Jonathan Jr., Bacon, Bruce R., Bruno, Savino, Manns, Michael P., Sulkowski, Mark S., Jacobson, Ira M., Reddy, K. Rajender, Goodman, Zachary D., Boparai, Navdeep, DiNubile, Mark J., Sniukiene, Vilma, Brass, Clifford A., Albrecht, Janice K., Bronowicki, Jean-Pierre, . (2011) Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine 364:13, 1195-1206
Full Text319
Samuel B. Ho, Bashar Aqel, Eric Dieperink, Shanglei Liu, Lori Tetrick, Yngve Falck-Ytter, Charles DeComarmond, Coleman I. Smith, Daniel P. McKee, William Boyd, Clark C. Kulig, Edmund J. Bini, Marcos C. Pedrosa. (2011) U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients. Digestive Diseases and Sciences 56:3, 880-888
CrossRef320
Janna Huskey, Alexander C. Wiseman. (2011) Chronic viral hepatitis in kidney transplantation. Nature Reviews Nephrology 7:3, 156-165
CrossRef321
Masayuki Kurosaki, Naoya Sakamoto, Manabu Iwasaki, Minoru Sakamoto, Yoshiyuki Suzuki, Naoki Hiramatsu, Fuminaka Sugauchi, Hiroshi Yatsuhashi, Namiki Izumi. (2011) Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. Journal of Gastroenterology 46:3, 401-409
CrossRef322
Vincent Soriano, Eugenia Vispo, Luz Martin-Carbonero, Pablo Barreiro. (2011) HCV and HIV Coinfection. Current Hepatitis Reports 10:1, 52-61
CrossRef323
Stephen R. Lee, Keith W. Kardos, Eugene Schiff, Cheryl A. Berne, Karam Mounzer, Alpha T. Banks, Harvey A. Tatum, Timothy J. Friel, Michael P. DeMicco, William M. Lee. (2011) Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. Journal of Virological Methods 172:1-2, 27-31
CrossRef324
Saad Zaky, Sherif Ebrahiem Kamel, Magda Shahata Hassan, Nadia Abdel Sallam, Mohamad Ahmad Shahata, Shaaban Redwan Helal, Heba Mahmoud. (2011) Preliminary Results of Ozone Therapy as a Possible Treatment for Patients with Chronic Hepatitis C. The Journal of Alternative and Complementary Medicine 17:3, 259-263
CrossRef325
Stevan A. Gonzalez. (2011) Consensus Interferon: Tailored Therapy and the Impact of Adherence. Digestive Diseases and Sciences 56:3, 631-634
CrossRef326
Machi Yamamoto, Naoya Sakamoto, Tetsuya Nakamura, Yasuhiro Itsui, Mina Nakagawa, Yuki Nishimura-Sakurai, Sei Kakinuma, Seishin Azuma, Kiichiro Tsuchiya, Takanobu Kato, Takaji Wakita, Mamoru Watanabe. (2011) Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture. Hepatology Research 41:3, 258-269
CrossRef327
Jonathan J Hubbard, Shyam Kottilil. (2011) Extra-hepatic replication of the hepatitis C virus: current issues and future directions. Future Virology 6:3, 275-278
CrossRef328
Charles E. Samuel. (2011) Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 411:2, 180-193
CrossRef329
Nancy Reau, Rohit Satoskar, Helen Te, Amanda DeVoss, Carolyn Elsen, Gautham Reddy, Smruti Mohanty, Donald Jensen. (2011) Evaluation of Early Null Response to Pegylated Interferon and Ribavirin as a Predictor of Therapeutic Nonresponse in Patients Undergoing Treatment for Chronic Hepatitis C. The American Journal of Gastroenterology 106:3, 452-458
CrossRef330
Mitchell L. Shiffman. (2011) HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?. Current Hepatitis Reports 10:1, 4-10
CrossRef331
Elena Vezali, Alessio Aghemo, Massimo Colombo. (2011) Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opinion on Biological Therapy 11:3, 301-313
CrossRef332
Masayuki Kurosaki, Yasuhito Tanaka, Nao Nishida, Naoya Sakamoto, Nobuyuki Enomoto, Masao Honda, Masaya Sugiyama, Kentaro Matsuura, Fuminaka Sugauchi, Yasuhiro Asahina, Mina Nakagawa, Mamoru Watanabe, Minoru Sakamoto, Shinya Maekawa, Akito Sakai, Shuichi Kaneko, Kiyoaki Ito, Naohiko Masaki, Katsushi Tokunaga, Namiki Izumi, Masashi Mizokami. (2011) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. Journal of Hepatology 54:3, 439-448
CrossRef333
Dong Hyun Sinn, Su Rin Shin, Jae Sook Kil, Jeong Kim, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik. (2011) Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea. Journal of Gastroenterology and Hepatology 26:3, 469-476
CrossRef334
Amir Moghaddam, Espen Melum, Nils Reinton, Helmer Ring-Larsen, Hans Verbaan, Kristian Bjøro, Olav Dalgard. (2011) IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53:3, 746-754
CrossRef335
Jennifer Y. Chen, Raymond T. Chung. (2011) Can We Use the “C” Word With Confidence? Cure for Chronic Hepatitis C. Gastroenterology 140:3, 766-768
CrossRef336
Tomokazu Kawaoka, C. Nelson Hayes, Waka Ohishi, Hidenori Ochi, Toshiro Maekawa, Hiromi Abe, Masataka Tsuge, Fukiko Mitsui, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Michaki Kubo, Tatsuhiko Tsunoda, Yusuke Nakamura, Hiromitsu Kumada, Kazuaki Chayama. (2011) Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Journal of Hepatology 54:3, 408-414
CrossRef337
Sanaa M. Kamal, Amany Ahmed, Sara Mahmoud, Leila Nabegh, Iman El Gohary, Isi Obadan, Tamer Hafez, Dahlia Ghoraba, Ahmed A. Aziz, Mona Metaoei. (2011) Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver International 31:3, 401-411
CrossRef338
Hubert Sung, Michael Chang, Sammy Saab. (2011) Management of Hepatitis C Antiviral Therapy Adverse Effects. Current Hepatitis Reports 10:1, 33-40
CrossRef339
Saumya Jayakumar, Vincent Bain. (2011) Rational Guide to the Use of Erythropoietin in the Treatment of HCV Infection. Current Hepatitis Reports 10:1, 62-69
CrossRef340
Masayuki Kurosaki, Naoya Sakamoto, Manabu Iwasaki, Minoru Sakamoto, Yoshiyuki Suzuki, Naoki Hiramatsu, Fuminaka Sugauchi, Akihiro Tamori, Mina Nakagawa, Namiki Izumi. (2011) Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: Data mining analysis. Journal of Medical Virology 83:3, 445-452
CrossRef341
Yuko Inoue, Naoki Hiramatsu, Tsugiko Oze, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuto Fukuda, Eiji Mita, Yoshimichi Haruna, Atsuo Inoue, Yasuharu Imai, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi. (2011) Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. Journal of Medical Virology 83:3, 419-427
CrossRef342
Markus Peck–Radosavljevic, John Boletis, Fatih Besisik, Maria Lúcia Ferraz, Laurent Alric, Didier Samuel, Diethelm Messinger, Andreas Tietz, Hugo Cheinquer. (2011) Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease. Clinical Gastroenterology and Hepatology 9:3, 242-248
CrossRef343
G. López-Larramona, C. Ramos-Paesa, T. Omiste-Sanvicente, M. Ruiz-Mariscal, E. Valero-Tena, M.C. Vallejo-Rodríguez. (2011) Evolución y pronóstico de la infección por el virus de la hepatitis C en pacientes monoinfectados y coinfectados por VIH en una unidad de enfermedades infecciosas: análisis retrospectivo del periodo 1992-2005. SEMERGEN - Medicina de Familia 37:3, 125-129
CrossRef344
Christoph Sarrazin, Simone Susser, Alexandra Doehring, Christian Markus Lange, Tobias Müller, Christina Schlecker, Eva Herrmann, Jörn Lötsch, Thomas Berg. (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Journal of Hepatology 54:3, 415-421
CrossRef345
Jennifer R Kramer, Fasiha Kanwal, Peter Richardson, Thomas P Giordano, Laura A Petersen, Hashem B El-Serag. (2011) Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study. The American Journal of Gastroenterology 106:3, 483-491
CrossRef346
F. Nicot, L. Alric, K. Barange, S. Métivier, J.M. Dramard, J.M. Combis, B. Castan, J.J. Meurisse, J.L. Payen, D. Garipuy, H. Desmorat, J.M. Peron, S. Thebault, T. Morin, C. Renou, P. Barel, B. Guerin, Y. Imbert, S. Sire, K. Sauné, E. Chatelut, J. Izopet. (2011) Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. Journal of Medical Virology 83:3, 437-444
CrossRef347
Kimberly A. Forde, K. Rajender Reddy. (2011) Hormones: A Potential Explanation for Differences in Response Rates to Therapy for Chronic Hepatitis C Infection. Gastroenterology 140:3, 776-779
CrossRef348
Zobair M. Younossi, Dolores Limongi, Maria Stepanova, Mariaelena Pierobon, Arian Afendy, Rohini Mehta, Ancha Baranova, Lance. Liotta, Emanuel. Petricoin. (2011) Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). Journal of Proteome Research 10:2, 774-779
CrossRef349
P. Rosenberg, K. Hagen. (2011) Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection. Journal of Viral Hepatitis 18:2, 129-134
CrossRef350
Evaldo Stanislau Affonso de Araújo, Harel Dahari, Scott J Cotler, Thomas J Layden, Avidan U Neumann, Carlos Eduardo Melo, Antonio Alci Barone. (2011) Pharmacodynamics of PEG-IFN-α-2a and HCV Response as a Function of IL28B Polymorphism in HIV/HCV-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:2, 95-99
CrossRef351
Aaron Bossler, Cynthia Gunsolly, Michael T. Pyne, Angela Rendo, Jane Rachel, Ray Mills, Marjorie Miller, John Sipley, David Hillyard, Stephen Jenkins, Cynthia Essmyer, Steve Young, Michael Lewinski, Hanna Rennert. (2011) Performance of the COBAS® AmpliPrep/COBAS TaqMan® automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. Journal of Clinical Virology 50:2, 100-103
CrossRef352
A.-S. Duberg, H. Pettersson, S. Aleman, A. Blaxhult, L. Daviðsdóttir, R. Hultcrantz, E. Bäck, K. Ekdahl, S. M. Montgomery. (2011) The burden of hepatitis C in Sweden: a national study of inpatient care. Journal of Viral Hepatitis 18:2, 106-118
CrossRef353
Fred Poordad. (2011) Big Changes Are Coming in Hepatitis C. Current Gastroenterology Reports 13:1, 72-77
CrossRef354
Fred Poordad, Dickens Theodore, Jane Sullivan, Kelly Grotzinger. (2011) Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. Journal of Medical Economics 14:2, 194-206
CrossRef355
Alexander J. Thompson, Rosanna Santoro, Valeria Piazzolla, Paul J. Clark, Susanna Naggie, Hans L. Tillmann, Keyur Patel, Andrew J. Muir, Kevin V. Shianna, Leonardo Mottola, Daniela Petruzzellis, Mario Romano, Fernando Sogari, Domenico Facciorusso, David B. Goldstein, John G. McHutchison, Alessandra Mangia. (2011) Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 53:2, 389-395
CrossRef356
Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Hitomi Sezaki, Miharu Hirakawa, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saito, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Kazuaki Chayama, Naoyuki Kamatani, Yusuke Nakamura, Yuzo Miyakawa, Hiromitsu Kumada. (2011) Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53:2, 415-421
CrossRef357
Pierre Deltenre, Marion Corouge, Valérie Canva, Hélène Castel, Faustine Wartel, Sébastien Dharancy, Alexandre Louvet, Mouna Lazrek, Christophe Moreno, Jean Henrion, Philippe Mathurin. (2011) Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin. Journal of Hepatology
CrossRef358
J. Vermehren, C. Sarrazin. (2011) New HCV therapies on the horizon. Clinical Microbiology and Infection 17:2, 122-134
CrossRef359
Ourania M. Andrisani, Leo Studach, Philippe Merle. (2011) Gene signatures in hepatocellular carcinoma (HCC). Seminars in Cancer Biology 21:1, 4-9
CrossRef360
Brian L. Pearlman. (2011) The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection. Current Gastroenterology Reports 13:1, 78-86
CrossRef361
O. A. Smirnova, A. V. Ivanov, O. N. Ivanova, V. T. Valuev-Elliston, S. N. Kochetkov. (2011) Cell defense systems against oxidative stress and endoplasmic reticulum stress: Mechanisms of regulation and the effect of hepatitis C virus. Molecular Biology 45:1, 110-122
CrossRef362
Chen-Hua Liu, Jia-Horng Kao. (2011) Treatment of hepatitis C virus infection in patients with end-stage renal disease. Journal of Gastroenterology and Hepatology 26:2, 228-239
CrossRef363
T.-M. Chen, P.-T. Huang, C.-F. Wen, J.-N. Tung, K.-C. Chow, Y.-P. Chen. (2011) Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. Journal of Viral Hepatitis 18:2, 119-128
CrossRef364
Yoshito Itoh, Takeshi Nishimura, Hiroaki Hashimoto, Kanji Yamaguchi, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Kohichiroh Yasui, Hironori Mitsuyoshi, Takeshi Okanoue, Tetsuo Takehara, Yoichi Hiasa, Morikazu Onji, Toshikazu Yoshikawa. (2011) Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads. Hepatology Research 41:2, 126-132
CrossRef365
P.-Y. Bochud, S. Bibert, F. Negro, B. Haagmans, A. Soulier, C. Ferrari, G. Missale, S. Zeuzem, J.-M. Pawlotsky, S. Schalm, K. Hellstrand, A.U. Neumann, M. Lagging. (2011) IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. Journal of Hepatology
CrossRef366
Christopher P Farrell, Giancarlo Mercogliano, Victor J Navarro, Simona Rossi. (2011) Taribavirin: potential future in the treatment of hepatitis C. Future Virology 6:2, 147-155
CrossRef367
Tabinda Burney, Geoffrey Dusheiko. (2011) Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Review of Anti-infective Therapy 9:2, 151-160
CrossRef368
J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem, C. Sarrazin. (2011) Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. Journal of Viral Hepatitisno-no
CrossRef369
Kathleen B. Schwarz, Regino P. Gonzalez–Peralta, Karen F. Murray, Jean P. Molleston, Barbara A. Haber, Maureen M. Jonas, Philip Rosenthal, Parvathi Mohan, William F. Balistreri, Michael R. Narkewicz, Lesley Smith, Steven J. Lobritto, Stephen Rossi, Alexandra Valsamakis, Zachary Goodman, Patricia R. Robuck, Bruce A. Barton. (2011) The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C. Gastroenterology 140:2, 450-458.e1
CrossRef370
Patrick Marcellin, Xavier Forns, Tobias Goeser, Peter Ferenci, Frederik Nevens, Giampiero Carosi, Joost P. Drenth, Lawrence Serfaty, Koen De Backer, Rolf Van Heeswijk, Donghan Luo, Gaston Picchio, Maria Beumont. (2011) Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C. Gastroenterology 140:2, 459-468.e1
CrossRef371
Tetsuro Shimakami, Christoph Welsch, Daisuke Yamane, David R. McGivern, MinKyung Yi, Stefan Zeuzem, Stanley M. Lemon. (2011) Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus. Gastroenterology 140:2, 667-675
CrossRef372
Raymond Chung. (2011) Novel Therapies for Hepatitis C: Insights from the Structure of the Hepatitis C Virus. Annual Review of Medicine 63:1, 110301100719093
CrossRef373
Rajeev Raghavan, Laura Ferlic-Stark, Cinda Clarke, Manish Rungta, Richard Goodgame. (2011) The Role of Patient Religiosity in the Evaluation and Treatment Outcomes for Chronic HCV Infection. Journal of Religion and Health
CrossRef374
Ana Maria Sandri, Usama Elewa, John J. Poterucha, Fernando C. Fervenza. (2011) Treatment of Hepatitis C-Mediated Glomerular Disease. Nephron Clinical Practice 119:2, c121-c130
CrossRef375
Tomohide Tatsumi, Tetsuo Takehara, Takuya Miyagi, Shoichi Nakazuru, Eiji Mita, Tatsuya Kanto, Naoki Hiramatsu, Norio Hayashi. (2011) Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-α and ribavirin combination therapy in patients with chronic hepatitis C virus infection. Hepatology Research 41:1, 30-38
CrossRef376
S. Zhao, E. Liu, K. Wei, Y. Wang, Y. Li, B. Huang, Y. Chen, P. Yang. (2011) Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C. European Journal of Clinical Microbiology & Infectious Diseases 30:1, 51-57
CrossRef377
Prodromos Hytiroglou. 2011. Hepatitis C. , 225-233.
CrossRef378
Stephen M. Lambert, Andrew N. Page, Johannes Wittmann, Jeremy S. Hayllar, Clint W. Ferndale, Tanya M. Bain, Graeme A. Macdonald. (2011) General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting. Australian Journal of Primary Health 17:3, 282
CrossRef379
N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama, H. Kumada. (2011) Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C : Telaprevir triple therapy in genotype 1 HCV difficult-to-treat patients. Journal of Viral Hepatitisno
CrossRef380
Sanaa M. Kamal. (2011) Hepatitis C virus genotype 4 therapy: progress and challenges. Liver International 31, 45-52
CrossRef381
Jae Young Jang, Raymond T. Chung. (2011) Chronic Hepatitis C. Gut and Liver 5:2, 117
CrossRef382
Kazuaki Chayama, C Nelson Hayes. (2011) Hepatitis C virus: How genetic variability affects pathobiology of disease. Journal of Gastroenterology and Hepatology 26, 83-95
CrossRef383
Marcello Persico, Savino Bruno, Andrea Costantino, Marta Mazza, Piero Luigi Almasio. (2011) The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection. International Journal of Hepatology 2011, 1-8
CrossRef384
Yasuhito Tanaka. (2011) Interleukin28B and Inosine Triphosphatase Help to Personalize Hepatitis C Treatment. Digestion 84:s1, 50-55
CrossRef385
Nanna Hansen, Niels Obel, Peer B Christensen, Mette Kjær, Alex L Laursen, Henrik B Krarup, Axel Møller, Poul Schlichting, Jens Bukh, Nina Weis, . (2011) Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. BMC Infectious Diseases 11:1, 177
CrossRef386
Yasuji Arase, Yoshiyuki Suzuki, Fumitaka Suzuki, Naoki Matsumoto, Norio Akuta, Norihiro Imai, Yuya Seko, Hitomi Sezaki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2011) Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients. Internal Medicine 50:19, 2083-2088
CrossRef387
Felix Stickel, Beat Helbling, Markus Heim, Andreas Geier, Claudia Hirschi, Benedetta Terziroli, Klaus Wehr, Andrea De Gottardi, Francesco Negro, Tilman Gerlach. (2011) Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C : EPO and hepatitis C treatment. Journal of Viral Hepatitisno
CrossRef388
Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Takanori Hosokawa, Takahiro Arakawa, Masashi Fujimori. (2011) Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b. Journal of Medical Virology 83:1, 101-107
CrossRef389
Masaya Sugiyama, Yasuhito Tanaka, Makoto Nakanishi, Masashi Mizokami. (2011) Novel Findings for the Development of Drug Therapy for Various Liver Diseases: Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C. Journal of Pharmacological Sciences 115:3, 263-269
CrossRef390
Andreas Maieron, Sigrid Metz-Gercek, Thomas-Matthias Scherzer, Hermann Laferl, Gabriele Fischer, Martin Bischof, Michael Gschwantler, Peter Ferenci. (2011) Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial. BMC Research Notes 4:1, 220
CrossRef391
Gowtham A. Rao, Prashant K. Pandya. (2011) Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C. Gastroenterology 140:1, 144-152.e2
CrossRef392
Edward Gane. (2011) Future hepatitis C virus treatment: interferon-sparing combinations. Liver International 31, 62-67
CrossRef393
Emmanuel Thomas, Jordan J. Feld, Qisheng Li, Zongyi Hu, Michael W. Fried, T. Jake Liang. (2011) Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53:1, 32-41
CrossRef394
Jama M. Darling, Stanley M. Lemon, Michael W. Fried. 2011. , 582.
CrossRef395
Liana Fraenkel. (2011) Uncertainty and patients’ preferred role in decision making. Patient Education and Counseling 82:1, 130-132
CrossRef396
P. D. Griffiths. (2011) Mixed results from combination therapy : Editorials. Reviews in Medical Virology 21:6, 333
CrossRef397
Steevens N. S. Alconcel, Arnold S. Baas, Heather D. Maynard. (2011) FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polymer Chemistry 2:7, 1442
CrossRef398
Tomokazu Kawaoka, Hiroshi Aikata, Daisuke Miyaki, Eisuke Murakami, Takahiro Azakami, Shintaro Takaki, Yuko Nagaoki, Yoshimasa Hashimoto, Yoshio Katamura, Akira Hiramatsu. (2011) Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining regio : IFN therapy before LT. Hepatology Research 41:11, 1126
CrossRef399
Ming-Lung Yu, Chung-Feng Huang, Jee-Fu Huang, Ning-Chia Chang, Jeng-Fu Yang, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Yi-Ning Li, Mei-Shin Wu, Chia-Yen Dai, Suh-Hang Hank Juo, Wan-Long Chuang. (2011) Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53:1, 7-13
CrossRef400
Dange V. Kumar, Roopa Rai, Ken A. Brameld, John R. Somoza, Ravi Rajagopalan, James W. Janc, Yu M. Xia, Tony L. Ton, Michael B. Shaghafi, Huiyong Hu, Isabelle Lehoux, Nhat To, Wendy B. Young, Michael J. Green. (2011) Quinolones as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, 82-87
CrossRef401
Sang Bun Choi, Youn Jae Lee, Jae Ik Lee, Young Jin Song, Byoung Jin Choi, Jong Han Kim, Eun Uk Jung, Sung Jae Park, Sang Heon Lee, Ji Hyun Kim, Jung Sik Choi, Sam Ryong Jee, Sang Yong Seol. (2011) Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. The Korean Journal of Hepatology 17:3, 183
CrossRef402
Catharina E.A. Lindenburg, Femke A.E. Lambers, Anouk T. Urbanus, Janke Schinkel, Peter L.M. Jansen, Anneke Krol, Gerty Casteelen, Gerrit van Santen, Charlotte H.S.B. van den Berg, Roel A. Coutinho, Maria Prins, Christine J. Weegink. (2011) Hepatitis C testing and treatment among active drug users in Amsterdam. European Journal of Gastroenterology & Hepatology 23:1, 23-31
CrossRef403
N. D. Freedman, T. M. Curto, C. Morishima, L. B. Seeff, Z. D. Goodman, E. C. Wright, R. Sinha, J. E. Everhart, . (2011) Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Alimentary Pharmacology & Therapeutics 33:1, 127-137
CrossRef404
Mitchell L. Shiffman. 2011. , 160.
CrossRef405
Su Hyun Cho, Sung Wook Lee, Seok Reyol Choi, Sang Young Han, Myung Hwan Roh, Jong Hoon Lee, Jin Seok Jang, Yang Hyun Baek, Su Young Kim. (2011) Delayed Viral Clearance of Chronic Hepatitis C in Patients after Treatment Failure. Gut and Liver 5:1, 110
CrossRef406
Kyung-Ah Kim. (2011) Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin. The Korean Journal of Hepatology 17:1, 84
CrossRef407
Tarik Asselah, Patrick Marcellin. (2011) New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver International 31, 68-77
CrossRef408
Rebekah G. Gross, Ira M. Jacobson. 2011. , 65.
CrossRef409
Sanaa M. Kamal. 2011. , 113.
CrossRef410
Olav Dalgard, Zbigniew Konopski, Franziskus Bosse, Berit Nordstrand, Per Sandvei, Lars Karlsen, Jon Florholmen, Astrid Rojahn, Rune Almaas, Steinar Skrede, Arne Eskesen, Bjørn Myrvang. (2011) Hepatitt C - utredning og behandling. Tidsskrift for Den norske legeforening 131:1, 2-9
CrossRef411
Keiko Irishio, Yasuharu Imai, Eiji Mita, Takashi Toyama, Noriyoshi Kuzushita, Toshihiko Nagase, Yoshinori Doi, Akira Yamada, Michio Kato, Kazuto Fukuda, Takumi Igura, Yoshiyuki Sawai, Sachiyo Kogita, Naoki Hiramatsu, Tetsuo Takehara, Norio Hayashi. (2011) Factors affecting efficacy of pegylated interferon alpha-2a in chronic hepatitis C patients with serotype 2. Kanzo 52:4, 236-243
CrossRef412
K. S. Louie, J. M. Micallef, J. M. Pimenta, U. M. Forssen. (2011) Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. Journal of Viral Hepatitis 18:1, 1-7
CrossRef413
I. Yamada, F. Suzuki, N. Kamiya, K. Aoki, Y. Sakurai, M. Kano, H. Matsui, H. Kumada. (2011) Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection : Telaprevir monotherapy in genotype 1b HCV patients. Journal of Viral Hepatitisno
CrossRef414
Jinhong Chang, Wouter Schul, Terry D. Butters, Andy Yip, Boping Liu, Anne Goh, Suresh B. Lakshminarayana, Dominic Alonzi, Gabriele Reinkensmeier, Xiaoben Pan, Xiaowang Qu, Jessica M. Weidner, Lijuan Wang, Wenquan Yu, Nigel Borune, Mark A. Kinch, Jamie E. Rayahin, Robert Moriarty, Xiaodong Xu, Pei-Yong Shi, Ju-Tao Guo, Timothy M. Block. (2011) Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Research 89:1, 26-34
CrossRef415
Su Rin Shin, Seung Woon Paik, Geum-Youn Gwak, Moon Seok Choi, Joon Hyoek Lee, Kwang Cheol Koh, Byung Chul Yoo. (2011) Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma. Gut and Liver 5:1, 77
CrossRef416
Tetsushi Tomoguri, Keiko Katayama, Junko Tanaka, Hisao Yugi, Masaaki Mizui, Yuzo Miyakawa, Hiroshi Yoshizawa. (2011) Interferon Alone or Combined with Ribavirin for Acute Prolonged Infection with Hepatitis C Virus in Chimpanzees. Intervirology 54:4, 229-232
CrossRef417
David R. Nelson. (2011) The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Liver International 31, 53-57
CrossRef418
Philipp de Leuw, Christoph Sarrazin, Stefan Zeuzem. (2011) How to use virological tools for the optimal management of chronic hepatitis C. Liver International 31, 3-12
CrossRef419
Redouane Qesmi, Susie ElSaadany, Jane Marie Heffernan, Jianhong Wu. (2011) A Hepatitis B and C Virus Model with Age since Infection that Exhibits Backward Bifurcation. SIAM Journal on Applied Mathematics 71:4, 1509
CrossRef420
Kenneth Yan, Amany Zekry. 2011. , 90.
CrossRef421
Hiroshi Adachi, Katsuhisa Inamura, Toshiyuki Okamura, Tatsuho Sugimoto. (2011) The anti-viral effect and the influence on the values of ALT and AFP by low-dose PEG-IFNα2a treatment for prevention of cancer in patients with chronic hepatitis C. Kanzo 52:2, 94-101
CrossRef422
Pyung Gohn Goh, Min Jung Kim, Hye Jin Kim, Hyuk Soo Eun, Eui Sik Kim, Yun Jeung Kim, Soo Youn Lee, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Byung Seok Lee, Heon Young Lee. (2011) Importance of Medication Adherence to Peginterferon-Ribavirin Combination Therapy in Patients with Chronic Hepatitis C. The Korean Journal of Gastroenterology 57:5, 294
CrossRef423
Jama M. Darling, Jeroen Aerssens, Gregory Fanning, John G. McHutchison, David B. Goldstein, Alexander J. Thompson, Kevin V. Shianna, Nezam H. Afdhal, Michael L. Hudson, Charles D. Howell, Willem Talloen, Jacques Bollekens, Mieke De Wit, Annick Scholliers, Michael W. Fried. (2011) Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53:1, 14-22
CrossRef424
Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh. (2011) Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. The Korean Journal of Hepatology 17:3, 220
CrossRef425
Alessandra Mangia, Leonardo Mottola, Angelo Andriulli. 2011. , 97.
CrossRef426
Fred Poordad, Grace M. Chee. 2011. , 36.
CrossRef427
Jang Eun Lee, Na Ri Yoon, Jin Dong Kim, Myeong Jun Song, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Sung Won Jeong, Seung Kew Yoon. (2011) Durability of Sustained Virologic Response in Chronic Hepatitis C: Analysis of Factors Related to Relapse after Sustained Virologic Response with Peginterferon Plus Ribavirin Combination Therapy. The Korean Journal of Gastroenterology 57:3, 173
CrossRef428
Paulo Dias, Judith A Hahn, Eric Delwart, Brian Edlin, Jeff Martin, Paula Lum, Jennifer Evans, Alex Kral, Steve Deeks, Michael P Busch, Kimberly Page. (2011) Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infectious Diseases 11:1, 208
CrossRef429
Maria López, Laura Moreno, Angelina Dosal, Marta Maria Pujol, Mercedes Vergara, Montserrat Gil. (2011) Interferon and the Fear of Needles. Gastroenterology Nursing 34:5, 384-388
CrossRef430
Shuanghu Liu, Cassie A. Nelson, Li Xiao, Ling Lu, Punit P. Seth, Darrell R. Davis, Curt H. Hagedorn. (2011) Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Research 89:1, 54-63
CrossRef431
John B. Patton, David George, Kyeong-Ok Chang. (2011) Bile Acids Promote HCV Replication through the EGFR/ERK Pathway in Replicon-Harboring Cells. Intervirology 54:6, 339-348
CrossRef432
M. Inokuchi, T. Ito, H. Nozawa, M. Miyashita, K. Morikawa, M. Uchikoshi, Y. Shimozuma, J. Arai, T. Shimazaki, K. Hiroishi. (2011) Lymphotropic hepatitis C virus has an interferon-resistant phenotype : Interferon resistance of lymphotropic HCV. Journal of Viral Hepatitisno
CrossRef433
Soo Ryang Kim, Jun Saito, Susumu Imoto, Takamitsu Komaki, Yoshiaki Nagata, Taisuke Nakajima, Kenji Ando, Katsumi Fukuda, Yumi Otono, Ke Ih Kim, Aya Ohtani, Kayo Sugimoto, Yutaka Hasegawa, Aya Fujinami, Mitsuhiro Ohta, Hak Hotta, Yoko Maekawa, Yoshitake Hayashi, Masatoshi Kudo. (2011) Correlation between Insulin Resistance and Outcome of Pegylated Interferon and Ribavirin Therapy, Hepatic Steatosis, Hepatic Fibrosis in Chronic Hepatitis C-1b and High Viral Load. Digestion 84:s1, 5-9
CrossRef434
Shazia Rafique, Muhammad Idrees, Muhammad Ilyas, Abrar Hussain, Muhammad Ali, Liaqat Ali, Sadia Butt, Samia Afzal, Irshad Ur Rehman, Sana Saleem. (2011) Positional effect of phosphorylation sites 266 and 267 in the cytoplasmic domain of the E2 protein of hepatitis C virus 3a genotype: Interferon Resistance analysis via Sequence Alignment. Virology Journal 8:1, 204
CrossRef435
Erik Alestig, Birgitta Arnholm, Anders Eilard, Martin Lagging, Staffan Nilsson, Gunnar Norkrans, Thomas Wahlberg, Rune Wejstål, Johan Westin, Magnus Lindh. (2011) Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases 11:1, 124
CrossRef436
S. M. Martinez, G. Fernández-Varo, P. González, E. Sampson, M. Bruguera, M. Navasa, W. Jiménez, J. M. Sánchez-Tapias, X. Forns. (2011) Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics 33:1, 138-148
CrossRef437
Salvatore Petta, Antonio Craxì. 2011. , 84.
CrossRef438
Damien J. Lowry, John D. Ryan, Naeem Ullah, Thomas Barry Kelleher, John Crowe. (2011) Hepatitis C management. European Journal of Gastroenterology & Hepatology 23:1, 32-40
CrossRef439
Diarmuid S. Manning, Nezam H. Afdhal. 2011. , 132.
CrossRef440
McKenzie C Ferguson. (2011) Current Therapies for Chronic Hepatitis C. Pharmacotherapy 31:1, 92-111
CrossRef441
Keisuke Shiina, Atsushi Naganuma, Tomofumi Takakusaki, Masashi Namikawa, Hiroki Tahara, Kazuhisa Yuasa, Sakae Maruta, Katsue Yoshida, Akira Kojima, Hitoshi Takagi. (2011) Sustained viral response (SVR) in type C liver cirrhosis patients undergoing peginterferon α-2b/ribavirin combination therapy after partial splenic embolization. Kanzo 52:1, 26-35
CrossRef442
Ellen Sloth Andersen, Belinda Klemmensen Moessner, Peer Brehm Christensen, Mette Kjær, Henrik Krarup, Søren Lillevang, Nina Weis. (2011) Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. European Journal of Gastroenterology & Hepatology 23:1, 41-44
CrossRef443
Paolo A Ascierto, Francesco M Marincola. (2011) Combination therapy: the next opportunity and challenge of medicine. Journal of Translational Medicine 9:1, 115
CrossRef444
Muhammad Ansar, Usman Ashfaq, Imran shahid, Muhammad Sarwar, Tariq Javed, Sidra Rehman, Sajida Hassan, Sheikh Riazuddin. (2011) Inhibition of full length Hepatitis C Virus particles of 1a genotype through small interference RNA. Virology Journal 8:1, 203
CrossRef445
Salvatore Petta, Antonio Craxì. (2011) Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. Liver International 31, 36-44
CrossRef446
Oluwaseun Falade-Nwulia, Chloe L. Thio. (2011) Liver disease, HIV and aging. Sexual Health 8:4, 512
CrossRef447
Susie H. Park. (2011) Completion of Chronic Hepatitis C Virus Treatment in Interferon-Induced Major Depressive Disorder with Psychotic Features. Psychiatry Investigation 8:4, 381
CrossRef448
K Jurczyk, Ł Laurans, E Karpińska, M Wawrzynowicz-Syczewska, M Parczewski, A Boroń-Kaczmarska. (2011) Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients. Advances in Medical Sciences 1:-1, 1-7
CrossRef449
N. Reau, F. M. Hamzeh, E. Lentz, X. Zhou, D. Jensen. (2011) Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. Journal of Viral Hepatitisno-no
CrossRef450
Hamish A Innes, Sharon J Hutchinson, Samuel Allen, Diptendu Bhattacharyya, Peter Bramley, Toby E S Delahooke, John F Dillon, Ewan Forrest, Andrew Fraser, Ruth Gillespie, David J Goldberg, Nicholas Kennedy, Scott McDonald, Allan McLeod, Peter R Mills, Judith Morris, Peter Hayes, . (2011) Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatologyn/a-n/a
CrossRef451
Johannes Vermehren, Christoph Sarrazin. (2011) New hepatitis C therapies in clinical development. European Journal of Medical Research 16:7, 303
CrossRef452
Kazuaki Chayama, Shoichi Takahashi, Joji Toyota, Yoshiyasu Karino, Kenji Ikeda, Hiroki Ishikawa, Hideaki Watanabe, Fiona McPhee, Eric Hughes, Hiromitsu Kumada. (2011) Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatologyn/a-n/a
CrossRef453
R. Parker, J. Dutrieux, S. Beq, B. Lemercier, S. Rozlan, V. Fabre-Mersseman, M. Rancez, C. Gommet, B. Assouline, I. Rance, A. Lim, M. Morre, R. Cheynier. (2010) Interleukin-7 treatment counteracts IFN- therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques. Blood 116:25, 5589-5599
CrossRef454
H. Mawatari, M. Yoneda, K. Fujita, Y. Nozaki, Y. Shinohara, H. Sasaki, H. Iida, H. Takahashi, M. Inamori, Y. Abe, N. Kobayashi, K. Kubota, H. Kirikoshi, A. Nakajima, S. Saito. (2010) Association between phospholipids and free cholesterol in high-density lipoprotein and the response to hepatitis C treatment in Japanese with genotype 1b. Journal of Viral Hepatitis 17:12, 859-865
CrossRef455
Tariq Tajuddin, Elizabeth J Ryan, Suzanne Norris, John E Hegarty, Cliona O'Farrelly. (2010) Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist. Journal of Gastroenterology and Hepatology 25:12, 1883-1890
CrossRef456
J. Guedj, A.U. Neumann. (2010) Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. Journal of Theoretical Biology 267:3, 330-340
CrossRef457
Rachel H. McMahan, Lucy Golden-Mason, Michael I. Nishimura, Brian J. McMahon, Michael Kemper, Todd M. Allen, David R. Gretch, Hugo R. Rosen. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. Journal of Clinical Investigation 120:12, 4546-4557
CrossRef458
Raymond T. Chung, Fred F. Poordad, Tarek Hassanein, Xiaolei Zhou, Ellen Lentz, Avinash Prabhakar, Adrian M. Di Bisceglie. (2010) Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology 52:6, 1906-1914
CrossRef459
P. Ganapati Reddy, Donghui Bao, Wonsuk Chang, Byoung-Kwon Chun, Jinfa Du, Dhanapalan Nagarathnam, Suguna Rachakonda, Bruce S. Ross, Hai-Ren Zhang, Shalini Bansal, Christine L. Espiritu, Meg Keilman, Angela M. Lam, Congrong Niu, Holly Micolochick Steuer, Phillip A. Furman, Michael J. Otto, Michael J. Sofia. (2010) 2′-Deoxy-2′-α-fluoro-2′-β-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938. Bioorganic & Medicinal Chemistry Letters 20:24, 7376-7380
CrossRef460
Kenneth Kar-Lung Yan, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan. (2010) Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. Digestive Diseases and Sciences 55:12, 3541-3547
CrossRef461
I. Maida, L. Martin-Carbonero, G. Sotgiu, E. Vispo, P. Barreiro, J. Gonzalez-Lahoz, V. Soriano. (2010) Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. Journal of Viral Hepatitis 17:12, 866-871
CrossRef462
Alessandra Mangia, Franco Bandiera, Giuseppe Montalto, Leonardo Mottola, Valeria Piazzolla, Nicola Minerva, Adriano Pellicelli, Giovanni L. Ricci, Marina Cela, Vito Carretta, Gaetano Scotto, Donato Bacca, Brigida Annicchiarico, Mario Romano, Maurizio Russello, Giorgio Barbarini, Ernesto Agostinacchio, Angelo Andriulli. (2010) Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. Journal of Hepatology 53:6, 1000-1005
CrossRef463
Javier Velasco, Itziar Oriñuela, Ainhoa Z. Sanjuán, Zuriñe Ortiz de Zárate. (2010) Derrame pericárdico asociado a interferón en un paciente inmunocompetente. Enfermedades Infecciosas y Microbiología Clínica 28:10, 749-750
CrossRef464
Jeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wan-Long Chuang, Ming-Lung Yu. (2010) Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatology International 4:4, 732-740
CrossRef465
Venessa Pattullo, E. Jenny Heathcote, David K. H. Wong. (2010) Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatology International 4:4, 723-731
CrossRef466
Haripriya Maddur, Paul Y. Kwo. (2010) Boceprevir. Hepatology 54:6, 2254-2258
CrossRef467
K. Rajender Reddy, Mitchell L. Shiffman, Maribel Rodriguez–Torres, Hugo Cheinquer, Djamal Abdurakhmanov, Igor Bakulin, Viacheslav Morozov, Giovanni Faria Silva, Natalia Geyvandova, Carol Stanciu, Michael Rabbia, Michael McKenna, James A. Thommes, Stephen A. Harrison. (2010) Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads. Gastroenterology 139:6, 1972-1983
CrossRef468
Barbara Zanini, Loredana Covolo, Francesco Donato, Alberto Lanzini. (2010) Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: Meta-analysis of prospective studies. Clinical Therapeutics 32:13, 2139-2159
CrossRef469
Chuanghong Wu, Richard Gilroy, Ryan Taylor, Mojtaba Olyaee, Bashar Abdulkarim, Jameson Forster, Maura O'Neil, Ivan Damjanov, Yu-Jui Yvonne Wan. (2010) Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology 54:6, 1966-1974
CrossRef470
Elena Vezali, Alessio Aghemo, Massimo Colombo. (2010) A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clinical Therapeutics 32:13, 2117-2138
CrossRef471
A. D. Martinez, R. Dimova, K. M. Marks, A. B. Beeder, M. Zeremski, M. J. Kreek, A. H. Talal. (2010) Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. Journal of Viral Hepatitisno-no
CrossRef472
V. Hope, J. V. Parry, A. Marongui, F. Ncube. (2010) Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference?. Journal of Viral Hepatitisno-no
CrossRef473
Shuichi Kaneko, Michio Sata, Tatsuya Ide, Tatsuya Yamashita, Shuhei Hige, Eiichi Tomita, Satoshi Mochida, Yukitaka Yamashita, Yoshiaki Inui, Soo Ryang Kim, Naoto Komada, Takafumi Mikami, Shinichi Satoh, Sumiharu Morita, Koichi Takaguchi, Noboru Hirashima, Yuji Nishio, Daisuke Watanabe, Kiyohide Kioka, Kenji Fujiwara. (2010) Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Hepatology Research 40:11, 1072-1081
CrossRef474
Tommaso Stroffolini, Aldo Spadaro, Vincenzo Guadagnino, Stefano Cosentino, Filippo Fatuzzo, Antonio Galdieri, Bruno Cacopardo, Ignazio Scalisi, Mauro Sapienza, Maurizio Russello, Gaetano Scifo, Pierluigi Frugiuele, Giuseppe Foti, Piero Luigi Almasio. (2010) Current practice of hepatitis C treatment in Southern Italy. Digestive and Liver Disease 42:11, 822-825
CrossRef475
Juan Li, Chun Hui Liu, Feng Shan Wang. (2010) Thymosin alpha 1: Biological activities, applications and genetic engineering production. Peptides 31:11, 2151-2158
CrossRef476
Christian M. Lange, Michael von Wagner, Jörg Bojunga, Thomas Berg, Harald Farnik, Angela Hassler, Christoph Sarrazin, Eva Herrmann, Stefan Zeuzem. (2010) Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin. European Journal of Gastroenterology & Hepatology 22:11, 1303-1307
CrossRef477
Lotte G. Van Vlerken, Hanneke Van Soest, Mart P. Janssen, Greet J. Boland, Joost P.H. Drenth, David M. Burger, Peter D. Siersema, Karel J. Van Erpecum. (2010) Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment. European Journal of Gastroenterology & Hepatology 22:11, 1308-1315
CrossRef478
Mario Furlanut, Giorgio Soardo, Debora Donnini, Leonardo Sechi, Loretta Franceschi. (2010) Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α. Clinical Pharmacokinetics 49:11, 767-772
CrossRef479
Alexandre Pariente, Pierre Lahmek, Christel Duprat, Jacques Denis, Roger Faroux, Christophe Renou, Bernard Nalet, Thierry Morin, Jean-François Cadranel. (2010) Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’. European Journal of Gastroenterology & Hepatology 22:11, 1297-1302
CrossRef480
Edoardo G. Giannini, Monica Basso, Vincenzo Savarino, Antonino Picciotto. (2010) Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More. Digestive Diseases and Sciences 55:11, 3193-3199
CrossRef481
Yalena Amador-Cañizares, Santiago Dueñas-Carrera. (2010) Early Interferon-Based Treatment After Detection of Persistent Hepatitis C Virus Infection: A Critical Decision. Journal of Interferon & Cytokine Research 30:11, 817-824
CrossRef482
Naoya Sakamoto, Yasuhito Tanaka, Mina Nakagawa, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Nobuyuki Enomoto, Seishin Azuma, Yuki Nishimura-Sakurai, Sei Kakinuma, Nao Nishida, Katsushi Tokunaga, Masao Honda, Kiyoaki Ito, Masashi Mizokami, Mamoru Watanabe. (2010) ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research 40:11, 1063-1071
CrossRef483
Mark G. Swain, Ming–Yang Lai, Mitchell L. Shiffman, W. Graham E. Cooksley, Stefan Zeuzem, Douglas T. Dieterich, Armand Abergel, Mário G. Pessôa, Amy Lin, Andreas Tietz, Edward V. Connell, Moisés Diago. (2010) A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin. Gastroenterology 139:5, 1593-1601
CrossRef484
Mark S. Sulkowski, Mitchell L. Shiffman, Nezam H. Afdhal, K. Rajender Reddy, Jonathan McCone, William M. Lee, Steven K. Herrine, Stephen A. Harrison, F. Fred Poordad, Kenneth Koury, Weiping Deng, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison. (2010) Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. Gastroenterology 139:5, 1602-1611.e1
CrossRef485
Naveen C. Srivastav, Neeraj Shakya, Michelle Mak, Chao Liang, D. Lorne J. Tyrrell, Babita Agrawal, Rakesh Kumar. (2010) Synthesis and in vitro antiviral activities of 3′-fluoro (or chloro) and 2′,3′-difluoro 2′,3′-dideoxynucleoside analogs against hepatitis B and C viruses. Bioorganic & Medicinal Chemistry 18:21, 7542-7547
CrossRef486
Spilios Manolakopoulos, Melanie J. Deutsch, Olga Anagnostou, Stelios Karatapanis, Elli Tiniakou, George V. Papatheodoridis, Ekaterini Georgiou, Emmanuel Manesis, Dimitris Tzourmakliotis, Athanasios J. Archimandritis. (2010) Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver International 30:10, 1454-1460
CrossRef487
Takasuke Fukuhara, Akinobu Taketomi, Takashi Motomura, Shinji Okano, Akinori Ninomiya, Takayuki Abe, Hideaki Uchiyama, Yuji Soejima, Ken Shirabe, Yoshiharu Matsuura, Yoshihiko Maehara. (2010) Variants in IL28B in Liver Recipients and Donors Correlate With Response to Peg-Interferon and Ribavirin Therapy for Recurrent Hepatitis C. Gastroenterology 139:5, 1577-1585.e3
CrossRef488
Lauren A. Beste, George N. Ioannou, Meaghan S. Larson, Michael Chapko, Jason A. Dominitz. (2010) Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication. Clinical Gastroenterology and Hepatology 8:11, 972-978
CrossRef489
Goki Suda, Naoya Sakamoto, Yasuhiro Itsui, Mina Nakagawa, Megumi Tasaka-Fujita, Yusuke Funaoka, Takako Watanabe, Sayuri Nitta, Kei Kiyohashi, Seishin Azuma, Sei Kakinuma, Kiichiro Tsuchiya, Michio Imamura, Nobuhiko Hiraga, Kazuaki Chayama, Mamoru Watanabe. (2010) IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 407:1, 80-90
CrossRef490
Masao Honda, Mikiko Nakamura, Makoto Tateno, Akito Sakai, Tetsuro Shimakami, Takayoshi Shirasaki, Tatsuya Yamashita, Kuniaki Arai, Taro Yamashita, Yoshio Sakai, Shuichi Kaneko. (2010) Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C. Journal of Hepatology 53:5, 817-826
CrossRef491
S.-C. C. Sun, A. Bae, X. Qi, J. Harris, K. A. Wong, M. D. Miller, H. Mo. (2010) Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates. Journal of Viral Hepatitisno-no
CrossRef492
Khoa D. Lam, Huy N. Trinh, Son T. Do, Thuan T. Nguyen, Ruel T. Garcia, Tuan Nguyen, Quang Q. Phan, Huy A. Nguyen, Khanh K. Nguyen, Long H. Nguyen, Mindie H. Nguyen. (2010) Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 52:5, 1573-1580
CrossRef493
Diane M. Settles, Rakesh Vinayek. (2010) Hepatitis C and End-stage Liver Disease. Current Hepatitis Reports 9:4, 243-252
CrossRef494
Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco Negro, Christian Trépo. (2010) Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 8:11, 924-933
CrossRef495
L. G. Van Vlerken, E. J. Huisman, H. Van Soest, G. J. Boland, J. P. H. Drenth, P. D. Siersema, D. M. Burger, K. J. Van Erpecum. (2010) Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients. Journal of Viral Hepatitisno-no
CrossRef496
Michael J. Lipp, Lionel S. D’Souza, David J. Clain, Henry C. Bodenheimer, Albert D. Min. (2010) Trends in the Indication and Method of Liver Biopsy for Hepatitis B and C. Digestive Diseases and Sciences 55:10, 2971-2976
CrossRef497
N. H. Nguyen, P. VuTien, R. T. Garcia, H. Trinh, H. Nguyen, K. Nguyen, B. Levitt, M. H. Nguyen. (2010) Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. Journal of Viral Hepatitis 17:10, 691-697
CrossRef498
Martin-Walter Welker, Michael von Wagner, Dana Ochs, Vincent Zimmer, Wolf Peter Hofmann, Albrecht Piiper, Rolf W. Hartmann, Eva Herrmann, Stefan Zeuzem, Bernd Kronenberger. (2010) Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. Digestive and Liver Disease 42:10, 735-740
CrossRef499
Stefan Zeuzem, Mark S. Sulkowski, Eric J. Lawitz, Vinod K. Rustgi, Maribel Rodriguez–Torres, Bruce R. Bacon, Mircea Grigorescu, Alan D. Tice, Yoav Lurie, Janusz Cianciara, Andrew J. Muir, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison. (2010) Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1. Gastroenterology 139:4, 1257-1266
CrossRef500
A. G. Singal, A. K. Waljee, M. Shiffman, B. R. Bacon, P. S. Schoenfeld. (2010) Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Alimentary Pharmacology & Therapeutics 32:8, 969-983
CrossRef501
Tarik Asselah, Emilie Estrabaud, Ivan Bieche, Martine Lapalus, Simon De Muynck, Michel Vidaud, David Saadoun, Vassili Soumelis, Patrick Marcellin. (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International 30:9, 1259-1269
CrossRef502
Paul Y. Kwo, Rakesh Vinayek. (2010) The next step for taribavirin. Hepatology 52:4, 1185-1188
CrossRef503
Fred Poordad, Eric Lawitz, Mitchell L. Shiffman, Tarek Hassanein, Andrew J. Muir, Bruce R. Bacon, Jamie Heise, Deanine Halliman, Eric Chun, Janet Hammond. (2010) Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 52:4, 1208-1215
CrossRef504
A. Birerdinc, A. Afendy, M. Stepanova, I. Younossi, G. Manyam, A. Baranova, Z. M. Younossi. (2010) Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. Journal of Viral Hepatitis 17:10, 730-736
CrossRef505
Hidenori Ochi, Toshiro Maekawa, Hiromi Abe, Yasufumi Hayashida, Rikita Nakano, Michaki Kubo, Tatsuhiko Tsunoda, C. Nelson Hayes, Hiromitsu Kumada, Yusuke Nakamura, Kazuaki Chayama. (2010) ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy—A Genome-Wide Study of Japanese HCV Virus Patients. Gastroenterology 139:4, 1190-1197.e3
CrossRef506
David R. Nelson, Yves Benhamou, Wan–Long Chuang, Eric J. Lawitz, Maribel Rodriguez–Torres, Robert Flisiak, Jens W.F. Rasenack, Wiesław Kryczka, Chuan–Mo Lee, Vincent G. Bain, Stephen Pianko, Keyur Patel, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison. (2010) Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3. Gastroenterology 139:4, 1267-1276.e4
CrossRef507
Timothy Sheahan, Christopher T Jones, Alexander Ploss. (2010) Advances and challenges in studying hepatitis C virus in its native environment. Expert Review of Gastroenterology & Hepatology 4:5, 541-550
CrossRef508
Masatoshi Ishigami, Kazuhiko Hayashi, Yoshiaki Katano, Akihiro Itoh, Yoshiki Hirooka, Hidemi Goto. (2010) Impact of early elevation of serum bilirubin during treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C. Hepatology Research 40:10, 963-970
CrossRef509
Robert Roomer, Bettina E. Hansen, Harry L. A. Janssen, Robert J. de Knegt. (2010) Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 52:4, 1225-1231
CrossRef510
Pablo Ryan, Salvador Resino, Pilar Miralles, Jaime Cosín, Juan Carlos López, Silvia Moreno, Pilar Catalán, Margarita Ramírez, Isabel Gutiérrez, Juan Berenguer. (2010) Insulin Resistance Impairs Response to Interferon Plus Ribavirin in Patients Coinfected With HIV and Hepatitis C Virus. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 176-181
CrossRef511
Darren P. Baker, Robert Blake Pepinsky, Margot Brickelmaier, Robert S. Gronke, Xiao Hu, Kenneth Olivier, Michaela Lerner, Larisa Miller, Mary Crossman, Ivan Nestorov, Meena Subramanyam, Stacy Hitchman, Gabrielle Glick, Sandra Richman, Shifang Liu, Ying Zhu, Michael A. Panzara, Gudarz Davar. (2010) PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis. Journal of Interferon & Cytokine Research 30:10, 777-785
CrossRef512
Dirk Graf, Katrin Haselow, Ivo Münks, Johannes G. Bode, Dieter Häussinger. (2010) Inhibition of interferon-α-induced signaling by hyperosmolarity and hydrophobic bile acids. Biological Chemistry 391:10, 1175-1187
CrossRef513
Daniel X.M. Zhou, Paul K.S. Chan, Tiejun Zhang, Damien C. Tully, John S. Tam. (2010) Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes. Virus Research 153:1, 44-49
CrossRef514
Sergio Neri, Gaetano Bertino, Antonio Petralia, Crisafulli Giancarlo, Agostino Rizzotto, Giuseppe Stefano Calvagno, Barbara Mauceri, Giuseppe Abate, Patrizia Boemi, Antonino Di Pino, Luca Ignaccolo, Giuseppe Vadalà, Maria Misseri, Daniela Maiorca, Gianluca Mastrosimone, Antonino Judica, Filippo Palermo. (2010) A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and Ribavirin. Journal of Clinical Gastroenterology 44:9, e210-e217
CrossRef515
Gaetano Bertino, Annalisa Ardiri, Patrizia Maria Boemi, Giuseppe Stefano Calvagno, Irene Maria Ruggeri, Annalisa Speranza, Maria Milena Santonocito, Dario Ierna, Cosimo Marcello Bruno, Maria Valenti, Roberta Boemi, Simona Naimo, Sergio Neri. (2010) Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. European Journal of Clinical Pharmacology 66:10, 1055-1063
CrossRef516
J. M. Tait, P. G. McIntyre, S. McLeod, D. Nathwani, J. F. Dillon. (2010) The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. Journal of Viral Hepatitis 17:10, 698-704
CrossRef517
Catherine François, Véronique Descamps, Etienne Brochot, Isabelle Bernard, Valérie Canva, Philippe Mathurin, Sandrine Castelain, Gilles Duverlie. (2010) Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy. Journal of Medical Virology 82:10, 1640-1646
CrossRef518
Harald Farnik, Christian M. Lange, Christoph Sarrazin, Bernd Kronenberger, Stefan Zeuzem, Eva Herrmann. (2010) Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology 8:10, 884-890
CrossRef519
Debika Bhattacharya, T Umbleja, F Carrat, R T Chung, M G Peters, F Torriani, J Andersen, J S Currier. (2010) Women Experience Higher Rates of Adverse Events During Hepatitis C Virus Therapy in HIV Infection: A Meta-Analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 170-175
CrossRef520
Maria Buti, Yoav Lurie, Natalia G. Zakharova, Natalia P. Blokhina, Andrzej Horban, Gerlinde Teuber, Christoph Sarrazin, Ligita Balciuniene, Saya V. Feinman, Rab Faruqi, Lisa D. Pedicone, Rafael Esteban. (2010) Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 52:4, 1201-1207
CrossRef521
Alexander J. Thompson, Jacques Fellay, Keyur Patel, Hans L. Tillmann, Susanna Naggie, Dongliang Ge, Thomas J. Urban, Kevin V. Shianna, Andrew J. Muir, Michael W. Fried, Nezam H. Afdhal, David B. Goldstein, John G. McHutchison. (2010) Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. Gastroenterology 139:4, 1181-1189.e2
CrossRef522
David L Thomas. (2010) Curing hepatitis C with pills: a step toward global control. The Lancet 376:9751, 1441-1442
CrossRef523
Srunthron Akkarathamrongsin, Masaya Sugiyama, Kentaro Matsuura, Fuat Kurbanov, Yong Poovorawan, Yasuhito Tanaka, Masashi Mizokami. (2010) High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatology Research 40:10, 956-962
CrossRef524
Paul J. Pockros, Fayez M. Hamzeh, Paul Martin, Ellen Lentz, Xiaolei Zhou, Sugantha Govindarajan, Anna S. Lok. (2010) Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 52:4, 1193-1200
CrossRef525
W. Ray Kim, John J. Poterucha. 2010. Hepatitis B and C. , 186-199.
CrossRef526
Bloom Jonathan, Zapf Christoph, Levin Jeremy, Flint Michael. 2010. Recent Advances in Hepatitis C Therapies. .
CrossRef527
Keyur Patel, Hans L Tillmann, John G McHutchison. 2010. Hepatitis C. , 435-447.
CrossRef528
Robert Roomer, Bettina E. Hansen, Harry L.A. Janssen, Robert J. de Knegt. (2010) Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Journal of Hepatology 53:3, 455-459
CrossRef529
Paraskevi Aggelopoulou-Tiga, Dimitrios Dimitroulopoulos, Konstantinos Kaligeros, Sotirios Koutsounas, Elias Kouroumalis, Helen Diamanti, Panagiota Ioannidou, Jannis Kountouras, Christos Papaioannou, Maria Dimopoulou, Grigoris Giannoulis, Ioannis Ketikoglou, Andreas Protopapas, Harry Bassaris, Vassilios Delis, Stylianos Karatapanis, Spilios Manolakopoulos, Konstantinos Mimidis, Antonios Nikolaou, Konstantinos Thomopoulos, Georgios Tzelas, Epameinondas Tsianos, Maria Kardasi, Antonios Perperas. (2010) Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction. European Journal of Gastroenterology & Hepatology 22:9, 1058-1065
CrossRef530
Mazen Noureddin, Marc G. Ghany. (2010) Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C. Gastroenterology Clinics of North America 39:3, 649-658
CrossRef531
Jorge Méndez-Navarro, Ruby A. Chirino, Kathleen E. Corey, Emmanuel C. Gorospe, Hui Zheng, Segundo Morán, Raymond T. Chung, Margarita Dehesa-Violante. (2010) A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients. Digestive Diseases and Sciences 55:9, 2629-2635
CrossRef532
Harel Dahari, Evaldo S. Affonso de Araujo, Bart L. Haagmans, Thomas J. Layden, Scott J. Cotler, Antonio A. Barone, Avidan U. Neumann. (2010) Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes. Journal of Hepatology 53:3, 460-467
CrossRef533
Hans Orlent, Isabelle Desombere, Bettina Hansen, Hans Van Vlierberghe, Bart Haagmans, Robert J. De Knegt, Solko W. Schalm, Geert Leroux-Roels, Harry L.A. Janssen. (2010) Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment. European Journal of Gastroenterology & Hepatology1
CrossRef534
Takuya Miyagi, Tetsuo Takehara, Kumiko Nishio, Satoshi Shimizu, Keisuke Kohga, Wei Li, Tomohide Tatsumi, Naoki Hiramatsu, Tatsuya Kanto, Norio Hayashi. (2010) Altered interferon-α-signaling in natural killer cells from patients with chronic hepatitis C virus infection. Journal of Hepatology 53:3, 424-430
CrossRef535
Darmendra Ramcharran, Abdus S. Wahed, Hari S. Conjeevaram, Rhobert W. Evans, Tianyi Wang, Steven H. Belle, Leland J. Yee, . (2010) Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52:3, 854-863
CrossRef536
Pascal Melin, Michel Chousterman, Thierry Fontanges, Denis Ouzan, Michel Rotily, Jean-Philippe Lang, Patrick Marcellin, Patrice Cacoub. (2010) Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. European Journal of Gastroenterology & Hepatology 22:9, 1050-1057
CrossRef537
Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Makiko Takagi, Takeshi Hiramatsu, Takanori Hosokawa, Takahiro Arakawa, Masashi Fujimori. (2010) An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1. Journal of Medical Virology 82:9, 1537-1544
CrossRef538
Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo. (2010) Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. Nature Reviews Gastroenterology & Hepatology 7:9, 485-494
CrossRef539
Mikio Zeniya, Keitaro Yokoyama, Noritsugu Imamura, Seizo Murai, Tomohisa Ishikawa, Atsushi Hokari, Kazuhiko Koike, Hiroki Takahashi, Syunichi Sadaoka. (2010) Significance of interferon-β for the treatment of hepatitis C virus infection in hemodialyzed patients. Hepatology Research 40:9, 862-869
CrossRef540
Andi Utama, Navessa Padma Tania, Rama Dhenni, Rino Alvani Gani, Irsan Hasan, Andri Sanityoso, Syafruddin A. R. Lelosutan, Ruswhandi Martamala, Laurentius Adrianus Lesmana, Ali Sulaiman, Susan Tai. (2010) Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver International 30:8, 1152-1160
CrossRef541
Kako Mishima, Naoya Sakamoto, Yuko Sekine-Osajima, Mina Nakagawa, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Kei Kiyohashi, Akiko Kitazume, Kiichiro Tsuchiya, Michio Imamura, Nobuhiko Hiraga, Kazuaki Chayama, Takaji Wakita, Mamoru Watanabe. (2010) Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants. Virology 405:2, 361-369
CrossRef542
Omar M. E. Abdel Salam, Amany A. Sleem, Nermeen Shafee. (2010) The effect of serotonin reuptake inhibitors on hepatic injury induced by carbon tetrachloride. Comparative Clinical Pathology
CrossRef543
Frances H. Phillips, Melanie Prebis, Catherine Grumbeck, Teresa Hale, Raul Cubillas, Geri R. Brown. (2010) Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-α-2b and ribavirin. European Journal of Gastroenterology & Hepatology1
CrossRef544
Andrew J. Fowell, Kathryn L. Nash. (2010) Telaprevir: a new hope in the treatment of chronic hepatitis C?. Advances in Therapy 27:8, 512-522
CrossRef545
I. Alam, T. Stainbrook, B. Cecil, K. D. Kistler. (2010) Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Alimentary Pharmacology & Therapeutics 32:4, 535-542
CrossRef546
Jean-Pierre Zarski, Nathalie Sturm, Hervé Desmorat, Pascal Melin, Jean-Jacques Raabe, Corinne Bonny, Philippe Sogni, Alexandrina Pinta, Stéphanie Rouanet, Gérard Babany, Alice Cheveau, Michèle Chevallier. (2010) Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study. Liver International 30:7, 1049-1058
CrossRef547
Paul Lamb, Stephen Harrison. (2010) Metabolic Syndrome and HCV: Where Do We Stand in 2010?. Current Hepatitis Reports 9:3, 133-139
CrossRef548
Masao Honda, Akito Sakai, Tatsuya Yamashita, Yasunari Nakamoto, Eishiro Mizukoshi, Yoshio Sakai, Taro Yamashita, Mikiko Nakamura, Takayoshi Shirasaki, Katsuhisa Horimoto, Yasuhito Tanaka, Katsushi Tokunaga, Masashi Mizokami, Shuichi Kaneko. (2010) Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C. Gastroenterology 139:2, 499-509
CrossRef549
Kai Lin. (2010) Development of novel antiviral therapies for hepatitis C virus. Virologica Sinica 25:4, 246-266
CrossRef550
Laura Milazzo, Spinello Antinori. (2010) STAT-C: a full revolution or just a step forward?. The Lancet 376:9742, 662-663
CrossRef551
Eric Chak, Sammy Saab. (2010) Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. Current Hepatitis Reports 9:3, 147-154
CrossRef552
Nyingi M. Kemmer, Tiffany E. Kaiser, Guy W. Neff. (2010) Hepatitis C After Liver Transplantation: Treatment and Impact on Patient and Graft Survival. Current Hepatitis Reports 9:3, 161-168
CrossRef553
Peter Derek Christian Leutscher, Martin Lagging, Mads Rauning Buhl, Court Pedersen, Gunnar Norkrans, Nina Langeland, Kristine Mørch, Martti Färkkilä, Simon Hjerrild, Kristoffer Hellstrand, Per Bech, . (2010) Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52:2, 430-435
CrossRef554
Vincent Rijckborst, Martijn J ter Borg, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Maria Raptopoulou-Gigi, Necati Örmeci, Pieter E Zondervan, Elke Verhey, Anneke J van Vuuren, Bettina E Hansen, Harry LA Janssen. (2010) A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. The American Journal of Gastroenterology 105:8, 1762-1769
CrossRef555
Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Kazuaki Chayama, Yusuke Nakamura, Hiromitsu Kumada. (2010) Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:2, 421-429
CrossRef556
Paul Kwo. (2010) Viral Kinetics and Duration of Hepatitis C Therapy. Current Hepatitis Reports 9:3, 140-146
CrossRef557
Gabriele Giliberti, Cristina Ibba, Esther Marongiu, Roberta Loddo, Michele Tonelli, Vito Boido, Erik Laurini, Paola Posocco, Maurizio Fermeglia, Sabrina Pricl. (2010) Synergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase. Bioorganic & Medicinal Chemistry 18:16, 6055-6068
CrossRef558
Paul Y Kwo, Eric J Lawitz, Jonathan McCone, Eugene R Schiff, John M Vierling, David Pound, Mitchell N Davis, Joseph S Galati, Stuart C Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Frank H Anderson, Ira M Jacobson, Raymond Rubin, Kenneth Koury, Lisa D Pedicone, Clifford A Brass, Eirum Chaudhri, Janice K Albrecht. (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet 376:9742, 705-716
CrossRef559
Jules L Dienstag. (2010) Editorial: Peginterferon Therapy for HBeAg-Negative Chronic Hepatitis B: Less Than Meets the Eye. The American Journal of Gastroenterology 105:8, 1770-1772
CrossRef560
Jenny Nilsson, Ola Weiland. (2010) Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients. Scandinavian Journal of Infectious Diseases 42:6-7, 533-539
CrossRef561
Hanneke van Soest, Peter J. van der Schaar, Ger H. Koek, Richard A. de Vries, Nancy A. van Ooteghem, Bart van Hoek, Joost P.H. Drenth, Jan M. Vrolijk, Rob J. Lieverse, Peter Houben, Annet van der Sluys Veer, Peter D. Siersema, Marguerite E.I. Schipper, Karel J. van Erpecum, Greet J. Boland. (2010) No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Digestive and Liver Disease 42:7, 496-502
CrossRef562
Magnus Nilsson, Anna Karin Belfrage, Stefan Lindström, Horst Wähling, Charlotta Lindquist, Susana Ayesa, Pia Kahnberg, Mikael Pelcman, Kurt Benkestock, Tatiana Agback, Lotta Vrang, Ylva Terelius, Kristina Wikström, Elizabeth Hamelink, Christina Rydergård, Michael Edlund, Anders Eneroth, Pierre Raboisson, Tse-I Lin, Herman de Kock, Piet Wigerinck, Kenneth Simmen, Bertil Samuelsson, Åsa Rosenquist. (2010) Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: Exploration of P2 quinazoline substituents. Bioorganic & Medicinal Chemistry Letters 20:14, 4004-4011
CrossRef563
Paul E. Holtzheimer, Jason Veitengruber, Chia C. Wang, Meighan Krows, Hanne Thiede, Anna Wald, Peter Roy-Byrne. (2010) Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. General Hospital Psychiatry 32:4, 426-432
CrossRef564
C. M. Lange, C. Sarrazin, S. Zeuzem. (2010) Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Alimentary Pharmacology & Therapeutics 32:1, 14-28
CrossRef565
Thijs JW van de Laar, Gail V Matthews, Maria Prins, Mark Danta. (2010) Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 24:12, 1799-1812
CrossRef566
Alexander J. Thompson, Andrew J. Muir, Mark S. Sulkowski, Dongliang Ge, Jacques Fellay, Kevin V. Shianna, Thomas Urban, Nezam H. Afdhal, Ira M. Jacobson, Rafael Esteban, Fred Poordad, Eric J. Lawitz, Jonathan McCone, Mitchell L. Shiffman, Greg W. Galler, William M. Lee, Robert Reindollar, John W. King, Paul Y. Kwo, Reem H. Ghalib, Bradley Freilich, Lisa M. Nyberg, Stefan Zeuzem, Thierry Poynard, David M. Vock, Karen S. Pieper, Keyur Patel, Hans L. Tillmann, Stephanie Noviello, Kenneth Koury, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, David B. Goldstein, John G. McHutchison. (2010) Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology 139:1, 120-129.e18
CrossRef567
Ryota Masuzaki, Haruhiko Yoshida, Masao Omata. (2010) Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Digestive and Liver Disease 42, S281-S286
CrossRef568
Francis E. Lotrich, Robert E. Ferrell, Mordechai Rabinovitz, Bruce G. Pollock. (2010) Labile Anger During Interferon Alfa Treatment is Associated With a Polymorphism in Tumor Necrosis Factor α. Clinical Neuropharmacology 33:4, 191-197
CrossRef569
Stefan Zeuzem, Fred Poordad. (2010) Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response. Current Medical Research and Opinion 26:7, 1733-1743
CrossRef570
M. V. RAGNI, K. E. SHERMAN, J. A. JORDAN. (2010) Viral pathogens. Haemophilia 16, 40-46
CrossRef571
Giuseppe Barbesino. (2010) Drugs Affecting Thyroid Function. Thyroid 20:7, 763-770
CrossRef572
N. Kamiya, E. Iwao, N. Hiraga, M. Tsuge, M. Imamura, S. Takahashi, S. Miyoshi, C. Tateno, K. Yoshizato, K. Chayama. (2010) Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. Journal of General Virology 91:7, 1668-1677
CrossRef573
Gerardo Alvarez-Uria, Jeremy N. Day, Anisa J. Nasir, Susan K. Russell, F. Javier Vilar. (2010) Reduction in Neutrophil Count During Hepatitis C Treatment: Drug Toxicity or Predictor of Good Response?. Digestive Diseases and Sciences 55:7, 2058-2062
CrossRef574
Sonu Dhillon, Anshul Kaker, Aneil Dosanjh, Deepa Japra, David H. VanThiel. (2010) Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis C. Digestive Diseases and Sciences 55:6, 1785-1790
CrossRef575
Jeanette J. McCarthy, Josephine H. Li, Alexander Thompson, Sunil Suchindran, Xiang Qian Lao, Keyur Patel, Hans L. Tillmann, Andrew J. Muir, John G. McHutchison. (2010) Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology 138:7, 2307-2314
CrossRef576
E Snoeck, P Chanu, M Lavielle, P Jacqmin, E N Jonsson, K Jorga, T Goggin, J Grippo, N L Jumbe, N Frey. (2010) A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure. Clinical Pharmacology & Therapeutics 87:6, 706-713
CrossRef577
Etienne M. Sokal, Annick Bourgois, Xavier Stéphenne, Themis Silveira, Gilda Porta, Dace Gardovska, Björn Fischler, Deirdre Kelly. (2010) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. Journal of Hepatology 52:6, 827-831
CrossRef578
Michael Waizmann, Grit Ackermann. (2010) High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. Journal of Substance Abuse Treatment 38:4, 338-345
CrossRef579
A. MANGIA, O. DALGARD, N. MINERVA, H. VERBAAN, D. BACCA, H. RING-LARSEN, M. COPETTI, V. CARRETTA, V. PIAZZOLLA, R. COZZOLONGO, L. MOTTOLA, A. ANDRIULLI. (2010) Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin. Alimentary Pharmacology & Therapeutics 31:12, 1346-1353
CrossRef580
S. S. Tan, M. R. Abu Hassan, A. Abdullah, B. P. Ooi, T. Korompis, M. I. Merican. (2010) Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C. Journal of Viral Hepatitis 17:6, 410-418
CrossRef581
K. Seden, D. Back, S. Khoo. (2010) New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy 65:6, 1079-1085
CrossRef582
Javid Fazili, Sue Mallonee, William M. Tierney, Teddy F. Bader, Arun K. Sachdev, Philip C. Bird, Robert D. Schmidt, Sikander A. Mesiya, Charles L. Lackey. (2010) Outcome of a Hepatitis C Outbreak Among Patients in a Pain Management Clinic. Digestive Diseases and Sciences 55:6, 1738-1743
CrossRef583
F. F. POORDAD. (2010) Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 31:12, 1251-1267
CrossRef584
F. Morisco, T. Stroffolini, E. Medda, D. C. Amoruso, P. L. Almasio, E. Villa, M. Zuin, B. Paris, M. Stanzione, N. Caporaso, . (2010) Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. Journal of Viral Hepatitis 17:6, 427-434
CrossRef585
Mina Nakagawa, Naoya Sakamoto, Mayumi Ueyama, Kaoru Mogushi, Satoshi Nagaie, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Hiroshi Tanaka, Nobuyuki Enomoto, Mamoru Watanabe. (2010) Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. Journal of Gastroenterology 45:6, 656-665
CrossRef586
Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili, Ran Tur-Kaspa, Lior H Katz. 2010. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response. .
CrossRef587
L. Rong, H. Dahari, R. M. Ribeiro, A. S. Perelson. (2010) Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus. Science Translational Medicine 2:30, 30ra32-30ra32
CrossRef588
Sorin A. Petre, Mankanwal S. Sachdev, Brie N. Noble, Marianne Rosati, Marek J. Mazur, Raymond L. Heilman, M. Edwyn Harrison, David D. Douglas, Vijayan Balan. (2010) Increased Prevalence of Reduced Estimated Glomerular Filtration Rate in Chronic Hepatitis C Patients. Digestive Diseases and Sciences 55:5, 1450-1457
CrossRef589
Yasuhito Tanaka, Nao Nishida, Masaya Sugiyama, Katsushi Tokunaga, Masashi Mizokami. (2010) λ-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. Hepatology Research 40:5, 449-460
CrossRef590
J. H. Patel, J. F. L. Cobbold, H. C. Thomas, S. D. Taylor-Robinson. (2010) Hepatitis C and hepatic steatosis. QJM 103:5, 293-303
CrossRef591
Anthony J Michaels, David R Nelson. (2010) New therapies in the management of hepatitis C virus. Current Opinion in Gastroenterology 26:3, 196-201
CrossRef592
Mikio Kajihara, Sara Montagnese, Pooja Khanna, Piero Amodio, Anthony H.V. Schapira, Geoffrey M. Dusheiko, Marsha Y. Morgan. (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-α2b: a report of two cases. European Journal of Gastroenterology & Hepatology 22:5, 628-631
CrossRef593
S.R. Lee, G.D. Yearwood, G.B. Guillon, L.A. Kurtz, M. Fischl, T. Friel, C.A. Berne, K.W. Kardos. (2010) Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. Journal of Clinical Virology 48:1, 15-17
CrossRef594
T.J.S. Cross, A. Quaglia, J. Nolan, S. Hughes, P.M. Harrison. (2010) Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?. Journal of Medical Virology 82:6, 958-964
CrossRef595
Kenneth E. Sherman. (2010) Thymosin α 1 for treatment of hepatitis C virus: promise and proof. Annals of the New York Academy of Sciences 1194:1, 136-140
CrossRef596
Alexander Monto, Robert T Schooley, Jennifer C Lai, Mark S Sulkowski, Raymond T Chung, Jean-Michel Pawlotsky, John G McHutchison, Ira M Jacobson. (2010) Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. The American Journal of Gastroenterology 105:5, 989-1004
CrossRef597
Peter L. Franzen, Daniel J. Buysse, Mordechai Rabinovitz, Bruce G. Pollock, Francis E. Lotrich. (2010) Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Research 177:1-2, 240-245
CrossRef598
E. Lukasiewicz, M. Gorfine, L. S. Freedman, J.-M. Pawlotsky, S. W. Schalm, C. Ferrari, S. Zeuzem, A. U. Neumann, . (2010) Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. Journal of Viral Hepatitis 17:5, 345-351
CrossRef599
Philip Vutien, Nghia H Nguyen, Huy N Trinh, Jiayi Li, Ruel T Garcia, Gabriel Garcia, Khanh K Nguyen, Huy A Nguyen, Brian S Levitt, Emmet B Keeffe, Mindie H Nguyen. (2010) Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis C. The American Journal of Gastroenterology 105:5, 1110-1115
CrossRef600
K. Yusim, W. Fischer, H. Yoon, J. Thurmond, P. W. Fenimore, G. Lauer, B. Korber, C. Kuiken. (2010) Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. Journal of General Virology 91:5, 1194-1206
CrossRef601
Xavier Forns, Jordi Bruix. (2010) Treating hepatitis C in patients with cirrhosis: The effort is worth it. Journal of Hepatology 52:5, 624-626
CrossRef602
Xiao-Song He, Santosh Nanda, Xuhuai Ji, Gloria M. Calderon-Rodriguez, Harry B. Greenberg, T. Jake Liang. (2010) Differential Transcriptional Responses to Interferon-α and Interferon-γ in Primary Human Hepatocytes. Journal of Interferon & Cytokine Research 30:5, 311-320
CrossRef603
Eric R. Kallwitz. (2010) Ethnic and Racial Differences in the Natural History of Hepatitis C. Current Hepatitis Reports 9:2, 106-112
CrossRef604
Ana-Carolina Cardoso, Rami Moucari, Claudio Figueiredo-Mendes, Marie-Pierre Ripault, Nathalie Giuily, Corinne Castelnau, Nathalie Boyer, Tarik Asselah, Michelle Martinot-Peignoux, Sarah Maylin, Roberto J. Carvalho-Filho, Dominique Valla, Pierre Bedossa, Patrick Marcellin. (2010) Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. Journal of Hepatology 52:5, 652-657
CrossRef605
Yaron Tomer. (2010) Hepatitis C and interferon induced thyroiditis. Journal of Autoimmunity 34:3, J322-J326
CrossRef606
Marc Deschênes, Vincent G. Bain, Samuel S. Lee, Morris Sherman, Curtis L. Cooper, Eric M. Yoshida, Paul J. Marotta, Mel Krajden, Christopher Usaty, Robert Balshaw, Kevork M. Peltekian. (2010) Identifying HCV genotype 1 patients at risk of relapse. European Journal of Gastroenterology & Hepatology 22:5, 546-551
CrossRef607
Y. Inoue, N. Hiramatsu, T. Oze, T. Yakushijin, K. Mochizuki, H. Hagiwara, M. Oshita, E. Mita, H. Fukui, M. Inada, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, T. Miyagi, A. Hohsui, H. Ishida, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi. (2010) Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. Journal of Viral Hepatitis 17:5, 336-344
CrossRef608
A. Ciancio, M. Rizzetto. (2010) Thymalfasin in the treatment of hepatitis B and C. Annals of the New York Academy of Sciences 1194:1, 141-146
CrossRef609
Francesco Iannuzzella, Augusto Vaglio, Giovanni Garini. (2010) Management of Hepatitis C Virus-related Mixed Cryoglobulinemia. The American Journal of Medicine 123:5, 400-408
CrossRef610
Rafael Bárcena, Ana Moreno, José R Foruny, Javier Blázquez, Javier Graus, José M Riesco, Carlos Blesa, Fernando García-Hoz, Juan Sánchez, Luis Gil-Grande, Javier Nuño, Jesús Fortún, Miguel A Rodriguez-Sagrado, Alberto Moreno. (2010) Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: safety, efficacy and long-term outcome. Clinical Transplantation 24:3, 366-374
CrossRef611
Matthew L. Cowan, Tony M. Rahman, Sanjeev Krishna. (2010) Proteomic approaches in the search for biomarkers of liver fibrosis. Trends in Molecular Medicine 16:4, 171-183
CrossRef612
Veronica D. Gonzalez, Alan L. Landay, Johan K. Sandberg. (2010) Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clinical Immunology 135:1, 12-25
CrossRef613
Andreas Maieron, Sigrid Metz-Gercek, Franz Hackl, Alexander Ziachehabi, Harri Fuchsteiner, Christoph Luger, Helmut Mittermayer, Rainer Schöfl. (2010) Antiviral treatment of chronic hepatitis C in clinical routine. Wiener klinische Wochenschrift 122:7-8, 237-242
CrossRef614
Yong-Hak Sohn, Sun-Young Ko, Myeong Hee Kim, Heung-Bum Oh. (2010) Performance evaluation of the Abbott RealTi m e HCV Genotype II for hepatitis C virus genotyping. Clinical Chemistry and Laboratory Medicine 48:4, 469-474
CrossRef615
H. Mawatari, M. Yoneda, K. Fujita, Y. Nozaki, Y. Shinohara, H. Sasaki, H. Iida, H. Takahashi, M. Inamori, Y. Abe, N. Kobayashi, K. Kubota, H. Kirikoshi, A. Nakajima, S. Saito. (2010) Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. Journal of Viral Hepatitis 17:4, 274-279
CrossRef616
Francesco Negro. (2010) Adverse effects of drugs in the treatment of viral hepatitis. Best Practice & Research Clinical Gastroenterology 24:2, 183-192
CrossRef617
Andri Rauch, Zoltán Kutalik, Patrick Descombes, Tao Cai, Julia Di Iulio, Tobias Mueller, Murielle Bochud, Manuel Battegay, Enos Bernasconi, Jan Borovicka, Sara Colombo, Andreas Cerny, Jean–François Dufour, Hansjakob Furrer, Huldrych F. Günthard, Markus Heim, Bernard Hirschel, Raffaele Malinverni, Darius Moradpour, Beat Müllhaupt, Andrea Witteck, Jacques S. Beckmann, Thomas Berg, Sven Bergmann, Francesco Negro, Amalio Telenti, Pierre–Yves Bochud. (2010) Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology 138:4, 1338-1345.e7
CrossRef618
W. J. Cash, K. Patterson, M. E. Callender, N. I. McDougall. (2010) Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients. Journal of Viral Hepatitis 17:4, 269-273
CrossRef619
Paul Feuerstadt, Ari L. Bunim, Heriberto Garcia, Jordan J. Karlitz, Hatef Massoumi, Amar J. Thosani, Andrew Pellecchia, Allan W. Wolkoff, Paul J. Gaglio, John F. Reinus. (2010) Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 51:4, 1137-1143
CrossRef620
Omar Mohamed E. Abdel Salam, Amany A. Sleem, Nermeen Shafee. (2010) Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology 18:2, 87-94
CrossRef621
Mark D. Berzsenyi, Stuart K. Roberts. (2010) Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents. Journal of Gastroenterology and Hepatology 25:4, 655-656
CrossRef622
Cliff C. Cheng, Gerald W. Shipps, Zhiwei Yang, Noriyuki Kawahata, Charles A. Lesburg, José S. Duca, Jamie Bandouveres, Jack D. Bracken, Chuan-kui Jiang, Sony Agrawal, Eric Ferrari, H.-C. Huang. (2010) Inhibitors of hepatitis C virus polymerase: Synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides. Bioorganic & Medicinal Chemistry Letters 20:7, 2119-2124
CrossRef623
Eugenia Vispo, Pablo Labarga, Josep M. Guardiola, Pablo Barreiro, Celia Miralles, Rafael Rubio, Pilar Miralles, Koldo Aguirrebengoa, Joseba Portu, Judit Morello, Sonia Rodriguez-Novoa, Vincent Soriano. (2010) Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. AIDS Research and Human Retroviruses 26:4, 419-424
CrossRef624
Eva Van den Eynde, Juan Manuel Tiraboschi, Cristina Tural, Ricard Solà, José Antonio Mira, Daniel Podzamczer, Antoni Jou, Nuria Cañete, Juan Antonio Pineda, Albert Pahissa, Manuel Crespo. (2010) Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS 24:7, 975-982
CrossRef625
Akito Nozaki, Manabu Morimoto, Masaaki Kondo, Takashi Oshima, Kazushi Numata, Shin Fujisawa, Takeshi Kaneko, Eiji Miyajima, Satoshi Morita, Kyoko Mori, Masanori Ikeda, Nobuyuki Kato, Katsuaki Tanaka. (2010) Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. Archives of Virology 155:4, 601-605
CrossRef626
Paola Piccolo. (2010) Author's reply to Comment on “Treating chronic hepatitis C in recovering opiate addicts: Yes, we can”. Digestive and Liver Disease 42:4, 305-306
CrossRef627
Owen T-Y Tsang, Jonpaul S-T Zee, Jacky M-C Chan, Reggie S-T Li, Yee-Man Kan, Francis T-W Li, Fu-Hang Lo, David A Chow, Kent W-L Cheung, Kam-Hon Chan, Yat-Wah Yeung, Fook-Hong Ng, Michael K-K Li, Wai-Keung Kwan, Thomas S-T Lai. (2010) Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. Journal of Gastroenterology and Hepatology 25:4, 766-771
CrossRef628
François Bailly, Si Nafa Si Ahmed, Pierre Pradat, Christian Trepo. (2010) Management of nonresponsive hepatitis C. Expert Review of Anti-infective Therapy 8:4, 379-395
CrossRef629
Yuko Arima, Naoto Kawabe, Senju Hashimoto, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Kyoko Kobayashi, Naohiro Ichino, Keisuke Osakabe, Toru Nishikawa, Akihiko Okumura, Tetsuya Ishikawa, Kentaro Yoshioka. (2010) Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatology Research 40:4, 383-392
CrossRef630
Izumi Namiki, Shuhei Nishiguchi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshihito Itoh, Yusuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi, Masatoshi Kudo. (2010) Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatology Research 40:4, 347-368
CrossRef631
Ni. Zhang, Zhengwen. Liu, Qunying. Han, Jinghong. Chen, Yi. Lv. (2010) Xanthohumol enhances antiviral effect of interferon α-2b against bovine viral diarrhea virus, a surrogate of hepatitis C virus. Phytomedicine 17:5, 310-316
CrossRef632
Chung-Feng Huang, Jeng-Fu Yang, Jee-Fu Huang, Chia-Yen Dai, Chang-Fu Chiu, Nai-Jen Hou, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang, Ming-Lung Yu. (2010) Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. Journal of Gastroenterology and Hepatology 25:4, 758-765
CrossRef633
Michelle Martinot-Peignoux, Christiane Stern, Sarah Maylin, Marie-Pierre Ripault, Nathalie Boyer, Laurence Leclere, Corinne Castelnau, Nathalie Giuily, Ahmed El Ray, Ana-Carolina Cardoso, Rami Moucari, Tarik Asselah, Patrick Marcellin. (2010) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51:4, 1122-1126
CrossRef634
Y. Miyake, A. Takaki, Y. Iwasaki, K. Yamamoto. (2010) Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 17:4, 287-292
CrossRef635
Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2010) Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Journal of Medical Virology 82:4, 575-582
CrossRef636
Raffaella Lionetti, Giuseppe Tisone, Giampiero Palmieri, Cristiana Almerighi, Alessandra Anselmo, Laura Tariciotti, Ilaria Lenci, Linda De Luca, Andrea Monaco, Mario Angelico. (2010) Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. Digestive and Liver Disease 42:4, 297-303
CrossRef637
S. J. Polyak, C. Morishima, V. Lohmann, S. Pal, D. Y. W. Lee, Y. Liu, T. N. Graf, N. H. Oberlies. (2010) Identification of hepatoprotective flavonolignans from silymarin. Proceedings of the National Academy of Sciences 107:13, 5995-5999
CrossRef638
Peter Simmonds, David Mutimer. 2010. Hepatitis C Virus. .
CrossRef639
Jason Grebely, Elizabeth Knight, Krista A. Genoway, Mark Viljoen, Milan Khara, Doug Elliott, Lesley Gallagher, Michelle Storms, Jesse D. Raffa, Stanley DeVlaming, Fiona Duncan, Brian Conway. (2010) Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology 22:3, 270-277
CrossRef640
Michele Tonelli, Vito Boido, Paolo La Colla, Roberta Loddo, Paola Posocco, Maria Silvia Paneni, Maurizio Fermeglia, Sabrina Pricl. (2010) Pharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: Combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV). Bioorganic & Medicinal Chemistry 18:6, 2304-2316
CrossRef641
Y. Imai, S. Tamura, H. Tanaka, N. Hiramatsu, S. Kiso, Y. Doi, M. Inada, T. Nagase, T. Kitada, K. Imanaka, K. Fukuda, T. Takehara, A. Kasahara, N. Hayashi. (2010) Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. Journal of Viral Hepatitis 17:3, 185-191
CrossRef642
Brian Rha, David Kimberlin, Richard Whitley. 2010. Antiviral Therapy. , 210-225.
CrossRef643
Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Makiko Takagi, Takeshi Hiramatsu, Takanori Hosokawa, Takahiro Arakawa, Masashi Fujimori. (2010) Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b. Journal of Clinical Virology 47:3, 258-262
CrossRef644
Ashwani K. Singal, Bhupinder S. Anand. (2010) Tailoring Treatment Duration to 12 to 16 Weeks in Hepatitis C Genotype 2 or 3 With Rapid Virologic Response. Journal of Clinical Gastroenterology1
CrossRef645
U. Mihm, W. P. Hofmann, C. Welsch, A. Polta, T. Lengauer, S. Zeuzem, C. Sarrazin, E. Herrmann. (2010) Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. Journal of Viral Hepatitis 17:3, 217-221
CrossRef646
Mamta K Jain, Cindy Zoellner. (2010) Role of ribavirin in HCV treatment response: now and in the future. Expert Opinion on Pharmacotherapy 11:4, 673-683
CrossRef647
V. Bekker, S. J. Chanock, M. Yeager, A. A. Hutchinson, T. von Hahn, S. Chen, N. Xiao, M. Dotrang, M. Brown, M. P. Busch, B. R. Edlin, C. M. Rice, T. R. O’Brien. (2010) Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. Journal of Viral Hepatitis 17:3, 192-200
CrossRef648
Y Horsmans. (2010) Treatment of chronic hepatitis C in elderly patients. Expert Opinion on Pharmacotherapy 11:4, 571-577
CrossRef649
Masayuki Kurosaki, Kotaro Matsunaga, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Yutaka Yasui, Nobuharu Tamaki, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Hiroki Ikeda, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Megumu Higaki, Nobuyuki Enomoto, Namiki Izumi. (2010) A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatology Research 40:3, 251-260
CrossRef650
Henk W. Reesink, Gregory C. Fanning, Khalid Abou Farha, Christine Weegink, André Van Vliet, Gerben van 't Klooster, Oliver Lenz, Fatima Aharchi, Kris Mariën, Pieter Van Remoortere, Herman de Kock, Fabrice Broeckaert, Paul Meyvisch, Els Van Beirendonck, Kenneth Simmen, René Verloes. (2010) Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients. Gastroenterology 138:3, 913-921
CrossRef651
Abdelhakim Ahmed–Belkacem, Nazim Ahnou, Laetitia Barbotte, Czeslaw Wychowski, Coralie Pallier, Rozenn Brillet, Ralf–Torsten Pohl, Jean–Michel Pawlotsky. (2010) Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology 138:3, 1112-1122
CrossRef652
John Scott, Atif Zaman, Michael Chang. 2010. Viral Hepatitis. , 315-327.
CrossRef653
H. J. Yuan, M. Jain, K. K. Snow, M. Gale Jr, W. M. Lee, . (2010) Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. Journal of Viral Hepatitis 17:3, 208-216
CrossRef654
Limin Chen, Ivan Borozan, Jing Sun, Maha Guindi, Sandra Fischer, Jordan Feld, Nitasha Anand, Jenny Heathcote, Aled M. Edwards, Ian D. McGilvray. (2010) Cell-Type Specific Gene Expression Signature in Liver Underlies Response to Interferon Therapy in Chronic Hepatitis C Infection. Gastroenterology 138:3, 1123-1133.e3
CrossRef655
Omar Dessouki, Yasuyuki Kamiya, Hiroyasu Nagahama, Motohiko Tanaka, Shinya Suzu, Yutaka Sasaki, Seiji Okada. (2010) Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment. Biochemical and Biophysical Research Communications 393:2, 331-337
CrossRef656
Tomohiko Akahoshi, Morimasa Tomikawa, Daisuke Korenaga, Koji Ikejiri, Motonori Saku, Kenji Takenaka. (2010) Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surgical Endoscopy 24:3, 680-685
CrossRef657
Satoru Tamura, Gang-Ming Yang, Natsuko Yasueda, Yoshiharu Matsuura, Yasumasa Komoda, Nobutoshi Murakami. (2010) Tellimagrandin I, HCV invasion inhibitor from Rosae Rugosae Flos. Bioorganic & Medicinal Chemistry Letters 20:5, 1598-1600
CrossRef658
Kenneth A. Harris, Julia H. Arnsten, Alain H. Litwin. (2010) Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance. Journal of Addiction Medicine 4:1, 20-26
CrossRef659
Amira Pierucci-Lagha, Jonathan Covault, Herbert L. Bonkovsky, Richard Feinn, Christine Abreu, Richard K. Sterling, Robert J. Fontana, Henry R. Kranzler. (2010) A Functional Serotonin Transporter Gene Polymorphism and Depressive Effects Associated With Interferon-α Treatment. Psychosomatics 51:2, 137-148
CrossRef660
E. G. GIANNINI, M. BASSO, V. SAVARINO, A. PICCIOTTO. (2010) Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Alimentary Pharmacology & Therapeutics 31:4, 502-508
CrossRef661
M. Rodriguez-Torres, M. S. Sulkowski, R. T. Chung, F. M. Hamzeh, D. M. Jensen. (2010) Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. Journal of Viral Hepatitis 17:2, 139-147
CrossRef662
Gary L. Davis, Miriam J. Alter, Hashem El–Serag, Thierry Poynard, Linda W. Jennings. (2010) Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology 138:2, 513-521.e6
CrossRef663
Jagdish S. Nachnani, Gowtham A. Rao, Deepti Bulchandani, Prashant K. Pandya, Laura M. Alba. (2010) Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Annals of Hematology 89:2, 121-125
CrossRef664
T. L. Kieffer, A. D. Kwong, G. R. Picchio. (2010) Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). Journal of Antimicrobial Chemotherapy 65:2, 202-212
CrossRef665
Sumio Watanabe, Nobuyuki Enomoto, Kazuhiko Koike, Namiki Izumi, Hajime Takikawa, Etsuko Hashimoto, Fuminori Moriyasu, Hiromitsu Kumada, Michio Imawari, . (2010) Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatology Research 40:2, 135-144
CrossRef666
Thomas von Hahn, Eike Steinmann, Sandra Ciesek, Thomas Pietschmann. (2010) Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology & Hepatology 4:1, 63-79
CrossRef667
K. NOUSO, Y. KOBAYASHI, S. NAKAMURA, S. KOBAYASHI, J. TOSHIMORI, K. KUWAKI, H. HAGIHARA, H. ONISHI, Y. MIYAKE, F. IKEDA, H. SHIRAHA, A. TAKAKI, Y. IWASAKI, H. KOBASHI, K. YAMAMOTO. (2010) Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology & Therapeutics 31:3, 407-414
CrossRef668
Savino Bruno, Mitchell L. Shiffman, Stuart K. Roberts, Edward J. Gane, Diethelm Messinger, Stephanos J. Hadziyannis, Patrick Marcellin. (2010) Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51:2, 388-397
CrossRef669
María Luisa Gutiérrez García, Sonia Alonso López, Conrado Fernández Rodríguez. (2010) Tratamiento actual de la hepatitis crónica C. Factores que influyen en las tasas de recidiva y su efecto en la respuesta virológica sostenida. Medicina Clínica 134:4, 169-172
CrossRef670
Li-Wei Chen, Rong-Nan Chien, Cho-Li Yen, Jia-Jang Chang, Ching-Jung Liu, Chih-Lang Lin. (2010) Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. Journal of Gastroenterology and Hepatology 25:2, 259-263
CrossRef671
Chihiro Morishima, Margaret C. Shuhart, Chia C. Wang, Denise M. Paschal, Minjun C. Apodaca, Yanze Liu, Derek D. Sloan, Tyler N. Graf, Nicholas H. Oberlies, David Y.–W. Lee. (2010) Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection. Gastroenterology 138:2, 671-681.e2
CrossRef672
Sanjaya K. Satapathy, Chandra Sekhar Lingisetty, Shawnette Proper, Shobhana Chaudhari, Susan Williams. (2010) Equally Poor Outcomes to Pegylated Interferon-based Therapy in African Americans and Hispanics With Chronic Hepatitis C Infection. Journal of Clinical Gastroenterology 44:2, 140-145
CrossRef673
Gary L. Davis, William L. Roberts. (2010) The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers. Current Gastroenterology Reports 12:1, 1-6
CrossRef674
Conrado M. Fernández Rodríguez, Sonia Alonso López. (2010) Optimización del tratamiento de la hepatitis crónica por virus C. Gastroenterología y Hepatología 33:2, 119-125
CrossRef675
Peter Ferenci, Hermann Laferl, Thomas–Matthias Scherzer, Andreas Maieron, Harald Hofer, Rudolf Stauber, Michael Gschwantler, Harald Brunner, Christoph Wenisch, Martin Bischof. (2010) Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response. Gastroenterology 138:2, 503-512.e1
CrossRef676
Jeffery M. Klco, Bob Geng, Elizabeth M. Brunt, Anjum Hassan, Tu-Dung Nguyen, Friederike H. Kreisel, Mauricio Lisker-Melman, John L. Frater. (2010) Bone marrow biopsy in patients with hepatitis C virus infection: Spectrum of findings and diagnostic utility. American Journal of Hematology 85:2, 106-110
CrossRef677
Mitchell L. Shiffman. (2010) Treatment of Hepatitis C in 2011: What Can We Expect?. Current Gastroenterology Reports 12:1, 70-75
CrossRef678
Neelam Mohan, Regino P González-Peralta, Tomoo Fujisawa, Mei-Hwei Chang, Solange Heller, Paloma Jara, Deirdre Kelly, Giorgina Mieli-Vergani, Uzma Shah, Karen F Murray. (2010) Chronic Hepatitis C Virus Infection in Children. Journal of Pediatric Gastroenterology and Nutrition 50:2, 123-131
CrossRef679
T. Witthoeft, D. Hueppe, C. John, J. Goelz, R. Heyne, B. Moeller, G. Teuber, S. Wollschlaeger, A. Baumgarten, K.-G. Simon, G. Moog, N. Dikopoulos, S. Mauss. (2010) Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study. Journal of Viral Hepatitis
CrossRef680
Norah Terrault, Mandana Khalili, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. (2010) A glimpse of future hepatitis C virus treatment paradigms. Hepatology 51:2, 707-710
CrossRef681
Jesper Brok, Lise Lotte Gluud, Christian Gluud, Jesper Brok. 2010. Ribavirin plus interferon versus interferon for chronic hepatitis C. .
CrossRef682
Maja Ruzic, Milotka Fabri, Biljana Klasnja, Marta Pobor, Daniela Svarc, Aleksandra Jovelic, Izabela Fabri. (2010) Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users. Srpski arhiv za celokupno lekarstvo 138:1-2, 43-49
CrossRef683
Robert M. Friedman, Sara Contente. (2010) Treatment of Hepatitis C Infections with Interferon: A Historical Perspective. Hepatitis Research and Treatment 2010, 1-4
CrossRef684
Toshihiko Mizuta, Yasunori Kawaguchi, Yuichiro Eguchi, Hirokazu Takahashi, Keisuke Ario, Takumi Akiyama, Noriko Oza, Taiga Otsuka, Takuya Kuwashiro, Toru Yoshimura, Akitaka Hisatomi, Iwata Ozaki. (2010) Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load. Digestive Diseases and Sciences 55:1, 183-189
CrossRef685
Antonio Ascione, Massimo De Luca, Maria Teresa Tartaglione, Filippo Lampasi, Giovan Giuseppe Di Costanzo, Alfonso Galeota Lanza, Francesco Paolo Picciotto, Giuseppina Marino–Marsilia, Luca Fontanella, Gioacchino Leandro. (2010) Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology 138:1, 116-122
CrossRef686
Yasuhiko Sugawara, Sumihito Tamura, Norihiro Kokudo. (2010) Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation. Hepatitis Research and Treatment 2010, 1-9
CrossRef687
Antonio Craxì. (2010) PEG IFN alfa-2a vs. alfa-2b: And the winner is …?. Journal of Hepatology 52:1, 133-135
CrossRef688
Chun I. Yu, Bor-Luen Chiang. (2010) A New Insight into Hepatitis C Vaccine Development. Journal of Biomedicine and Biotechnology 2010, 1-12
CrossRef689
Mariko Kobayashi, Norio Akuta, Fumitaka Suzuki, Tetsuya Hosaka, Hitomi Sezaki, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Sachiyo Watahiki, Rie Mineta, Satomi Iwasaki, Yuzo Miyakawa, Hiromitsu Kumada. (2010) Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. Journal of Medical Virology 82:1, 41-48
CrossRef690
Katia Falasca, Claudio Ucciferri, Paola Mancino, Valeria Gorgoretti, Eligio Pizzigallo, Jacopo Vecchiet. (2010) Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. Journal of Medical Virology 82:1, 49-56
CrossRef691
Arne Schäfer, Michael Scheurlen, Jochen Seufert, Christian Keicher, Benedikt Weißbrich, Peter Rieger, Michael R. Kraus. (2010) Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. Journal of Hepatology 52:1, 10-15
CrossRef692
Yasuji Arase, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Naoki Matsumoto, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2010) Efficacy and Safety of Combination Therapy of Natural Human Interferon β and Ribavirin in Chronic Hepatitis C Patients with Genotype 2 and High Virus Load. Internal Medicine 49:11, 965-970
CrossRef693
Yun Nah Lee, Soung Won Jeong, Jae Hee Lim, Yang Seon Ryu, Seong Ran Jeon, Sang Kyun Kim, Jae Young Jang, Young Seok Kim, Boo Sung Kim, Mi Oh Roh. (2010) Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. The Korean Journal of Hepatology 16:2, 187
CrossRef694
Toshiro Ogata, Masayoshi Kage. (2010) Reconsideration of splenectomy for cirrhotic patients -Tracing the history and pitfalls-. Kanzo 51:5, 205-218
CrossRef695
G. Sroczynski, E. Esteban, A. Conrads-Frank, R. Schwarzer, N. Mühlberger, D. Wright, S. Zeuzem, U. Siebert. (2010) Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. Journal of Viral Hepatitis 17:1, 34-50
CrossRef696
Graham R. Foster. (2010) Pegylated Interferons for the Treatment of Chronic Hepatitis C. Drugs 70:2, 147-165
CrossRef697
Hideaki Kato, Takuya Fujishiro, Makoto Narita. (2010) A Case of Severe Thrombocytopenia in a Patient with Chronic Hepatitis C Caused by a Single Administration of Pegylated Interferon Alpha 2a Subsequent to 48 Weeks of Pegylated Interferon Alpha 2b Plus Ribavirin Therapy. Internal Medicine 49:16, 1741-1744
CrossRef698
Patrick Marcellin, Robert G. Gish, Norman Gitlin, Jamie Heise, Deanine G. Halliman, Eric Chun, Maribel Rodriguez-Torres. (2010) Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients. Journal of Hepatology 52:1, 32-38
CrossRef699
Tetsuo TAKEHARA. (2010) Antiviral Therapy for Chronic Hepatitis C: Current Status and Perspectives. YAKUGAKU ZASSHI 130:2, 143-156
CrossRef700
Ashok Jain, Rajeev Sharma, Charlotte Ryan, Saman Safadjou, Randeep Kashyap, Parvez Mantry, Benedict Maliakkal, Mark Orloff. (2010) Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clinical Transplantation 24:1, 104-111
CrossRef701
Nobuo Waguri, Koichi Furukawa, Haruo Ikeda, Masahiro Hayashi, Junji Kouhisa, Isamu Hama, Takeshi Yokoo, Tsuneo Aiba, Osamu Yoneyama, Kazuhito Sugimura, Kentaro Igarashi, Satoshi Tsukioka. (2010) A case of hepatitis C related cirrhosis with sustained virological response by a long-term, intermittent use of low-dose natural interferon-alpha. Kanzo 51:1, 6-12
CrossRef702
Tsung-Ming Chen, Pi-Teh Huang, Ching-Heng Lin, Ming-Hung Tsai, Lien-Fu Lin, Chung-Cheng Liu, Ka-Sic Ho, Jai-Nien Tung. (2010) Feasibility of individualized treatment for hepatitis C patients in the real world. Journal of Gastroenterology and Hepatology 25:1, 61-69
CrossRef703
Stefan Zeuzem. (2010) Do Differences in Pegylation of Interferon Alfa Matter?. Gastroenterology 138:1, 34-36
CrossRef704
(2010) Unmasking of coeliac disease on interferon treatment for hepatitis C. Internal Medicine Journal 40:1, 85-87
CrossRef705
M. Rodriguez-Torres, F. Torriani, J. Rockstroh, J. Depamphilis, G. Carosi, D.T. Dieterich. (2010) Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin. HIV Clinical Trials 11:1, 1-10
CrossRef706
Rinat Cohen-Moreno, Miriam Schiff, Shabtay Levitt, Rachel Bar-Hamburger, Shiela Strauss, Yehuda Neumark. (2010) Knowledge About Hepatitis-C Among Methadone Maintenance Treatment Patients in Israel. Substance Use & Misuse 45:1-2, 58-76
CrossRef707
Christophe Moreno, Pierre Deltenre, Jean-Michel Pawlotsky, Jean Henrion, Michael Adler, Philippe Mathurin. (2010) Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis. Journal of Hepatology 52:1, 25-31
CrossRef708
Makoto Numata, Tatehiro Kagawa, Sei-ichiro Kojima, Shunji Hirose, Naruhiko Nagata, Koichi Shiraishi, Norihito Watanabe, Hirokazu Shiozawa, Yasuhiro Nishizaki, Shigeyuki Motegi, Shinji Takashimizu, Jun-ichiro Kamochi, Mitsuru Wasada, Takashi Ohno, Yoshihiro Tei, Atsushi Nakano, Takuji Yamada, Kazuhiro Atsukawa, Tetsu Watanabe, Tetsuya Mine. (2010) Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C. Hepatitis Research and Treatment 2010, 1-6
CrossRef709
Joseph Moussalli, Helene Delaquaize, Dominique Boubilley, Jean Pierre Lhomme, Jules Merleau Ponty, David Sabot, Anne Kerever, Marc Valleur, Thierry Poynard. (2010) Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre. Gastroenterology Research and Practice 2010, 1-4
CrossRef710
Rie Kubota, Takako Komiyama, Naoki Kumagai, Miyuki Kimijima, Keiko Mitsuki, Junko Uetake, Fumihiko Kaneko, Satoshi Tsunematsu, Kanji Tsuchimoto. (2010) Optimal Erythrocyte Ribavirin Level to Reduce the Risk of Anemia and Obtain an Early Virological Response in Patients with Chronic Hepatitis C Caused by Genotype 1b Infection. Hepatitis Research and Treatment 2010, 1-5
CrossRef711
Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Hitomi Sezaki, Hiromi Yatsuji, Yasuji Arase, Miharu Hirakawa, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Sachiyo Watahiki, Rie Mineta, Satomi Iwasaki, Hiromitsu Kumada. (2010) Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. Journal of Clinical Virology 47:1, 76-78
CrossRef712
Chun-Hao Chen, Ming-Lung Yu. (2010) Evolution of Interferon-Based Therapy for Chronic Hepatitis C. Hepatitis Research and Treatment 2010, 1-12
CrossRef713
Yasuji Arase, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2010) Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C Patients with Genotype 1b and High Virus Load. Internal Medicine 49:11, 957-963
CrossRef714
Tatehiro Kagawa, Emmet B. Keeffe. (2010) Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C. Hepatitis Research and Treatment 2010, 1-9
CrossRef715
Fariba S. Younai. (2010) Health Care–Associated Transmission of Hepatitis B & C Viruses in Dental Care (Dentistry). Clinics in Liver Disease 14:1, 93
CrossRef716
Katharina C. Kaehler, Vernon K. Sondak, Dirk Schadendorf, Axel Hauschild. (2010) Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. European Journal of Cancer 46:1, 41-46
CrossRef717
In Hee Kim. (2010) Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response. The Korean Journal of Hepatology 16:2, 201
CrossRef718
C. Kent Martin, Jeffrey E. Hostetter, John J. Hagan. (2010) New Opportunities for the Management and Therapy of Hepatitis C in Correctional Settings. American Journal of Public Health 100:1, 13-17
CrossRef719
Maria Grazia Rumi, Alessio Aghemo, Gian Maria Prati, Roberta D'Ambrosio, Maria Francesca Donato, Roberta Soffredini, Ersilio Del Ninno, Antonio Russo, Massimo Colombo. (2010) Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology 138:1, 108-115
CrossRef720
Sung Soo Moon, Hyoun Gu Kang, Jeong Ah Seo, Eun Uk Jung, Sang Heon Lee, Sung Jae Park, Youn Jae Lee, Sang Yong Seol. (2010) 24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia. The Korean Journal of Gastroenterology 56:1, 33
CrossRef721
Hong Ryeol Cheong, Hyun Young Woo, Jeong Heo, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Dae Hwan Kang, Geun Am Song, Mong Cho. (2010) Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection. The Korean Journal of Hepatology 16:1, 38
CrossRef722
Halim Muslu. 2010. Viral Hepatitis. , 100-106.
CrossRef723
Harald Farnik, Juliane El-Duweik, Christoph Welsch, Christoph Sarrazin, Jörn Lötsch, Stefan Zeuzem, Gerd Geisslinger, Helmut Schmidt. (2009) Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC–MS/MS. Journal of Chromatography B 877:31, 4001-4006
CrossRef724
Neumann U Avidan, Deborah Goldstein, Lynn Rozenberg, Mary McLaughlin, Peter Ferenci, Henry Masur, Maria Buti, Anthony S Fauci, Michael A Polis, Shyam Kottilil. (2009) Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell Counts. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:4, 452-458
CrossRef725
Yaron Tomer, Francesca Menconi. (2009) Interferon induced thyroiditis. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, 703-712
CrossRef726
Donna M Evon, Darmendra Ramcharran, Steven H Belle, Norah A Terrault, Robert J Fontana, Michael W Fried. (2009) Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C: Results of the Virahep-C Study. The American Journal of Gastroenterology 104:12, 2949-2958
CrossRef727
D. T. Dieterich, M. Rizzetto, M. P. Manns. (2009) Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. Journal of Viral Hepatitis 16:12, 833-843
CrossRef728
Florence Legrand-Abravanel, Philippe Colson, Hélène Leguillou-Guillemette, Laurent Alric, Isabelle Ravaux, Françoise Lunel-Fabiani, Magali Bouviers-Alias, Pascale Trimoulet, Marie Laure Chaix, Christophe Hézode, Juliette Foucher, Hélène Fontaine, Anne-Marie Roque-Afonso, Michèle Gassin, Evelyne Schvoerer, Catherine Gaudy, Bruno Roche, Michel Doffoël, Louis D'Alteroche, Sophie Vallet, Yazid Baazia, Bruno Pozzetto, Vincent Thibault, Jean-Baptiste Nousbaum, Dominique Roulot, Henry Coppere, Thierry Poinard, Christopher Payan, Jacques Izopet. (2009) Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology 81:12, 2029-2035
CrossRef729
Vinod K. Rustgi, William M. Lee, Eric Lawitz, Stuart C. Gordon, Nezam Afdhal, Fred Poordad, Herbert L. Bonkovsky, Leif Bengtsson, Gurudatt Chandorkar, Matthew Harding, Lindsay McNair, Molly Aalyson, John Alam, Robert Kauffman, Shahin Gharakhanian, John G. McHutchison, . (2009) Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology 50:6, 1719-1726
CrossRef730
Karen Chan Osilla, Gery Ryan, Laveeza Bhatti, Matthew Goetz, Mallory Witt, Glenn Wagner. (2009) Factors That Influence an HIV Coinfected Patient's Decision to Start Hepatitis C Treatment. AIDS Patient Care and STDs 23:12, 993-999
CrossRef731
Dimitrios Dimitroulopoulos, Elefteria Petroulaki, Spilios Manolakopoulos, Olga Anagnostou, Domna Tsaklakidou, Dimitrios Xinopoulos, Klisthenis Tsamakidis, Dimitrios Tzourmakliotis, Emmanouel Paraskevas. (2009) Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance. European Journal of Gastroenterology & Hepatology 21:12, 1407-1412
CrossRef732
E. G. Giannini, M. Basso, V. Savarino, A. Picciotto. (2009) Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. Journal of Internal Medicine 266:6, 537-546
CrossRef733
Gillian M. Keating. (2009) Peginterferon-α-2a (40 kD). Drugs 69:18, 2633-2660
CrossRef734
J. Levitsky, K. Doucette, . (2009) Viral Hepatitis in Solid Organ Transplant Recipients. American Journal of Transplantation 9, S116-S130
CrossRef735
R.-F. ZHANG, H.-Q. SUN, Q. HUANG, J.-R. WANG, X.-X. ZHANG, X.-N. LIU, Q. MA, H.-Z. LU. (2009) Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia. Haemophilia
CrossRef736
Urtzi Garaigorta, Francis V. Chisari. (2009) Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation. Cell Host & Microbe 6:6, 513-522
CrossRef737
Sarah L. Fishman, Andrea D. Branch. (2009) The quasispecies nature and biological implications of the hepatitis C virus. Infection, Genetics and Evolution 9:6, 1158-1167
CrossRef738
Julian Schulze zur Wiesch, Ansgar W. Lohse, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. (2009) Results of the IDEAL trial: “Mirror, mirror on the wall … Which's the fairest peg-interferon of them all?”. Hepatology 50:6, 2034-2037
CrossRef739
Mitchell L. Shiffman, Chihiro Morishima, Jules L. Dienstag, Karen L. Lindsay, John C. Hoefs, William M. Lee, Elizabeth C. Wright, Deepa Naishadham, Gregory T. Everson, Anna S. Lok, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, Marc G. Ghany. (2009) Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology 137:6, 1986-1994
CrossRef740
Catherine François, Sandrine Castelain, Gilles Duverlie, Dominique Capron, Eric Nguyen-Khac. (2009) Optimizing the treatment of chronic viral hepatitis C. Expert Review of Gastroenterology & Hepatology 3:6, 607-613
CrossRef741
N. Bouzgarrou, E. Hassen, W. Mahfoudh, S. Gabbouj, E. Schvoerer, A. Ben Yahia, N. Ben Mami, H. Triki, L. Chouchane. (2009) NS5A ISDR-V3 region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/Ribavirin therapy. Journal of Medical Virology 81:12, 2021-2028
CrossRef742
M. E. MANCUSO, M. G. RUMI, A. AGHEMO, E. SANTAGOSTINO, M. PUOTI, A. COPPOLA, M. COLOMBO, P. M. MANNUCCI. (2009) Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. Journal of Thrombosis and Haemostasis 7:12, 1997-2005
CrossRef743
Hesham M. Elgouhari, Claudia O. Zein, Ibrahim Hanouneh, Ariel E. Feldstein, Nizar N. Zein. (2009) Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection. Digestive Diseases and Sciences 54:12, 2699-2705
CrossRef744
Luigi E. Adinolfi, Emanuele Durante-Mangoni, Marta Salzillo, Aldo Marrone, Marie-Francoise Tripodi, Luciano Restivo, Antonietta Merola, Rosa Zampino, Giuseppe Ruggiero. (2009) Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon. Internal and Emergency Medicine 4:6, 485-490
CrossRef745
Hitoshi Tajiri, Ayano Inui, Yuki Kiyohara, Mitsuyoshi Suzuki, Seiichi Kagimoto, Yuri Etani, Toshiaki Shimizu, Tomoo Fujisawa. (2009) Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. European Journal of Gastroenterology & Hepatology 21:11, 1256-1260
CrossRef746
Neal D. Freedman, James E. Everhart, Karen L. Lindsay, Marc G. Ghany, Teresa M. Curto, Mitchell L. Shiffman, William M. Lee, Anna S. Lok, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, John C. Hoefs, Jules L. Dienstag, Chihiro Morishima, Christian C. Abnet, Rashmi Sinha, . (2009) Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 50:5, 1360-1369
CrossRef747
John D. Scott, Anna Wald, Mari Kitahata, Elizabeth Krantz, Linda Drolette, Lawrence Corey, Chia C. Wang. (2009) Hepatitis C Virus Is Infrequently Evaluated and Treated in an Urban HIV Clinic Population. AIDS Patient Care and STDs 23:11, 925-929
CrossRef748
Jeffrey J. Weiss, Susan Morgello. (2009) Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. General Hospital Psychiatry 31:6, 531-537
CrossRef749
Sylvie Deuffic-Burban, Gérard Babany, Isabelle Lonjon-Domanec, Pierre Deltenre, Valérie Canva-Delcambre, Sébastien Dharancy, Alexandre Louvet, Françoise Roudot-Thoraval, Philippe Mathurin. (2009) Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 50:5, 1351-1359
CrossRef750
F. SCHMIDT, G. JANSSEN, G. MARTIN, R. LORENZ, K. LOESCHKE, M. SOYKA, C. FOLWACZNY, M. SCHAEFER. (2009) Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Alimentary Pharmacology & Therapeutics 30:10, 1049-1059
CrossRef751
Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Hitomi Sezaki, Hiromi Yatsuji, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Yasuji Arase, Kenji Ikeda, Rie Mineta, Satomi Iwasaki, Sachiyo Watahiki, Mariko Kobayashi, Yuzo Miyakawa, Hiromitsu Kumada. (2009) Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatology Research 39:11, 1056-1063
CrossRef752
Robert Chase, Angela Skelton, Ellen Xia, Stephanie Curry, Shaotang Liu, Patricia McMonagle, H.-C. Huang, Xiao Tong. (2009) A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Research 84:2, 178-184
CrossRef753
Michelle Martinot-Peignoux, Hacène Khiri, Laurence Leclere, Sarah Maylin, Patrick Marcellin, Philippe Halfon. (2009) Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. Journal of Clinical Virology 46:3, 216-221
CrossRef754
W. Ray Kim, Norah A. Terrault, Rachel A. Pedersen, Terry M. Therneau, Erick Edwards, Andrew A. Hindman, Carol L. Brosgart. (2009) Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. Gastroenterology 137:5, 1680-1686
CrossRef755
Nazia Selzner, Eberhard L. Renner, Markus Selzner, Oyedele Adeyi, Arash Kashfi, George Therapondos, Nigel Girgrah, Chaturika Herath, Gary A. Levy, Leslie Lilly. (2009) Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome. Transplantation 88:10, 1214-1221
CrossRef756
Emilio Palumbo. (2009) Peg-Interferon in Acute and Chronic Hepatitis C: A Review. American Journal of Therapeutics 16:6, 573-578
CrossRef757
Lynn Rozenberg, Bart L Haagmans, Avidan U Neumann, Grace Chen, Mary McLaughlin, Rachel S Levy-Drummer, H Masur, Robin L Dewar, Peter Ferenci, Marcelo Silva, Maria S Viola, Michael A Polis, Shyam Kottilil. (2009) Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 23:18, 2439-2450
CrossRef758
H.-H. Thein, Q. Yi, E. J. Heathcote, M. D. Krahn. (2009) Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. Journal of Viral Hepatitis 16:11, 802-813
CrossRef759
Medhat Askar, Robin Avery, Rebecca Corey, Rocio Lopez, Dawn Thomas, Diane Pidwell, Bijan Eghtesad, Charles Miller, John Fung, Nizar N. Zein. (2009) Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients. Liver Transplantation 15:11, 1557-1563
CrossRef760
Andri Rauch, Ian James, Katja Pfafferott, David Nolan, Paul Klenerman, Wendy Cheng, Lindsay Mollison, Geoff McCaughan, Nick Shackel, Gary P. Jeffrey, Ross Baker, Elizabeth Freitas, Isla Humphreys, Hansjakob Furrer, Huldrych F. Günthard, Bernard Hirschel, Simon Mallal, Mina John, Michaela Lucas, Eleanor Barnes, Silvana Gaudieri. (2009) Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 50:4, 1017-1029
CrossRef761
Marcello Persico, Roberta Russo, Eliana Persico, Monica Svelto, Daniela Spano, Immacolata Andolfo, Vincenzo La Mura, Mario Capasso, Claudio Tiribelli, Roberto Torella, Achille Iolascon. (2009) SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clinical Chemistry and Laboratory Medicine 47:10, 1217-1225
CrossRef762
F. Negro, S. Clément. (2009) Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Journal of Viral Hepatitis 16:10, 681-688
CrossRef763
K. Ikezawa, M. Naito, T. Yumiba, K. Iwahashi, Y. Onishi, H. Kita, A. Nishio, T. Kanno, T. Matsuura, A. Ono, M. Chiba, T. Mizuno, H. Aketa, K. Maeda, T. Michida, K. Katayama. (2009) Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis
CrossRef764
Ken-ichi Abe, Masanori Ikeda, Yasuo Ariumi, Hiromichi Dansako, Takaji Wakita, Nobuyuki Kato. (2009) HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. Archives of Virology 154:10, 1671-1677
CrossRef765
Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo. (2009) Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Review of Anti-infective Therapy 7:8, 925-935
CrossRef766
Vijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, Thomas Berg, Martin Weltman, Maria Lorena Abate, Margaret Bassendine, Ulrich Spengler, Gregory J Dore, Elizabeth Powell, Stephen Riordan, David Sheridan, Antonina Smedile, Vincenzo Fragomeli, Tobias Müller, Melanie Bahlo, Graeme J Stewart, David R Booth, Jacob George. (2009) IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics 41:10, 1100-1104
CrossRef767
K. R. Reddy, D. Messinger, M. Popescu, S. J. Hadziyannis. (2009) Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. Journal of Viral Hepatitis 16:10, 724-731
CrossRef768
James Fung. (2009) Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. Expert Review of Anti-infective Therapy 7:8, 945-949
CrossRef769
Stuart K. Roberts, Martin D. Weltman, Darrell H. G. Crawford, Geoffrey W. McCaughan, William Sievert, Wendy S. Cheng, William Rawlinson, Paul V. Desmond, Phillipa S. Marks, Motoko Yoshihara, Bishoy Rizkalla, Jean K. DePamphilis, Gregory J. Dore, . (2009) Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology 50:4, 1045-1055
CrossRef770
I. S. Elefsiniotis, C. Pavlidis, D. Dimitroulopoulos, E. Vezali, C. Mihas, T. Mariolis-Sapsakos, S. Koutsounas, E. Paraskevas, G. Saroglou. (2009) Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. Journal of Viral Hepatitis 16:10, 738-742
CrossRef771
Shinya Maekawa, Nobuyuki Enomoto. (2009) Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. Journal of Gastroenterology 44:10, 1009-1015
CrossRef772
M. Iwasa, N. Hara, H. Miyachi, H. Tanaka, M. Takeo, N. Fujita, Y. Kobayashi, Y. Kojima, M. Kaito, Y. Takei. (2009) Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. Journal of Viral Hepatitis 16:10, 716-723
CrossRef773
I. M. V. G. C. Mello, C. Thumann, E. Schvoerer, E. Soulier, J. R. R. Pinho, D. A. M. M. Silvestre, A. T. L. Queiroz, P. Wolf, T. F. Baumert, F. S. Keller, C. A. Pereira. (2009) Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation. Journal of Viral Hepatitis 16:10, 732-737
CrossRef774
Kaku Goto, Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kunitada Shimotohno. (2009) Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Science 100:10, 1943-1950
CrossRef775
Mahmoud Mohamed Bahgat, Ahmed Atef Ibrahim, Dina Nadeem Abd-Elshafy, Ahmed Atef Mesalam, Hossam Eid Gewaid, Amany Abd-Elghany Ismaeil, Ahmed Mohamed El-Waseef, Amany Sayed Maghraby, Ahmed Barakat Barakat, Mohamed Abd-Elhafez El-Far, Hossam El-Din Ahmed Ghanem, Amro Mahmoud Mohamed, Mohamed Ahmed Ali. (2009) Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate. Archives of Virology 154:10, 1649-1657
CrossRef776
Yasuhito Tanaka, Nao Nishida, Masaya Sugiyama, Masayuki Kurosaki, Kentaro Matsuura, Naoya Sakamoto, Mina Nakagawa, Masaaki Korenaga, Keisuke Hino, Shuhei Hige, Yoshito Ito, Eiji Mita, Eiji Tanaka, Satoshi Mochida, Yoshikazu Murawaki, Masao Honda, Akito Sakai, Yoichi Hiasa, Shuhei Nishiguchi, Asako Koike, Isao Sakaida, Masatoshi Imamura, Kiyoaki Ito, Koji Yano, Naohiko Masaki, Fuminaka Sugauchi, Namiki Izumi, Katsushi Tokunaga, Masashi Mizokami. (2009) Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genetics 41:10, 1105-1109
CrossRef777
Paul Marotta, Dietrich Hueppe, Elmar Zehnter, Paul Kwo, Ira Jacobson. (2009) Efficacy of Chronic Hepatitis C Therapy in Community-Based Trials. Clinical Gastroenterology and Hepatology 7:10, 1028-1036
CrossRef778
S.-H. Zhao, Y.-L. Chu, D.-X. Cheng, A. B. Waqar, Q. Yu, P.-H. Yang, X. Xue, H.-J. Yang, E.-Q. Liu. (2009) Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. International Journal of Clinical Practice 63:9, 1334-1339
CrossRef779
Hatef Massoumi, Hussein Elsiesy, Viktoriya Khaitova, Brent Peterson, Edward Norkus, Priya Grewal, Lawrence Liu, Charissa Chang, Nancy Bach, Thomas D. Schiano. (2009) An Escalating Dose Regimen of Pegylated Interferon and Ribavirin in HCV Cirrhotic Patients Referred for Liver Transplant. Transplantation 88:5, 729-735
CrossRef780
N. Hansen, N. Obel, P. B. Christensen, H. Krarup, A. L. Laursen, M. R. Clausen, S. Lunding, A. Møller, P. Schlichting, H. Kromann-Andersen, J. Bukh, N. Weis, . (2009) Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. Journal of Viral Hepatitis 16:9, 659-665
CrossRef781
R. Huber, M. Müller, J. Naumann, T. Schenk, R. Lüdtke. (2009) Artichoke leave extract for chronic hepatitis C – A pilot study. Phytomedicine 16:9, 801-804
CrossRef782
Yves Benhamou, Nezam H. Afdhal, David R. Nelson, Mitchell L. Shiffman, Deanine G. Halliman, Jamie Heise, Eric Chun, Paul J. Pockros. (2009) A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology 50:3, 717-726
CrossRef783
János Fehér, Gabriella Lengyel. (2009) Silymarin in the treatment of chronic liver diseases: Past and future. Clinical and Experimental Medical Journal 3:3, 403-413
CrossRef784
G. R. Foster. (2009) Quality of life considerations for patients with chronic hepatitis C. Journal of Viral Hepatitis 16:9, 605-611
CrossRef785
Takeshi Okanoue, Yoshito Itoh, Hiroaki Hashimoto, Kohichiroh Yasui, Masahito Minami, Tetsuo Takehara, Eiji Tanaka, Morikazu Onji, Joji Toyota, Kazuaki Chayama, Kentaro Yoshioka, Namiki Izumi, Norio Akuta, Hiromitsu Kumada. (2009) Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. Journal of Gastroenterology 44:9, 952-963
CrossRef786
I. CASTILLO, J. BARTOLOMÉ, J. A. QUIROGA, G. BARRIL, V. CARREÑO. (2009) Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Alimentary Pharmacology & Therapeutics 30:5, 477-486
CrossRef787
Alessia Giorgini, Franco Capsoni, Mauro Podda, Ana Lleó, Pier Maria Battezzati, Anna Maria Ongari, Carlo Selmi, Alberto Benetti, Federica Malinverno, Lorenzo Rossaro, M. Eric Gershwin, Massimo Zuin. (2009) Treatment with PEG-interferon and Ribavirin for Chronic Hepatitis C Increases Neutrophil and Monocyte Chemotaxis. Annals of the New York Academy of Sciences 1173:1, 847-857
CrossRef788
Hussein Hassan Aly, Yue Qi, Kimie Atsuzawa, Nobuteru Usuda, Yasutsugu Takada, Masashi Mizokami, Kunitada Shimotohno, Makoto Hijikata. (2009) Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus. Hepatology 50:3, 689-696
CrossRef789
David L. Wyles. (2009) The Potential for Combination Treatment Using STAT-C Drugs. Current Hepatitis Reports 8:S1, 27-34
CrossRef790
Yoshiaki Iwasaki, Yasushi Shiratori, Shuhei Hige, Shuhei Nishiguchi, Hitoshi Takagi, Morikazu Onji, Haruhiko Yoshida, Namiki Izumi, Yutaka Kohgo, Kyosuke Yamamoto, Nobuhiro Sato, Akitaka Shibuya, Hidetsugu Saito, Michio Sata, Kazuyuki Suzuki, Shuichi Kaneko, Mitsuhiko Moriyama, Masao Omata. (2009) A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatology International 3:3, 468-479
CrossRef791
D. BREILH, J. FOUCHER, L. CASTÉRA, P. TRIMOULET, S. DJABAROUTI, W. MERROUCHE, P. COUZIGOU, M.-C. SAUX, V. DE LÉDINGHEN. (2009) Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 30:5, 487-494
CrossRef792
Glenn Wagner, Gery Ryan, Karen Chan Osilla, Laveeza Bhatti, Matthew Goetz, Mallory Witt. (2009) Treat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV Coinfection. AIDS Patient Care and STDs 23:9, 715-725
CrossRef793
Ju-Chien Cheng, Yung-Ju Yeh, Li-Mei Pai, Ming-Ling Chang, Chau-Ting Yeh. (2009) 293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection. Journal of Medical Virology 81:9, 1560-1568
CrossRef794
Stevan A Gonzalez, Emmet B Keeffe. (2009) Chronic hepatitis B and C: update on therapy. Future Virology 4:5, 437-452
CrossRef795
F. ANGELICO, S. FRANCIOSO, M. DEL BEN, K. FEOLE, M. CARBONE, P. PIGNATELLI, F. VIOLI, M. ANGELICO. (2009) Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Alimentary Pharmacology & Therapeutics 30:5, 444-451
CrossRef796
Hesham El Makhzangy, Gamal Esmat, Mohamed Said, Maissa ElRaziky, Soheir Shouman, Rasha Refai, Claire Rekacewicz, Rita Raafat Gad, Nicolas Vignier, Mohamed Abdel-Hamid, Khaled Zalata, Pierre Bedossa, Stanislas Pol, Arnaud Fontanet, Mostafa K. Mohamed. (2009) Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. Journal of Medical Virology 81:9, 1576-1583
CrossRef797
Naoya Sakamoto, George Y Wu. (2009) Prospects for future therapy of HCV infection. Future Virology 4:5, 453-462
CrossRef798
Ira M. Jacobson. (2009) Treatment Options for Patients With Chronic Hepatitis C Not Responding to Initial Antiviral Therapy. Clinical Gastroenterology and Hepatology 7:9, 921-930
CrossRef799
Peter Hauser, Benjamin J. Morasco, Alex Linke, Dannell Bjornson, Samantha Ruimy, Annette Matthews, Aly Rifai, David W. Indest, Jennifer M. Loftis. (2009) Antiviral Completion Rates and Sustained Viral Response in Hepatitis C Patients With and Without Preexisting Major Depressive Disorder. Psychosomatics 50:5, 500-505
CrossRef800
McHutchison, John G., Lawitz, Eric J., Shiffman, Mitchell L., Muir, Andrew J., Galler, Greg W., McCone, Jonathan, Nyberg, Lisa M., Lee, William M., Ghalib, Reem H., Schiff, Eugene R., Galati, Joseph S., Bacon, Bruce R., Davis, Mitchell N., Mukhopadhyay, Pabak, Koury, Kenneth, Noviello, Stephanie, Pedicone, Lisa D., Brass, Clifford A., Albrecht, Janice K., Sulkowski, Mark S., . (2009) Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. New England Journal of Medicine 361:6, 580-593
Full Text801
Heiner Wedemeyer, Elisabeth Schuller, Verena Schlaphoff, Rudolf E. Stauber, Johannes Wiegand, Ingolf Schiefke, Christa Firbas, Bernd Jilma, Mark Thursz, Stefan Zeuzem, Wolf P. Hofmann, Holger Hinrichsen, Erich Tauber, Michael P. Manns, Christoph S. Klade. (2009) Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27:37, 5142-5151
CrossRef802
James R. Burton, Gregory T. Everson. (2009) HCV NS5B Polymerase Inhibitors. Clinics in Liver Disease 13:3, 453-465
CrossRef803
Kara W. Chew, Scott A. Allen, Lynn E. Taylor, Josiah D. Rich, Edward Feller. (2009) Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis C. Journal of Clinical Gastroenterology 43:7, 686-691
CrossRef804
Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Yasuhiro Sone, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Hiroyuki Atsumi, Makiko Takagi, Satoshi Nakano, Takahiro Arakawa, Masashi Fujimori. (2009) Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha. Journal of Medical Virology 81:8, 1354-1362
CrossRef805
Virginia Clark, David R. Nelson. (2009) Novel Interferons for Treatment of Hepatitis C Virus. Clinics in Liver Disease 13:3, 351-363
CrossRef806
William K. Decker, Amar Safdar. (2009) Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine & Growth Factor Reviews 20:4, 271-281
CrossRef807
William W. Shields, Paul J. Pockros. (2009) Ribavirin Analogs. Clinics in Liver Disease 13:3, 419-427
CrossRef808
M. NAGAKI, M. SHIMIZU, J. I. SUGIHARA, E. TOMITA, C. SANO, T. NAIKI, K. KIMURA, K. AMANO, T. SAKAI, M. NINOMIYA, T. KOJIMA, N. KATSUMURA, M. FUJIMOTO, H. MORIWAKI. (2009) Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders. Alimentary Pharmacology & Therapeutics 30:4, 343-351
CrossRef809
N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi. (2009) Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. Journal of Viral Hepatitis 16:8, 586-594
CrossRef810
Pablo Tebas. (2009) Hepatitis C virus treatment: The beginning of a new era. Current HIV/AIDS Reports 6:3, 117-118
CrossRef811
Hiroki Ikeda, Michihiro Suzuki, Chiaki Okuse, Norie Yamada, Masaru Okamoto, Minoru Kobayashi, Yoshihiko Nagase, Hideaki Takahashi, Koutarou Matsunaga, Nobuyuki Matsumoto, Fumio Itoh, Hiroshi Yotsuyanagi, Yu Koitabashi, Kiyomi Yasuda, Shiro Iino. (2009) Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatology Research 39:8, 753-759
CrossRef812
Kimberly A. Forde, K. Rajender Reddy. (2009) Hepatitis C Virus Infection and Immunomodulatory Therapies. Clinics in Liver Disease 13:3, 391-401
CrossRef813
Philippe A. Gallay. (2009) Cyclophilin Inhibitors. Clinics in Liver Disease 13:3, 403-417
CrossRef814
Adeel A. Butt, Xiaoqiang Wang, Charity G. Moore. (2009) Effect of hepatitis C virus and its treatment on survival. Hepatology 50:2, 387-392
CrossRef815
Andrew Aronsohn, Nancy Reau. (2009) Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 43:7, 661-671
CrossRef816
T. Oze, N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, A. Yamada, M. Oshita, H. Hagiwara, E. Mita, T. Ito, Y. Inui, T. Hijioka, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi. (2009) Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin. Journal of Viral Hepatitis 16:8, 578-585
CrossRef817
Deborah Chavez, Bernadette Guerra, Robert E. Lanford. (2009) Antiviral activity and host gene induction by tamarin and marmoset interferon-α and interferon-γ in the GBV-B primary hepatocyte culture model. Virology 390:2, 186-196
CrossRef818
Ilan S. Weisberg, Ira M. Jacobson. (2009) Telaprevir: Hope on the Horizon, Getting Closer. Clinics in Liver Disease 13:3, 441-452
CrossRef819
N. A. Cannon, M. J. Donlin, L. M. Mayes, A. C. Lyra, A. M. Di Bisceglie, J. E. Tavis. (2009) Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. Journal of Viral Hepatitis 16:8, 595-604
CrossRef820
Matthew S. Paulson, Huiling Yang, I-hung Shih, Joy Y. Feng, Eric M. Mabery, Margaret F. Robinson, Weidong Zhong, William E. Delaney. (2009) Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Research 83:2, 135-142
CrossRef821
Okba Haj-Ali Saflo, Jesús Miguel Hernández Guijo. (2009) Coste-eficacia del tratamiento de la hepatitis C crónica en España. Gastroenterología y Hepatología 32:7, 472-482
CrossRef822
Hyung-Jung Pyun, Kleem Chaudhary, John R. Somoza, X. Christopher Sheng, Choung U. Kim. (2009) Synthesis and resolution of diethyl (1S,2S)-1-amino-2-vinylcyclopropane-1-phosphonate for HCV NS3 protease inhibitors. Tetrahedron Letters 50:27, 3833-3835
CrossRef823
Alain H. Litwin, Kenneth A. Harris, Shadi Nahvi, Philippe J. Zamor, Irene J. Soloway, Peter L. Tenore, Daniel Kaswan, Marc. N. Gourevitch, Julia H. Arnsten. (2009) Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 37:1, 32-40
CrossRef824
P. Deltenre, V. Canva, M. El Nady, C. François, S. Castelain, S. Dharancy, A. Louvet, L. Bocket, M. Lazrek, A. Hollebecque, F. Wartel, J. Henrion, G. Duverlie, P. Mathurin. (2009) A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. Journal of Viral Hepatitis 16:7, 500-505
CrossRef825
Erik De Clercq. (2009) Another ten stories in antiviral drug discovery (part C): “Old” and “new” antivirals, strategies, and perspectives. Medicinal Research Reviews 29:4, 611-645
CrossRef826
A. Mariano, C. Caserta, G.M. Pendino, C. Vacalebre, P. Surace, M.T. Fiorillo, I. Polito, M. Surace, S. Alicante, A. Amante, G. Foti, M. Marra, G. Gutamo, F. Amato, A. Messineo, A. Mele. (2009) Antiviral treatment for hepatitis C virus infection: Effectiveness at general population level in a highly endemic area. Digestive and Liver Disease 41:7, 509-515
CrossRef827
Adeel A. Butt, Joel Tsevat, Anthony C. Leonard, Obaid S. Shaikh, Deborah McMahon, Uzma A. Khan, Zachariah Dorey-Stein, Vincent Lo Re. (2009) Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. International Journal of Infectious Diseases 13:4, 449-455
CrossRef828
Swati Joshi-Barve, Kiranmayi Amancherla, Madhuvanti Patil, Aruni Bhatnagar, Stephanie Mathews, Leila Gobejishvili, Matthew Cave, Craig McClain, Shirish Barve. (2009) Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-α: relevance to hepatitis C. Free Radical Biology and Medicine 47:1, 47-54
CrossRef829
Kathleen A. Brady, Mark Weiner, Barbara J. Turner. (2009) Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. Journal of Infection 59:1, 62-69
CrossRef830
Rosa Quelhas, Alice Lopes. (2009) Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review. Journal of Psychiatric Practice 15:4, 262-281
CrossRef831
J. J. WEISS, N. BRÄU, A. STIVALA, T. SWAN, D. FISHBEIN. (2009) Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Alimentary Pharmacology & Therapeutics 30:1, 14-27
CrossRef832
E. P. MAUSER-BUNSCHOTEN, D. E. FRANSEN VAN DE PUTTE, R. E. G. SCHUTGENS. (2009) Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 15:4, 853-863
CrossRef833
J. de Bruijne, C. J. Weegink, P. L. M. Jansen, H. W. Reesink. (2009) New developments in the antiviral treatment of hepatitis C. Vox Sanguinis 97:1, 1-12
CrossRef834
Wilck, Marissa B., Hamel, Mary Beth, Baden, Lindsey R., . (2009) Management of Incidental Hepatitis C Virus Infection — Polling Results. New England Journal of Medicine 360:23,
Full Text835
He YingLi, Lin Shumei, Yang Qian, Chen Tianyan, Zhao Yingren, Chen Wei. (2009) Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha. Clinical and Experimental Medicine 9:2, 173-178
CrossRef836
Bruce R. Bacon, Mitchell L. Shiffman, Flavia Mendes, Reem Ghalib, Tarek Hassanein, Giuseppe Morelli, Shobha Joshi, Kenneth Rothstein, Paul Kwo, Norman Gitlin. (2009) Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49:6, 1838-1846
CrossRef837
Yutaka Kishida, Yoshimichi Haruna, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi. (2009) Multiple Cytokine Profiling of the Therapeutic Responses to Ribavirin and Pegylated Interferon-α2b Using an “Induction” Approach With Natural Interferon-β in Difficult-to-Treat Chronic Hepatitis C. Journal of Interferon & Cytokine Research 29:6, 353-368
CrossRef838
J.Y. Chuang, S.S. Yang, Y.T. Lu, Y.Y. Hsieh, C.Y. Chen, S.C. Chang, C.S. Chang, H.Z. Yeh, J.H. Kao. (2009) IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Digestive and Liver Disease 41:6, 424-430
CrossRef839
Francois-Ludovic Sauvage, Francoise Stanke-Labesque, Marie-Claude Gagnieu, Jean-Francois Jourdil, Gerard Babany, Pierre Marquet. (2009) Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C. Therapeutic Drug Monitoring 31:3, 374-381
CrossRef840
Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming-Yen Hsieh, Ming-Lung Yu. (2009) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: Some concerns. Hepatology 49:6, 2125-2125
CrossRef841
Keiji Tsuji, Yoshiiku Kawakami, Shiomi Aimitsu, Hiroshi Kohno, Yasuyuki Aisaka, Shigeru Kimura, Shinji Nagata, Hiroaki Ohgoshi, Mikiya Kitamoto, Tohru Hidaka, Hiroiku Kawakami, Toshio Nakanishi, Kazuaki Chayama. (2009) Predicting the response to 48-week combination therapy with peginterferon α-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients. Hepatology Research 39:6, 531-538
CrossRef842
P. Qiu, V. Sanfiorenzo, S. Curry, Z. Guo, S. Liu, A. Skelton, E. Xia, C. Cullen, R. Ralston, J. Greene, X. Tong. (2009) Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Research 37:10, e74-e74
CrossRef843
Paul Strock, Joël Mossong, Karine Hawotte, Vic Arendt. (2009) Access to Treatment of Hepatitis C in Prison Inmates. Digestive Diseases and Sciences 54:6, 1325-1330
CrossRef844
Paul J. Gaglio. (2009) Treatment of chronic hepatitis C in a slow responder: a case for extended therapy. Nature Reviews Gastroenterology & Hepatology 6:6, 372-375
CrossRef845
M. Wada, H. Marusawa, R. Yamada, A. Nasu, Y. Osaki, M. Kudo, M. Nabeshima, Y. Fukuda, T. Chiba, F. Matsuda. (2009) Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. Journal of Viral Hepatitis 16:6, 388-396
CrossRef846
Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yuzo Miyakawa, Hiromitsu Kumada. (2009) Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads. Digestive Diseases and Sciences 54:6, 1317-1324
CrossRef847
Tania Mara Welzel, Timothy R. Morgan, Herbert L. Bonkovsky, Deepa Naishadham, Ruth M. Pfeiffer, Elizabeth C. Wright, Amy A. Hutchinson, Andrew T. Crenshaw, Arman Bashirova, Mary Carrington, Myhanh Dotrang, Richard K. Sterling, Karen L. Lindsay, Robert J. Fontana, William M. Lee, Adrian M. Di Bisceglie, Marc G. Ghany, David R. Gretch, Stephen J. Chanock, Raymond T. Chung, Thomas R. O'Brien, . (2009) Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49:6, 1847-1858
CrossRef848
Mika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, Kiyoshi Mochizuki, Takayuki Yakushijin, Nao Kurashige, Yuko Inoue, Takumi Igura, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi. (2009) Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatology Research 39:5, 432-438
CrossRef849
Giuseppe Morelli, David R. Nelson. (2009) STAT-C: New therapies cannot get here fast enough. Current Hepatitis Reports 8:2, 73-80
CrossRef850
Daisuke Morihara, Masahiro Kobayashi, Kenji Ikeda, Yusuke Kawamura, Hiromi Saneto, Hiromi Yatuji, Tetuya Hosaka, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitu Kumada. (2009) Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatology Research 39:5, 439-447
CrossRef851
Thierry Poynard, Massimo Colombo, Jordi Bruix, Eugene Schiff, Ruben Terg, Steven Flamm, Ricardo Moreno-Otero, Flair Carrilho, Warren Schmidt, Thomas Berg, Thomas McGarrity, E. Jenny Heathcote, Fernando Gonçales, Moises Diago, Antonio Craxi, Marcelo Silva, Pierre Bedossa, Pabak Mukhopadhyay, Louis Griffel, Margaret Burroughs, Clifford Brass, Janice Albrecht. (2009) Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. Gastroenterology 136:5, 1618-1628.e2
CrossRef852
J.-F. YANG, M.-Y. HSIEH, N.-J. HOU, C.-Y. DAI, J.-F. HUANG, Z.-Y. LIN, S.-C. CHEN, M.-Y. HSIEH, L.-Y. WANG, W.-L. CHUANG, M.-L. YU. (2009) Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Alimentary Pharmacology & Therapeutics 29:9, 1000-1010
CrossRef853
Craig A Belon, David N Frick. (2009) Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virology 4:3, 277-293
CrossRef854
Hironobu Tsukada, Hidenori Ochi, Toshiro Maekawa, Hiromi Abe, Yoshifumi Fujimoto, Masataka Tsuge, Hiroshi Takahashi, Hiromitsu Kumada, Naoyuki Kamatani, Yusuke Nakamura, Kazuaki Chayama. (2009) A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C. Gastroenterology 136:5, 1796-1805.e6
CrossRef855
Vinod Rustgi, David R. Nelson, Vijayan Balan, Robert D. Abelson, Michele Fiscella, Thi-Sau Migone, Erik Pulkstenis, G. Mani Subramanian. (2009) Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapy. Hepatology Research 39:5, 455-462
CrossRef856
E. K. MANESIS, G. V. PAPATHEODORIDIS, G. TOULOUMI, A. KARAFOULIDOU, J. KETIKOGLOU, G. E. KITIS, A. ANTONIOU, S. KANATAKIS, S. J. KOUTSOUNAS, I. VAFIADIS, . (2009) Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet . Greece cohort study. Alimentary Pharmacology & Therapeutics 29:10, 1121-1130
CrossRef857
Carmen Landaverde, Sammy Saab. (2009) Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations. Current Hepatitis Reports 8:2, 43-51
CrossRef858
Y. Rotman, L. Katz, M. Cohen, O. Cohen-Ezra, V. Manhaim, M. Braun, Z. Ben-Ari, R. Tur-Kaspa. (2009) Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C. Journal of Viral Hepatitis 16:5, 340-345
CrossRef859
David McGowan, Origène Nyanguile, Maxwell D. Cummings, Sandrine Vendeville, Koen Vandyck, Walter Van den Broeck, Carlo W. Boutton, Hendrik De Bondt, Ludo Quirynen, Katie Amssoms, Jean-François Bonfanti, Stefaan Last, Klara Rombauts, Abdellah Tahri, Lili Hu, Frédéric Delouvroy, Katrien Vermeiren, Geneviève Vandercruyssen, Liesbet Van der Helm, Erna Cleiren, Wendy Mostmans, Pedro Lory, Geert Pille, Kristof Van Emelen, Gregory Fanning, Frederik Pauwels, Tse-I Lin, Kenneth Simmen, Pierre Raboisson. (2009) 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 19:9, 2492-2496
CrossRef860
M.-L. Chang, K.-F. Sung, I.-S. Sheen, S.-M. Lin, C.-T. Yeh. (2009) A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C. Journal of Viral Hepatitis 16:5, 359-366
CrossRef861
H. Nomura, Y. Miyagi, H. Tanimoto, H. Ishibashi. (2009) Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C. Journal of Viral Hepatitis 16:5, 346-351
CrossRef862
John Koskinas, George Zacharakis, John Sidiropoulos, John Elefsiniotis, Savvas Savvas, Stamatia Kotsiou, Dimitrios Kountouras, Maria Schina, Panagiotis Kostopoulos, Athanasios Archimandritis. (2009) Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-α2b related severe neutropenia: A preliminary report on treatment, safety and efficacy. Journal of Medical Virology 81:5, 848-852
CrossRef863
Monica Basso, Edoardo G. Giannini, Francesco Torre, Sabrina Blanchi, Vincenzo Savarino, Antonino Picciotto. (2009) Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. Hepatology 49:5, 1442-1448
CrossRef864
Josh J Carlson, Kris V Kowdley, Sean D Sullivan, Scott D Ramsey, David L Veenstra. (2009) An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. Journal of Gastroenterology and Hepatology 24:5, 786-791
CrossRef865
Fred Poordad, Nancy Reau. (2009) Viral-guided hepatitis C therapy. Current Hepatitis Reports 8:2, 66-72
CrossRef866
Hoofnagle, Jay H., . (2009) A Step Forward in Therapy for Hepatitis C. New England Journal of Medicine 360:18, 1899-1901
Full Text867
Hézode, Christophe, Forestier, Nicole, Dusheiko, Geoffrey, Ferenci, Peter, Pol, Stanislas, Goeser, Tobias, Bronowicki, Jean-Pierre, Bourlière, Marc, Gharakhanian, Shahin, Bengtsson, Leif, McNair, Lindsay, George, Shelley, Kieffer, Tara, Kwong, Ann, Kauffman, Robert S., Alam, John, Pawlotsky, Jean-Michel, Zeuzem, Stefan, . (2009) Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. New England Journal of Medicine 360:18, 1839-1850
Full Text868
McHutchison, John G., Everson, Gregory T., Gordon, Stuart C., Jacobson, Ira M., Sulkowski, Mark, Kauffman, Robert, McNair, Lindsay, Alam, John, Muir, Andrew J., . (2009) Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. New England Journal of Medicine 360:18, 1827-1838
Full Text869
(2009) Management of Incidental Hepatitis C Virus Infection. New England Journal of Medicine 360:18, 1902-1906
Full Text870
David R. Nelson, Gary L. Davis, Ira Jacobson, Gregory T. Everson, Michael W. Fried, Stephen A. Harrison, Tarek Hassanein, Donald M. Jensen, Karen L. Lindsay, Norah Terrault, Nizar Zein. (2009) Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. Clinical Gastroenterology and Hepatology 7:4, 397-414
CrossRef871
Kyung-Ah Kim, Wenyu Lin, Andrew W. Tai, Run-Xuan Shao, Ethan Weinberg, Carolina B. De Sa Borges, Atul K. Bhan, Hui Zheng, Yoshitaka Kamegaya, Raymond T. Chung. (2009) Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. Journal of Hepatology 50:4, 705-711
CrossRef872
Ying Wei, Chao-Mei Ma, Masao Hattori. (2009) Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases. Bioorganic & Medicinal Chemistry 17:8, 3003-3010
CrossRef873
Hideyuki Nomura, Yugo Miyagi, Hironori Tanimoto, Masashi Higashi, Hiromi Ishibashi. (2009) Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. Journal of Gastroenterology 44:4, 338-345
CrossRef874
Chia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Chern Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang, Ming-Lung Yu. (2009) Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. Journal of Hepatology 50:4, 712-718
CrossRef875
I. Zubkova, Y.H. Choi, E. Chang, K. Pirollo, T. Uren, H. Watanabe, F. Wells, A. Kachko, K. Krawczynski, M.E. Major. (2009) T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 27:19, 2594-2602
CrossRef876
Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet, François Denis, Sophie Alain. (2009) Ribavirin in chronic hepatitis C: past and future. Expert Review of Anti-infective Therapy 7:3, 249-253
CrossRef877
Arne Schäfer, Hans-Ulrich Wittchen, Markus Backmund, Michael Soyka, Jörg Gölz, Jens Siegert, Martin Schäfer, Felix Tretter, Michael R. Kraus. (2009) Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction 104:4, 630-640
CrossRef878
A. J. V. THOMPSON, J. G. MCHUTCHISON. (2009) Review article: investigational agents for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 29:7, 689-705
CrossRef879
José M. Cuevas, Manuela Torres-Puente, Nuria Jiménez-Hernández, María A. Bracho, Inmaculada García-Robles, Fernando Carnicer, Juan del Olmo, Enrique Ortega, Fernando González-Candelas, Andrés Moya. (2009) Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus. Journal of Medical Virology 81:4, 650-656
CrossRef880
Nami Mori, Michio Imamura, Yoshiiku Kawakami, Hiromi Saneto, Tomokazu Kawaoka, Shintaro Takaki, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama, . (2009) Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. Journal of Medical Virology 81:4, 640-649
CrossRef881
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff. (2009) Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:4, 1335-1374
CrossRef882
Vinod K. Rustgi. (2009) Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Current Medical Research and Opinion 25:4, 991-1002
CrossRef883
Omar M.E. Abdel Salam, Amany A. Sleem, Enayat A. Omara, Nabila S. Hassan. (2009) Hepatoprotective effects of misoprostol and silymarin on carbon tetrachloride-induced hepatic damage in rats. Fundamental & Clinical Pharmacology 23:2, 179-188
CrossRef884
Jing Xu, Shufeng Liu, Yihui Xu, Po Tien, Guangxia Gao. (2009) Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha. Virus Research 141:1, 55-62
CrossRef885
Rubina Mondal, Gennadiy Koev, Tami Pilot-Matias, Yupeng He, Teresa Ng, Warren Kati, Akhteruzzaman Molla. (2009) Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well. Antiviral Research 82:1, 82-88
CrossRef886
Marina Grishchenko, Richard D. Grieve, Michael J. Sweeting, Daniela De Angelis, Brian J. Thomson, Stephen D. Ryder, William L. Irving, . (2009) Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. International Journal of Technology Assessment in Health Care 25:02, 171
CrossRef887
P.L. Almasio, G. Esmat, A. Fateen. (2009) Clinical experience with different pegylated interferons: Is there a difference?. Digestive and Liver Disease Supplements 3:1, 21-24
CrossRef888
Jorge André de Segadas-Soares, Cristiane A. Villela-Nogueira, Renata M. Perez, Letícia C. Nabuco, Carlos Eduardo Brandão-Mello, Henrique Sérgio M. Coelho. (2009) Is the Rapid Virologic Response a Positive Predictive Factor of Sustained Virologic Response in all Pretreatment Status Genotype 1 Hepatitis C Patients Treated With Peginterferon-α2b and Ribavirin?. Journal of Clinical Gastroenterology 43:4, 362-366
CrossRef889
Claudio Argentini, Domenico Genovese, Stefano Dettori, Maria Rapicetta. (2009) HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiology 4:3, 359-373
CrossRef890
Nina Ebner, Christian Wanner, Bernadette Winklbaur, Christian Matzenauer, Crispa Aeschbach Jachmann, Kenneth Thau, Gabriele Fischer. (2009) Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addiction Biology 14:2, 227-237
CrossRef891
Harel Dahari, Jennifer E. Layden–Almer, Eric Kallwitz, Ruy M. Ribeiro, Scott J. Cotler, Thomas J. Layden, Alan S. Perelson. (2009) A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease. Gastroenterology 136:4, 1402-1409
CrossRef892
M. E. Burlone, A. Budkowska. (2009) Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. Journal of General Virology 90:5, 1055-1070
CrossRef893
Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2009) A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. Journal of Medical Virology 81:3, 452-458
CrossRef894
G. T. EVERSON, M. L. SHIFFMAN, J. C. HOEFS, T. R. MORGAN, R. K. STERLING, D. A. WAGNER, J. L. DESANTO, T. M. CURTO, E. C. WRIGHT, . (2009) Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Alimentary Pharmacology & Therapeutics 29:5, 589-601
CrossRef895
Pablo Abellán Galiana, Antonia Pérez-Lázaro, Victoria Aguilera Sancho-Tello, Juan Francisco Merino Torres, Marina Berenguer Haym, Francisco Piñón Sellés. (2009) Tiroiditis subaguda inducida por el tratamiento con interferón alfa pegilado y ribavirina en un caso de hepatitis crónica por virus C. Endocrinología y Nutrición 56:3, 136-139
CrossRef896
Zobair M. Younossi, Ancha Baranova, Arian Afendy, Rochelle Collantes, Maria Stepanova, Ganiraju Manyam, Anita Bakshi, Christopher L. Sigua, Joanne P. Chan, Ayuko A. Iverson, Christopher D. Santini, Sheng-Yung P. Chang. (2009) Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 49:3, 763-774
CrossRef897
Maire Robert, Andre N. Sofair, Ann Thomas, Beth Bell, Stephanie Bialek, Christopher Corless, Grace Van Ness, Sharon Huie–White, Nicole Stabach, Atif Zaman. (2009) A Comparison of Hepatopathologists' and Community Pathologists' Review of Liver Biopsy Specimens From Patients With Hepatitis C. Clinical Gastroenterology and Hepatology 7:3, 335-338
CrossRef898
Ming-Lung Yu, Wan-Long Chuang. (2009) Treatment of chronic hepatitis C in Asia: When East meets West. Journal of Gastroenterology and Hepatology 24:3, 336-345
CrossRef899
Brian Bressler, Ka Wang, Joseph F. Grippo, E. Jenny Heathcote. (2009) Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN α-2a (40KD) (PEGASYS ® ). British Journal of Clinical Pharmacology 67:3, 280-287
CrossRef900
Jama M. Darling, Michael W. Fried. (2009) Nitazoxanide: Beyond Parasites Toward a Novel Agent for Hepatitis C. Gastroenterology 136:3, 760-763
CrossRef901
D. E. FRANSEN VAN DE PUTTE, K. FISCHER, D. POSTHOUWER, K. VAN ERPECUM, E. P. MAUSER-BUNSCHOTEN. (2009) Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study. Haemophilia 15:2, 544-551
CrossRef902
M. Friedrich-Rust, J. Theobald, S. Zeuzem, J. Bojunga. (2009) Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. Journal of Viral Hepatitis 16:3, 168-177
CrossRef903
Tomokazu Kawaoka, Yoshiiku Kawakami, Keiji Tsuji, Hiroyuki Ito, Mikiya Kitamoto, Shiomi Aimitsu, Hiroiku Kawakami, Soo Cheol Jeong, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama. (2009) Dose comparison study of pegylated interferon-α-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial. Journal of Gastroenterology and Hepatology 24:3, 366-371
CrossRef904
J. T. DENHOLM, E. J. WRIGHT, A. STREET, J. J. SASADEUSZ. (2009) HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection. Haemophilia 15:2, 538-543
CrossRef905
Takashi Kumada, Hidenori Toyoda, Seiki Kiriyama, Yasuhiro Sone, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Hiroyuki Atsumi, Makiko Takagi, Satoshi Nakano, Takahiro Arakawa, Masashi Fujimori. (2009) Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase. Journal of Medical Virology 81:3, 446-451
CrossRef906
Fred F Poordad, Grace Chee. (2009) Taribavirin: a potential alternative to ribavirin. Future Virology 4:2, 113-120
CrossRef907
Sumalee Thitinan, Jason T. McConville. (2009) Interferon alpha delivery systems for the treatment of hepatitis C. International Journal of Pharmaceutics 369:1-2, 121-135
CrossRef908
Françoise Stoll-Keller, Heidi Barth, Samira Fafi-Kremer, Mirjam B Zeisel, Thomas F Baumert. (2009) Development of hepatitis C virus vaccines: challenges and progress. Expert Review of Vaccines 8:3, 333-345
CrossRef909
Kazuhiko Hayashi, Yoshiaki Katano, Takashi Honda, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Fumihiro Urano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto. (2009) Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. Journal of Medical Virology 81:3, 459-466
CrossRef910
Martin Potter, Marina B Klein. (2009) Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. HIV Therapy 3:2, 189-207
CrossRef911
Daniel P Webster, Paul Klenerman, Jane Collier, Katie JM Jeffery. (2009) Development of novel treatments for hepatitis C. The Lancet Infectious Diseases 9:2, 108-117
CrossRef912
Tatsuya FUJINO, Makoto NAKAMUTA, Yoko AOYAGI, Kunitaka FUKUIZUMI, Ryosuke TAKEMOTO, Tsuyoshi YOSHIMOTO, Toshihiko MIYAHARA, Naohiko HARADA, Hironori SAKAI, Manabu NAKASHIMA, Munechika ENJOJI. (2009) Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy. Journal of Digestive Diseases 10:1, 21-25
CrossRef913
Nabil Antaki, Patrick Marcellin. (2009) What is the safe duration of therapy for patients infected with HCV genotype 6?. Nature Clinical Practice Gastroenterology & Hepatology 6:2, 78-79
CrossRef914
D. Kmieciak, P. Migdalski, J. Juszczyk, P. P. Jagodziński, W. H. Trzeciak. (2009) Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-α/ribavirin therapy. European Journal of Clinical Microbiology & Infectious Diseases 28:2, 211-213
CrossRef915
Alessio Aghemo, Maria Grazia Rumi, Gian Maria Prati, Massimo Colombo. (2009) The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?. Hepatology 49:2, NA-NA
CrossRef916
Andrew W. Tai, Raymond T. Chung. (2009) Treatment failure in hepatitis C: Mechanisms of non-response. Journal of Hepatology 50:2, 412-420
CrossRef917
Ayse L. Mindikoglu, Ram R. Miller. (2009) Hepatitis C in the Elderly: Epidemiology, Natural History, and Treatment. Clinical Gastroenterology and Hepatology 7:2, 128-134
CrossRef918
K. Rajender Reddy, David R. Nelson, Stefan Zeuzem. (2009) Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. Journal of Hepatology 50:2, 402-411
CrossRef919
Alessandra Fraternale, Maria Filomena Paoletti, Anna Casabianca, Lucia Nencioni, Enrico Garaci, Anna Teresa Palamara, Mauro Magnani. (2009) GSH and analogs in antiviral therapy. Molecular Aspects of Medicine 30:1-2, 99-110
CrossRef920
J. Foucher, B. Reiller, V. Jullien, F. Léal, E. S. di Cesare, W. Merrouche, J.-M. Delile, V. de Lédinghen. (2009) FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. Journal of Viral Hepatitis 16:2, 121-131
CrossRef921
Ivo W. Graziadei, Wolfgang Vogel. (2009) Treatment of patients infected with chronic hepatitis C genotype 2 and 3: More data, more questions?. Hepatology 49:2, 345-347
CrossRef922
Richard Grieve, Marina Grishchenko, John Cairns. (2009) SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. The European Journal of Health Economics 10:1, 15-23
CrossRef923
S. Zeuzem, T. Berg, B. Moeller, H. Hinrichsen, S. Mauss, H. Wedemeyer, C. Sarrazin, D. Hueppe, E. Zehnter, M. P. Manns. (2009) Expert opinion on the treatment of patients with chronic hepatitis C. Journal of Viral Hepatitis 16:2, 75-90
CrossRef924
Robert J. Fontana, Herbert L. Bonkovsky, Deepa Naishadham, Jules L. Dienstag, Richard K. Sterling, Anna S.F. Lok, Grace L. Su. (2009) Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology 7:2, 219-226
CrossRef925
Hussein Hassan Aly, Kunitada Shimotohno, Makoto Hijikata. (2009) 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV. Biochemical and Biophysical Research Communications 379:2, 330-334
CrossRef926
David R. Nelson, Vinod Rustgi, Vijayan Balan, Mark S. Sulkowski, Gary L. Davis, Andrew J. Muir, Louis R. Lambiase, Rolland C. Dickson, Russell H. Weisner, Michele Fiscella, Patrick W. Cronin, Erik Pulkstenis, John G. McHutchison, G. Mani Subramanian. (2009) Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 7:2, 212-218
CrossRef927
Shinichiro Tada, Hidetsugu Saito, Hirotoshi Ebinuma, Keisuke Ojiro, Yoshiyuki Yamagishi, Naoki Kumagai, Yasutaka Inagaki, Tetsuya Masuda, Jiro Nishida, Masahiko Takahashi, Hiroshi Nagata, Toshifumi Hibi. (2009) Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatology Research 39:2, 195-199
CrossRef928
Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Ernesto Agostinacchio, Fernando Sogari, Gaetano Scotto, Francesco Vinelli, Giovanni Luciano Ricci, Mario Romano, Vito Carretta, Daniela Petruzzellis, Angelo Andriulli. (2009) Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 49:2, 358-363
CrossRef929
Chun–Jen Liu, Wan–Long Chuang, Chuan–Mo Lee, Ming–Lung Yu, Sheng–Nan Lu, Shun–Sheng Wu, Li–Ying Liao, Chi–Ling Chen, Hsing–Tao Kuo, You–Chen Chao, Shui–Yi Tung, Sien–Sing Yang, Jia–Horng Kao, Chen–Hua Liu, Wei–Wen Su, Chih–Lin Lin, Yung–Ming Jeng, Pei–Jer Chen, Ding–Shinn Chen. (2009) Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. Gastroenterology 136:2, 496-504.e3
CrossRef930
J. Vergniol, J. Foucher, L. Castéra, P.-H. Bernard, R. Tournan, E. Terrebonne, E. Chanteloup, W. Merrouche, P. Couzigou, V. de Lédinghen. (2009) Changes of non-invasive markers and FibroScan values during HCV treatment. Journal of Viral Hepatitis 16:2, 132-140
CrossRef931
Gerond Lake-Bakaar. (2009) The effect of controlled therapy interruption in chronic HCV infection: Enhanced host immune response? A hypothesis. Journal of Clinical Virology 44:2, 149-151
CrossRef932
Tahany Awad, Kristian Thorlund, Goran Hauser, Mahasen Mabrouk, Davor Stimac, Christian Gluud, Tahany Awad. 2009. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C. .
CrossRef933
Vincent Lo Re III, Valerianna K. Amorosa, A. Russell Localio, Rose O’Flynn, Valerie Teal, Zachariah Dorey‐Stein, Jay R. Kostman, Robert Gross. (2009) Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes. Clinical Infectious Diseases 48:2, 186-193
CrossRef934
Rodriguez-Torres, Maribel, Jeffers, Lennox J., Sheikh, Muhammad Y., Rossaro, Lorenzo, Ankoma-Sey, Victor, Hamzeh, Fayez M., Martin, Paul, . (2009) Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. New England Journal of Medicine 360:3, 257-267
Full Text935
Tomoko Komiya, Akiko Saito, Yuki Yoneda, Sneha Patel, Michiyo Chiba, Keiko Shiratori, Makoto Kawashima. (2009) Two HCV-related chronic hepatitis patients with Peg-interferon α-2a induced generalized rash. Kanzo 50:10, 565-570
CrossRef936
Ji Hun Kim, Jeong Won Jang, Chan Ran You, Si Young You, Mun Kyung Jung, Jin Hwan Jung. (2009) Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection. Gut and Liver 3:3, 218
CrossRef937
Michiko Shindo. (2009) Treatment of chronic hepatitis C: present and future. Kanzo 50:7, 345-355
CrossRef938
Mi Na Kim, Ki Tae Yoon, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Kwang-Hyub Han. (2009) A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C. The Korean Journal of Hepatology 15:4, 496
CrossRef939
Yasuji Arase, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2009) Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C Patients with Genotype 1b and Low-virus Load. Internal Medicine 48:5, 253-258
CrossRef940
Sang Hoon Ahn, Hyun Woong Lee, Yong Soo Kim, Ja Kyung Kim, Kwang-Hyub Han, Chae Yoon Chon, Young Myoung Moon. (2009) Recombinant Interferon-Beta-1α Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study. Gut and Liver 3:1, 20
CrossRef941
Timothy C. Reluga, Harel Dahari, Alan S. Perelson. (2009) Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis. SIAM Journal on Applied Mathematics 69:4, 999
CrossRef942
Montserrat Laguno, Carmen Cifuentes, Javier Murillas, Sergio Veloso, Maria Larrousse, Antoni Payeras, Lucia Bonet, Francese Vidal, Ana Milinkovic, Antoni Bassa, Concha Villalonga, Iñaki Pérez, Cristina Tural, Maria Martínez-Rebollar, Marta Calvo, Jose Luis Blanco, Estaban Martínez, Jose M. Sánchez-Tapias, Jose M. Gatell, Jose Mallolas. (2009) Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49:1, 22-31
CrossRef943
Noritomo Shimada, Kai Yoshizawa, Makiko Ika, Akira Dobashi, Naoto Nomura, Gotaro Toda, Akihito Tsubota, Hiroshi Abe, Yoshio Aizawa. (2009) Response-guided therapy in Japanese chronic hepatitis C patients infected with genotype 1b and high viral load. Kanzo 50:12, 687-702
CrossRef944
B. de Felipe, M. Leal, N. Soriano-Sarabia, A. Gutiérrez, L. López-Cortés, S. Molina-Pinelo, A. Vallejo. (2009) HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse. Journal of Viral Hepatitis 16:1, 21-27
CrossRef945
C.-J. CHU, S.-D. LEE, T.-H. HUNG, H.-C. LIN, S.-J. HWANG, F.-Y. LEE, R.-H. LU, M.-I. YU, C.-Y. CHANG, P.-L. YANG, C.-Y. LEE, F.-Y. CHANG. (2009) Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon α-2b plus ribavirin. Alimentary Pharmacology & Therapeutics 29:1, 46-54
CrossRef946
Soung Won Jeong, Jin Dong Kim, Hyun Young Woo, Chan Ran You, Sung Won Lee, Myeong Jun Song, Jung Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon. (2009) Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. The Korean Journal of Hepatology 15:3, 338
CrossRef947
Akira Kawano, Yuichiro Kado, Hirohisa Shigematsu, Koichiro Miki, Toshihiro Maruyama, Hideyuki Nomura, Shinji Shimoda. (2009) Rapid virological response obtained by natural IFN αfor a patient of chronic hepatitis C with a high viral load of HCV genotype 1b who is refractory to peg-interferon α+ribavirin combination therapy. Kanzo 50:10, 590-592
CrossRef948
Susan J. Keam, Risto S. Cvetković. (2009) Spotlight on Peginterferon-α-2a (40 kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection†. BioDrugs 23:1, 63-68
CrossRef949
A. Andriulli, C. Cursaro, R. Cozzolongo, A. Iacobellis, M. R. Valvano, A. Mangia, N. Minerva, D. Bacca, M. Stanzione, A. Scuteri, G. Montalto, P. Andreone. (2009) Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. Journal of Viral Hepatitis 16:1, 28-35
CrossRef950
M. WILKINSON, V. CRAWFORD, A. TIPPET, F. JOLLY, J. TURTON, E. SIMS, M. HEKKER, J. DALTON, R. MARLEY, G. R. FOSTER. (2009) Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Alimentary Pharmacology & Therapeutics 29:1, 29-37
CrossRef951
Ulrike Mihm, Oliver Ackermann, Christoph Welsch, Eva Herrmann, Wolf Peter Hofmann, Natalia Grigorian, Martin Walter Welker, Thomas Lengauer, Stefan Zeuzem, Christoph Sarrazin. (2009) Clinical relevance of the 2′–5′-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. Journal of Hepatology 50:1, 49-58
CrossRef952
W. L. GIANOTTEN, L. HEIJNEN. (2009) Haemophilia, aging and sexuality. Haemophilia 15:1, 55-62
CrossRef953
Natasha Walzer, Steven L Flamm. (2009) Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert Review of Clinical Pharmacology 2:1, 67-76
CrossRef954
Magdalena Sarasin-Filipowicz, Jacek Krol, Ilona Markiewicz, Markus H Heim, Witold Filipowicz. (2009) Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nature Medicine 15:1, 31-33
CrossRef955
Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kwan Soo Byun, Seung Woon Paik, Young Suk Lim, Han Chu Lee, Kwang Hyub Han, Kwan Sik Lee. (2009) Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C. The Korean Journal of Internal Medicine 24:3, 203
CrossRef956
H. PATEL, E. J. HEATHCOTE. (2009) When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia 15:1, 20-32
CrossRef957
Ioannis S. Elefsiniotis, Christos Pavlidis, Elena Vezali, Theodoros Mariolis-Sapsakos, Sotirios Koutsounas, George Saroglou. (2009) Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients. Gastroenterology Research and Practice 2009, 1-5
CrossRef958
Yuko Sekine-Osajima, Naoya Sakamoto, Mina Nakagawa, Yasuhiro Itsui, Megumi Tasaka, Yuki Nishimura-Sakurai, Cheng-Hsin Chen, Goki Suda, Kako Mishima, Yuko Onuki, Machi Yamamoto, Shinya Maekawa, Nobuyuki Enomoto, Takanori Kanai, Kiichiro Tsuchiya, Mamoru Watanabe. (2009) Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication. Hepatology Research 39:1, 60-69
CrossRef959
Jean-Philippe Lang, Laurent Michel, Pascal Melin, Marc Schoeffler, Aurélie Gauchet, Véronique Cartier, Chantal Henry. 2009. État des lieux de la prise en charge psychiatrique et psychologique des patients VHC+ et VIH/VHC+ en France. , 8-15.
CrossRef960
Stéphane Schmitter, Jean-Philippe Lang, Laurent Michel, Laurent Castera. 2009. Les troubles psychiatriques liés au traitement de l'hépatite chronique C. , 80-92.
CrossRef961
Rajeev Aurora, Maureen J. Donlin, Nathan A. Cannon, John E. Tavis. (2008) Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. Journal of Clinical Investigation
CrossRef962
Prem H. Thurairajah, Doha Hegazy, Shilpa Chokshi, Steve Shaw, Andrew Demaine, Edward R. Kaminski, Nikolai V. Naoumov, Matthew E. Cramp. (2008) Hepatitis C Virus (HCV)–Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection. The Journal of Infectious Diseases 198:12, 1749-1755
CrossRef963
B. Cacopardo, G. Nunnari, F. Benanti, A. Cappellani, A. Onorante, E. Caltabiano, R. Russo. (2008) Leukocyte Interferon Alpha Early Retreatment for Child A HCV Genotype 1b-Infected Cirrhotics Intolerant to Pegylated Interferons. Infection
CrossRef964
Di Bisceglie, Adrian M., Shiffman, Mitchell L., Everson, Gregory T., Lindsay, Karen L., Everhart, James E., Wright, Elizabeth C., Lee, William M., Lok, Anna S., Bonkovsky, Herbert L., Morgan, Timothy R., Ghany, Marc G., Morishima, Chihiro, Snow, Kristin K., Dienstag, Jules L., . (2008) Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine 359:23, 2429-2441
Full Text965
János Fehér, Gabriella Lengyel. (2008) Silymarin az idült májbetegségek kezelésében: múlt és jövő. Orvosi Hetilap 149:51, 2413-2418
CrossRef966
L. J. Brant, M. E. Ramsay, M. A. Balogun, E. Boxall, A. Hale, M. Hurrelle, L. Kaluba, P. Klapper, D. Lewis, B. C. Patel, J. Parry, W. L. Irving. (2008) Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. Journal of Viral Hepatitis 15:12, 871-877
CrossRef967
Haruaki Shirakawa, Akihiro Matsumoto, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Kendo Kiyosawa, Eiji Tanaka, . (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48:6, 1753-1760
CrossRef968
Matthew L. Albert, Jérémie Decalf, Stanislas Pol. (2008) Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C. Journal of Hepatology 49:6, 1069-1078
CrossRef969
Sandrine Vendeville, Magnus Nilsson, Herman de Kock, Tse-I Lin, Dmitry Antonov, Björn Classon, Susana Ayesa, Vladimir Ivanov, Per-Ola Johansson, Pia Kahnberg, Anders Eneroth, Kristina Wikstrom, Lotta Vrang, Michael Edlund, Stefan Lindström, Wim Van de Vreken, David McGowan, Abdellah Tahri, Lili Hu, Oliver Lenz, Frederic Delouvroy, Marleen Van Dooren, Natalie Kindermans, Dominique Surleraux, Piet Wigerinck, Åsa Rosenquist, Bertil Samuelsson, Kenneth Simmen, Pierre Raboisson. (2008) Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorganic & Medicinal Chemistry Letters 18:23, 6189-6193
CrossRef970
Richard Njouom, Michèle Tagni Sartre, Isabelle Timba, Eric Nerrienet, Patrice Tchendjou, Christophe Pasquier, Dominique Rousset. (2008) Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. Journal of Medical Virology 80:12, 2079-2085
CrossRef971
Keith R Kearney, James J Thornton, Victor J Navarro. (2008) Taribavirin for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 9:18, 3243-3249
CrossRef972
Erik J. Groessl, Kimberly R. Weingart, Robert M. Kaplan, Jack A. Clark, Allen L. Gifford, Samuel B. Ho. (2008) Living with Hepatitis C: Qualitative Interviews with Hepatitis C-infected Veterans. Journal of General Internal Medicine 23:12, 1959-1965
CrossRef973
Erik H.C.J. Buster, Solko W. Schalm, Harry L.A. Janssen. (2008) Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Practice & Research Clinical Gastroenterology 22:6, 1093-1108
CrossRef974
P. Ferenci. (2008) Peginterferon and ribavirin in HCV: Improvement of sustained viral response. Best Practice & Research Clinical Gastroenterology 22:6, 1109-1122
CrossRef975
S. Zhao, D. Cheng, E. Liu, H. Yu, H. Yang, X. Xue, Y. Chu. (2008) Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients. European Journal of Clinical Microbiology & Infectious Diseases 27:12, 1183-1192
CrossRef976
Chen‐Hua Liu, Chun‐Jen Liu, Chih‐Lin Lin, Cheng‐Chao Liang, Shih‐Jer Hsu, Sheng‐Shun Yang, Ching‐Sheng Hsu, Tai‐Chung Tseng, Chia‐Chi Wang, Ming‐Yang Lai, Jun‐Herng Chen, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao. (2008) Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. Clinical Infectious Diseases 47:10, 1260-1269
CrossRef977
Craig E. Gordon, Ethan M. Balk, Bryan N. Becker, Peter A. Crooks, Bertrand L. Jaber, Cynda A. Johnson, Maureen A. Michael, Brian J.G. Pereira, Katrin Uhlig, Adeera Levin. (2008) KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD. American Journal of Kidney Diseases 52:5, 811-825
CrossRef978
Andrej Potthoff, Heiner Wedemeyer, Wulf O. Boecher, Thomas Berg, Stefan Zeuzem, Joachim Arnold, Ulrich Spengler, Kurt Gruengreiff, Thomas Kaeser, Marcus Schuchmann, Alexandra Bergk, Nicole Forestier, Katja Deterding, Michael P. Manns, Christian Trautwein. (2008) The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection. Journal of Hepatology 49:5, 688-694
CrossRef979
Herbert L. Bonkovsky, Alan D. Tice, Rockford G. Yapp, Henry C. Bodenheimer, Jr, Alexander Monto, Stephen J. Rossi, Mark S. Sulkowski. (2008) Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration. The American Journal of Gastroenterology 103:11, 2757-2765
CrossRef980
Wolf Peter Hofmann, Eva Herrmann, Christoph Sarrazin, Stefan Zeuzem. (2008) Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver International 28:10, 1332-1343
CrossRef981
Jennifer A. Tan, Tom A. Joseph, Sammy Saab. (2008) Treating hepatitis C in the prison population is cost-saving. Hepatology 48:5, 1387-1395
CrossRef982
Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, Thomas Berg, Tobias Goeser, Ulrich Spengler, Holger Hinrichsen, Hans Weidenbach, Guido Gerken, Michael Manns, Peter Buggisch, Eva Herrmann, Stefan Zeuzem. (2008) Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology 48:5, 1404-1411
CrossRef983
Krisztina Hagymási, János Fehér. (2008) A testsúlycsökkentés hatása a kombinált interferon-alfa-2a + ribavirin kezelésre adott válaszra idült HCV-hepatitisben. Orvosi Hetilap 149:46, 2189-2192
CrossRef984
LF Lopez-Cortes, B Valera-Bestard, A Gutierrez-Valencia, R Ruiz-Valderas, L Jimenez, A Arizcorreta, A Terrón, P Viciana. (2008) Role of Pegylated Interferon-α-2a and Ribavirin Concentrations in Sustained Viral Response in HCV/HIV-Coinfected Patients. Clinical Pharmacology & Therapeutics 84:5, 573-580
CrossRef985
Barbara H. McGovern, Barham K. Abu Dayyeh, Raymond T. Chung. (2008) Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection. Hepatology 48:5, 1700-1712
CrossRef986
Moisés Diago. (2008) Tratamiento de la infección por el virus de la hepatitis C. Estado actual y perspectivas. Gastroenterología y Hepatología 31:9, 596-605
CrossRef987
Stefan Zeuzem. (2008) Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & Hepatology 5:11, 610-622
CrossRef988
Naim Alkhouri, Nizar N. Zein. (2008) Hepatitis C in children and adolescents: The good, the bad, and the ugly. Current Hepatitis Reports 7:4, 145-151
CrossRef989
Katia Falasca, Claudio Ucciferri, Paola Mancino, Ester Vitacolonna, Domenico De Tullio, Eligio Pizzigallo, Pio Conti, Jacopo Vecchiet. (2008) Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. Journal of Medical Virology 80:11, 1900-1906
CrossRef990
Alexandra Wimmer, János Fehér, Gabriella Lengyel. (2008) Hepatitis C-vírus sikeres eliminálása hepatocellularis carcinoma miatti lobectomiát követően. Orvosi Hetilap 149:45, 2143-2148
CrossRef991
Nikroo Hashemi, Simona Rossi, Victor J Navarro, Steven K Herrine. (2008) Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opinion on Drug Safety 7:6, 771-781
CrossRef992
Anna Stankiewicz-Drogon, Larisa G. Palchykovska, Valentina G. Kostina, Inna V. Alexeeva, Anatoly D. Shved, Anna M. Boguszewska-Chachulska. (2008) New acridone-4-carboxylic acid derivatives as potential inhibitors of Hepatitis C virus infection. Bioorganic & Medicinal Chemistry 16:19, 8846-8852
CrossRef993
Mahathi Adla, Kathy K. Downey, Jawad Ahmad. (2008) Hepatic Sarcoidosis Associated with Pegylated Interferon Alfa Therapy for Chronic Hepatitis C—Case Report and Review of Literature. Digestive Diseases and Sciences 53:10, 2810-2812
CrossRef994
Duncan Smith‐Rohrberg Maru, Robert Douglas Bruce, Sanjay Basu, Frederick L. Altice. (2008) Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations. Clinical Infectious Diseases 47:7, 952-961
CrossRef995
Shinobu Tatsunami, Junichi Mimaya, Akira Shirahata, Jiří Zelinka, Ivana Horová, Jugo Hanai, Yutaka Nishina, Katsumi Ohira, Masashi Taki. (2008) Current status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCV. International Journal of Hematology 88:3, 304-310
CrossRef996
C. Hamer. (2008) The impact of combination therapy with peginterferon alfa-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients. Journal of Human Nutrition and Dietetics 21:5, 486-493
CrossRef997
Michael W. Fried, Donald M. Jensen, Maribel Rodriguez-Torres, Lisa M. Nyberg, Adrian M. Di Bisceglie, Timothy R. Morgan, Paul J. Pockros, Amy Lin, Lisa Cupelli, Frank Duff, Ka Wang, David R. Nelson. (2008) Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology 48:4, 1033-1043
CrossRef998
Claudio Velati, Luisa Romanò, Laura Fomiatti, Lorella Baruffi, Alessandro Remo Zanetti, . (2008) Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 48:10, 2205-2213
CrossRef999
Adeel A. Butt, Uzma A. Khan, Melissa Skanderson. (2008) Comorbidities and Their Impact on Mortality in HCV and HCV-HIV–coinfected Persons on Dialysis. Journal of Clinical Gastroenterology 42:9, 1054-1059
CrossRef1000
Qi Qiu, Richard Yuan-Hu Wang, Xuanmao Jiao, Bo Jin, Fuminaka Sugauchi, Teresa Grandinetti, Harvey J. Alter, J. Wai-Kuo Shih. (2008) Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 26:43, 5527-5534
CrossRef1001
E. Xirouchakis, C. Triantos, P. Manousou, A. Sigalas, V. Calvaruso, A. Corbani, G. Leandro, D. Patch, A. Burroughs. (2008) Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. Journal of Viral Hepatitis 15:10, 699-709
CrossRef1002
Annika Kau, Johannes Vermehren, Christoph Sarrazin. (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 49:4, 634-651
CrossRef1003
Timothy R. Morgan, Richard W. Lambrecht, Herbert L. Bonkovsky, Raymond T. Chung, Deepa Naishadham, Richard K. Sterling, Robert J. Fontana, William M. Lee, Marc G. Ghany, Elizabeth C. Wright, Thomas R. O’Brien. (2008) DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology 49:4, 548-556
CrossRef1004
P. Bruggmann, L. Falcato, S. Dober, B. Helbling, O. Keiser, F. Negro, D. Meili, . (2008) Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. Journal of Viral Hepatitis 15:10, 747-752
CrossRef1005
Renee Pozza. (2008) Clinical management of HIV/hepatitis C virus coinfection. Journal of the American Academy of Nurse Practitioners 20:10, 496-505
CrossRef1006
L. Martín-Carbonero, M. Puoti, J. García-Samaniego, A. De Luca, E. Losada, G. Quinzan, R. Bruno, A. Mariño, M. González, M. Núñez, V. Soriano. (2008) Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Journal of Viral Hepatitis 15:10, 710-715
CrossRef1007
Johannes G. Bode, Erwin D. Brenndörfer, Dieter Häussinger. (2008) Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biological Chemistry 389:10, 1283-1298
CrossRef1008
N SELZNER, I MCGILVRAY. (2008) Can genetic variations predict HCV treatment outcomes?
. Journal of Hepatology 49:4, 494-497
CrossRef1009
B LETTMEIER, N MUHLBERGER, R SCHWARZER, G SROCZYNSKI, D WRIGHT, S ZEUZEM, U SIEBERT. (2008) Market uptake of new antiviral drugs for the treatment of hepatitis C
CrossRef1010
C. Niederau. (2008) Aktuelle Therapie der chronischen Hepatitis B und C. Der Internist 49:10, 1265-1273
CrossRef1011
Gaetano Scotto, Vincenzina Fazio, Chiara Fornabaio, Alessandra Tartaglia, Rocco Di Tullio, Annalisa Saracino, Gioacchino Angarano. (2008) Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study. Journal of Interferon & Cytokine Research 28:10, 623-630
CrossRef1012
James Fung, Ching‐Lung Lai, Ivan Hung, John Young, Charles Cheng, Danny Wong, Man‐Fung Yuen. (2008) Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. The Journal of Infectious Diseases 198:6, 808-812
CrossRef1013
J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, V. Soriano. (2008) Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy 62:6, 1174-1180
CrossRef1014
J. A. Mira, L. F. Lopez-Cortes, P. Barreiro, C. Tural, M. Torres-Tortosa, I. de los Santos Gil, P. Martin-Rico, M. J. Rios-Villegas, J. J. Hernandez-Burruezo, D. Merino, M. A. Lopez-Ruz, A. Rivero, L. Munoz, M. Gonzalez-Serrano, A. Collado, J. Macias, P. Viciana, V. Soriano, J. A. Pineda. (2008) Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. Journal of Antimicrobial Chemotherapy 62:6, 1365-1373
CrossRef1015
Sarah Maylin, Michelle Martinot–Peignoux, Rami Moucari, Nathalie Boyer, Marie–Pierre Ripault, Dominique Cazals–Hatem, Nathalie Giuily, Corinne Castelnau, Ana Carolina Cardoso, Tarik Asselah, Cyrille Féray, Marie Hélène Nicolas–Chanoine, Pierre Bedossa, Patrick Marcellin. (2008) Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C. Gastroenterology 135:3, 821-829
CrossRef1016
O. Weiland, A. Hollander, L. Mattsson, H. Glaumann, K. Lindahl, R. Schvarcz, G. Lindh, R. Enquist, A. Quist. (2008) Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. Journal of Viral Hepatitis 15:9, 641-645
CrossRef1017
Nasser S.M. Ismail, Riham Salah El Dine, Masao Hattori, Kazunori Takahashi, Masataka Ihara. (2008) Computer based design, synthesis and biological evaluation of novel indole derivatives as HCV NS3-4A serine protease inhibitors. Bioorganic & Medicinal Chemistry 16:17, 7877-7887
CrossRef1018
S SARAVANAN, V VELU, N KUMARASAMY, E SHANKAR, S NANDAKUMAR, K MURUGAVEL, P BALAKRISHNAN, S SOLOMON, S SOLOMON, S THYAGARAJAN. (2008) The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. International Journal of Infectious Diseases 12:5, 513-518
CrossRef1019
M. Gambarin-Gelwan, I. M. Jacobson. (2008) Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. Journal of Viral Hepatitis 15:9, 623-633
CrossRef1020
I. Lenci, P. Piccolo, S. Francioso, D. Di Paolo, A. Galante, M. Angelico. (2008) Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels. Digestive and Liver Disease 40:9, 785-790
CrossRef1021
Krystle Lang, David B Weiner. (2008) Immunotherapy for HCV infection: next steps. Expert Review of Vaccines 7:7, 915-923
CrossRef1022
Juan F. Gallegos-Orozco, Jorge Rakela, Marianne J. Rosati, Hugo E. Vargas, Vijayan Balan. (2008) Persistence of Hepatitis C Virus in Peripheral Blood Mononuclear Cells of Sustained Viral Responders to Pegylated Interferon and Ribavirin Therapy. Digestive Diseases and Sciences 53:9, 2564-2568
CrossRef1023
Pierre Raboisson, Herman de Kock, Åsa Rosenquist, Magnus Nilsson, Lourdes Salvador-Oden, Tse-I Lin, Natalie Roue, Vladimir Ivanov, Horst Wähling, Kristina Wickström, Elizabeth Hamelink, Michael Edlund, Lotta Vrang, Sandrine Vendeville, Wim Van de Vreken, David McGowan, Abdellah Tahri, Lili Hu, Carlo Boutton, Oliver Lenz, Frederic Delouvroy, Geert Pille, Dominique Surleraux, Piet Wigerinck, Bertil Samuelsson, Kenneth Simmen. (2008) Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorganic & Medicinal Chemistry Letters 18:17, 4853-4858
CrossRef1024
Maribel Rodríguez-Torres, Carlos F. Ríos-Bedoya, Grisell Ortiz-Lasanta, Dagmary Purcell-Arevalo, Acisclo Marxuach-Cuétara, Josselyn Jiménez-Rivera. (2008) Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks. Journal of Medical Virology 80:9, 1576-1580
CrossRef1025
P. Hraber, C. Kuiken, M. Waugh, S. Geer, W. J. Bruno, T. Leitner. (2008) Classification of hepatitis C virus and human immunodeficiency virus-1 sequences with the branching index. Journal of General Virology 89:9, 2098-2107
CrossRef1026
Mie Ando, Masaaki Korenaga, Keisuke Hino, Masanori Ikeda, Nobuyuki Kato, Sohji Nishina, Isao Hidaka, Isao Sakaida. (2008) Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication. Liver International 28:8, 1158-1166
CrossRef1027
Florence Nicot, Florence Legrand-Abravanel, Thierry Lafont, Martine Dubois, Karine Sauné, Christophe Pasquier, Etienne Chatelut, Jacques Izopet. (2008) Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. Journal of Medical Virology 80:9, 1523-1529
CrossRef1028
Yuji Miura, Masahiro Kami, Ron Yotsuya, Nobuo Toda, Tsunehiko Komatsu. (2008) Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin. American Journal of Hematology 83:9, 758-759
CrossRef1029
Michiko Shindo, Kazushige Hamada, Teruhisa Morikawa, Yuichi Harano, Tomoaki Nakajima, Tadao Okuno. (2008) In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. Hepatology Research
CrossRef1030
Jason P Smith. (2008) Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events. Pharmacotherapy 28:9, 1151-1161
CrossRef1031
T. Kimura, M. Imamura, N. Hiraga, T. Hatakeyama, D. Miki, C. Noguchi, N. Mori, M. Tsuge, S. Takahashi, Y. Fujimoto, E. Iwao, H. Ochi, H. Abe, T. Maekawa, K. Arataki, C. Tateno, K. Yoshizato, T. Wakita, T. Okamoto, Y. Matsuura, K. Chayama. (2008) Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. Journal of General Virology 89:9, 2108-2113
CrossRef1032
T.-M. Scherzer, K. R. Reddy, F. Wrba, H. Hofer, K. Staufer, P. Steindl-Munda, A. Gangl, P. Ferenci. (2008) Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 15:9, 659-665
CrossRef1033
Julie M. Bares, Jose Berger, James E. Nelson, Donald J. Messner, Sandra Schildt, Leanna J. Standish, Kris V. Kowdley. (2008) Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C. Journal of Clinical Gastroenterology 42:8, 937-944
CrossRef1034
H. Toyoda, T. Kumada, S. Kiriyama, Y. Sone, M. Tanikawa, Y. Hisanaga, A. Kanamori, H. Atsumi, S. Nakano, T. Arakawa, T. Honda, K. Hayashi, Y. Katano, H. Goto. (2008) Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin. Journal of Viral Hepatitis 15:9, 651-658
CrossRef1035
Jag H. Khalsa, Glenn Treisman, Elinore McCance-Katz, Ellen Tedaldi. (2008) Medical Consequences of Drug Abuse and Co-Occurring Infections: Research at the National Institute on Drug Abuse. Substance Abuse 29:3, 5-16
CrossRef1036
F. LODATO, S. BERARDI, A. GRAMENZI, G. MAZZELLA, M. LENZI, M. C. MORELLI, M. R. TAME, F. PISCAGLIA, P. ANDREONE, , G. BALLARDINI, M. BERNARDI, F. B. BIANCHI, M. BISELLI, L. BOLONDI, M. CESCON, A. COLECCHIA, A. D’ERRICO, M. DEL GAUDIO, G. ERCOLANI, G. L. GRAZI, W. GRIGIONI, S. LORENZINI, A. D. PINNA, M. RAVAIOLI, E. RODA, C. SAMA, M. VIVARELLI. (2008) Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology & Therapeutics 28:4, 450-457
CrossRef1037
C. L. Ward, A. Dev, S. Rigby, W. T. Symonds, K. Patel, A. Zekry, J.-M. Pawlotsky, J. G. McHutchison. (2008) Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. Journal of Viral Hepatitis 15:8, 571-577
CrossRef1038
E. Righi, A. Beltrame, M. Bassetti, V. Lindstrom, G. Mazzarello, C. Dentone, A. Biagio, S. Ratto, C. Viscoli. (2008) Therapeutical Aspects and Outcome of HIV/HCV Coinfected Patients Treated with Pegylated Interferon plus Ribavirin in an Italian Cohort. Infection 36:4, 358-361
CrossRef1039
E LAWITZ, M RODRIGUEZTORRES, A MUIR, T KIEFFER, L MCNAIR, A KHUNVICHAI, J MCHUTCHISON. (2008) Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
CrossRef1040
Shigeaki Ishii, Margaret James Koziel. (2008) Immune responses during acute and chronic infection with hepatitis C virus. Clinical Immunology 128:2, 133-147
CrossRef1041
S DEUFFICBURBAN, P DELTENRE, A LOUVET, V CANVA, S DHARANCY, A HOLLEBECQUE, J BOITARD, J HENRION, Y YAZDANPANAH, P MATHURIN. (2008) Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France
CrossRef1042
Maribel Rodríguez-Torres. (2008) Chronic hepatitis C in the Latino population. Current Hepatitis Reports 7:3, 106-112
CrossRef1043
R. Chou, S. Carson, B. K. S. Chan. (2008) Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. Journal of Viral Hepatitis 15:8, 551-570
CrossRef1044
Stefan Zeuzem, Eric M. Yoshida, Yves Benhamou, Stephen Pianko, Vincent G. Bain, Daniel Shouval, Robert Flisiak, Vratislav Rehak, Mircea Grigorescu, Kelly Kaita, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison. (2008) Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 48:2, 407-417
CrossRef1045
Timothy Cross, Charalambos Antoniades, Phillip Harrison. (2008) Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatology Research 38:8, 762-769
CrossRef1046
Qunying Han, Zhengwen Liu, Wen Kang, Han Li, Lei Zhang, Ni Zhang. (2008) Interferon Beta 1a versus Interferon Beta 1a plus Ribavirin for the Treatment of Chronic Hepatitis C in Chinese Patients: A Randomized, Placebo-Controlled Trial. Digestive Diseases and Sciences 53:8, 2238-2245
CrossRef1047
Thomas Kuntzen, Andrew Berical, Jean Ndjomou, Phil Bennett, Arne Schneidewind, Niall Lennon, Bruce W. Birren, Carla Kuiken, Matthew R. Henn, Peter Simmonds, Todd M. Allen. (2008) A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame. Journal of Medical Virology 80:8, 1370-1378
CrossRef1048
Thomas Berg. (2008) Tailored Treatment for Hepatitis C. Clinics in Liver Disease 12:3, 507-528
CrossRef1049
A. ANDRIULLI, A. MANGIA, A. IACOBELLIS, A. IPPOLITO, G. LEANDRO, S. ZEUZEM. (2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Alimentary Pharmacology & Therapeutics 28:4, 397-404
CrossRef1050
Arthur Y Kim, Joerg Timm. (2008) Resistance mechanisms in HCV: from evolution to intervention. Expert Review of Anti-infective Therapy 6:4, 463-478
CrossRef1051
M BERENGUER. (2008) Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
CrossRef1052
A. Yamane, T. Nakamura, H. Suzuki, M. Ito, Y. Ohnishi, Y. Ikeda, Y. Miyakawa. (2008) Interferon- 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 112:3, 542-550
CrossRef1053
J. M. Cuevas, M. Torres-Puente, N. Jimnez-Hernndez, M. A. Bracho, I. Garca-Robles, F. Carnicer, J. D. Olmo, E. Ortega, A. Moya, F. Gonzlez-Candelas. (2008) Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response. Journal of Viral Hepatitis 15:8, 578-590
CrossRef1054
P Colombatto, P Ciccorossi, AM Maina, L Civitano, F Oliveri, B Coco, V Romagnoli, F Bonino, MR Brunetto. (2008) Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells. Clinical Pharmacology & Therapeutics 84:2, 212-215
CrossRef1055
Paul J. Pockros, David Nelson, Eliot Godofsky, Maribel Rodriguez-Torres, Gregory T. Everson, Michael W. Fried, Reem Ghalib, Stephen Harrison, Lisa Nyberg, Mitchell L. Shiffman, Isabel Najera, Anna Chan, George Hill. (2008) R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48:2, 385-397
CrossRef1056
Nancy Reau, Stephanos J. Hadziyannis, Diethelm Messinger, Michael W. Fried, Donald M. Jensen. (2008) Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin. The American Journal of Gastroenterology 103:8, 1981-1988
CrossRef1057
Zania Stamataki, Joe Grove, Peter Balfe, Jane A. McKeating. (2008) Hepatitis C Virus Entry and Neutralization. Clinics in Liver Disease 12:3, 693-712
CrossRef1058
Karen F Murray, Uzma Shah, Neelam Mohan, Solange Heller, Regino P González-Peralta, Deirdre Kelly, Mei-Hwei Chang, Giorgina Mieli-Vergani, Paloma Jara, Tomoo Fujisawa. (2008) Chronic Hepatitis. Journal of Pediatric Gastroenterology and Nutrition 47:2, 225-233
CrossRef1059
Hesham M. Elgouhari, Hari S. Conjeevaram. (2008) Impact of obesity, hepatic steatosis, and insulin resistance on hepatitis C treatment outcomes. Current Hepatitis Reports 7:3, 127-133
CrossRef1060
Mitchell L. Shiffman. (2008) Optimizing the Current Therapy for Chronic Hepatitis C Virus: Peginterferon and Ribavirin Dosing and the Utility of Growth Factors. Clinics in Liver Disease 12:3, 487-505
CrossRef1061
Stuart K. Roberts, Graham Cooksley, Gregory J. Dore, Richard Robson, David Shaw, Heather Berns, George Hill, Klaus Klumpp, Isabel Najera, Carla Washington. (2008) Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48:2, 398-406
CrossRef1062
Peter Ferenci, Hermann Laferl, Thomas–Matthias Scherzer, Michael Gschwantler, Andreas Maieron, Harald Brunner, Rudolf Stauber, Martin Bischof, Bernhard Bauer, Christian Datz, Karin Löschenberger, Elisabeth Formann, Katharina Staufer, Petra Steindl–Munda. (2008) Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response. Gastroenterology 135:2, 451-458
CrossRef1063
Satheesh Nair, Jeannie Lipscomb, James Eason. (2008) Efficacy of Interferon Based Antiviral Therapy for Recurrent Hepatitis C in Patients Who Received Steroid Free Immunosuppression for Liver Transplantation. Transplantation 86:3, 418-422
CrossRef1064
M. TRAPERO-MARUGAN, M. MARIN, J. P. PIVEL, J. M. DEL RIO, O. NUNEZ, G. CLEMENTE, J. P. GISBERT, R. MORENO-OTERO. (2008) Predictive graphical model, network-based medical tool for the prognosis of chronic hepatitis C patients treated with peg-interferon plus ribavirin. Alimentary Pharmacology & Therapeutics 28:4, 468-474
CrossRef1065
J. J. WEISS, L. BHATTI, D. T. DIETERICH, B. R. EDLIN, D. A. FISHBEIN, M. B. GOETZ, K. YU, G. J. WAGNER. (2008) Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Alimentary Pharmacology & Therapeutics 28:3, 289-293
CrossRef1066
Poonam Mishra, Donald M. Jensen. (2008) Hepatitis C: current and future therapies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:4, 405-414
CrossRef1067
Vincent Lo Re, Jay R. Kostman, Valerianna K. Amorosa. (2008) Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century. Clinics in Liver Disease 12:3, 587-609
CrossRef1068
J. Wiegand, K. Deterding, M. Cornberg, H. Wedemeyer. (2008) Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon . Journal of Antimicrobial Chemotherapy 62:5, 860-865
CrossRef1069
Haofan Jin, Atsuya Yamashita, Shinya Maekawa, Pinting Yang, Limin He, Satoru Takayanagi, Takaji Wakita, Naoya Sakamoto, Nobuyuki Enomoto, Masahiko Ito. (2008) Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication in vitro. Hepatology Research???-???
CrossRef1070
Mario Angelico, Beate Koehler-Horst, Paola Piccolo, Francesco Angelico, Silvia Gentile, Simona Francioso, Pierluigi Tarquini, Roberto Della Vecchia, Laura Ponti, Giampaolo Pilleri, Angelo Barlattani, Antonio Grieco, Francesco Soccorsi, Paolo Guarascio, Luigi Demelia, Orazio Sorbello, Zaccaria Rossi, Giuseppe Forlini, Salvatore Zaru, Franco Bandiera. (2008) Peginterferon ??-2a and ribavirin versus peginterferon ??-2a monotherapy in early virological responders and peginterferon ??-2a and ribavirin versus peginterferon ??-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in na??ve patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology 20:7, 680-687
CrossRef1071
Sumio Watanabe, Reiko Yaginuma, Kenichi Ikejima, Akihisa Miyazaki. (2008) Liver diseases and metabolic syndrome. Journal of Gastroenterology 43:7, 509-518
CrossRef1072
Ahmed El‐Shamy, Motoko Nagano‐Fujii, Noriko Sasase, Susumu Imoto, Soo‐Ryang Kim, Hak Hotta. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:1, 38-47
CrossRef1073
V. G. BAIN, S. S. LEE, K. PELTEKIAN, E. M. YOSHIDA, M. DESCHÊNES, M. SHERMAN, R. BAILEY, H. WITT-SULLIVAN, R. BALSHAW, M. KRAJDEN, . (2008) Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. Alimentary Pharmacology & Therapeutics 28:1, 43-50
CrossRef1074
Emanuel Sikuler, Ran Tur-Kaspa, Yonat Shemer-Avni, Jorge Delgado, Doron Zilberman, Alexander Fich, Yaacov Baruch, Eytan Hyam. (2008) Sustained Virologic Response to Treatment in 100% of Patients Recently Infected, Nosocomially, With HCV Genotype 2. Journal of Clinical Gastroenterology 42:6, 730-733
CrossRef1075
Eva Herrmann, Stefan Zeuzem. (2008) Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection?. Nature Clinical Practice Gastroenterology & Hepatology 5:7, 362-363
CrossRef1076
J. McHutchison, M. Sulkowski. (2008) Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis 15:7, 475-481
CrossRef1077
Ricard Navinés, Pere Castellví, Ricard Solà, Rocío Martín-Santos. (2008) Peginterferon- and ribavirin-induced bipolar episode successfully treated with lamotrigine without discontinuation of antiviral therapy. General Hospital Psychiatry 30:4, 387-389
CrossRef1078
Douglas K. Hutchinson, Teresa Rosenberg, Larry L. Klein, Todd D. Bosse, Daniel P. Larson, Wenping He, Wen W. Jiang, Warren M. Kati, William E. Kohlbrenner, Yaya Liu, Sherie V. Masse, Tim Middleton, Akhteruzzaman Molla, Debra A. Montgomery, David W.A. Beno, Kent D. Stewart, Vincent S. Stoll, Dale J. Kempf. (2008) Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives. Bioorganic & Medicinal Chemistry Letters 18:14, 3887-3890
CrossRef1079
Samuel B. Ho, Erik Groessl, Adrian Dollarhide, Shannon Robinson, David Kravetz, Eric Dieperink. (2008) Management of Chronic Hepatitis C in Veterans: The Potential of Integrated Care Models. The American Journal of Gastroenterology 103:7, 1810-1823
CrossRef1080
Carroll B. Leevy. (2008) Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin. Digestive Diseases and Sciences 53:7, 1961-1966
CrossRef1081
J. Wiegand, J. Mössner, H.L. Tillmann. (2008) Diagnostik und Therapie der chronischen Hepatitis B und C. Der Internist 49:7, 817-832
CrossRef1082
I. Mimura, Y. Ishibashi, R. Tateishi, S. Kaname, T. Fujita. (2008) Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT Plus 1:4, 233-235
CrossRef1083
D. Hegazy, P. Thurairajah, M. Metzner, A. Houldsworth, S. Shaw, E. Kaminski, A. G. Demaine, M. E. Cramp. (2008) Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clinical & Experimental Immunology 152:3, 538-541
CrossRef1084
David M. Novick, Mary Jeanne Kreek. (2008) Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 103:6, 905-918
CrossRef1085
S. U. Iqbal, F. Cunningham, A. Lee, D. R. Miller, N.-C. Li, R. Cheung, L. Kazis. (2008) Persistence with hepatitis C therapy in the Department of Veterans Affairs. Journal of Clinical Pharmacy and Therapeutics 33:3, 251-261
CrossRef1086
S L Rhodes, H Erlich, K A Im, J Wang, J Li, T Bugawan, L Jeffers, X Tong, X Su, H R Rosen, L J Yee, T J Liang, H Yang. (2008) Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes and Immunity 9:4, 328-333
CrossRef1087
Vincent G. Bain, Kelly D. Kaita, Paul Marotta, Eric M. Yoshida, Mark G. Swain, Robert J. Bailey, Keyur Patel, Patrick W. Cronin, Erik Pulkstenis, John G. McHutchison, G. Mani Subramanian. (2008) Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients. Clinical Gastroenterology and Hepatology 6:6, 701-706
CrossRef1088
Paula Tuma, Eugenia Vispo, Pablo Barreiro, Vicente Soriano. (2008) Papel de tenofovir en la coinfección por el virus de la inmunodeficiencia humana y el virus de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 26, 31-37
CrossRef1089
Evelyn K Hsu, Karen F Murray. (2008) Hepatitis B and C in children. Nature Clinical Practice Gastroenterology & Hepatology 5:6, 311-320
CrossRef1090
Alessandra Mangia, Angelo Andriulli. (2008) Are HCV genotypes 2 and 3 the same or different?. Current Hepatitis Reports 7:2, 88-92
CrossRef1091
Ioannis S. Elefsiniotis, Christos Pavlidis, Ioannis Ketikoglou, Sotirios Koutsounas, Nikolaos Scarmeas, Konstantinos D. Pantazis, Antonios Moulakakis, Epameinondas V. Tsianos. (2008) Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. European Journal of Internal Medicine 19:4, 266-270
CrossRef1092
Shruti H. Mehta, Becky L. Genberg, Jacquie Astemborski, Ravi Kavasery, Gregory D. Kirk, David Vlahov, Steffanie A. Strathdee, David L. Thomas. (2008) Limited Uptake of Hepatitis C Treatment Among Injection Drug Users. Journal of Community Health 33:3, 126-133
CrossRef1093
Martin Lagging, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Amar P. Dhillon, Åsa Alsiö, Kristoffer Hellstrand, Johan Westin, Gunnar Norkrans, . (2008) Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47:6, 1837-1845
CrossRef1094
Régis Peffault de Latour, Patricia Ribaud, Marie Robin, Dominique Valla, Patrick Marcellin, Gérard Socié, Tarik Asselah. (2008) Allogeneic hematopoietic cell transplant in HCV-infected patients. Journal of Hepatology 48:6, 1008-1017
CrossRef1095
Nezam Afdhal, John McHutchison, Robert Brown, Ira Jacobson, Michael Manns, Fred Poordad, Babette Weksler, Rafael Esteban. (2008) Thrombocytopenia associated with chronic liver disease. Journal of Hepatology 48:6, 1000-1007
CrossRef1096
A. Mangia, F. Antonucci, M. Brunetto, M. Capobianchi, S. Fagiuoli, M. Guido, P. Farci, P. Lampertico, A. Marzano, G. Niro, G. Pisani, D. Prati, M. Puoti, G. Raimondo, T. Santantonio, A. Smedile, F. Lauria. (2008) The use of molecular assays in the management of viral hepatitis. Digestive and Liver Disease 40:6, 395-404
CrossRef1097
Laurence H. Beck, David J. Salant. (2008) Glomerular and Tubulointerstitial Diseases. Primary Care: Clinics in Office Practice 35:2, 265-296
CrossRef1098
Jose L. Tovar, Maria Buti, Alfonso Segarra, Joaquim Majó, Rafael Esteban. (2008) De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. International Urology and Nephrology 40:2, 539-541
CrossRef1099
Paul Martin, Donald M Jensen. (2008) Ribavirin in the treatment of chronic hepatitis C. Journal of Gastroenterology and Hepatology 23:6, 844-855
CrossRef1100
Paolo Pugnale, Eva Herrmann, Avidan U. Neumann, Jean-Michel Pawlotsky, Solko W. Schalm, Carlo Ferrari, Yonit Homburger, Stefan Zeuzem, Francesco Negro. (2008) Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-α2a/ribavirin therapy. Journal of Hepatology 48:6, 932-938
CrossRef1101
Peter Ferenci, Harald Brunner, Hermann Laferl, Thomas-Matthias Scherzer, Andreas Maieron, Michael Strasser, Gabriele Fischer, Harald Hofer, Martin Bischof, Rudolf Stauber, Michael Gschwantler, Petra Steindl-Munda, Katharina Staufer, Karin Löschenberger, . (2008) A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 47:6, 1816-1823
CrossRef1102
Amparo Escudero, Felicidad Rodríguez, Miguel A Serra, Juan A del Olmo, Francisco Montes, José M Rodrigo. (2008) Pegylated α-interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study. Journal of Gastroenterology and Hepatology 23:6, 861-866
CrossRef1103
Ming-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, Chang-Fu Chiu, Yi-Hsin C. Yang, Nai-Jen Hou, Li-Po Lee, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang. (2008) Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 47:6, 1884-1893
CrossRef1104
Eliana Z. Agudelo, Norah A. Terrault. (2008) Optimizing therapy in treatment-naïve genotype 1 patients. Current Hepatitis Reports 7:2, 64-71
CrossRef1105
Manuela G. Neuman, Kevin Sha, Rustan Esguerra, Sam Zakhari, Robert E. Winkler, Nir Hilzenrat, Jonathan Wyse, Curtis L. Cooper, Devanshi Seth, Mark D. Gorrell, Paul S. Haber, Geoffrey W. McCaughan, Maria A. Leo, Charles S. Lieber, Mihai Voiculescu, Eugenia Buzatu, Camelia Ionescu, Jozsef Dudas, Bernhard Saile, Giuliano Ramadori. (2008) Inflammation and Repair in Viral Hepatitis C. Digestive Diseases and Sciences 53:6, 1468-1487
CrossRef1106
Gustine Liu-Young, Michael J. Kozal. (2008) Review: Hepatitis C Protease and Polymerase Inhibitors in Development. AIDS Patient Care and STDs 22:6, 449-457
CrossRef1107
Nizar N. Zein. (2008) Steatosis and metabolic syndrome: An emerging enigma in the natural history of chronic hepatitis C. Current Hepatitis Reports 7:2, 60-63
CrossRef1108
Yukiko Miura, Akitaka Shibuya, Shigeru Adachi, Atsuko Takeuchi, Takeshi Tsuchihashi, Takahide Nakazawa, Katsunori Saigenji. (2008) Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatology Research 38:6, 546-556
CrossRef1109
M. Sarasin-Filipowicz, E. J. Oakeley, F. H. T. Duong, V. Christen, L. Terracciano, W. Filipowicz, M. H. Heim. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences 105:19, 7034-7039
CrossRef1110
K. H. TANG, E. HERRMANN, I. PACHIADAKIS, E. PAULON, N. TATMAN, S. ZEUZEM, N. V. NAOUMOV. (2008) Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin. Alimentary Pharmacology & Therapeutics 27:9, 810-819
CrossRef1111
F. Pons Renedo, J. de la Revilla Negro, J.L. Calleja Panero. (2008) Farmacología del tratamiento de las infecciones por el virus C y B de la hepatitis. Interferones. Antivirales. Medicine - Programa de Formación Médica Continuada Acreditado 10:9, 555-562
CrossRef1112
Christine M. Rousseau, George N. Ioannou, Jeffrey A. Todd-Stenberg, Kevin L. Sloan, Meaghan F. Larson, Christopher W. Forsberg, Jason A. Dominitz. (2008) Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study. American Journal of Public Health 98:5, 846-852
CrossRef1113
Véronique Loustaud-Ratti, Sophie Alain, Annick Rousseau, Isabelle Fouchard Hubert, François Ludovic Sauvage, Pierre Marquet, François Denis, Françoise Lunel, Paul Calès, Annie Lefebvre, Anne-Laure Fauchais, Eric Liozon, Elisabeth Vidal. (2008) Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 47:5, 1453-1461
CrossRef1114
Yasuhiro Asahina, Namiki Izumi, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Yutaka Yasui, Nobutoshi Komatsu, Naoki Umeda, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Masayuki Kurosaki, Nobuyuki Enomoto, Megumi Tasaka, Naoya Sakamoto, Shozo Miyake. (2008) Potential Relevance of Cytoplasmic Viral Sensors and Related Regulators Involving Innate Immunity in Antiviral Response. Gastroenterology 134:5, 1396-1405
CrossRef1115
N. Antaki, A. Hermes, M. Hadad, M. Ftayeh, F. Antaki, N. Abdo, K. Kebbewar. (2008) Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. Journal of Viral Hepatitis 15:5, 383-386
CrossRef1116
I ALTUGLU, I SOYLER, T OZACAR, S ERENSOY. (2008) Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. International Journal of Infectious Diseases 12:3, 239-244
CrossRef1117
Ibrahim A. Hanouneh, Ariel E. Feldstein, Rocio Lopez, Lisa Yerian, Anjana Pillai, Claudia O. Zein, Nizar N. Zein. (2008) Clinical Significance of Metabolic Syndrome in the Setting of Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 6:5, 584-589
CrossRef1118
Charles D. Howell, Thomas C. Dowling, Marika Paul, Abdus S. Wahed, Norah A. Terrault, Milton Taylor, Lennox Jeffers, Jay H. Hoofnagle. (2008) Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology 6:5, 575-583
CrossRef1119
Z. M. Younossi, F. H. Nader, C. Bai, R. Sjogren, J. P. Ong, R. Collantes, M. Sjogren, D. Farmer, L. Ramsey, K. Terra, H. Gujral, C. Gurung, M. Srishord, Y. Fang. (2008) A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. Journal of Viral Hepatitis 15:5, 370-378
CrossRef1120
Tony Carlsson, Anne Quist, Ola Weiland. (2008) Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. Journal of Medical Virology 80:5, 803-807
CrossRef1121
Masayuki Kurosaki, Kotaro Matsunaga, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Nobutoshi Komatsu, Naoki Umeda, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yasuhiro Asahina, Shozo Miyake, Nobuyuki Enomoto, Namiki Izumi. (2008) The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. Journal of Hepatology 48:5, 736-742
CrossRef1122
Chee-Kin Hui, Nancy Leung, Wai-Hung Shek, Hai-Ying Zhang, John M. Luk, Ronnie T. P. Poon, Chung-Mau Lo, Sheung-Tat Fan, George K. K. Lau. (2008) Changes in Liver Histology as a ???Surrogate??? End Point of Antiviral Therapy for Chronic HBV Can Predict Progression to Liver Complications. Journal of Clinical Gastroenterology 42:5, 533-538
CrossRef1123
Nazia Selzner, Limin Chen, Ivan Borozan, Aled Edwards, E. Jenny Heathcote, Ian McGilvray. (2008) Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. Journal of Hepatology 48:5, 708-713
CrossRef1124
Mercedes Vergara, Marta Gallach, Blai Dalmau, Montserrat Gil, Mireia Miquel, Núria Rudi, Antoni Gavarro, Alba Cebollero, Montserrat Masip, Jordi Real. (2008) Resultados del tratamiento con interferón pegilado y ribavirina para la hepatitis crónica por el virus C en la práctica clínica. Experiencia de 5 años. Gastroenterología y Hepatología 31:5, 274-279
CrossRef1125
Maribel Rodríguez–Torres. (2008) Latinos and Chronic Hepatitis C: A Singular Population. Clinical Gastroenterology and Hepatology 6:5, 484-490
CrossRef1126
Shintaro Abe, Ryoichi Narita, Toru Matsuhashi, Takeshi Oto, Akinari Tabaru, Makoto Otsuki. (2008) Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology 20:5, 373-378
CrossRef1127
Mindie H. Nguyen, Huy N. Trinh, Ruel Garcia, Gloria Nguyen, Khoa D. Lam, Emmet B. Keeffe. (2008) Higher Rate of Sustained Virologic Response in Chronic Hepatitis C Genotype 6 Treated With 48 Weeks Versus 24 Weeks of Peginterferon Plus Ribavirin. The American Journal of Gastroenterology 103:5, 1131-1135
CrossRef1128
Éva Bátyi, János Szegedi. (2008) A peginterferon és a ribavirin hatásossága hepatitis C-vírus-fertőzésben hipertónia és vesefunkció beszűkülése esetén. Orvosi Hetilap 149:19, 889-892
CrossRef1129
Jacqueline G. O'Leary, Rita Lepe, Gary L. Davis. (2008) Indications for Liver Transplantation. Gastroenterology 134:6, 1764-1776
CrossRef1130
G. BORRONI, M. ANDREOLETTI, M. A. CASIRAGHI, R. CERIANI, P. GUERZONI, B. OMAZZI, N. TERRENI, F. SALERNO. (2008) Effectiveness of pegylated interferon/ribavirin combination in ‘real world’ patients with chronic hepatitis C virus infection. Alimentary Pharmacology & Therapeutics 27:9, 790-797
CrossRef1131
E. Dieperink, J. Leskela, M. E. Dieperink, B. Evans, P. Thuras, S. B. Ho. (2008) The Effect of Pegylated Interferon- 2b and Ribavirin on Posttraumatic Stress Disorder Symptoms. Psychosomatics 49:3, 225-229
CrossRef1132
J. Nakamura, S.-I. Toyabe, Y. Aoyagi, K. Akazawa. (2008) Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders. Journal of Viral Hepatitis 15:4, 293-299
CrossRef1133
N. Napoli, G. Giannelli, A. Antonaci, S. Antonaci. (2008) The use of different Peg-interferon α-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. Journal of Viral Hepatitis 15:4, 300-304
CrossRef1134
B. J. Thomson, G. Kwong, S. Ratib, M. Sweeting, S. D. Ryder, D. De Angelis, R. Grieve, W. L. Irving, . (2008) Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. Journal of Viral Hepatitis 15:4, 271-278
CrossRef1135
Karlström Olle, Sönnerborg Anders, Weiland Ola. (2008) Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy. AIDS 22:7, 899-901
CrossRef1136
Narayan Dharel, Naoya Kato, Ryosuke Muroyama, Hiroyoshi Taniguchi, Motoyuki Otsuka, Yue Wang, Amarsanaa Jazag, Run-Xuan Shao, Jin-Hai Chang, Mark K. Adler, Takao Kawabe, Masao Omata. (2008) Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology 47:4, 1136-1149
CrossRef1137
Jann LÜBBE. (2008) Adverse skin reactions associated with hepatitis C treatment: Comment. The Journal of Dermatology 35:4, 250-250
CrossRef1138
Patrick Marcellin, George K. K. Lau, Stefan Zeuzem, E. Jenny Heathcote, Paul J. Pockros, K. Rajender Reddy, Teerha Piratvisuth, Patrizia Farci, Wan-Cheng Chow, Ji-Dong Jia, Woon Paik, Neil Wintfeld, Nigel Pluck. (2008) Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver International 28:4, 477-485
CrossRef1139
Federico Di Lello, Gabriel Garcia, Verónica Kott, Silvia Sookoian, Rodolfo Campos. (2008) Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment. Journal of Medical Virology 80:4, 619-627
CrossRef1140
Jee-Fu Huang, Chia-Yen Dai, Ya-Yun Lin, Ming-Lung Yu, Shu-Fen Liu, I-Ling Lin, Ming-Yen Hsieh, Li-Po Lee, Zu-Yau Lin, Shinn-Chern Chen, Ming-Yuh Hsieh, Wen-Yu Chang, Wan-Long Chuang. (2008) Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections. Clinical Chemistry and Laboratory Medicine 46:4, 475-480
CrossRef1141
Mitsuyasu Nakamura, Hidetsugu Saito, Masanori Ikeda, Shinichiro Tada, Naoki Kumagai, Nobuyuki Kato, Kunitada Shimotohno, Toshifumi Hibi. (2008) Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. Journal of Medical Virology 80:4, 632-639
CrossRef1142
Javier Salmerón, Jorge Casado, Paloma Muñoz de Rueda, Victor Lafuente, Moises Diago, Manuel Romero-Gómez, Ángel Palacios, Josefa León, Ana Gila, Rosa Quiles, Luis Rodriguez, Angeles Ruiz-Extremera. (2008) Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon–ribavirin. Journal of Clinical Virology 41:4, 264-269
CrossRef1143
Heidi E. Hamilton, Cynthia Gordon, Meaghan Nelson, Scott J. Cotler, Paul Martin. (2008) How Physicians Describe Outcomes to HCV Therapy. Journal of Clinical Gastroenterology 42:4, 419-424
CrossRef1144
Chi-Jen Chu, Shou-Dong Lee. (2008) Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. Journal of Gastroenterology and Hepatology 23:4, 512-520
CrossRef1145
F. Bani-Sadr, N. Lapidus, J.-C. Melchior, I. Ravaux, M. Bensalem, I. Rosa, P. Cacoub, S. Pol, C. Perronne, F. Carrat. (2008) Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. Journal of Viral Hepatitis 15:4, 255-260
CrossRef1146
Rinaldo Pellicano, Giovanni Puglisi, Alessia Ciancio, Federico Balzola, Giorgio Saracco, Giovannino Ciccone, Ileana Baldi, Maria Lorena Abate, Antonina Smedile, Mario Rizzetto. (2008) Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?. Journal of Medical Virology 80:4, 628-631
CrossRef1147
Nader Dbouk, Miguel R. Arguedas, Aasim Sheikh. (2008) Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C. Digestive Diseases and Sciences 53:4, 1100-1106
CrossRef1148
Rinaldo Pellicano, Armelle Ménard, Mario Rizzetto, Francis Mégraud. (2008) Helicobacter species and liver diseases: association or causation?. The Lancet Infectious Diseases 8:4, 254-260
CrossRef1149
Curtis L. Cooper. (2008) An Overview of HIV and Chronic Viral Hepatitis Co-Infection. Digestive Diseases and Sciences 53:4, 899-904
CrossRef1150
Ira M. Jacobson, Robert S. Brown. (2008) WIN-R revisited: Response to editorial. Hepatology 47:4, 1427-1427
CrossRef1151
Soocheol Jeong, Yoshiiku Kawakami, Mikiya Kitamoto, Hiroto Ishihara, Keiji Tsuji, Shiomi Aimitsu, Hiroiku Kawakami, Kiminori Uka, Shintaro Takaki, Hideaki Kodama, Koji Waki, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama. (2008) Prospective study of short-term peginterferon-α-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. Journal of Gastroenterology and Hepatology 23:4, 541-545
CrossRef1152
Paola Nasta, Francesca Gatti, Massimo Puoti, Giuliana Cologni, Viviana Bergamaschi, Federica Borghi, Alessandro Matti, Antonella Ricci, Giampiero Carosi. (2008) Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 22:7, 857-861
CrossRef1153
Deepak Kumar, Abdul Malik, Mohammad Asim, Anita Chakravarti, Rakha H. Das, Premashis Kar. (2008) Response of Combination Therapy on Viral Load and Disease Severity in Chronic Hepatitis C. Digestive Diseases and Sciences 53:4, 1107-1113
CrossRef1154
Edmond Vartany, Cary A. Caldwell, Terence K. Trow. (2008) Adult respiratory distress syndrome after treatment with pegylated interferon α-2a and ribavirin. Heart & Lung: The Journal of Acute and Critical Care 37:2, 153-156
CrossRef1155
J FRANCISCOMARQUEZPEIRO. (2008) Efectividad del tratamiento de la hepatitis C con peginterferón alfa (2a o 2b) más ribavirina en pacientes naïve. Enfermedades Infecciosas y Microbiología Clínica 26:3, 135-140
CrossRef1156
Y. MAOR, J. M. SCHAPIRO, D. BASHARI, Y. LURIE, R. SAFADI, O. SEGOL, M. PARITSKY, Z. RACHLIS, B. AVIDAN, S. BAR-MEIR, U. MARTINOWITZ. (2008) Treatment of hepatitis C in patients with haemophilia – the Israeli National Hemophilia Center experience. Haemophilia 14:2, 336-342
CrossRef1157
Seema Baid-Agrawal, Manuel Pascual, Darius Moradpour, Ulrich Frei, Nina Tolkoff-Rubin. (2008) Hepatitis C virus infection in haemodialysis and kidney transplant patients. Reviews in Medical Virology 18:2, 97-115
CrossRef1158
Wulf O. Böcher, Christian Wallasch, Thomas Höhler, Peter R. Galle. (2008) All-trans retinoic acid for treatment of chronic hepatitis C. Liver International 28:3, 347-354
CrossRef1159
J TRULLASVILA. (2008) Neumonía organizada asociada a tratamiento con peginterferón alfa. Archivos de Bronconeumología 44:3, 173-174
CrossRef1160
Julia Dambacher, Florian Beigel, Kathrin Zitzmann, Malte H.J. Heeg, Burkhard Göke, Helmut M. Diepolder, Christoph J. Auernhammer, Stephan Brand. (2008) The role of interleukin-22 in hepatitis C virus infection. Cytokine 41:3, 209-216
CrossRef1161
J. G. MCHUTCHISON, K. PATEL, E. R. SCHIFF, N. GITLIN, R. E. MUR, G. T. EVERSON, R. L. CARITHERS, G. L. DAVIS, P. MARCELLIN, M. L. SHIFFMAN, J. HARVEY, J. K. ALBRECHT, . (2008) Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. Alimentary Pharmacology & Therapeutics 27:5, 422-432
CrossRef1162
Sumihito Tamura, Yasuhiko Sugawara. (2008) Treatment strategy for hepatitis C after liver transplantation. Journal of Hepato-Biliary-Pancreatic Surgery 15:2, 111-123
CrossRef1163
M BUTI. (2008) ¿Es el tipo de interferón pegilado importante en la respuesta al tratamiento de la hepatitis crónica C?. Enfermedades Infecciosas y Microbiología Clínica 26:3, 125-126
CrossRef1164
Tatehiro Kagawa, Hirokazu Shiozawa, Sei-ichiro Kojima, Shinji Takashimizu, Naruhiko Nagata, Makoto Numata, Fumitoshi Morino, Yasuhiro Nishizaki, Kaori Mochizuki, Norihito Watanabe, Tetsu Watanabe, Shohei Matsuzaki, Tetsuya Mine. (2008) Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C. Hepatology Research 38:3, 259-266
CrossRef1165
P. Roingeard, C. Hourioux. (2008) Hepatitis C virus core protein, lipid droplets and steatosis. Journal of Viral Hepatitis 15:3, 157-164
CrossRef1166
Takeaki Satoh, Akihide Masumoto. (2008) Accordion Index: A new tool for the prediction of the efficacy of peg-interferon-α-2b and ribavirin combination therapy for chronic hepatitis C. Hepatology Research 38:3, 315-318
CrossRef1167
M. Torres-Puente, J. M. Cuevas, N. Jiménez-Hernández, M. A. Bracho, I. García-Robles, B. Wrobel, F. Carnicer, J. Del Olmo, E. Ortega, A. Moya, F. González-Candelas. (2008) Genetic variability in hepatitis C virus and its role in antiviral treatment response. Journal of Viral Hepatitis 15:3, 188-199
CrossRef1168
V. K. RUSTGI, S. ESPOSITO, F. M. HAMZEH, M. L. SHIFFMAN. (2008) Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Alimentary Pharmacology & Therapeutics 27:5, 433-440
CrossRef1169
Ellen M. Tedaldi. (2008) Emerging Therapies for Hepatitis C and HIV in Drug Abusers. Journal of Addictive Diseases 27:2, 83-91
CrossRef1170
Curtis L. Cooper. (2008) Obstacles to Successful HCV Treatment in Substance Addicted Patients. Journal of Addictive Diseases 27:2, 61-68
CrossRef1171
Jason Grebely, Stanley Devlaming, Fiona Duncan, Mark Viljoen, Brian Conway. (2008) Current Approaches to HCV Infection in Current and Former Injection Drug Users. Journal of Addictive Diseases 27:2, 25-35
CrossRef1172
Ajit Sood, Vandana Midha, Syed Hissar, Manoj Kumar, Pothakamuri V Suneetha, Manu Bansal, Nina Sood, Puja Sakhuja, Shiv K Sarin. (2008) Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: An Indian experience. Journal of Gastroenterology and Hepatology 23:2, 203-207
CrossRef1173
Leo G.J. De Leede, John E. Humphries, Anne C. Bechet, Ewoud J. Van Hoogdalem, Ruud Verrijk, David G. Spencer. (2008) Novel Controlled-Release Lemna -Derived IFN- α 2b (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial. Journal of Interferon & Cytokine Research 28:2, 113-122
CrossRef1174
Emmanuel Thomas, Michael W. Fried. (2008) Hepatitis C: Current options for nonresponders to peginterferon and ribavirin. Current Gastroenterology Reports 10:1, 53-59
CrossRef1175
Patrick Marcellin, Françoise Pequignot, Elisabeth Delarocque-Astagneau, Jean-Pierre Zarski, Nathalie Ganne, Patrick Hillon, Denise Antona, Martine Bovet, Murielle Mechain, Tarik Asselah, Jean-Claude Desenclos, Eric Jougla. (2008) Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. Journal of Hepatology 48:2, 200-207
CrossRef1176
C GORDON, K UHLIG, J LAU, C SCHMID, A LEVEY, J WONG. (2008) Interferon Treatment in Hemodialysis Patients With Chronic Hepatitis C Virus Infection: A Systematic Review of the Literature and Meta-analysis of Treatment Efficacy and Harms. American Journal of Kidney Diseases 51:2, 263-277
CrossRef1177
Leonard B. Seeff, Teresa M. Curto, Gyongyi Szabo, Gregory T. Everson, Herbert L. Bonkovsky, Jules L. Dienstag, Mitchell L. Shiffman, Karen L. Lindsay, Anna S. F. Lok, Adrian M. Di Bisceglie, William M. Lee, Marc G. Ghany. (2008) Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47:2, 605-612
CrossRef1178
Karen L. Lindsay, Chihiro Morishima, Elizabeth C. Wright, Jules L. Dienstag, Mitchell L. Shiffman, Gregory T. Everson, Anna S.F. Lok, Herbert L. Bonkovsky, William M. Lee, Timothy R. Morgan, Marc G. Ghany. (2008) Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 6:2, 234-241
CrossRef1179
R. MARTÍN-SANTOS, C. DÍEZ-QUEVEDO, P. CASTELLVÍ, R. NAVINÉS, M. MIQUEL, H. MASNOU, A. SOLER, M. ARDEVOL, F. GARCÍA, J. A. GALERAS, R. PLANAS, R. SOLÀ. (2008) De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology & Therapeutics 27:3, 257-265
CrossRef1180
Antonio Craxì, Giacomo Laffi, Anna Linda Zignego. (2008) Hepatitis C virus (HCV) infection: A systemic disease. Molecular Aspects of Medicine 29:1-2, 85-95
CrossRef1181
Bart Takkenberg, Joep Bruijne, Christine Weegink, Peter Jansen, Hendrik Reesink. (2008) Novel therapies in hepatitis B and C. Current Gastroenterology Reports 10:1, 81-90
CrossRef1182
Fumitake Amemiya, Shinya Maekawa, Yoshie Itakura, Asuka Kanayama, Akira Matsui, Shinichi Takano, Tatsuya Yamaguchi, Jun Itakura, Takatoshi Kitamura, Taisuke Inoue, Minoru Sakamoto, Kozue Yamauchi, Shunichi Okada, Atsuya Yamashita, Naoya Sakamoto, Masahiko Itoh, Nobuyuki Enomoto. (2008) Targeting Lipid Metabolism in the Treatment of Hepatitis C Virus Infection. The Journal of Infectious Diseases 197:3, 361-370
CrossRef1183
Patrice Cacoub, Philippe Halfon, Eric Rosenthal, Gilles Pialoux, Yves Benhamou, Christian Perronne, Stanislas Pol. (2008) Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: Modifications in two large surveys between 2004 and 2006. Journal of Hepatology 48:1, 35-42
CrossRef1184
Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Giovanni L. Ricci, Vito Carretta, Francesco Vinelli, Gaetano Scotto, Giuseppe Montalto, Mario Romano, Giuseppe Cristofaro, Leonardo Mottola, Fulvio Spirito, Angelo Andriulli. (2008) Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 47:1, 43-50
CrossRef1185
Naoki Hiramatsu, Nao Kurashige, Tsugiko Oze, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Masahide Oshita, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Sumio Kawata, Hirohito Tsubouchi, Hiromitsu Kumada, Takeshi Okanoue, Shinichi Kakumu, Norio Hayashi. (2008) Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatology Research 38:1, 52-59
CrossRef1186
Eric Snoeck, Stephanos J. Hadziyannis, Claudio Puoti, Mark G. Swain, Thomas Berg, Patrick Marcellin, Jean-Pierre Zarski, Karin Jorga, Stefan Zeuzem. (2008) Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α-2a (40KD) plus ribavirin. Liver International 28:1, 61-71
CrossRef1187
Hojun Lee, Yoo-Kyung Cho, Heung Up Kim, Eun Kwang Choi, Soyoung Hyun, Donggu Kang, Seung Uk Jeong, Hyun Ju Kim, Kwang Sik Kim, Byung-Cheol Song. (2008) Distribution of hepatitis C virus genotypes in Jeju Island. The Korean Journal of Hepatology 14:1, 28
CrossRef1188
Hossein Poustchi, Francesco Negro, Jason Hui, Ian Homer Y. Cua, Laura Rubbia Brandt, James G. Kench, Jacob George. (2008) Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology 48:1, 28-34
CrossRef1189
Francesca Cainelli. (2008) Hepatitis C Virus Infection in the Elderly. Drugs & Aging 25:1, 9-18
CrossRef1190
Yoshio Katamura, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Hiromi Yatsuji, Norihiro Nomura, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saito, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2008) Natural Human Interferon β Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load. Internal Medicine 47:21, 1827-1834
CrossRef1191
Takeshi Okanoue, Yoshito Itoh, Masahito Minami, Hiroaki Hashimoto, Kohichiro Yasui, Hiroshi Yotsuyanagi, Tetsuo Takehara, Takashi Kumada, Eiji Tanaka, Shuhei Nishiguchi, Namiki Izumi, Michio Sata, Morikazu Onji, Gotaro Yamada, Kiwamu Okita, Hiromitsu Kumada. (2008) Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatology Research 38:1, 27-36
CrossRef1192
Myoung Joo Kang, Eun Uk Jung, Sang Won Park, Paul Choi, Ji Hyun Kim, Sung Jae Park, Eun Taek Park, Youn Jae Lee, Sang Hyuk Lee, Sang Yong Seol. (2008) Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. The Korean Journal of Hepatology 14:3, 318
CrossRef1193
Yuko Inoue, Kenya Iyoda, Noriyoshi Kuzushita, Eiji Mita, Michio Kato. (2008) 0-2/0-4 ratios are predictor of virological non-response to pegylated interferon alpha-2b plus ribavirin therapy for patients with hepatitis C virus of genotype 1b and high viral load. Kanzo 49:9, 452-453
CrossRef1194
Kyoung-Tae Kim, Sang-Young Han, Jong-Han Kim, Hyun-Ah Yoon, Yang-Hyun Baek, Min-Ji Kim, Sung-Wook Lee, Jin-Seok Jang, Jong-Hun Lee, Myung-Hwan Roh. (2008) Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. The Korean Journal of Hepatology 14:1, 36
CrossRef1195
Raymond T. Chung, Michael Gale, Stephen J. Polyak, Stanley M. Lemon, T. Jake Liang, Jay H. Hoofnagle. (2008) Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 47:1, 306-320
CrossRef1196
Suzanne M Davison, Deirdre A Kelly. (2008) Management Strategies for Hepatitis C Virus Infection in Children. Pediatric Drugs 10:6, 357-365
CrossRef1197
Chiaki Okuse, Daisuke Kumon, Minoru Kobayashi, Akira Endo, Yuichi Kinoshita, Yohei Noguchi, Naoki Izawa, Shunichiro Ozawa, Kazunari Nakahara, Norie Yamada, Masaru Okamoto, Hideaki Takahashi, Yoshiki Katakura, Kotaro Matsunaga, Nobuyuki Matsumoto, Toshiya Ishii, Hiroshi Yotsuyanagi, Shiro Iino, Michihiro Suzuki, Fumio Itoh. (2008) A case of chronic hepatitis C in which a 72-week course of pegylated interferon and ribavirin combination therapy resulted in relapse but a subsequent interferon monotherapy could induce sustained virological response. Kanzo 49:11, 495-500
CrossRef1198
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
CrossRef1199
John W. Steinke, Gabor Illei, Gülbû Uzel, JoAnn M. Mican. 2008. Cytokine therapy. , 1393-1404.
CrossRef1200
Yasuji Arase, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hiromi Yatsuji, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2008) Suitable Treatment Period in Patients with Virological Response during Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C. Internal Medicine 47:14, 1301-1307
CrossRef1201
AA Modi, TJ Liang. (2008) Hepatitis C: a clinical review. Oral Diseases 14:1, 10-14
CrossRef1202
Yeon-Joo Kim, Young-Il Kim, Young-A Song, Nam-Cheol Jin, Sung-Ryoun Lim, Dae-Yeul Ryang, Kyoung-Myeun Chung, Seon-Young Park, Chang-Hwan Park, Hyun-Soo Kim, Sung-Kyu Choi, Jong-Sun Rew. (2008) The Effectiveness of Combination Therapy with Peginterferon α-2a and Ribavirin in Chronic Hepatitis C. Chonnam Medical Journal 44:2, 72
CrossRef1203
Rie Kubota, Naoki Kumagai, Takako Komiyama, Miyuki Kimijima, Fumihiko Kaneko, Satoshi Tsunematsu, Kanji Tsuchimoto. (2008) Osmotic fragility of erythrocyte for the prediction of Ribavirin induced anemia in patients with chronic hepatitis C viral infection. Kanzo 49:1, 6-13
CrossRef1204
Manuela Torres-Puente, José M. Cuevas, Nuria Jiménez-Hernández, María Alma Bracho, Inmaculada García-Robles, Borys Wrobel, Fernando Carnicer, Juan del Olmo, Enrique Ortega, Andrés Moya, Fernando González-Candelas. (2008) Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus. Infection, Genetics and Evolution 8:1, 74-82
CrossRef1205
Yinping Lu, Baoju Wang, Hongping Huang, Yongjun Tian, Junjie Bao, Jihua Dong, Michael Roggendorf, Mengji Lu, Dongliang Yang. (2008) The interferon-α gene family of Marmota himalayana, a Chinese marmot species with susceptibility to woodchuck hepatitis virus infection. Developmental & Comparative Immunology 32:4, 445-457
CrossRef1206
Noriko Sasase, Soo Ryang Kim, Ke Ih Kim, Miyuki Taniguchi, Susumu Imoto, Keiji Mita, Hak Hotta, Ikuo Shouji, Ahmed El-Shamy, Norifumi Kawada, Masatoshi Kudo, Yoshitake Hayashi. (2008) Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b. Intervirology 51:1, 70-75
CrossRef1207
Maria Cubero, Juan Ignacio Esteban, Teresa Otero, Silvia Sauleda, Marta Bes, Rafael Esteban, Jaume Guardia, Josep Quer. (2008) Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370:2, 237-245
CrossRef1208
Carol Mallette, Maura A Flynn, Kittichai Promrat. (2008) Outcome of Screening for Hepatitis C Virus Infection Based on Risk Factors. The American Journal of Gastroenterology 103:1, 131-137
CrossRef1209
Youn Jae Lee. (2008) Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients. The Korean Journal of Hepatology 14:4, 443
CrossRef1210
Eric Lorent, Horst Bierau, Yves Engelborghs, Gert Verheyden, Fons Bosman. (2008) Structural characterisation of the hepatitis C envelope glycoprotein E1 ectodomain derived from a mammalian and a yeast expression system. Vaccine 26:3, 399-410
CrossRef1211
Steve Brocchini, Antony Godwin, Sibu Balan, Ji-won Choi, Mire Zloh, Sunil Shaunak. (2008) Disulfide bridge based PEGylation of proteins. Advanced Drug Delivery Reviews 60:1, 3-12
CrossRef1212
Christian Grünberger, David L. Wyles, Kelly A. Kaihara, Robert T. Schooley. (2008) 3‐Drug Synergistic Interactions of Small Molecular Inhibitors of Hepatitis C Virus Replication. The Journal of Infectious Diseases 197:1, 42-45
CrossRef1213
Susan J Keam, Risto S Cvetković. (2008) Peginterferon-α-2a (40 kD) Plus Ribavirin. Drugs 68:9, 1273-1317
CrossRef1214
Jeong Il Kim, Seok Hyun Kim, Byung Seok Lee, Heon Young Lee, Tae Hee Lee, Young Woo Kang, Hyang Ie Lee, An Na Kim, Soon Woo Nam, Byeong Chool Park, Hee Bok Chae, Seok Bae Kim, Il Han Song, Ji Young Park, Hong Su Kim. (2008) Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study. The Korean Journal of Hepatology 14:4, 493
CrossRef1215
Heon Ju Lee, Jong Ryul Eun, Jae Won Choi, Kyung Ok Kim, Hee Jung Moon. (2008) Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C. The Korean Journal of Hepatology 14:1, 46
CrossRef1216
F. Poordad, K. R. Reddy, P. Martin. (2008) Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C. Clinical Infectious Diseases 46:1, 78-84
CrossRef1217
He-Jun Yuan, William M Lee. (2008) Nonresponse to Treatment for Hepatitis C. Drugs 68:1, 27-42
CrossRef1218
Yoshiyasu Karino, Joji Toyota, Tomohiro Arakawa, Yasuaki Kuwata, Jun Akaike, Katsu Yamazaki, Takahiro Sato, Takumi Ohmura. (2008) Nadir platelet and neutrophil counts during the course of PEG-IFN α-2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy. Kanzo 49:6, 239-247
CrossRef1219
Y.-H. YEN, C.-H. HUNG, T.-H. HU, C.-H. CHEN, C.-M. WU, J.-H. WANG, S.-N. LU, C.-M. LEE. (2008) Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Alimentary Pharmacology & Therapeutics 27:1, 72-79
CrossRef1220
Takashi Tanaka, Satoshi Shakado, Daisuke Morihara, Shinya Nishizawa, Kunitoshi Sakurai, Shinjiro Inomata, Takayuki Hanano, Genryu Hirano, Shu-ichi Ueda, Teruo Matsumoto, Makoto Yoshikane, Akira Anan, Yasuaki Takeyama, Makoto Irie, Kaoru Iwata, Tetsuro Sohda, Hiroshi Watanabe, Shotaro Sakisaka. (2008) The prognostic factors of sustained virologic response among patients of chronic hepatitis C treated with peg-interferon alpha 2a monotherapy. Kanzo 49:9, 417-425
CrossRef1221
Milos Opravil, Joe Sasadeusz, David A Cooper, Jürgen K Rockstroh, Nathan Clumeck, Bonaventura Clotet, Julio Montaner, Francesca J Torriani, Jean DePamphilis, Douglas T Dieterich. (2008) Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:1, 36-49
CrossRef1222
Ibrahim A. Hanouneh, Charles Miller, Federico Aucejo, Rocio Lopez, Mary Kay Quinn, Nizar N. Zein. (2008) Recurrent hepatitis C after liver transplantation: On-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transplantation 14:1, 53-58
CrossRef1223
Jason Grebely, Krista A. Genoway, Jesse D. Raffa, Gurbir Dhadwal, Tasleem Rajan, Grey Showler, Kate Kalousek, Fiona Duncan, Mark W. Tyndall, Chris Fraser, Brian Conway, Benedikt Fischer. (2008) Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence 93:1-2, 141-147
CrossRef1224
Olav Dalgard, Kristian Bjøro, Helmer Ring-Larsen, Einar Bjornsson, Mona Holberg-Petersen, Eva Skovlund, Olle Reichard, Bjørn Myrvang, Bo Sundelöf, Ståle Ritland, Kjell Hellum, Aril Frydén, Jon Florholmen, Hans Verbaan. (2008) Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47:1, 35-42
CrossRef1225
Soo Ryang Kim, Susumu Imoto, Shuichi Fuki, Ke Ih Kim, Miyuki Taniguchi, Motoko Nagano, Hak Hotta, Ikuo Shouji, Yoshihiro Kanbara, Yoko Maekawa, Masatoshi Kudo, Yoshitake Hayashi. (2008) Pegylated interferon α-2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b. Kanzo 49:4, 145-152
CrossRef1226
Konstantinos D. Pantazis, Ioannis S. Elefsiniotis, Dimitrios Papaioannou, Hero Brokalaki, Gerasimos Bonatsos, Christos Mavrogiannis. (2008) Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients. Gastroenterology Research and Practice 2008, 1-3
CrossRef1227
Francesca Zaccheddu, Angela Maria Mamusa, Maria Giuseppina Cabras, Fabio Culurgioni, Martina Pettinau, Maria Pina Simula, Andrea Bacigalupo, Emanuele Angelucci. (2008) Marginal zone B-cell lymphoma arising in donor cells in a Hepatitis-C virus infected patient over 20 years after allogeneic bone marrow transplantation. Leukemia & Lymphoma 49:11, 2219-2221
CrossRef1228
David Van der Poorten, Dianna T. Kenny, Tony Butler, Jacob George. (2007) Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology 46:6, 1750-1758
CrossRef1229
Nyingi Kemmer, Guy W. Neff. (2007) Managing chronic hepatitis C in the difficult-to-treat patient. Liver International 27:10, 1297-1310
CrossRef1230
A. Barbado Cano, S. Alonso López, C. Fernández Rodríguez. (2007) Tratamiento de las hepatitis virales. Medicine - Programa de Formación Médica Continuada Acreditado 9:92, 5921-5930
CrossRef1231
Brian L. Pearlman, Carole Ehleben, Sophia Saifee. (2007) Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1
infected slow responders. Hepatology 46:6, 1688-1694
CrossRef1232
Yaron Tomer, Jason T. Blackard, Nagako Akeno. (2007) Interferon Alpha Treatment and Thyroid Dysfunction. Endocrinology & Metabolism Clinics of North America 36:4, 1051-1066
CrossRef1233
Arne Schäfer, Hans-Ulrich Wittchen, Jochen Seufert, Michael R. Kraus. (2007) Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review. International Journal of Methods in Psychiatric Research 16:4, 186-201
CrossRef1234
Erik De Clercq. (2007) The design of drugs for HIV and HCV. Nature Reviews Drug Discovery 6:12, 1001-1018
CrossRef1235
Kenneth E. Sherman, Russell Fleischer, Katherine Laessig, Jeffrey Murray, William Tauber, Debra Birnkrant. (2007) Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 46:6, 2014-2020
CrossRef1236
G Mani Subramanian, Michele Fiscella, Araba Lamousé-Smith, Stefan Zeuzem, John G McHutchison. (2007) Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nature Biotechnology 25:12, 1411-1419
CrossRef1237
Masaaki Mizui, Junko Tanaka, Keiko Katayama, Toshio Nakanishi, Makoto Obayashi, Shiomi Aimitsu, Tomoo Yoshida, Junichi Inoue, Tatsuji Yokoyama, Keiji Tsuji, Keiko Arataki, Syuji Yamaguchi, Toshio Miura, Mikiya Kitamoto, Eiichi Takezaki, Shigeo Orimen, Tatsurou Sakata, Kouji Kamada, Akira Maruhashi, Tooru Tamura, Toshio Nakamura, Kunio Ishida, Kazushi Teramen, Yuzo Miyakawa, Hiroshi Yoshizawa. (2007) Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5–10 years. Hepatology Research 37:12, 994-1001
CrossRef1238
Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton. (2007) The way forward in HCV treatment — finding the right path. Nature Reviews Drug Discovery 6:12, 991-1000
CrossRef1239
Jonathan Shepherd, Jeremy Jones. (2007) A systematic review of the cost–effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, 577-595
CrossRef1240
J.P. Zarski, V. Leroy, M.N. Hilleret. (2007) Tolérance et adhérence au traitement de l’hépatite C. Antibiotiques 9:4, 221-225
CrossRef1241
K. Sandres-Sauné, F. Abravanel, F. Nicot, J.M. Peron, L. Alric, J. Boineau, C. Pasquier, J. Izopet. (2007) Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. Journal of Medical Virology 79:12, 1821-1826
CrossRef1242
Ursula Plöckinger, Denny Krüger, Alexandra Bergk, Viola Weich, Bertram Wiedenmann, Thomas Berg. (2007) Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α. The American Journal of Gastroenterology 102:12, 2724-2731
CrossRef1243
B. H. McGovern, C. Birch, M. T. Zaman, I. Bica, D. Stone, J. R. Quirk, B. Davis, K. Zachary, N. Basgoz, F. G. Cook, R. T. Gandhi. (2007) Managing Symptomatic Drug-Induced Liver Injury in HIV--Hepatitis C Virus--Coinfected Patients: A Role for Interferon. Clinical Infectious Diseases 45:10, 1386-1392
CrossRef1244
Masahiro Ikejiri, Takayuki Ohshima, Keizo Kato, Masaaki Toyama, Takayuki Murata, Kunitada Shimotohno, Tokumi Maruyama. (2007) 5′-O-Masked 2′-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents. Bioorganic & Medicinal Chemistry 15:22, 6882-6892
CrossRef1245
Sanaa M. Kamal. (2007) Improving Outcome in Patients With Hepatitis C Virus Genotype 4. The American Journal of Gastroenterology 102:11, 2582-2588
CrossRef1246
Vincent Soriano, Eugenia Vispo, Luz Martin-Carbonero, Pablo Labarga, Javier Garcia-Samaniego, Pablo Barreiro. (2007) Management and therapy of chronic hepatitis C in HIV. Current Opinion in HIV and AIDS 2:6, 482-488
CrossRef1247
Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2007) Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Journal of Medical Virology 79:11, 1686-1695
CrossRef1248
J. Koirala, S. D. Gandotra, S. Rao, G. Sangwan, A. Mushtaq, T. H. Htwe, A. Adamski, D. Blessman, N. M. Khardori. (2007) Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. Journal of Viral Hepatitis 14:11, 782-787
CrossRef1249
V. Brass, D. Moradpour, H. E. Blum. (2007) Hepatitis C virus infection: in vivo and in vitro models. Journal of Viral Hepatitis 14:s1, 64-67
CrossRef1250
Chen Liu, Haizhen Zhu, G. Mani Subramanian, Paul A. Moore, Yiling Xu, David R. Nelson. (2007) Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatology Research 37:11, 941-947
CrossRef1251
Haizhen Zhu, Huijia Dong, Erika Eksioglu, Alan Hemming, Mengde Cao, James M. Crawford, David R. Nelson, Chen Liu. (2007) Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System. Gastroenterology 133:5, 1649-1659
CrossRef1252
Carla W. Brady, Cynthia J. Coffman, Dawn Provenzale. (2007) Compliance With Referral for Hepatitis C Evaluation Among Veterans. Journal of Clinical Gastroenterology 41:10, 927-931
CrossRef1253
S. Chris Pappas. (2007) Good science behind hepatitis C virus antiviral drug development: Necessary but not sufficient. Hepatology 46:5, 1317-1318
CrossRef1254
Omer Junaidi, Adrian M. Di Bisceglie. (2007) Aging Liver and Hepatitis. Clinics in Geriatric Medicine 23:4, 889-903
CrossRef1255
Frank Yeh, Fredric D Gordon. (2007) Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. Future Virology 2:6, 553-563
CrossRef1256
Robert E. Booth, Steffanie A. Strathdee. (2007) Baseline findings from the third collaborative injection drug users study/drug users intervention trial (CIDUS III/DUIT). Drug and Alcohol Dependence 91, S1-S3
CrossRef1257
Juan-Ramón Larrubia, Miryam Calvino, Selma Benito, Eduardo Sanz-de-Villalobos, Cristian Perna, Jaime Pérez-Hornedo, Fernando González-Mateos, Silvia García-Garzón, Antonio Bienvenido, Trinidad Parra. (2007) The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. Journal of Hepatology 47:5, 632-641
CrossRef1258
W. Jessner, T. Watkins-Riedel, C. Müller, E. Formann, M. Gschwantler, P. Ferenci. (2007) Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection. Journal of Viral Hepatitis 14:11, 775-781
CrossRef1259
Antoine Jakiche, Edward C. Paredez, Pawan K. Tannan, Cynthia Geppert, Vicki L. Sontag, Clifford R. Qualls, David A. Blair, Elizabeth L. Dettmer. (2007) Trend of Depression and the Use of Psychiatric Medications in U.S. Veterans With Hepatitis C During Interferon-Based Therapy. The American Journal of Gastroenterology 102:11, 2426-2433
CrossRef1260
Masahiko Kaito, Motoh Iwasa, Naoki Fujita, Yoshinao Kobayashi, Yuji Kojima, Jiro Ikoma, Ichiro Imoto, Yukihiko Adachi, Hirokazu Hamano, Koji Yamauchi. (2007) Effect of lactoferrin in patients with chronic hepatitis C: Combination therapy with interferon and ribavirin. Journal of Gastroenterology and Hepatology 22:11, 1894-1897
CrossRef1261
E. Jenny Heathcote. (2007) Antiviral therapy: chronic hepatitis C. Journal of Viral Hepatitis 14:s1, 82-88
CrossRef1262
Jordan J. Feld, Santosh Nanda, Ying Huang, Weiping Chen, Maggie Cam, Susan N. Pusek, Lisa M. Schweigler, Dickens Theodore, Steven L. Zacks, T. Jake Liang, Michael W. Fried. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46:5, 1548-1563
CrossRef1263
Cristina Tural, Ramon Planas, Guillermo Sirera, Bonaventura Clotet. (2007) Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers. Current Opinion in HIV and AIDS 2:6, 496-502
CrossRef1264
Srinivas Cheruvu, Kristen Marks, Andrew H. Talal. (2007) Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection. Clinics in Liver Disease 11:4, 917-943
CrossRef1265
S. Chevaliez, J.-M. Pawlotsky. (2007) Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C. Journal of Viral Hepatitis 14:s1, 77-81
CrossRef1266
Chuanlai Shen, Ting Hu, Ling Shen, Lei Gao, Wei Xie, Jianqiong Zhang. (2007) Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection. Journal of Gastroenterology and Hepatology 22:11, 1898-1903
CrossRef1267
Kumi Kitamura, Shinichiro Tada, Nobuhiro Nakamoto, Kyoko Toda, Hitomi Horikawa, Satoshi Kurita, Satoshi Tsunematsu, Naoki Kumagai, Hiromasa Ishii, Hidetsugu Saito, Toshifumi Hibi. (2007) Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. Journal of Gastroenterology and Hepatology 22:11, 2022-2033
CrossRef1268
Eric Nguyen-Khac, Dominique Capron, Sandrine Castelain, Catherine François, Alain Braillon. (2007) Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?. European Journal of Internal Medicine 18:7, 510-515
CrossRef1269
J MARQUEZPEIRO, V VALEROALCOCER, M MORALESSUAREZVARELA, A LLOPISGONZALEZ, C PEREZPEIRO. (2007) Toxicidad del tratamiento de la hepatitis C crónica con peginterferón α (2a o 2b) y ribavirina en pacientes no tratados anteriormente. Medicina Clínica 129:16, 612-614
CrossRef1270
John G. McHutchison, Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz, Mitchell Shiffman, Nezam H. Afdhal, Ira M. Jacobson, Andrew Muir, Mohammed Al-Adhami, Mary L. Morris, Julie A. Lekstrom-Himes, Susan M. Efler, Heather L. Davis. (2007) Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46:5, 1341-1349
CrossRef1271
Benjamin J. Morasco, Muhamad Aly Rifai, Jennifer M. Loftis, David W. Indest, James Kelly Moles, Peter Hauser. (2007) A randomized trial of paroxetine to prevent interferon-α-induced depression in patients with hepatitis C. Journal of Affective Disorders 103:1-3, 83-90
CrossRef1272
Th. Witthöft, B. Möller, K. H. Wiedmann, St. Mauss, R. Link, J. Lohmeyer, M. Lafrenz, C. M. Gelbmann, D. Hüppe, C. Niederau, U. Alshuth. (2007) Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. Journal of Viral Hepatitis 14:11, 788-796
CrossRef1273
Marija Zeremski, Andrew H Talal. (2007) Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients. Current Opinion in HIV and AIDS 2:6, 489-495
CrossRef1274
Edmund J. Bini. (2007) Singin' the Blues: The Downside of Hepatitis C Virus Treatment. The American Journal of Gastroenterology 102:11, 2434-2436
CrossRef1275
Howard Liebman. (2007) Other Immune Thrombocytopenias. Seminars in Hematology 44, S24-S34
CrossRef1276
M. DIAGO, J. CRESPO, A. OLVEIRA, R. PÉREZ, R. BÁRCENA, J. M. SÁNCHEZ-TAPIAS, M. MUÑOZ-SÁNCHEZ, M. ROMERO-GÓMEZ. (2007) Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon α-2a in hepatitis C virus genotype 1 true non-responder patients. Alimentary Pharmacology & Therapeutics 26:8, 1131-1138
CrossRef1277
Patrick Marcellin, E. Jenny Heathcote, Antonio Craxì. (2007) Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?. Journal of Hepatology 47:4, 580-587
CrossRef1278
Lucas C. Quarantini, Rodrigo A. Bressan, Amanda Galvão, Susana Batista-Neves, Raymundo Paraná, Ângela Miranda-Scippa. (2007) Incidence of psychiatric side effects during pegylated interferon- ? retreatment in nonresponder hepatitis C virus-infected patients. Liver International 27:8, 1098-1102
CrossRef1279
Arathi Rajendra, John B. Wong. (2007) Economics of chronic hepatitis B and hepatitis C. Journal of Hepatology 47:4, 608-617
CrossRef1280
Marcello Persico, Mario Capasso, Eliana Persico, Monica Svelto, Roberta Russo, Daniela Spano, Lori Crocè, Vincenzo La Mura, Francesco Moschella, Flora Masutti, Roberto Torella, Claudio Tiribelli, Achille Iolascon. (2007) Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus–related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 46:4, 1009-1015
CrossRef1281
Oanh K. Nguyen, Gregory J. Dore, John M. Kaldor, Margaret E. Hellard. (2007) Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. International Journal of Drug Policy 18:5, 447-451
CrossRef1282
Masanori Ikeda, Nobuyuki Kato. (2007) Modulation of host metabolism as a target of new antivirals. Advanced Drug Delivery Reviews 59:12, 1277-1289
CrossRef1283
Ira M. Jacobson, Robert S. Brown, Jonathan McCone, Martin Black, Clive Albert, Michael S. Dragutsky, Firdous A. Siddiqui, Thomas Hargrave, Paul Y. Kwo, Louis Lambiase, Greg W. Galler, Victor Araya, Bradley Freilich, Joann Harvey, Louis H. Griffel, Clifford A. Brass, . (2007) Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. Hepatology 46:4, 982-990
CrossRef1284
Norma Ibón Rallón, Vicente Soriano, José Miguel Benito. (2007) Respuesta inmunitaria celular adaptativa frente a la infección por el virus de la hepatitis C. Medicina Clínica 129:12, 469-476
CrossRef1285
Geoffrey S. Jensen, James F. Trotter. (2007) Treatment of chronic HCV in advanced liver disease: Unmet challenges, reason for optimism. Journal of Hepatology 47:4, 441-443
CrossRef1286
Diarmuid S Manning, Katherine M Sheehan, Michael F Byrne, Elaine W Kay, Frank E Murray. (2007) Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon ? treatment. Journal of Gastroenterology and Hepatology 22:10, 1633-1637
CrossRef1287
Jacob Nattermann, Martin Vogel, Thomas Berg, Mark Danta, Baumgarten Axel, Christoph Mayr, Raffaele Bruno, Christina Tural, Gerd Klausen, Bonaventura Clotet, Thomas Lutz, Frank Grünhage, Michael Rausch, Hans Dieter Nischalke, Knud Schewe, Bernhard Bienek, Georg Haerter, Tilman Sauerbruch, Juergen K. Rockstroh, Ulrich Spengler, . (2007) Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 46:4, 1016-1025
CrossRef1288
Stéphane Chevaliez, Jean-Michel Pawlotsky. (2007) Interferon-based therapy of hepatitis C. Advanced Drug Delivery Reviews 59:12, 1222-1241
CrossRef1289
Eugene Lin, Yuchi Hwang, Ellson Y Chen. (2007) Gene–gene and gene–environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics 8:10, 1327-1335
CrossRef1290
G. SEBASTIANI, A. FERRARI, S. BOCCATO, R. PISTIS, A. ALBERTI. (2007) Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics 26:7, 1077-1082
CrossRef1291
Martin Schaefer, Axel Hinzpeter, Ariane Mohmand, Gesa Janssen, Maurice Pich, Markus Schwaiger, Rahul Sarkar, Astrid Friebe, Andreas Heinz, Michael Kluschke, Marlene Ziemer, Juri Gutsche, Viola Weich, Juliane Halangk, Thomas Berg. (2007) Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 46:4, 991-998
CrossRef1292
Robert E. Lanford, Bernadette Guerra, Catherine B. Bigger, Helen Lee, Deborah Chavez, Kathleen M. Brasky. (2007) Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 46:4, 999-1008
CrossRef1293
Ken Sato, Tetsuya Ishikawa, Akihiko Okumura, Taeko Yamauchi, Sayaka Sato, Minoru Ayada, Eiji Matsumoto, Naoki Hotta, Tomohiko Oohashi, Yoshitaka Fukuzawa, Shinichi Kakumu. (2007) Expression of Toll-like receptors in chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology 22:10, 1627-1632
CrossRef1294
Vito Di Marco, Piero Luigi Almasio, Donatella Ferraro, Vincenza Calvaruso, Giuseppe Alaimo, Sergio Peralta, Rosa Di Stefano, Antonio Craxì. (2007) Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. Journal of Hepatology 47:4, 484-491
CrossRef1295
Sharif Missiha, Jenny Heathcote, Tamara Arenovich, Kamran Khan, . (2007) Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C. The American Journal of Gastroenterology 102:10, 2181-2188
CrossRef1296
Yan-zi Chang, Yan-chang Lei, Wen Wu, Shan-shan Chen, Han-ju Huang, Dong-liang Yang, Meng-ji Lu. (2007) Effect of hepatitis C virus core protein on interferon-induced antiviral genes expression and its mechanisms. Virologica Sinica 22:5, 374-379
CrossRef1297
Arleta Kowala-Piaskowska, Iwona Mozer-Lisewska, Magdalena Figlerowicz, Wojciech Służewski. (2007) Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiology and Drug Safety 16:10, 1095-1103
CrossRef1298
Kohji Moriishi, Yoshiharu Matsuura. (2007) Evaluation systems for anti-HCV drugs. Advanced Drug Delivery Reviews 59:12, 1213-1221
CrossRef1299
Jason Grebely, Krista Genoway, Milan Khara, Fiona Duncan, Mark Viljoen, Doug Elliott, Jesse D. Raffa, Stanley DeVlaming, Brian Conway. (2007) Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy 18:5, 437-443
CrossRef1300
Rohit Satoskar, Donald M Jensen. (2007) Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opinion on Pharmacotherapy 8:15, 2491-2503
CrossRef1301
Jason Smith, Steven-Huy B. Han. (2007) “True” weight-based dosing versus “flat” dosing of ribavirin: Will the WIN-R please come forward?. Hepatology 46:4, 953-956
CrossRef1302
Patrick Marcellin, Yves Horsmans, Frederik Nevens, Jean-Didier Grange, Jean-Pierre Bronowicki, Denis Vetter, Susan Purdy, Varun Garg, Leif Bengtsson, Lindsay McNair, John Alam. (2007) Phase 2 study of the combination of merimepodib with peginterferon-α2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. Journal of Hepatology 47:4, 476-483
CrossRef1303
Massimo Pilli, Alessandro Zerbini, Amalia Penna, Alessandra Orlandini, Esther Lukasiewicz, Jean–Michel Pawlotsky, Stefan Zeuzem, Solko W. Schalm, Michael von Wagner, Georgios Germanidis, Yoav Lurie, Juan I. Esteban, Bart L. Haagmans, Christophe Hezode, Martin Lagging, Francesco Negro, Yonit Homburger, Avidan U. Neumann, Carlo Ferrari, Gabriele Missale. (2007) HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology 133:4, 1132-1143
CrossRef1304
Paul J Pockros. (2007) New drugs for hepatitis C virus. Expert Review of Gastroenterology & Hepatology 1:1, 145-154
CrossRef1305
Vicente Lorenzo-Zúñiga, Ramon Bartolí, Helena Masnou, Silvia Montoliu, Rosa M a Morillas, Ramon Planas. (2007) Serum Concentrations of Insulin-Like Growth Factor-I (IGF-I) as a Marker of Liver Fibrosis in Patients With Chronic Hepatitis C. Digestive Diseases and Sciences 52:11, 3245-3250
CrossRef1306
Donna M. Evon, Amit Verma, Karen A. Dougherty, Betty Batey, Mark Russo, Steven Zacks, Roshan Shrestha, Michael W. Fried. (2007) High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities. Digestive Diseases and Sciences 52:11, 3251-3258
CrossRef1307
D. KEVANS, G. FARRELL, S. HOPKINS, N. MAHMUD, B. WHITE, S. NORRIS, C. BERGIN. (2007) Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia 13:5, 593-598
CrossRef1308
Jason Grebely, Jesse D Raffa, Caite Meagher, Fiona Duncan, Krista A Genoway, Milan Khara, Mark McLean, Annabel Mead, Mark Viljoen, Stanley deVlaming, Chris Fraser, Brian Conway. (2007) Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology and Hepatology 22:9, 1519-1525
CrossRef1309
Vicki M. Park, Barbara C. Mason, Julia Krushkal, Rongling Li, Caroline Riely, Jaquelyn Fleckenstein. (2007) Hepatitis C Hypervariable Region 1: Association of Reduced Selection Pressure in African Americans with Treatment Failure. Digestive Diseases and Sciences 52:10, 2540-2549
CrossRef1310
Nicole Forestier, Hendrik W. Reesink, Christine J. Weegink, Lindsay McNair, Tara L. Kieffer, Hui-May Chu, Susan Purdy, Peter L.M. Jansen, Stefan Zeuzem. (2007) Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:3, 640-648
CrossRef1311
Apurva A. Modi, Jay H. Hoofnagle. (2007) New therapies for hepatitis C. Hepatology 46:3, 615-617
CrossRef1312
Judith Garrard, Veena Choudary, Holly Groom, Eric Dieperink, Mark L. Willenbring, Janet M. Durfee, Samuel B. Ho. (2007) Organizational change in management of hepatitis C: Evaluation of a CME program. Journal of Continuing Education in the Health Professions 26:2, 145-160
CrossRef1313
Kenji Fujiwara, Shuichi Kaneko, Shinichi Kakumu, Michio Sata, Shuhei Hige, Eiichi Tomita, Satoshi Mochida, . (2007) Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatology Research 37:9, 701-710
CrossRef1314
Arianna Loregian, Maria Cristina Scarpa, Silvana Pagni, Saverio Giuseppe Parisi, Giorgio Palù. (2007) Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. Journal of Chromatography B 856:1-2, 358-364
CrossRef1315
Piero Luigi Almasio, Claudia Cottone, Francesca D'Angelo. (2007) Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment. Digestive and Liver Disease 39, S88-S95
CrossRef1316
Teresa L. Wright. (2007) Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatology Research 37:s2 Fourth JSH S, S294-S298
CrossRef1317
Felice Piccinino, Nicola Coppola. (2007) Antiviral treatment of HCV-related cirrhosis. Digestive and Liver Disease 39, S96-S101
CrossRef1318
A SAUER, P LENOBLE, P BADER, C SPEEGSCHATZ, T BOURCIER, X NASICA. (2007) Complications ophtalmologiques du traitement de l’hépatite C. Journal Français d'Ophtalmologie 30:7, 746.e1-746.e5
CrossRef1319
Mitchell L. Shiffman. (2007) A BALANCING VIEW: We Cannot Do It Alone. The American Journal of Gastroenterology 102:9, 1841-1843
CrossRef1320
Bart J. Veldt, Hans J.J. van der Vliet, B. Mary E. von Blomberg, Hans van Vlierberghe, Guido Gerken, Nobusuke Nishi, Kunihiko Hayashi, Rik J. Scheper, Robert J. de Knegt, Alfons J.M. van den Eertwegh, Harry L.A. Janssen, Carin M.J. van Nieuwkerk. (2007) Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C. Journal of Hepatology 47:3, 356-365
CrossRef1321
Abdurrahman Sagir, Tobias Heintges, Zübeyde Akyazi, Mark Oette, Andreas Erhardt, Dieter Häussinger. (2007) Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver International 27:7, 954-959
CrossRef1322
A. Sagir, T. Heintges, Z. Akyazi, M. Oette, A. Erhardt, D. Häussinger. (2007) Therapy outcome in patients with chronic hepatitis C: role of therapy supervision by expert hepatologists. Journal of Viral Hepatitis 14:9, 633-638
CrossRef1323
János Fehér, Gabriella Lengyel. (2007) Interferon in the Treatment of Viral Hepatitis. On the 50th Anniversary of Interferon’s Discovery. Hungarian Medical Journal 1:3, 271-279
CrossRef1324
Robert Flisiak, Jean-Maurice Dumont, Raf Crabbé. (2007) Cyclophilin inhibitors in hepatitis C viral infection. Expert Opinion on Investigational Drugs 16:9, 1345-1354
CrossRef1325
M. BUTI, M. A. CASADO, R. ESTEBAN. (2007) Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte. Alimentary Pharmacology & Therapeutics 26:5, 705-716
CrossRef1326
Scott Seronello, Muhammad Y. Sheikh, Jinah Choi. (2007) Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radical Biology and Medicine 43:6, 869-882
CrossRef1327
Kohji Moriishi, Yoshiharu Matsuura. (2007) Host factors involved in the replication of hepatitis C virus. Reviews in Medical Virology 17:5, 343-354
CrossRef1328
Gábor Horváth, Gyula Tolvaj, Tünde Halász, Gyula Stotz. (2007) The Role and the Possibilities of Natural Interferon Treatment for Chronic Hepatitis C: Our Experiences with Natural Interferon Treatment for Patients Debarred from Combined Antiviral Therapy due to the STOP Rule. Hungarian Medical Journal 1:3, 331-339
CrossRef1329
F. Bani-Sadr, I. Goderel, C. Penalba, E. Billaud, J. Doll, Y. Welker, P. Cacoub, S. Pol, C. Perronne, F. Carrat, . (2007) Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. Journal of Viral Hepatitis 14:9, 639-644
CrossRef1330
Ondria C. Gleason, John C. Fucci, William R. Yates, Michelle A. Philipsen. (2007) Preventing Relapse of Major Depression During Interferon-α Therapy for Hepatitis C—A Pilot Study. Digestive Diseases and Sciences 52:10, 2557-2563
CrossRef1331
Jaydeep S. Kadam, Stevan A. Gonzalez, Furqaan Ahmed, Alia Menezes, Ira M. Jacobson. (2007) Prognostic Significance of Hepatitis C Virus RNA Detection by Transcription-Mediated Amplification with Negative Polymerase Chain Reaction During Therapy with Peginterferon α and Ribavirin. Digestive Diseases and Sciences 52:10, 2525-2530
CrossRef1332
AU Neumann, MA Polis, L Rozenberg, JO Jackson, KN Reitano, M McLaughlin, C Koratich, RL Dewar, H Masur, BL Haagmans, Shyam Kottilil. (2007) Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 21:14, 1855-1865
CrossRef1333
J. Powis, K. M. Peltekian, S. S. Lee, M. Sherman, V. G. Bain, C. Cooper, M. Krajden, M. Deschenes, R. F. Balshaw, E. Jenny Heathcote, E. M. Yoshida, . (2007) Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. Journal of Viral Hepatitis 0:0, 070901052026007-???
CrossRef1334
D. A. Freshwater, K. O?Donnell, D. J. Mutimer. (2007) Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. Journal of Viral Hepatitis 0:0, 070901052026002-???
CrossRef1335
F. Fabrizi, V. Dixit, P. Messa, P. Martin. (2007) Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. Journal of Viral Hepatitis 0:0, 070827235139001-???
CrossRef1336
Jilling F. Bergmann, Jan M. Vrolijk, Peter van der Schaar, Brigitte Vroom, Bart van Hoek, Annet van der Sluys Veer, Richard A. de Vries, Elke Verhey, Bettina E. Hansen, Johannes T. Brouwer, Harry L. A. Janssen, Solko W. Schalm, Robert J. de Knegt. (2007) ?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?-2b in chronic hepatitis C non-responders. Liver International 0:0, 070816165951003-???
CrossRef1337
Supriya Joshi, Magdalena Kuczynski, E. Jenny Heathcote. (2007) Symptomatic and Virological Response to Antiviral Therapy in Hepatitis C Associated with Extrahepatic Complications of Cryoglobulimia. Digestive Diseases and Sciences 52:9, 2410-2417
CrossRef1338
Marina Núñez, Celia Miralles, Miguel Angel Berdún, Elena Losada, Koldo Aguirrebengoa, Antonio Ocampo, Piedad Arazo, Manuel Cervantes, Ignacio de los Santos, Isabel San Joaquín, Santiago Echeverría, María José Galindo, Victor Asensi, Pablo Barreiro, Julio Sola, Juan José Hernandez-Burruezo, Josep Maria Guardiola, Miriam Romero, Javier García-Samaniego, Vincent Soriano, . (2007) Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. AIDS Research and Human Retroviruses 23:8, 972-982
CrossRef1339
R. BRUNO, P. SACCHI, C. SCAGNOLARI, F. TORRIANI, L. MAIOCCHI, S. PATRUNO, F. BELLOMI, G. FILICE, G. ANTONELLI. (2007) Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Alimentary Pharmacology & Therapeutics 26:3, 369-376
CrossRef1340
Gábor Horváth, Gyula Tolvaj, Tünde Halász, Gyula Stotz. (2007) A természetes interferon helye és lehetőségei a krónikus C-hepatitis kezelésében: a stopszabály miatt a kombinált antivirális terápiából kizárt betegek kezelésével szerzett tapasztalataink. Orvosi Hetilap 148:33, 1545-1550
CrossRef1341
Mauricio Lisker-Melman, Gregory S. Sayuk. (2007) Defining Optimal Therapeutic Outcomes in Chronic Hepatitis. Archives of Medical Research 38:6, 652-660
CrossRef1342
Roberto J. Firpi, David R. Nelson. (2007) Current and Future Hepatitis C Therapies. Archives of Medical Research 38:6, 678-690
CrossRef1343
Yintang Jia, Lai Wei, Dong Jiang, Jianghua Wang, Xu Cong, Ran Fei. (2007) Antiviral action of interferon-? against hepatitis C virus replicon and its modulation by interferon-? and interleukin-8. Journal of Gastroenterology and Hepatology 22:8, 1278-1285
CrossRef1344
Ei Kinai, Hideji Hanabusa, Shingo Kato. (2007) Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay. Journal of Medical Virology 79:8, 1113-1119
CrossRef1345
Mitchell L. Shiffman. (2007) Treating chronic hepatitis C virus after liver transplantation: Balancing the risks against the chance for success. Liver Transplantation 13:8, 1088-1091
CrossRef1346
Rosângela Teixeira, Luis A. Marcos, Scott L. Friedman. (2007) Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 37:8, 579-595
CrossRef1347
Charles S. Whang, Ke-Qin Hu. (2007) Hepatitis C in patients with chronic kidney disease: Course and management. Current Hepatitis Reports 6:3, 96-102
CrossRef1348
Gabor Butora, David B. Olsen, Steven S. Carroll, Daniel R. McMasters, Christoph Schmitt, Joseph F. Leone, Mark Stahlhut, Christine Burlein, Malcolm MacCoss. (2007) Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2′-C-methyladenosine. Bioorganic & Medicinal Chemistry 15:15, 5219-5229
CrossRef1349
Isao Hidaka, Keisuke Hino, Masaaki Korenaga, Toshikazu Gondo, Sohji Nishina, Miye Ando, Michiari Okuda, Isao Sakaida. (2007) Stronger Neo-Minophagen C ? , a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein. Liver International 27:6, 845-853
CrossRef1350
Einar Björnsson, Paul Angulo. (2007) Hepatitis C and Steatosis. Archives of Medical Research 38:6, 621-627
CrossRef1351
P POCKROS, D GUYADER, H PATTON, M TONG, T WRIGHT, J MCHUTCHISON, T MENG. (2007) Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
CrossRef1352
D. Webster, R. Ahmed, P. Tandon, L. Chui, R. R. McDonald, A. Obarianyk, N. Antonishyn, K. Doucette. (2007) Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection. Journal of Viral Hepatitis 14:8, 564-569
CrossRef1353
János Fehér, Gabriella Lengyel. (2007) Interferon a vírushepatitis kezelésében. 50 éve fedezték fel az interferont. Orvosi Hetilap 148:33, 1539-1543
CrossRef1354
S. Gerkens, M. Nechelput, L. Annemans, B. Peraux, M. Mouchart, C. Beguin, Y. Horsmans. (2007) A health economic model to assess the cost-effectiveness of PEG IFN ?-2a and ribavirin in patients with mild chronic hepatitis C. Journal of Viral Hepatitis 14:8, 523-536
CrossRef1355
Francis E. Lotrich, Mordechai Rabinovitz, Patricia Gironda, Bruce G. Pollock. (2007) Depression following pegylated interferon-alpha: Characteristics and vulnerability. Journal of Psychosomatic Research 63:2, 131-135
CrossRef1356
Mitchell L. Shiffman, Jennifer Salvatore, Sarah Hubbard, Angie Price, Richard K. Sterling, R. Todd Stravitz, Velimir A. Luketic, Arun J. Sanyal. (2007) Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 46:2, 371-379
CrossRef1357
Marco Antonio Olivera-Martínez, Juan F. Gallegos-Orozco. (2007) Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation. Archives of Medical Research 38:6, 691-701
CrossRef1358
Irene Boo, Alexandra E. Fischer, Doug Johnson, Ruth Chin, Maxine Giourouki, Mandvi Bharadwaj, Scott Bowden, Joseph Torresi, Heidi Drummer. (2007) Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin. Journal of Clinical Virology 39:4, 288-294
CrossRef1359
Henry L. Y. Chan, Hong Ren, Wan C. Chow, Theodore Wee, . (2007) Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 46:2, 315-323
CrossRef1360
Stuart Roberts, Adam Gordon, Catriona McLean, John Pedersen, Scott Bowden, Kenneth Thomson, Peter Angus. (2007) Effect of Sustained Viral Response on Hepatic Venous Pressure Gradient in Hepatitis C–Related Cirrhosis. Clinical Gastroenterology and Hepatology 5:8, 932-937
CrossRef1361
D. POSTHOUWER, T. T. YEE, M. MAKRIS, K. FISCHER, A. GRIFFIOEN, J. J. VAN VEEN, E. P. MAUSER-BUNSCHOTEN. (2007) Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. Journal of Thrombosis and Haemostasis 5:8, 1624-1629
CrossRef1362
Shiffman, Mitchell L., Suter, Fredy, Bacon, Bruce R., Nelson, David, Harley, Hugh, Solá, Ricard, Shafran, Stephen D., Barange, Karl, Lin, Amy, Soman, Ash, Zeuzem, Stefan, . (2007) Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine 357:2, 124-134
Full Text1363
Liang, T. Jake, . (2007) Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 — Is Less More?. New England Journal of Medicine 357:2, 176-178
Full Text1364
Barbara H McGovern. (2007) Hepatitis C in the HIV-Infected Patient. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:Supplement 2, S47-S56
CrossRef1365
V. R. CICINNATI, S. IACOB, C. G. KLEIN, H. A. BABA, G. C. SOTIROPOULOS, P. HILGARD, Y. ERIM, C. E. BROELSCH, G. GERKEN, S. BECKEBAUM. (2007) Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation. Alimentary Pharmacology & Therapeutics 26:2, 291-303
CrossRef1366
Takashi Honda, Yoshiaki Katano, Fumihiro Urano, Mutsumi Murayama, Kazuhiko Hayashi, Masatoshi Ishigami, Isao Nakano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto. (2007) Efficacy of ribavirin plus interferon-? in patients aged ?60
CrossRef1367
Harel Dahari, Arthur Lo, Ruy M. Ribeiro, Alan S. Perelson. (2007) Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. Journal of Theoretical Biology 247:2, 371-381
CrossRef1368
R GISH, S ARORA, K RAJENDERREDDY, D NELSON, C OBRIEN, Y XU, B MURPHY. (2007) Virological response and safety outcomes in therapy–naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study
CrossRef1369
Giorgio Antonucci, Maria Antonella Longo, Claudio Angeletti, Francesco Vairo, Alessandra Oliva, Ubaldo Visco Comandini, Guido Tocci, Evangelo Boumis, Pasquale Noto, Maria Carmela Solmone, Maria R. Capobianchi, Enrico Girardi. (2007) The Effect of Age on Response to Therapy With Peginterferon ? Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr. The American Journal of Gastroenterology 102:7, 1383-1391
CrossRef1370
Y BENHAMOU. (2007) Anemia and clinical outcomes in hepatitis C
CrossRef1371
Alain H. Litwin, Hillary V. Kunins, Karina M. Berg, Alex D. Federman, Karyn K. Heavner, Marc N. Gourevitch, Julia H. Arnsten. (2007) Hepatitis C management by addiction medicine physicians: Results from a national survey. Journal of Substance Abuse Treatment 33:1, 99-105
CrossRef1372
Tim Zimmermann, Wulf O. Böcher, Stefan Biesterfeld, Anca Zimmermann, Stefan Kanzler, Gertrud Greif-Higer, Ana Paula Barreiros, Martin F. Sprinzl, Marcus A. Wörns, Ansgar W. Lohse, Christian Mönch, Gerd Otto, Peter R. Galle, Marcus Schuchmann. (2007) Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transplant International 20:7, 583-590
CrossRef1373
Jeong Won Jang, Min Soo Kim, So Yeon Lee, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Sang Bok Cha, Seung Kew Yoon. (2007) Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy. Journal of Gastroenterology and Hepatology 22:7, 1092-1097
CrossRef1374
Lisa I. Backus, Derek B. Boothroyd, Barbara R. Phillips, Larry A. Mole. (2007) Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Hepatology 46:1, 37-47
CrossRef1375
Harel Dahari, Ruy M. Ribeiro, Alan S. Perelson. (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46:1, 16-21
CrossRef1376
D. Roulot, V. Bourcier, V. Grando, P. Deny, Y. Baazia, H. Fontaine, F. Bailly, L. Castera, V. De Ledinghen, P. Marcellin, R. Poupon, M. Bourlière, J. P. Zarski, F. Roudot-Thoraval, . (2007) Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis 14:7, 460-467
CrossRef1377
R. R. ARJAL, J. R. BURTON JR, F. VILLAMIL, H. R. ROSEN. (2007) Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Alimentary Pharmacology & Therapeutics 26:2, 127-140
CrossRef1378
Jia-Horng Kao. (2007) Appropriate use of interferon for treatment of chronic hepatitis B. Hepatology Research 37:s1, S47-S54
CrossRef1379
Władysław SUŁOWICZ, Andrzej RADZISZEWSKI, Eve CHOWANIEC. (2007) Hepatitis C virus infection in dialysis patients. Hemodialysis International 11:3, 286-295
CrossRef1380
Gregory J Dore, Francesca J Torriani, Maribel Rodriguez-Torres, Norber Br??u, Mark Sulkowski, Ricard Sola Lamoglia, Cristina Tural, Nathan Clumeck, Mark R Nelson, Maria C Mendes-Correa, Eliot W Godofsky, Douglas T Dieterich, Ellen Yetzer, Eduardo Lissen, David A Cooper. (2007) Baseline factors prognostic of sustained virological response in patients with HIV???hepatitis C virus co-infection. AIDS 21:12, 1555-1559
CrossRef1381
Harel Dahari, Marianthi Markatou, Marija Zeremski, Ivan Haller, Ruy M. Ribeiro, Teresa Licholai, Alan S. Perelson, Andrew H. Talal. (2007) Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of Hepatology 47:1, 23-30
CrossRef1382
Huy A. Tran. (2007) Hepatitis C Infection, Treatment Regimens, and Thyroid Function Abnormalities. The Endocrinologist 17:4, 231-235
CrossRef1383
Stéphane Chevaliez, Magali Bouvier-Alias, Rozenn Brillet, Jean-Michel Pawlotsky. (2007) Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46:1, 22-31
CrossRef1384
AI Kim, A Dorn, R Bouajram, S Saab. (2007) The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Medicine 8:5, 312-321
CrossRef1385
A. R. N. Zekri, H. A. Haleem, G. E. -D. Esmat, A. A. Bahnassy, H. M. A. El-Din, M. M. Hafez, A. F. Sharaby, H. Sharaf, M. S. E.-D. Zakaria. (2007) Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. Journal of Viral Hepatitis 14:7, 468-477
CrossRef1386
Hideyuki Nomura, Yoichiro Kashiwagi, Ryouko Hirano, Hironori Tanimoto, Nobuo Tsutsumi, Masashi Higashi, Hiromi Ishibashi. (2007) Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. Hepatology Research 37:7, 490-497
CrossRef1387
H. Miyatake, T. Kanto, M. Inoue, M. Sakakibara, A. Kaimori, T. Yakushijin, I. Itose, M. Miyazaki, N. Kuzushita, N. Hiramatsu, T. Takehara, A. Kasahara, N. Hayashi. (2007) Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. Journal of Viral Hepatitis 14:6, 404-412
CrossRef1388
Rui Sarmento-Castro, Ana Horta, Olga Vasconcelos, Helena Coelho, Josefina Mendez, Ana Paula Tavares, João Seabra, Manuela Duarte, Leonor Chaves, Olga Fortes, Cristina Recalde, Ângela Ventura, Nuno Pires, Luciana Pinho, Nancy Dias, Fátima Carneiro. (2007) Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV–HIV co-infection. Journal of Infection 54:6, 609-616
CrossRef1389
Claude Souvignet, Olivier Lejeune, Christian Trepo. (2007) Interferon-based treatment of chronic hepatitis C. Biochimie 89:6-7, 894-898
CrossRef1390
Shintaro Hirashima, Takahiro Oka, Kazutaka Ikegashira, Satoru Noji, Hiroshi Yamanaka, Yoshinori Hara, Hiroyuki Goto, Ryo Mizojiri, Yasushi Niwa, Toru Noguchi, Izuru Ando, Satoru Ikeda, Hiromasa Hashimoto. (2007) Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: Benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety. Bioorganic & Medicinal Chemistry Letters 17:11, 3181-3186
CrossRef1391
Mario Angelico, Alessandra Petrolati, Raffaella Lionetti, Ilaria Lenci, Patrizia Burra, Maria Francesca Donato, Manuela Merli, Mario Strazzabosco, Giuseppe Tisone. (2007) A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 46:6, 1009-1017
CrossRef1392
Wing Chia-Ming Chuang, Francis Sarkodie, Colin J. Brown, Shirley Owusu-Ofori, Juliette Brown, Chengyao Li, Cristina Navarrete, Paul Klenerman, Jean-Pierre Allain. (2007) Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. Journal of Medical Virology 79:6, 724-733
CrossRef1393
E. B. Devine, J. T. Cross, K. V. Kowdley, S. D. Sullivan. (2007) The cost of treating ribavirin-induced anemia in hepatitis C:the impact of using recombinant human erythropoietin*. Current Medical Research and Opinion 23:6, 1463-1472
CrossRef1394
Kenichi Morikawa, Zijiang Zhao, Tomoko Date, Michiko Miyamoto, Asako Murayama, Daisuke Akazawa, Junichi Tanabe, Saburo Sone, Takaji Wakita. (2007) The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. Journal of Medical Virology 79:6, 714-723
CrossRef1395
Brian Keefe. (2007) Interferon-induced depression in hepatitis C: An update. Current Psychiatry Reports 9:3, 255-261
CrossRef1396
B. Ramos, M. Núñez, A. Rendón, M. A. Berdún, E. Losada, I. Santos, S. Echevarría, A. Ocampo, C. Miralles, P. Arazo, P. Barreiro, M. Romero, P. Labarga, J. M. Guardiola, J. Garcia-Samaniego, V. Soriano. (2007) Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. Journal of Viral Hepatitis 14:6, 387-391
CrossRef1397
Alajos Pár, István Tornai, Ferenc Szalay. (2007) Experiences on Antiviral Treatment for Chronic Viral B and C Hepatitis in Hungary (1998–2004). A Nation-Wide Study. Hungarian Medical Journal 1:2, 207-219
CrossRef1398
Karen E. Doucette, Justin Weinkauf, Suzanne Sumner, Karen Ens, Dale Lien. (2007) Treatment of Hepatitis C in Potential Lung Transplant Candidates. Transplantation 83:12, 1652-1655
CrossRef1399
M. S. Sulkowski, Y. Benhamou. (2007) Therapeutic issues in HIV/HCV-coinfected patients. Journal of Viral Hepatitis 14:6, 371-386
CrossRef1400
István Tornai, János Mátyus. (2007) Treatment of Hepatitis C Virus Infection in Patients before and after Renal Transplantation. Hungarian Medical Journal 1:2, 225-234
CrossRef1401
Wei-Shi Yeh, Edward P Armstrong, Grant H Skrepnek, Daniel C Malone. (2007) Peginterferon alfa-2a versus Peginterferon alfa-2b as Initial Treatment of Hepatitis C Virus Infection: A Cost-Utility Analysis from the Perspective of the Veterans Affairs Health Care System. Pharmacotherapy 27:6, 813-824
CrossRef1402
Hiroshi Yotsuyanagi, Kazuhiko Koike. (2007) Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. Journal of Gastroenterology 42:5, 329-335
CrossRef1403
Annagiulia Gramenzi, Pietro Andreone, Carmela Cursaro, Gabriella Verucchi, Sergio Boccia, Pier Luigi Giacomoni, Silvia Galli, Giuliano Furlini, Maurizio Biselli, Stefania Lorenzini, Luciano Attard, Fiorenza Bonvicini, Mauro Bernardi. (2007) A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. Journal of Gastroenterology 42:5, 362-367
CrossRef1404
C. M. Behler, E. Vittinghoff, F. Lin, R. T. Chung, M. G. Peters, G. K. Robbins, P. A. Volberding. (2007) Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects. Clinical Infectious Diseases 44:10, 1375-1383
CrossRef1405
Maria H. Sjogren, Robert Sjogren, Michael F. Lyons, Michael Ryan, John Santoro, Coleman Smith, K. Rajender Reddy, Herbert Bonkovsky, Brooke Huntley, Sima Faris-Young. (2007) Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin. Digestive Diseases and Sciences 52:6, 1540-1547
CrossRef1406
Joseph K. Lim, Roberto J. Groszmann. (2007) Transient elastography for diagnosis of portal hypertension in liver cirrhosis: Is there still a role for hepatic venous pressure gradient measurement?. Hepatology 45:5, 1087-1090
CrossRef1407
Glen Lutchman, Susan Danehower, Byung–Cheol Song, T. Jake Liang, Jay H. Hoofnagle, Michael Thomson, Marc G. Ghany. (2007) Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy. Gastroenterology 132:5, 1757-1766
CrossRef1408
J.-F. HUANG, M.-L. YU, C.-M. LEE, C.-Y. DAI, N.-J. HOU, M.-Y. HSIEH, J.-H. WANG, S.-N. LU, I.-S. SHEEN, S.-M. LIN, W.-L. CHUANG, Y.-F. LIAW. (2007) Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386-patient study from Taiwan. Alimentary Pharmacology & Therapeutics 25:9, 1029-1037
CrossRef1409
Ichiyo Itose, Tatsuya Kanto, Michiyo Inoue, Masanori Miyazaki, Hideki Miyatake, Mitsuru Sakakibara, Takayuki Yakushijin, Tsugiko Oze, Naoki Hiramatsu, Tetsuo Takehara, Akinori Kasahara, Kazuhiro Katayama, Michio Kato, Norio Hayashi. (2007) Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients. Journal of Medical Virology 79:5, 511-521
CrossRef1410
Stephen J. Polyak, Chihiro Morishima, Margaret C. Shuhart, Chia C. Wang, Yanze Liu, David Y.–W. Lee. (2007) Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin. Gastroenterology 132:5, 1925-1936
CrossRef1411
Ilan S. Weisberg, Samuel H. Sigal, Ira M. Jacobson. (2007) New treatments for hepatitis C: Life cycle lessons. Current Hepatitis Reports 6:2, 75-82
CrossRef1412
M.-W. Welker, W.-P. Hofmann, C. Welsch, M. von Wagner, E. Herrmann, T. Lengauer, S. Zeuzem, C. Sarrazin. (2007) Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients. Journal of Viral Hepatitis 14:5, 338-349
CrossRef1413
Johan Westin, Kristoffer Hellstrand, Åsa Alsiö, Magdalena Ydreborg, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Elke Verhey-Hart, Martin Lagging. (2007) Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. Hepatology 45:5, 1333-1334
CrossRef1414
M. SIMIN, J. BROK, D. STIMAC, C. GLUUD, L. L. GLUUD. (2007) Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 25:10, 1153-1162
CrossRef1415
Christoph Sarrazin, Tara L. Kieffer, Doug Bartels, Brian Hanzelka, Ute Müh, Martin Welker, Dennis Wincheringer, Yi Zhou, Hui–May Chu, Chao Lin, Christine Weegink, Henk Reesink, Stefan Zeuzem, Ann D. Kwong. (2007) Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology 132:5, 1767-1777
CrossRef1416
Hirokazu Uyama, Hideji Nakamura, Eijiro Hayashi, Hiroyuki Ogawa, Hirayuki Enomoto, Kenya Yoshida, Yorihide Okuda, Mitsunari Yamamoto, Toshikazu Hada, Norio Hayashi. (2007) Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. Hepatology Research 37:5, 325-330
CrossRef1417
Tsung-Ming Chen, Pi-Teh Huang, Ming-Hung Tsai, Lien-Fu Lin, Chung-Cheng Liu, Ka-Sic Ho, Chuan-Pau Siauw, Po-Liang Chao, Jai-Nien Tung. (2007) Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. Journal of Gastroenterology and Hepatology 22:5, 669-675
CrossRef1418
Sidharth S. Bhardwaj, Paul Y. Kwo. (2007) Viral kinetics and duration of hepatitis C therapy. Current Hepatitis Reports 6:2, 68-74
CrossRef1419
Alan S. Perelson, Thomas J. Layden. (2007) Ribavirin: Is It a Mutagen for Hepatitis C Virus?. Gastroenterology 132:5, 2050-2052
CrossRef1420
Vincent Soriano, Massimo Puoti, Mark Sulkowski, Antonietta Cargnel, Yves Benhamou, Marion Peters, Stefan Mauss, Norbert Bräu, Angelos Hatzakis, Stanislas Pol, Juergen Rockstroh. (2007) Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS 21:9, 1073-1089
CrossRef1421
C. L. RAISON, B. J. WOOLWINE, M. F. DEMETRASHVILI, A. S. BORISOV, R. WEINREIB, J. P. STAAB, J. M. ZAJECKA, C. J. BRUNO, M. A. HENDERSON, J. F. REINUS, D. L. EVANS, G. M. ASNIS, A. H. MILLER. (2007) Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology & Therapeutics 25:10, 1163-1174
CrossRef1422
Alajos Pár, István Tornai, Ferenc Szalay. (2007) A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998–2004). Orvosi Hetilap 148:18, 819-826
CrossRef1423
(2007) Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. Journal of Gastroenterology and Hepatology 22:5, 615-633
CrossRef1424
Adeel A. Butt, Joel Tsevat, Jawad Ahmad, A Obaid Shakil, Joseph M. Mrus. (2007) Biochemical and Virologic Parameters in Patients Co-Infected with Hepatitis C and HIV Versus Patients with Hepatitis C Mono-Infection. The American Journal of the Medical Sciences 333:5, 271-275
CrossRef1425
J. Encke, W. Radunz, C. Eisenbach, J. Geib, S. Gehrke, E. Pfaff, W. Stremmel. (2007) Development of a heterologous, multigenotype vaccine against hepatitis C virus infection. European Journal of Clinical Investigation 37:5, 396-406
CrossRef1426
A. A. Butt, M. Skanderson, K. A. McGinnis, T. Ahuja, C. L. Bryce, A. E. Barnato, C.-C. H. Chang. (2007) Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. Journal of Viral Hepatitis 0:0, 070507054112003-???
CrossRef1427
A. M. Di Bisceglie, R. H. Ghalib, F. M. Hamzeh, V. K. Rustgi. (2007) Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis 0:0, 070701233506001-???
CrossRef1428
N. J. Shire, J. A. Welge, K. E. Sherman. (2007) Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. Journal of Viral Hepatitis 14:4, 239-248
CrossRef1429
A. Chris Krueger, Darold L. Madigan, Brian E. Green, Douglas K. Hutchinson, Wen W. Jiang, Warren M. Kati, Yaya Liu, Clarence J. Maring, Sherie V. Masse, Keith F. McDaniel, Tim R. Middleton, Hongmei Mo, Akhteruzzaman Molla, Debra A. Montgomery, Teresa I. Ng, Dale J. Kempf. (2007) Inhibitors of HCV NS5B polymerase: Synthesis and structure–activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives. Bioorganic & Medicinal Chemistry Letters 17:8, 2289-2292
CrossRef1430
Michael R. Kraus, Oliver Al-Taie, Arne Schäfer, Matthias Pfersdorff, Klaus–Peter Lesch, Michael Scheurlen. (2007) Serotonin-1A Receptor Gene HTR1A Variation Predicts Interferon-Induced Depression in Chronic Hepatitis C. Gastroenterology 132:4, 1279-1286
CrossRef1431
M. Crespo, S. Sauleda, J. I. Esteban, A. Juarez, E. Ribera, A. L. Andreu, V. Falco, J. Quer, I. Ocaña, I. Ruiz, M. Buti, A. Pahissa, R. Esteban, J. Guardia. (2007) Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. Journal of Viral Hepatitis 14:4, 228-238
CrossRef1432
A. Mallat. (2007) Traitement de la cirrhose virale C. Journal Africain d’Hépato-Gastroentérologie 1:1, 59-62
CrossRef1433
A. Mangia. (2007) Short-duration therapy for hepatitis C: suitable for all?. Journal of Viral Hepatitis 14:4, 221-227
CrossRef1434
Mitchell L. Shiffman, Anastasios A. Mihas, Farida Millwala, Richard K. Sterling, Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal. (2007) Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3. CME. The American Journal of Gastroenterology 102:4, 761-766
CrossRef1435
Stephen D Shafran. (2007) Early Initiation of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:5, 551-556
CrossRef1436
K OKAMOTO, N AKUTA, H KUMADA, M KOBAYASHI, Y MATSUO, H TAZAWA. (2007) A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. Journal of Virological Methods 141:1, 1-6
CrossRef1437
Jean–Michel Pawlotsky. (2007) Treatment of Hepatitis C: Don’t Put All Your Eggs in One Basket!. Gastroenterology 132:4, 1611-1615
CrossRef1438
Lennox J. Jeffers. (2007) Treating hepatitis C in African Americans. Liver International 27:3, 313-322
CrossRef1439
Pierre Raboisson, Oliver Lenz, Tse-I Lin, Dominique Surleraux, Sarvajit Chakravarty, Annick Scholliers, Katrien Vermeiren, Frederic Delouvroy, Thierry Verbinnen, Kenneth Simmen. (2007) Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:7, 1843-1849
CrossRef1440
Huy A Tran, John R Attia, Tracey L Jones, Robert G Batey. (2007) Pegylated interferon-?2? in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-?2? in a hepatitis C population: Meta-analysis. Journal of Gastroenterology and Hepatology 22:4, 472-476
CrossRef1441
John G. McHutchison, Michael P. Manns, Robert S. Brown, K. Rajender Reddy, Mitchell L. Shiffman, John B. Wong. (2007) Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. The American Journal of Gastroenterology 102:4, 880-889
CrossRef1442
Philip Erik Wikman Jorgensen, Francisco Mariano Jover Díaz, José María Cuadrado Pastor. (2007) Pancitopenia excepcional secundaria al tratamiento con interferón pegilado y ribavirina. Gastroenterología y Hepatología 30:4, 253-254
CrossRef1443
Michael S. Economou, Spyridon Filis, Helen Vienna, Dimitrios Christodoulou, Leonidas Christou, Epameinondas V. Tsianos. (2007) Treatment and retreatment in patients with chronic hepatitis C: 10 years clinical practice in a single centre. Liver International 27:3, 340-346
CrossRef1444
Rami Moucari, Marie-Pierre Ripault, Valérie Oulès, Michèle Martinot-Peignoux, Tarik Asselah, Nathalie Boyer, Ahmed El Ray, Dominique Cazals-Hatem, Dominique Vidaud, Dominique Valla, Marc Bourlière, Patrick Marcellin. (2007) High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. Journal of Hepatology 46:4, 596-604
CrossRef1445
Christoph Sarrazin, Regine Rouzier, Frank Wagner, Nicole Forestier, Dominique Larrey, Samir K. Gupta, Musaddeq Hussain, Amrik Shah, David Cutler, Jenny Zhang, Stefan Zeuzem. (2007) SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders. Gastroenterology 132:4, 1270-1278
CrossRef1446
Scott T Rottinghaus, Richard J Whitley. (2007) Current non-AIDS antiviral chemotherapy. Expert Review of Anti-infective Therapy 5:2, 217-230
CrossRef1447
Richard Hallinan, Andrew Byrne, Kingsley Agho, Gregory J. Dore. (2007) Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and Alcohol Dependence 88:1, 49-53
CrossRef1448
Kazuaki Inoue, Takuya Umehara, Urs T. Ruegg, Fumihiko Yasui, Tsunamasa Watanabe, Hiroshi Yasuda, Jean-Maurice Dumont, Pietro Scalfaro, Makoto Yoshiba, Michinori Kohara. (2007) Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:4, 921-928
CrossRef1449
M. DIAGO, A. OLVEIRA, R. SOLÁ, M. ROMERO-GÓMEZ, R. MORENO-OTERO, R. PÉREZ, J. SALMERÓN, J. ENRÍQUEZ, R. PLANAS, J. C. GAVILÁN, J. DEL OLMO, R. URIBARRENA, C. SILLERO, A. BENÍTEZ, S. SÁNCHEZ-GALDÓN, B. DALMAU, L. ERAÑA, M. MONTORO, J. PORTU, J. M. GARIJO, R. BARNIOL, A. DOMÍNGUEZ, R. ROTA, J. L. OLCOZ, M. ANTÓN, X. PAMPLONA, T. CASANOVAS, E. JIMÉNEZ, M. HUARTE, F. DÍAZ, J. SÁNCHEZ-RUANO, M. ORIVE, M. MUÑOZ-SÁNCHEZ, M. ROSET. (2007) Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. Alimentary Pharmacology & Therapeutics 25:8, 899-906
CrossRef1450
Jun Yang, Anto Satriyo Nugroho, Kazunobu Yamauchi, Kentaro Yoshioka, Jiang Zheng, Kai Wang, Ken Kato, Susumu Kuroyanagi, Akira Iwata. (2007) Efficacy of Interferon Treatment for Chronic Hepatitis C Predicted by Feature Subset Selection and Support Vector Machine. Journal of Medical Systems 31:2, 117-123
CrossRef1451
Gary L. Davis, Kris Krawczynski, Gyongyi Szabo. (2007) Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options. Digestive Diseases and Sciences 52:4, 857-875
CrossRef1452
Hitoshi Tajiri, Yuri Etani, Sotaro Mushiake, Yasuhiro Hasegawa, Keiichi Ozono. (2007) Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels. European Journal of Pediatrics 166:5, 501-502
CrossRef1453
H BONKOVSKY, K SNOW, P MALET, C BACKMADRUGA, R FONTANA, R STERLING, C KULIG, A DIBISCEGLIE, T MORGAN, J DIENSTAG. (2007) Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
CrossRef1454
L DELLOSSO, S PINI, L MAGGI, P RUCCI, A DELDEBBIO, M CARLINI, A BALDINI, G FERRARI, E MANCA, E BEVERINI. (2007) Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. Journal of Psychosomatic Research 62:3, 349-355
CrossRef1455
Eduardo Vilar Gomez, Bienvenido Gra Oramas, Enrique Arus Soler, Raimundo Llanio Navarro, Caridad Ruenes Domech. (2007) Viusid, a nutritional supplement, in combination with interferon ?-2b and ribavirin in patients with chronic hepatitis C. Liver International 27:2, 247-259
CrossRef1456
Jenny O. Smith, Richard K. Sterling. (2007) Hepatitis C and HIV. Current Gastroenterology Reports 9:1, 83-90
CrossRef1457
Jacob Alexander, Bruce Y. Tung, Anne Croghan, Kris V. Kowdley. (2007) Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver International 27:2, 268-273
CrossRef1458
Vincenzo Guadagnino, Maria Paola Trotta, Franco Montesano, Sergio Babudieri, Benedetto Caroleo, Orlando Armignacco, Jessica Carioti, Giuseppe Maio, Roberto Monarca, Andrea Antinori, . (2007) Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 102:3, 423-431
CrossRef1459
István Tornai, János Mátyus. (2007) A hepatitis C-vírusfertőzés terápiája vesepótló kezelésben részesülő betegekben. Orvosi Hetilap 148:11, 489-494
CrossRef1460
Ellis King, Christopher Trabue, Deling Yin, Zhi Q Yao, Jonathan P Moorman. (2007) Hepatitis C: the complications of immune dysfunction. Expert Review of Clinical Immunology 3:2, 145-157
CrossRef1461
Wolf Peter Hofmann, Andreas Polta, Eva Herrmann, Ulrike Mihm, Bernd Kronenberger, Tanja Sonntag, Volker Lohmann, Barbara Schönberger, Stefan Zeuzem, Christoph Sarrazin. (2007) Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy. Gastroenterology 132:3, 921-930
CrossRef1462
Zobair Younossi, Jillian Kallman, John Kincaid. (2007) The effects of HCV infection and management on health-related quality of life. Hepatology 45:3, 806-816
CrossRef1463
Jaydeep S. Kadam, Andrew H. Talal. (2007) Changing Treatment Paradigms: Hepatitis C Virus in HIV-Infected Patients. AIDS Patient Care and STDs 21:3, 154-168
CrossRef1464
Paul J. Pockros, Lennox Jeffers, Nezam Afdhal, Zachary D. Goodman, David Nelson, Robert G. Gish, K. Rajender Reddy, Robert Reindollar, Maribel Rodriguez-Torres, Sarah Sullivan, Lawrence M. Blatt, Sima Faris-Young. (2007) Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45:3, 569-578
CrossRef1465
S. Kobayashi, T. Takeda, M. Enomoto, A. Tamori, N. Kawada, D. Habu, H. Sakaguchi, T. Kuroda, K. Kioka, S. R. Kim, T. Kanno, T. Ueda, M. Hirano, S. Fujimoto, H. Jomura, S. Nishiguchi, S. Seki. (2007) Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver International 27:2, 186-191
CrossRef1466
N AKUTA, F SUZUKI, Y KAWAMURA, H YATSUJI, H SEZAKI, Y SUZUKI, T HOSAKA, M KOBAYASHI, M KOBAYASHI, Y ARASE. (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Journal of Hepatology 46:3, 403-410
CrossRef1467
Belen Ramos, Julie Sheldon, Andres Ruiz-Sancho, Carlos Toro, Pilar Ríos, Vincent Soriano. (2007) Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. AIDS 21:5, 652-653
CrossRef1468
Nicole G. Campos, Joshua A. Salomon, Julie C. Servoss, David P. Nunes, Jeffrey H. Samet, Kenneth A. Freedberg, Sue J. Goldie. (2007) Cost-effectiveness of Treatment for Hepatitis C in an Urban Cohort Co-infected with HIV. The American Journal of Medicine 120:3, 272-279
CrossRef1469
Mireen Friedrich-Rust, Stefan Zeuzem, Christoph Sarrazin. (2007) Current therapy for hepatitis C. International Journal of Colorectal Disease 22:4, 341-349
CrossRef1470
Makoto Kuboki, Shiro Iino, Tadao Okuno, Masao Omata, Kendo Kiyosawa, Hiromitsu Kumada, Norio Hayashi, Takahiro Sakai. (2007) Peginterferon ?-2a (40
CrossRef1471
Chiaki Okuse, Kayo Adachi, Yoshiki Katakura, Kotaro Matsunaga, Toshiya Ishii, Nobuyuki Matsumoto, Hiroshi Yotsuyanagi, Shiro Iino, Michihiro Suzuki, Fumio Itoh. (2007) A case of deep venous thrombosis associated with pegylated interferon α2b plus ribavirin treatment of chronic hepatitis C. Journal of Gastroenterology 41:12, 1231-1236
CrossRef1472
J. Salmerón, M. Diago, R. Andrade, R. Pérez, R. Solá, M. Romero, M. de la Mata, R. Granados, A. Ruiz-Extremera, P. Mu¯oz de Rueda. (2007) Induction doses of interferon-?-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis 14:2, 89-95
CrossRef1473
Nikolaos Pyrsopoulos, Lennox Jeffers. (2007) Hepatitis C in African Americans. Journal of Clinical Gastroenterology 41:2, 185-193
CrossRef1474
T. Bizollon, P. Pradat, J.-Y. Mabrut, S. Radenne, C. Ducerf, J. Baulieux, J. C. Souquet, C. Trepo. (2007) Histological Benefit of Retreatment by Pegylated Interferon Alfa-2b and Ribavirin in Patients with Recurrent Hepatitis C Virus Infection Posttransplantation. American Journal of Transplantation 7:2, 448-453
CrossRef1475
Karen H. Seal, Sue L. Currie, Hui Shen, Bhupinderjit S. Anand, Edmund J. Bini, Norbert Brau, Lennox Jeffers, Teresa L. Wright. (2007) Hepatitis C Treatment Candidacy and Outcomes Among 4318 US Veterans With Chronic Hepatitis C Virus Infection. Journal of Clinical Gastroenterology 41:2, 199-205
CrossRef1476
S. Vallet, S. Gouriou, G. Nkontchou, H. Hotta, M. Vilerio, M. C. Legrand-Quillien, M. Beaugrand, J. C. Trinchet, J. B. Nousbaum, P. Dény, C. Gaudy, A. Goudeau, B. Picard, C. Payan. (2007) Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?. Journal of Viral Hepatitis 14:2, 96-106
CrossRef1477
G. Calleri, G. Cariti, F. Gaiottino, F. G. De Rosa, O. Bargiacchi, S. Audagnotto, S. Quaglia, T. De Blasi, P. Romano, A. Traverso, G. Leo, R. Carbone, B. Del Mastro, M. Tinelli, P. Caramello, G. Di Perri. (2007) A short course of pegylated interferon-? in acute HCV hepatitis. Journal of Viral Hepatitis 14:2, 116-121
CrossRef1478
Thierry Thévenot, Jean-François Cadranel, Vincent Di Martino, Alexandre Pariente, Xavier Causse, Christophe Renou, Hervé Hagege, Jacques Denis, Françoise Lunel-Fabiani. (2007) A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology 45:2, 377-383
CrossRef1479
Moisés Diago. (2007) ¿Mejora el tratamiento antiviral el curso clínico de la cirrosis por virus de la hepatitis C?. Gastroenterología y Hepatología 30:2, 85-92
CrossRef1480
TAK MAO CHAN, STEPHEN K N HO, COLIN S O TANG, KAI CHUNG TSE, MAN FAI LAM, KAR NENG LAI, SUSAN YUNG. (2007) Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 12:1, 11-17
CrossRef1481
Graham S Cooke, Janice Main. (2007) Improving the treatment of hepatitis C infection in the UK. Expert Opinion on Pharmacotherapy 8:2, 183-191
CrossRef1482
Joseph Torresi, Alex Fischer, Lara Grollo, Weiguang Zeng, Heidi Drummer, David C Jackson. (2007) Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunology and Cell Biology 85:2, 169-173
CrossRef1483
Montserrat Laguno, Mar??a Larrousse, Javier Murillas, Jos?? Luis Blanco, Agathe Le??n, Ana Milinkovic, Montserrat Lonc??, Esteban Martinez, Jos?? Maria S??nchez-Tapias, Elisa de Lazzari, Josep Ma Gatell, Josep Costa, Josep Mallolas. (2007) Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:2, 174-178
CrossRef1484
Ankur Goyal, Wolf P. Hofmann, Eva Hermann, Stella Traver, Syed S. Hissar, Naveen Arora, Hubert E. Blum, Stefan Zeuzem, Christoph Sarrazin, Shiv K. Sarin. (2007) The hepatitis C virus NS5A protein and response to interferon α: mutational analyses in patients with chronic HCV genotype 3a infection from India. Medical Microbiology and Immunology 196:1, 11-21
CrossRef1485
M. Zeremski, L. M. Petrovic, A. H. Talal. (2007) The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. Journal of Viral Hepatitis 0:0, 070124051929001-???
CrossRef1486
Eun Uk Jung, Ji Hun Park, Kyung Im Pae, Suk Woo Kang, Sung Jae Park, Sam Ryong Jee, Eun Tak Park, Youn Jae Lee, Sang Hyuk Lee, Sang Young Seol. (2007) Short-term Therapy with Pegylated Interferon plus Ribavirin for the Chronic Hepatitis C Genotype 2 Patients. The Korean Journal of Hepatology 13:3, 341
CrossRef1487
David H. Henry, Jihad Slim, Anthony Lamarca, Peter Bowers, Gerhard Leitz. (2007) Natural History of Anemia Associated with Interferon/Ribavirin Therapy for Patients with HIV/HCV Coinfection. AIDS Research and Human Retroviruses 23:1, 1-9
CrossRef1488
Sam Nourani, Paul J Pockros. (2007) How should hepatitis C be managed in patients aged 65 years and older?. Nature Clinical Practice Gastroenterology & Hepatology 4:1, 22-23
CrossRef1489
M. Basso, F. Torre, A. Grasso, G. Percario, E. Azzola, S. Artioli, S. Blanchi, N. Pelli, A. Picciotto. (2007) Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Digestive and Liver Disease 39:1, 47-51
CrossRef1490
Shintaro Takaki, Yoshiiku Kawakami, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Hiroto Ishihara, Keiji Tsuji, Shiomi Aimitsu, Hiroiku Kawakami, Toshio Nakanishi, Mikiya Kitamoto, Takashi Moriya, Kenichi Satoh, Kazuaki Chayama. (2007) Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin. Intervirology 50:6, 439-446
CrossRef1491
Mitchell L. Shiffman, Marc G. Ghany, Timothy R. Morgan, Elizabeth C. Wright, Gregory T. Everson, Karen L. Lindsay, Anna S.F. Lok, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Jules L. Dienstag, David R. Gretch. (2007) Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology 132:1, 103-112
CrossRef1492
Robert D. Baker, Deborah Dee, Susan S. Baker. (2007) Response to Pegylated Interferon ??-2b and Ribavirin in Children With Chronic Hepatitis C. Journal of Clinical Gastroenterology 41:1, 111-114
CrossRef1493
Victor de Lédinghen, Pascale Trimoulet, Paul-Régis Mannant, Francis Dumas, Patrick Champbenoît, Christian Baldit, Juliette Foucher, Muriel Faure, Julien Vergniol, Laurent Castéra, Julien Bertet, Hervé Fleury, Patrice Couzigou, Pierre-Henri Bernard. (2007) Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years). Journal of Hepatology 46:1, 19-25
CrossRef1494
Arne Schäfer, Michael Scheurlen, Benedikt Weissbrich, Katrin Schöttker, Michael R. Kraus. (2007) Sustained Virological Response in the Antiviral Therapy of Chronic Hepatitis C: Is There a Predictive Value of Interferon-Induced Depression?. Chemotherapy 53:4, 292-299
CrossRef1495
Maribel Rodríguez-Torres, José F. Rodríguez-Orengo, Carlos F. Ríos-Bedoya, Alberto Fernández-Carbia, Elsa González-Lassalle, Rosa Salgado-Mercado, Acisclo M. Marxuach-Cuétara. (2007) Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Journal of Clinical Virology 38:1, 32-38
CrossRef1496
Amany Zekry, Kenneth Yan. (2007) Is re-treatment with peginterferon α-2a and ribavirin effective in patients with relapsed chronic hepatitis C?. Nature Clinical Practice Gastroenterology & Hepatology 4:1, 12-13
CrossRef1497
Oluwatoyin M. Adeyemi. (2007) Hepatitis C in HIV-positive Patients???Treatment and Liver Disease Outcomes. Journal of Clinical Gastroenterology 41:1, 75-87
CrossRef1498
K. Rajender Reddy, Mitchell L. Shiffman, Timothy R. Morgan, Stefan Zeuzem, Stephanos Hadziyannis, Fayez M. Hamzeh, Teresa L. Wright, Michael Fried. (2007) Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment. Clinical Gastroenterology and Hepatology 5:1, 124-129
CrossRef1499
Gennadiy Koev, Tatyana Dekhtyar, Lixin Han, Ping Yan, Teresa I. Ng, C. Thomas Lin, Hongmei Mo, Akhteruzzaman Molla. (2007) Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Research 73:1, 78-83
CrossRef1500
T. Umemura, H. Muto, E. Tanaka, A. Matsumoto, T. Ichijo, K. Yoshizawa, T. Akamatsu, K. Kiyosawa, . (2007) Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C. Journal of Viral Hepatitis 14:1, 48-54
CrossRef1501
D. POSTHOUWER, E. P. MAUSER-BUNSCHOTEN, K. FISCHER, K. J. VAN ERPECUM, R. J. DE KNEGT. (2007) Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. Journal of Thrombosis and Haemostasis 5:1, 25-30
CrossRef1502
Robert S Brown. (2007) Customizing treatment to patient populations. Nature Clinical Practice Gastroenterology & Hepatology 4, S3-S9
CrossRef1503
D. POSTHOUWER, K. FISCHER, N. DE HEUSDEN, E. P. MAUSER-BUNSCHOTEN. (2007) Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience. Haemophilia 13:1, 98-103
CrossRef1504
Ju Hyun Kim. (2007) Treatment of Chronic Hepatitis C Virus Infection in Older Adults. The Korean Journal of Hepatology 13:3, 432
CrossRef1505
Youn Ho Kim, Woo Sik Han, Sun Jae Lee, Sung Nam Oh, Do won Choi, Kwan Soo Byun, Jong Eun Yeon. (2007) A Case of Vasculitis in Chronic Hepatitis C Patient Treated with Pegylated Interferon Alpha-2a and Ribavirin. The Korean Journal of Hepatology 13:3, 419
CrossRef1506
Yoshio Sumida, Takako Wada, Naohisa Yoshida, Kyoko Sakai, Kazuyuki Kanemasa. (2007) Efficacy of a tailored regimen of peginterferon α2b/ribavirin therapy for chronic hepatitis C, in which the treatment was maintained for 44 weeks after HCV RNA became undetectable at 5-24 weeks post initiation. Kanzo 48:8, 380-381
CrossRef1507
Hussein H. Aly, Koichi Watashi, Makoto Hijikata, Hiroyasu Kaneko, Yasutugu Takada, Hiroto Egawa, Shinji Uemoto, Kunitada Shimotohno. (2007) Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. Journal of Hepatology 46:1, 26-36
CrossRef1508
L DEMELIA, A CIVOLANI, D MURGIA, A MURRU, O SORBELLO, M RIZZETTO. (2007) Tolerability of Peg interferon-α2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency. Journal of Hepatology 46:1, 171-173
CrossRef1509
C. R. Fumaz, J. A. Muñoz-Moreno, A. L. Ballesteros, R. Paredes, M. J. Ferrer, A. Salas, D. Fuster, E. Masmitjà, N. Pérez-Álvarez, G. Gómez, C. Tural, B. Clotet. (2007) Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 19:1, 138-145
CrossRef1510
Gary P. Jeffrey, Gerry MacQuillan, Fern Chua, Sam Galhenage, Judith Bull, Emma Young, Gary Hulse, George O'Neil. (2007) Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 45:1, 111-117
CrossRef1511
Yasuji Arase, Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hitomi Sezaki, Hiromi Yatsuji, Mariko Kobayashi, Kenji Ikeda, Hiromitsu Kumada. (2007) Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C. Internal Medicine 46:22, 1827-1832
CrossRef1512
Hoofnagle, Jay H., Seeff, Leonard B., . (2006) Peginterferon and Ribavirin for Chronic Hepatitis C. New England Journal of Medicine 355:23, 2444-2451
Full Text1513
Gloria Gonzalez-Aseguinolaza, Julien Crettaz, Laura Ochoa, Itziar Otano, Rafael Aldabe, Astrid Paneda. (2006) Gene therapy for viral hepatitis. Expert Opinion on Biological Therapy 6:12, 1263-1278
CrossRef1514
Sheng-Shun Yang, Lin-Shien Fu, Chi-Sen Chang, Hong-Zen Yeh, Gran-Hum Chen, Jia-Horng Kao. (2006) Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:12, 1789-1793
CrossRef1515
Inmaculada Fernández, Juan Carlos Meneu, Francisco Colina, Ignacio García, Raquel Muñoz, Gregorio Castellano, Antonio Fuertes, Manuel Abradelo, Carlos Lumbreras, Enrique Moreno, José Antonio Solís-Herruzo. (2006) Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transplantation 12:12, 1805-1812
CrossRef1516
M. Trapero Marugán, R. Moreno Otero. (2006) Aspectos actuales y perspectivas de futuro del tratamiento de las hepatitis virales. Medicine - Programa de Formación Médica Continuada Acreditado 9:69, 4443-4449
CrossRef1517
Anne Boulestin, Nassim Kamar, Karine Sandres-Sauné, Laurent Alric, Jean-Pierre Vinel, Lionel Rostaing, Jacques Izopet. (2006) Pegylation of IFN- α and Antiviral Activity. Journal of Interferon & Cytokine Research 26:12, 849-853
CrossRef1518
Steve Brocchini, Sibu Balan, Antony Godwin, Ji-Won Choi, Mire Zloh, Sunil Shaunak. (2006) PEGylation of native disulfide bonds in proteins. Nature Protocols 1:5, 2241-2252
CrossRef1519
Richard A. Del Rio, Anthony B. Post, Mendel E. Singer. (2006) Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 44:6, 1598-1606
CrossRef1520
Ming-Lung Yu, Chia-Yen Dai, Li-Po Lee, Nei-Jen Hou, Ming-Yen Hsieh, Jee-Fu Huang, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang. (2006) A 24-week course of high-dose interferon-? plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver International 26:10, 1187-1195
CrossRef1521
Sharon J Hutchinson, Sheila M Bird, David J Goldberg. (2006) Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications. Expert Review of Pharmacoeconomics & Outcomes Research 6:6, 627-639
CrossRef1522
Vincenzo Mazzaferro, Raffaele Romito, Marcello Schiavo, Luigi Mariani, Tiziana Camerini, Sherrie Bhoori, Lorenzo Capussotti, Fulvio Calise, Riccardo Pellicci, Giulio Belli, Alessandro Tagger, Massimo Colombo, Ferruccio Bonino, Pietro Majno, Josep M. Llovet, . (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:6, 1543-1554
CrossRef1523
David E. Kaplan. (2006) Propagation of hepatitis C virus infection: Elucidating targets for therapeutic intervention. Drug Discovery Today: Disease Mechanisms 3:4, 471-477
CrossRef1524
Stanislas Pol. (2006) Transplantation and viral hepatitis: major progress. Current Opinion in Organ Transplantation 11:6, 579-582
CrossRef1525
Eric Snoeck, Janet R. Wade, Frank Duff, Matthew Lamb, Karin Jorga. (2006) Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. British Journal of Clinical Pharmacology 62:6, 699-709
CrossRef1526
N. K. GATSELIS, S. P. GEORGIADOU, G. K. KOUKOULIS, N. TASSOPOULOS, K. ZACHOU, C. LIASKOS, A. HATZAKIS, G. N. DALEKOS. (2006) Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 24:11-12, 1563-1573
CrossRef1527
Gregory T. Everson, John C. Hoefs, Leonard B. Seeff, Herbert L. Bonkovsky, Deepa Naishadham, Mitchell L. Shiffman, Jeffrey A. Kahn, Anna S. F. Lok, Adrian M. Di Bisceglie, William M. Lee, Jules L. Dienstag, Marc G. Ghany, Chihiro Morishima, . (2006) Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 44:6, 1675-1684
CrossRef1528
Martin Lagging, Ana I. Romero, Johan Westin, Gunnar Norkrans, Amar P. Dhillon, Jean-Michel Pawlotsky, Stefan Zeuzem, Michael von Wagner, Francesco Negro, Solko W. Schalm, Bart L. Haagmans, Carlo Ferrari, Gabriele Missale, Avidan U. Neumann, Elke Verheij-Hart, Kristoffer Hellstrand, . (2006) IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44:6, 1617-1625
CrossRef1529
A. Abergel, C. Hezode, V. Leroy, K. Barange, J. P. Bronowicki, A. Tran, L. Alric, L. Castera, P.-H. Bernard, C. Henquell, H. Lafeuille, S. Ughetto, C. Darcha, M. Chevallier, N. Martineau, S. Dubost, K. Randl, D. Dhumeaux, G. Bommelaer, C. Bonny, . (2006) Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. Journal of Viral Hepatitis 13:12, 811-820
CrossRef1530
Daniel Yerly, Loriana Di Giammarino, Florian Bihl, Andreas Cerny. (2006) Targets of emerging therapies for viral hepatitis B and C. Expert Opinion on Therapeutic Targets 10:6, 833-850
CrossRef1531
Erik De Clercq. (2006) Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 5:12, 1015-1025
CrossRef1532
Janet R. Wade, Eric Snoeck, Frank Duff, Matthew Lamb, Karin Jorga. (2006) Pharmacokinetics of ribavirin in patients with hepatitis C virus. British Journal of Clinical Pharmacology 62:6, 710-714
CrossRef1533
Kazuhiko Koike. (2006) Antiviral treatment of hepatitis C: present status and future prospects. Journal of Infection and Chemotherapy 12:5, 227-232
CrossRef1534
Zeid Kayali, Douglas R. LaBrecque, Warren N. Schmidt. (2006) Treatment of hepatitis C cryoglobulinemia: Mission and challenges. Current Treatment Options in Gastroenterology 9:6, 497-507
CrossRef1535
Raymundo Paraná, Maria Isabel Schinoni, Luiz A. R. de Freitas, Liana Codes, Marla Cruz, Zilton Andrade, Christian Trepo. (2006) Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International 26:9, 1148-1154
CrossRef1536
Sergey Akimov, Oluwatoyin M Adeyemi. (2006) Peginterferon-α 2a in the treatment of chronic hepatitis C. Future Virology 1:6, 689-701
CrossRef1537
Vincent Soriano, Pablo Labarga, Andrés Ruiz-Sancho, Javier Garcia-Samaniego, Pablo Barreiro. (2006) Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 20:17, 2225-2227
CrossRef1538
Muhamad Aly Rifai, David Indest, Jennifer Loftis, Peter Hauser. (2006) Psychiatric management of the hepatitis C patient. Current Treatment Options in Gastroenterology 9:6, 508-519
CrossRef1539
Pablo Saiz De La Hoya-Zamácola, Andrés Marco-Mouriño, Gerardo Clemente-Ricote, Joaquín Portilla-Sogorb, Vicente Boix-Martínez, Óscar Núñez-Martínez, Sergio Reus-Bañuls, Nuria Teixidó i Pérez. (2006) Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Enfermedades Infecciosas y Microbiología Clínica 24:9, 568-575
CrossRef1540
Chao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu, Jing-Houng Wang, Chien-Hung Chen, Tsung-Hui Hu, Kwong-Ming Kee, Kuo-Chin Chang, Po-Lin Tseng, Yi-Hao Yen, Chi-Sin Changchien. (2006) Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver International 26:9, 1079-1086
CrossRef1541
Pablo Saiz de la Hoya-Zamácola, Andrés Marco-Mouriño, Gerardo Clemente-Ricote, Joaquín Portilla-Sogorb, Vicente Boix-Martínez, Óscar Núñez-Martínez, Sergio Reus-Bañuls, Nuria Teixidó i Pérez. (2006) Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 29:9, 551-559
CrossRef1542
Juan Carlos García-Pagán, José Luis Calleja, Rafael Bañares. (2006) Enfermedades hepáticas. Gastroenterología y Hepatología 29, 99-111
CrossRef1543
L. Krekulová, V. Řehák, L. W. Riley. (2006) Structure and functions of hepatitis C virus proteins: 15 years after. Folia Microbiologica 51:6, 665-680
CrossRef1544
Eui-Cheol Shin, Ulrike Seifert, Takanobu Kato, Charles M. Rice, Stephen M. Feinstone, Peter-M. Kloetzel, Barbara Rehermann. (2006) Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. Journal of Clinical Investigation 116:11, 3006-3014
CrossRef1545
G. Narasimhan, T. N. Sargios, R. Kalakuntla, P. Homel, D. J. Clain, N. D. Theise, H. C. Bodenheimer, A. D. Min. (2006) Treatment rates in patients with chronic hepatitis C after liver biopsy. Journal of Viral Hepatitis 13:11, 783-786
CrossRef1546
Ming-Lung Yu, Shi-Ming Lin, Chuan-Mo Lee, Chia-Yen Dai, Wen-Yu Chang, Shinn-Cherng Chen, Li-Po Lee, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Wan-Long Chuang, Yun-Fan Liaw. (2006) A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44:5, 1086-1097
CrossRef1547
R.K. Sharma, S.B. Bansal, A. Gupta, S. Gulati, A. Kumar, N. Prasad. (2006) Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clinical Transplantation 20:6, 677-683
CrossRef1548
Kazuhisa Yuasa, Atsushi Naganuma, Ken Sato, Masanori Ikeda, Nobuyuki Kato, Hitoshi Takagi, Masatomo Mori. (2006) Zinc is a negative regulator of hepatitis C virus RNA replication. Liver International 26:9, 1111-1118
CrossRef1549
Shruti H Mehta, Gregory M Lucas, Lisa B Mirel, Michael Torbenson, Yvonne Higgins, Richard D Moore, David L Thomas, Mark S Sulkowski. (2006) Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 20:18, 2361-2369
CrossRef1550
Norah J. Shire, Paul S. Horn, Susan D. Rouster, Sandra Stanford, M. Elaine Eyster, Kenneth E. Sherman, . (2006) HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology 44:5, 1146-1157
CrossRef1551
M. Soresi, S. Tripi, V. Franco, L. Giannitrapani, A. Alessandri, F. Rappa, O. Vuturo, G. Montalto. (2006) Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver International 26:9, 1119-1125
CrossRef1552
Benjamin L. Shneider, Regino González-Peralta, Eve A. Roberts. (2006) Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. Hepatology 44:5, 1344-1354
CrossRef1553
Jason Grebely, Brian Conway, Jesse D. Raffa, Calvin Lai, Mel Krajden, Mark W. Tyndall. (2006) Hepatitis C virus reinfection in injection drug users. Hepatology 44:5, 1139-1145
CrossRef1554
W.-A. LIN, Y.-H. TARN, S.-L. TANG. (2006) Cost?utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for na
CrossRef1555
David Saadoun, Mathieu Resche-Rigon, Vincent Thibault, Jean-Charles Piette, Patrice Cacoub. (2006) Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis & Rheumatism 54:11, 3696-3706
CrossRef1556
Beat Helbling, Wolfram Jochum, Ivan Stamenic, Marina Knöpfli, Andreas Cerny, J. Borovicka, Jean-Jacques Gonvers, Martin Wilhelmi, Sabine Dinges, Beat Müllhaupt, Alicia Esteban, Beat Meyer-Wyss, Eberhard L. Renner, . (2006) HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon ?-2a and ribavirin. Journal of Viral Hepatitis 13:11, 762-769
CrossRef1557
Lynne Wu, Shyam Kottilil, Richard Lempicki, Jun Yang, Mary McLaughlin, Zonghui Hu, Chad Koratich, Kristin N. Reitano, Catherine A. Rehm, Henry Masur, Brad Wood, David E. Kleiner, Michael A. Polis. (2006) Hepatic Histologic Response (HR) to Combination Therapy among HCV/HIV-Coinfected Individuals: Interferon Induces HR Independent of Sustained Virologic Response (SVR). AIDS Research and Human Retroviruses 22:11, 1091-1098
CrossRef1558
Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, Natsuko Tsuda, Takayuki Yakushijin, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Michio Kato, Harumasa Yoshihara, Kazuhiro Katayama, Shinji Kubota, Taizo Hijioka, Kazunobu Ishibashi, Masahide Oshita, Hideki Hagiwara, Yoshimichi Haruna, Eiji Mita, Shinji Tamura, Norio Hayashi. (2006) Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Journal of Gastroenterology 41:9, 862-872
CrossRef1559
Sanaa M. Kamal. (2006) Genotypic variations around the world: Is hepatitis C virus evolving?. Current Hepatitis Reports 5:4, 142-149
CrossRef1560
Eugene Lin, Yuchi Hwang, Shu-Ching Wang, Z John Gu, Ellson Y Chen. (2006) An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics 7:7, 1017-1024
CrossRef1561
M DIAGOMADRID. (2006) Tratamiento de pacientes genotipo 4. Gastroenterología y Hepatología 29, 146-149
CrossRef1562
Armando Sánchez-Quijano, Eduardo Lissen-Otero. (2006) Tratamiento de las hepatitis víricas (II). Tratamiento de la hepatitis crónica C. Enfermedades Infecciosas y Microbiología Clínica 24:8, 518-526
CrossRef1563
Jean–Pierre Bronowicki, Denis Ouzan, Tarik Asselah, Hervé Desmorat, Jean–Pierre Zarski, Juliette Foucher, Marc Bourlière, Christophe Renou, Albert Tran, Pascal Melin, Christophe Hézode, Michelle Chevalier, Magali Bouvier–Alias, Stéphane Chevaliez, François Montestruc, Isabelle Lonjon–Domanec, Jean–Michel Pawlotsky. (2006) Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin. Gastroenterology 131:4, 1040-1048
CrossRef1564
Diego Rincon, Cristina Ripoll, Oreste Lo Iacono, Magdalena Salcedo, Maria V. Catalina, Emilio Alvarez, Oscar Nuñez, Ana M. Matilla, Gerardo Clemente, Rafael Bañares. (2006) Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis. The American Journal of Gastroenterology 101:10, 2269-2274
CrossRef1565
M. Martinot-Peignoux, L. Comanor, J. M. Minor, M. P. Ripault, B.-N. Pham, N. Boyer, C. Castelnau, N. Giuily, D. Hendricks, Patrick Marcellin. (2006) Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. Journal of Viral Hepatitis 13:10, 701-707
CrossRef1566
M CASADOGOMEZ. (2006) Coste-efectividad de interferón pegilado alfa en el tratamiento de la hepatitis crónica por virus C. Gastroenterología y Hepatología 29, 200-205
CrossRef1567
M GARCIABENGOECHEA. (2006) Situación actual. Perspectivas y vacunación. Gastroenterología y Hepatología 29, 96-100
CrossRef1568
R.J. Andrade. (2006) Manejo de los efectos adversos del tratamiento. Gastroenterología y Hepatología 29, 184-189
CrossRef1569
L. CASTERA, A. CONSTANT, C. HENRY, P. CHAMPBENOIT, P.-H. BERNARD, V. DE LEDINGHEN, J. DEMOTES-MAINARD, P. COUZIGOU. (2006) Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 24:8, 1223-1230
CrossRef1570
R MORILLAS. (2006) Monitorización y biopsia. Gastroenterología y Hepatología 29, 121-124
CrossRef1571
Sean E. Doyle, Heidi Schreckhise, Kien Khuu-Duong, Katherine Henderson, Robert Rosler, Harold Storey, Lena Yao, Hong Liu, Fariba Barahmand-pour, Pallavur Sivakumar, Chung Chan, Carl Birks, Don Foster, Christopher H. Clegg, Perdita Wietzke-Braun, Sabine Mihm, Kevin M. Klucher. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44:4, 896-906
CrossRef1572
M. K. CHAPKO, J. A. DOMINITZ. (2006) Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Alimentary Pharmacology and Therapeutics 24:7, 1067-1077
CrossRef1573
Hendrik W. Reesink, Stefan Zeuzem, Christine J. Weegink, Nicole Forestier, Andre van Vliet, Jeroen van de Wetering de Rooij, Lindsay McNair, Susan Purdy, Robert Kauffman, John Alam, Peter L.M. Jansen. (2006) Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study. Gastroenterology 131:4, 997-1002
CrossRef1574
E. Oton, R. Barcena, J. M. Moreno-Planas, V. Cuervas-Mons, A. Moreno-Zamora, C. Barrios, S. Garcia-Garzon, A. Moreno, E. Boullosa-Grana, E. E. Rubio-Gonzalez, M. Garcia-Gonzalez, C. Blesa, M. L. Mateos. (2006) Hepatitis C Recurrence After Liver Transplantation: Viral and Histologic Response to Full-Dose Peg-Interferon and Ribavirin. American Journal of Transplantation 6:10, 2348-2355
CrossRef1575
Markus Cornberg, Katja Deterding, Michael P Manns. (2006) Present and future therapy for hepatitis C virus. Expert Review of Anti-infective Therapy 4:5, 781-793
CrossRef1576
Mitchell L. Shiffman, Vinod K. Rustgi. (2006) Use of Ribavirin in Patients With Chronic HCV Genotype 1: When Enough Is Really Enough. Gastroenterology 131:4, 1339-1341
CrossRef1577
M ROMEROGOMEZ. (2006) Tratamiento de la hepatitis crónica C por genotipos 2 y 3: revisión sistemática. Gastroenterología y Hepatología 29, 139-145
CrossRef1578
Harald Hofer, Calin Gurguta, Ulrike Bergholz, Petra Steindl-Munda, Peter Ferenci. (2006) Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. Wiener klinische Wochenschrift 118:19-20, 595-600
CrossRef1579
Kevin M. Comar, Richard K. Sterling. (2006) Coinfection with hepatitis C virus and HIV: The challenges of management. Current Hepatitis Reports 5:4, 154-161
CrossRef1580
Yunlong Liu, Milton W. Taylor, Howard J. Edenberg. (2006) Model-based identification of cis-acting elements from microarray data. Genomics 88:4, 452-461
CrossRef1581
Matthew L Cowan, James D Maxwell. (2006) Treatment of hepatitis C virus infection in intravenous drug users. Acta Neuropsychiatrica 18:5, 183-192
CrossRef1582
Helen S. Yee, Sue L. Currie, Jama M. Darling, Teresa L. Wright. (2006) Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. The American Journal of Gastroenterology 101:10, 2360-2378
CrossRef1583
J SALMERONESCOBAR. (2006) Ribavirina y análogos. Gastroenterología y Hepatología 29, 129-134
CrossRef1584
A. CIANCIO, A. PICCIOTTO, C. GIORDANINO, A. SMEDILE, M. TABONE, A. MANCA, G. MARENCO, P. GARBAGNOLI, M. ANDREONI, G. CARITI, G. CALLERI, M. SARTORI, S. CUSUMANO, A. GRASSO, R. RIZZI, M. GALLO, M. BASSO, M. ANSELMO, G. PERCARIO, G. CICCONE, M. RIZZETTO, G. SARACCO. (2006) A randomized trial of pegylated-interferon-?2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology and Therapeutics 24:7, 1079-1086
CrossRef1585
P. Cacoub, E. Rosenthal, P. Halfon, D. Sene, C. Perronne, S. Pol. (2006) Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. Journal of Viral Hepatitis 13:10, 678-682
CrossRef1586
Astrid Knott, Eric Dieperink, Mark L. Willenbring, Sara Heit, Janet M. Durfee, Mary Wingert, James R. Johnson, Paul Thuras, Samuel B. Ho. (2006) Integrated Psychiatric/Medical Care in a Chronic Hepatitis C Clinic: Effect on Antiviral Treatment Evaluation and Outcomes. The American Journal of Gastroenterology 101:10, 2254-2262
CrossRef1587
D. Alvarez, D. T. Dieterich, N. Brau, L. Moorehead, L. Ball, M. S. Sulkowski. (2006) Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. Journal of Viral Hepatitis 13:10, 683-689
CrossRef1588
Cristina Tural i Llàcher. (2006) Aplicabilidad de la cinética del virus de la hepatitis C en el paciente coinfectado por el virus de la inmunodeficiencia humana. Medicina Clínica 127:15, 574-575
CrossRef1589
Jun Gao, Yuping Gong, Ping Zhao, Qing Zhu, Xiaoping Yang, Zhongtian Qi. (2006) Construction and characterization of an HCV-derived multi-epitope peptide antigen containing B-cell HVR1 mimotopes and T-cell conserved epitopes. Science in China Series C: Life Sciences 49:5, 490-499
CrossRef1590
S. ZEUZEM, A. ALBERTI, W. ROSENBERG, P. MARCELLIN, M. DIAGO, F. NEGRO, D. PRATI, C. PUOTI, S. K. ROBERTS, M. L. SHIFFMAN. (2006) Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity. Alimentary Pharmacology and Therapeutics 24:8, 1133-1149
CrossRef1591
J SANCHEZTAPIAS. (2006) Pacientes naïve con genotipo 1. Gastroenterología y Hepatología 29, 135-138
CrossRef1592
Pierluigi Toniutto, Carlo Fabris, Mario Pirisi. (2006) Antiviral treatment of hepatitis C. Expert Opinion on Pharmacotherapy 7:15, 2025-2035
CrossRef1593
Nicasio Mancini, Silvia Carletti, Mario Perotti, Luisa Romanò, Rosellina Di Stefano Craxì, Antonio Craxì, Alessandro R. Zanetti, Massimo Clementi, Roberto Burioni. (2006) Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. Journal of Medical Virology 78:10, 1304-1311
CrossRef1594
Juan Buenestado-García, Manuel Rubio-Rivas, Josep Maria Reñé-Espinet, Carmen Piñol-Felis, Ramón Egido-García, Manuel Rubio-Caballero. (2006) Valor de la respuesta virológica precoz como factor predictivo de respuesta virológica sostenida al tratamiento con interferón α-2b y ribavirina en pacientes con hepatitis crónica C con o sin coinfección por el VIH. Medicina Clínica 127:15, 561-566
CrossRef1595
Tsuyoshi Yamashiro, Naoya Sakamoto, Masayuki Kurosaki, Nobuhiko Kanazawa, Yoko Tanabe, Mina Nakagawa, Cheng-Hsin Chen, Yasuhiro Itsui, Tomoyuki Koyama, Yoshie Takeda, Shinya Maekawa, Nobuyuki Enomoto, Hiroshi Sakugawa, Mamoru Watanabe. (2006) Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. Journal of Gastroenterology 41:8, 750-757
CrossRef1596
Stanislas Pol, Vincent O Mallet. (2006) Improving anti-hepatitis C virus therapy. Expert Opinion on Biological Therapy 6:9, 923-933
CrossRef1597
Ming-Lung Yu, Wan-Long Chuang, Chia-Yen Dai, Li-Po Lee, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Sun-Lung Tsai, Hsing-Tao Kuo. (2006) Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Translational Research 148:3, 120-127
CrossRef1598
Johan Neyts. (2006) Selective inhibitors of hepatitis C virus replication. Antiviral Research 71:2-3, 363-371
CrossRef1599
David Nunes, Richard Saitz, Howard Libman, Debbie M. Cheng, John Vidaver, Jeffrey H. Samet. (2006) Barriers to Treatment of Hepatitis C in HIV/HCV-Coinfected Adults with Alcohol Problems. Alcoholism: Clinical and Experimental Research 30:9, 1520-1526
CrossRef1600
Stéphane Chevaliez, Jean-Michel Pawlotsky. (2006) Clinical virology of hepatitis C virus. Future Virology 1:5, 649-657
CrossRef1601
Muriel R. Gillick. (2006) Molecular Medicine, the Medicare Drug Benefit, and the Need for Cost Control. Journal of the American Geriatrics Society 54:9, 1442-1446
CrossRef1602
Guido Piai, Elisa Scalice, Rosaria Focareta, Fulvia Terracciano, Francesca Romana Filippo, Giovambattista Forte. (2006) From Trials to a Real Hospital Setting: Effectiveness of Pegylated Interferon-α-2b/Ribavirin Combination Therapy for Naïve Chronic Hepatitis C Patients. Digestive Diseases and Sciences 51:9, 1619-1626
CrossRef1603
Pierre-Emmanuel Rautou, Tarik Asselah, David Saadoun, Mich??le Martinot, Dominique Valla, Patrick Marcellin. (2006) Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-??2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. European Journal of Gastroenterology & Hepatology 18:9, 1019-1022
CrossRef1604
T. Kohashi, S. Maekawa, N. Sakamoto, M. Kurosaki, H. Watanabe, Y. Tanabe, C.-H. Chen, N. Kanazawa, M. Nakagawa, S. Kakinuma, T. Yamashiro, Y. Itsui, T. Koyama, N. Enomoto, M. Watanabe. (2006) Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. Journal of Viral Hepatitis 13:9, 582-590
CrossRef1605
D. POSTHOUWER, E. P. MAUSER-BUNSCHOTEN, K. FISCHER, M. MAKRIS. (2006) Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia 12:5, 473-478
CrossRef1606
G. BORRONI, R. CERIANI, M. CAZZANIGA, M. TOMMASINI, M. RONCALLI, C. MALTEMPO, C. FELLINE, F. SALERNO. (2006) Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. Alimentary Pharmacology and Therapeutics 24:5, 797-804
CrossRef1607
Montserrat Puig, Kathleen Mihalik, John C. Tilton, Ollie Williams, Michael Merchlinsky, Mark Connors, Stephen M. Feinstone, Marian E. Major. (2006) CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 44:3, 736-745
CrossRef1608
Jenny O. Smith, Richard K. Sterling. (2006) Hiv coinfection with hepatitis C and hepatitis B. Current Infectious Disease Reports 8:5, 409-418
CrossRef1609
A. A. BUTT, A. C. JUSTICE, M. SKANDERSON, C. GOOD, C. K. KWOH. (2006) Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Alimentary Pharmacology & Therapeutics 24:4, 585-591
CrossRef1610
C. BONNY, H. FONTAINE, T. POYNARD, C. HÉZODE, D. LARREY, P. MARCELLIN, M. BOURLIÈRE, J. P. BRONOWICKI, P. MERLE, J. P. ZARSKI, T. SAPEY, C. GUILLEMARD, S. UGHETTO, C. HENQUELL, C. NICOLAS, C. ROCHE, K. RANDL, G. BOMMELAER, A. ABERGEL. (2006) Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Alimentary Pharmacology & Therapeutics 24:4, 593-600
CrossRef1611
Jeffrey D. Browning. (2006) Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. Hepatology 44:2, 466-471
CrossRef1612
Shigemi Hosogaya, Yukio Ozaki, Nobuyuki Enomoto, Yoshihiro Akahane. (2006) Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C. Translational Research 148:2, 79-86
CrossRef1613
Kavitha Gopal, Timothy C. Johnson, Saraswathi Gopal, Aaron Walfish, Christine T. Bang, Pauline Suwandhi, Helene N. Pena-Sahdala, David J. Clain, Henry C. Bodenheimer, Albert D. Min. (2006) Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44:2, 335-340
CrossRef1614
Barbara Horoldt, Geoffrey Haydon, Katrina O'Donnell, Tracey Dudley, Peter Nightingale, David Mutimer. (2006) Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver International 26:6, 650-659
CrossRef1615
Carla W. Brady, Andrew J. Muir. (2006) The impact of race and ethnicity on the treatment of hepatitis C disease. Current Hepatitis Reports 5:3, 79-85
CrossRef1616
Jennifer E. Layden-Almer, Scott J. Cotler, Thomas J. Layden. (2006) Viral kinetics in the treatment of chronic hepatitis C. Journal of Viral Hepatitis 13:8, 499-504
CrossRef1617
José M. Sánchez–Tapias, Moisés Diago, Pedro Escartín, Jaime Enríquez, Manuel Romero–Gómez, Rafael Bárcena, Javier Crespo, Raúl Andrade, Eva Martínez–Bauer, Ramón Pérez, Milagros Testillano, Ramón Planas, Ricard Solá, Manuel García–Bengoechea, Javier Garcia–Samaniego, Miguel Muñoz–Sánchez, Ricardo Moreno–Otero. (2006) Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. Gastroenterology 131:2, 451-460
CrossRef1618
A. Feliu, J. A. Carrion, A. Massaguer, E. Martinez-Bauer, M. Garcia-Retortillo, P. Gonzalez, J. Costa, J. M. Sanchez-Tapias, X. Forns. (2006) Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 13:8, 544-551
CrossRef1619
Hari S. Conjeevaram, Michael W. Fried, Lennox J. Jeffers, Norah A. Terrault, Thelma E. Wiley–Lucas, Nezam Afdhal, Robert S. Brown, Steven H. Belle, Jay H. Hoofnagle, David E. Kleiner, Charles D. Howell. (2006) Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. Gastroenterology 131:2, 470-477
CrossRef1620
Stephen N Wong, Anna SF Lok. (2006) Update on viral hepatitis: 2005. Current Opinion in Internal Medicine 5:4, 392-398
CrossRef1621
Asim S. Khokhar, Valerie Byrnes, Nezam H. Afdhal. (2006) Future therapies for hepatitis C. Current Hepatitis Reports 5:3, 121-128
CrossRef1622
Maya Gambarin-Gelwan, Ira M. Jacobson. (2006) Treatment of nonresponders to standard hepatitis C therapy. Current Hepatitis Reports 5:3, 108-113
CrossRef1623
Mitchell L. Shiffman. (2006) Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Current Hepatitis Reports 5:3, 114-120
CrossRef1624
Omana V. Nainan, Miriam J. Alter, Deanna Kruszon-Moran, Feng-Xiang Gao, Guoliang Xia, Geraldine McQuillan, Harold S. Margolis. (2006) Hepatitis C Virus Genotypes and Viral Concentrations in Participants of a General Population Survey in the United States. Gastroenterology 131:2, 478-484
CrossRef1625
Xiao-Song He, Xuhuai Ji, Matthew B. Hale, Ramsey Cheung, Aijaz Ahmed, Yaqian Guo, Garry P. Nolan, Lawrence M. Pfeffer, Teresa L. Wright, Neil Risch, Robert Tibshirani, Harry B. Greenberg. (2006) Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44:2, 352-359
CrossRef1626
Alessia Ciancio, Antonina Smedile, Chiara Giordanino, Cosimo Colletta, Guido Croce, Massimo Pozzi, Giuseppe Cariti, Antonio Macor, Alberto Biglino, Angelo Di Napoli, Gian Franco Tappero, Massimo Andreoni, Aldo Manca, Giancarlo Prandi, Guido Calleri, Pier Giulio Orsi, Giovannino Ciccone, Mario Rizzetto, Giorgio Saracco, . (2006) Long-Term Follow-Up of Previous Hepatitis C Virus Positive Nonresponders to Interferon Monotherapy Successfully Retreated with Combination Therapy: Are They Really Cured?. The American Journal of Gastroenterology 101:8, 1811-1816
CrossRef1627
Keisuke Hino, Yasuko Murakami, Ayako Nagai, Akira Kitase, Yuichi Hara, Takakazu Furutani, Fenyu Ren, Yuhki Yamaguchi, Kohki Yutoku, Satoyoshi Yamashita, Michiari Okuda, Misako Okita, Kiwamu Okita. (2006) 417–2α-Tocopherol and ascorbic acid attenuates the ribavirin-induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology 21:8, 1269-1275
CrossRef1628
C. Brandao, A. Barone, F. Carrilho, A. Silva, M. Patelli, C. Caramori, R. Focaccia, L. Pereira, M. Pedroso, F. Tatsch, M. Pessoa, . (2006) The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. Journal of Viral Hepatitis 13:8, 552-559
CrossRef1629
John Hornberger, Francesca J. Torriani, Douglas T. Dieterich, Norbert Bräu, Mark S. Sulkowski, Maribel Rodriguez Torres, Jesse Green, Kavita Patel. (2006) Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Journal of Clinical Virology 36:4, 283-291
CrossRef1630
Winita Hardikar, Kathleen B Schwarz. (2006) Treatment options for chronic hepatitis B and C infection in children. Expert Review of Anti-infective Therapy 4:4, 583-591
CrossRef1631
M. TRAPERO-MARUGAN, L. GARCIA-BUEY, C. MUNOZ, N. E. QUINTANA, J. A. MORENO-MONTEAGUDO, M. J. BORQUE, M. J. FERNANDEZ, F. R. SALVANES, J. MEDINA, R. MORENO-OTERO. (2006) Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Alimentary Pharmacology and Therapeutics 24:1, 117-128
CrossRef1632
N. Fujita, M. Kaito, M. Kai, R. Sugimoto, H. Tanaka, S. Horiike, M. Konishi, M. Iwasa, S. Watanabe, Y. Adachi. (2006) Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. Journal of Viral Hepatitis 13:7, 441-448
CrossRef1633
Esther Voigt, Christian Schulz, Gerd Klausen, Joerg Goelz, Stefan Mauss, Guenther Schmutz, Heiko Jessen, Lutwin Weitner, Antonius Mutz, Dietmar Schranz, Juergen K. Rockstroh, for the KAAD study group. (2006) Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection 53:1, 36-42
CrossRef1634
S. Ramia, J. Eid-Fares. (2006) Distribution of hepatitis C virus genotypes in the Middle East. International Journal of Infectious Diseases 10:4, 272-277
CrossRef1635
Liana Fraenkel, Sarah McGraw, Suchat Wongcharatrawee, Guadalupe Garcia-Tsao. (2006) Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Education and Counseling 62:1, 148-155
CrossRef1636
James R. Burton, Hugo R. Rosen. (2006) Treatment of HCV recurrence: Do the pretransplantation rules apply?. Liver Transplantation 12:7, 1044-1048
CrossRef1637
Yuchi Hwang, Ellson Y Chen, Z John Gu, Wan-Long Chuang, Ming-Lung Yu, Ming-Yang Lai, You-Chen Chao, Chuan-Mo Lee, Jing-Houng Wang, Chia-Yen Dai, Monica Shian-Jy Bey, Ya-Tang Liao, Pei-Jer Chen, Ding-Shinn Chen. (2006) Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics 7:5, 697-709
CrossRef1638
A. Moreno, R. Barcena, S. Garcia-Garzon, L. Moreno, C. Quereda, A. Muriel, J. Zamora, M. L. Mateos, M. J. Perez-Elias, A. Antela, S. Diz, A. Moreno, S. Moreno. (2006) Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus*. Journal of Viral Hepatitis 13:7, 466-473
CrossRef1639
Jean-Pierre Bronowicki. (2006) Traitements antiviraux au cours de la cirrhose virale C. Gastroentérologie Clinique et Biologique 30:6-7, 899-902
CrossRef1640
Tony Wang, Lawrence M. Blatt, Scott D. Seiwert. (2006) Immunomodulatory Activities of IFN-γ1b in Combination with Type I IFN: Implications for the Use of IFN-γ1b in the Treatment of Chronic HCV Infections. Journal of Interferon & Cytokine Research 26:7, 473-483
CrossRef1641
A. Chris Krueger, Darold L. Madigan, Wen W. Jiang, Warren M. Kati, Dachun Liu, Yaya Liu, Clarence J. Maring, Sherie Masse, Keith F. McDaniel, Tim Middleton, Hongmei Mo, Akhteruzzaman Molla, Debra Montgomery, John K. Pratt, Todd W. Rockway, Rong Zhang, Dale J. Kempf. (2006) Inhibitors of HCV NS5B polymerase: Synthesis and structure–activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides. Bioorganic & Medicinal Chemistry Letters 16:13, 3367-3370
CrossRef1642
Antonio Picardi, Delia D'Avola, Umberto Vespasiani Gentilucci, Giovanni Galati, Enrica Fiori, Sandro Spataro, Antonella Afeltra. (2006) Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes/Metabolism Research and Reviews 22:4, 274-283
CrossRef1643
C. Berg, F. L. Goncales, D. E. Bernstein, H. Sette, J. Rasenack, M. Diago, D. M. Jensen, P. Graham, G. Cooksley. (2006) Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. Journal of Viral Hepatitis 13:7, 435-440
CrossRef1644
Christian Müller. (2006) Chronic Hepatitis B and C – current treatment and future therapeutic prospects. Wiener Medizinische Wochenschrift 156:13-14, 391-396
CrossRef1645
B. Meyer-Wyss, P. Rich, Hp Egger, B. Helbling, B. Mullhaupt, C. Rammert, J.-J. Gonvers, C. Oneta, D. Criblez, L. Rossi, J. Borovicka, C. Meyenberger, M. Arn, E. L. Renner, . (2006) Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 mug/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. Journal of Viral Hepatitis 13:7, 457-465
CrossRef1646
GianPiero Benetti, Mauro Borzio, Giuliano Ramella, Giorgio Bellati, Silvia Fargion, Alberto Colombo, Guido Croce, Carlo Iamoletti, Federico Balzola, Mario Rizzetto, . (2006) Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. Internal and Emergency Medicine 1:2, 113-118
CrossRef1647
C. L. Cooper, S. Al-Bedwawi, C. Lee, G. Garber. (2006) Rate of Infectious Complications during Interferon-Based Therapy for Hepatitis C Is Not Related to Neutropenia. Clinical Infectious Diseases 42:12, 1674-1678
CrossRef1648
D. L. Thomas. (2006) Acute Hepatitis C: A Window of Opportunity. Clinical Infectious Diseases 42:12, 1671-1673
CrossRef1649
B. H. McGovern, A. Wurcel, A. Y. Kim, J. S. zur Wiesch, I. Bica, M. T. Zaman, J. Timm, B. D. Walker, G. M. Lauer. (2006) Acute Hepatitis C Virus Infection in Incarcerated Injection Drug Users. Clinical Infectious Diseases 42:12, 1663-1670
CrossRef1650
Valérie Paradis, Tarik Asselah, Delphine Dargere, Marie–Pierre Ripault, Michèle Martinot, Nathalie Boyer, Dominique Valla, Patrick Marcellin, Pierre Bedossa. (2006) Serum Proteome to Predict Virologic Response in Patients With Hepatitis C Treated by Pegylated Interferon Plus Ribavirin. Gastroenterology 130:7, 2189-2197
CrossRef1651
Michael R. Charlton, Paul J. Pockros, Stephen A. Harrison. (2006) Impact of obesity on treatment of chronic hepatitis C. Hepatology 43:6, 1177-1186
CrossRef1652
Homayon Sidiq, Victor Ankoma-Sey. (2006) HIV-Related Liver Disease: Infections Versus Drugs. Gastroenterology Clinics of North America 35:2, 487-505
CrossRef1653
S. Zeuzem. (2006) Individualisierte Behandlung der chronischen Hepatitis C. Der Internist 47:S01, S20-S25
CrossRef1654
C. D. Howell, L. S. Jeffers, W. Cassidy, K. R. Reddy, S. Hu, J. S. Lee. (2006) Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. Journal of Viral Hepatitis 13:6, 371-376
CrossRef1655
Mitsuhiko Moriyama, Yasuyuki Arakawa. (2006) Treatment of interferon-α for chronic hepatitis C. Expert Opinion on Pharmacotherapy 7:9, 1163-1179
CrossRef1656
Rise Stribling, Norman Sussman, John M. Vierling. (2006) Treatment of Hepatitis C Infection. Gastroenterology Clinics of North America 35:2, 463-486
CrossRef1657
Keiichi Fujiwara, Osamu Yokosuka, Fumihiko Komine, Mitsuhiko Moriyama, Naoya Kato, Haruhiko Yoshida, Naohide Tanaka, Fumio Imazeki, Yasushi Shiratori, Yasuyuki Arakawa, Masao Omata, . (2006) Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Liver International 26:5, 520-528
CrossRef1658
Masatoshi Akamatsu, Haruhiko Yoshida, Shuichiro Shiina, Takuma Teratani, Shuntaro Obi, Ryousuke Tateishi, Norio Mine, Yuji Kondo, Takao Kawabe, Masao Omata. (2006) Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver International 26:5, 536-542
CrossRef1659
Rafik Samuel, Robert Bettiker, Byungse Suh. (2006) Antiretroviral therapy 2006: Pharmacology, applications, and special situations. Archives of Pharmacal Research 29:6, 431-458
CrossRef1660
Gadi Lalazar, Yaron Ilan. (2006) Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 4:3, 377-385
CrossRef1661
C.-H. Hung, C.-M. Lee, S.-N. Lu, J.-H. Wang, T.-H. Hu, H.-D. Tung, C.-H. Chen, W.-J. Chen, C.-S. Changchien. (2006) Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Journal of Viral Hepatitis 13:6, 409-414
CrossRef1662
Dominique Thabut, Sophie Le Calvez, Vincent Thibault, Julien Massard, Mona Munteanu, Vincent Di Martino, Vlad Ratziu, Thierry Poynard. (2006) Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?. The American Journal of Gastroenterology 101:6, 1260-1267
CrossRef1663
Edward L. Krawitt, Stuart R. Gordon, Norman D. Grace, Takamaru Ashikaga, Mary Ann Ray, Melissa Palmer, Joseph C. Yarze, Sam Moskowitz, . (2006) A Study of Low Dose Peginterferon Alpha-2b with Ribavirin for the Initial Treatment of Chronic Hepatitis C. The American Journal of Gastroenterology 101:6, 1268-1273
CrossRef1664
Xandra Volkmann, Markus Cornberg, Heiner Wedemeyer, Frank Lehner, Michael P. Manns, Klaus Schulze-Osthoff, Heike Bantel. (2006) Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 43:6, 1311-1316
CrossRef1665
Kaku Goto, Koichi Watashi, Takayuki Murata, Takayuki Hishiki, Makoto Hijikata, Kunitada Shimotohno. (2006) Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochemical and Biophysical Research Communications 343:3, 879-884
CrossRef1666
C. O'Brien. (2006) Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C. Journal of Viral Hepatitis 13:s1, 6-14
CrossRef1667
B. R. Bacon. (2006) Assessing evidence from clinical trials in chronic hepatitis C. Journal of Viral Hepatitis 13:s1, 1-5
CrossRef1668
C. P. Desmond, S. K. Roberts, F. Dudley, J. Mitchell, C. Day, S. Nguyen, S. Pianko. (2006) Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. Journal of Viral Hepatitis 13:5, 311-315
CrossRef1669
John G. McHutchison, Michael P. Manns, Dan L. Longo. (2006) Definition and management of anemia in patients infected with hepatitis C virus. Liver International 26:4, 389-398
CrossRef1670
S. Boccato, R. Pistis, F. Noventa, M. Guido, L. Benvegnu, A. Alberti. (2006) Fibrosis progression in initially mild chronic hepatitis C. Journal of Viral Hepatitis 13:5, 297-302
CrossRef1671
Mitchell L. Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert Reindollar, Daniele Prati, Maribel Rodríguez–Torres, Pilar Lardelli, Steven Blotner, Stefan Zeuzem. (2006) Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels. Clinical Gastroenterology and Hepatology 4:5, 645-652
CrossRef1672
Donald M. Jensen, Timothy R. Morgan, Patrick Marcellin, Paul J. Pockros, K. Rajender Reddy, Stephanos J. Hadziyannis, Peter Ferenci, Andrew M. Ackrill, Bernard Willems. (2006) Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology 43:5, 954-960
CrossRef1673
Bhupinder S. Anand, Sue Currie, Eric Dieperink, Edmund J. Bini, Hui Shen, Samuel B. Ho, Teresa Wright. (2006) Alcohol Use and Treatment of Hepatitis C Virus: Results of a National Multicenter Study. Gastroenterology 130:6, 1607-1616
CrossRef1674
A. J. Muir, P. B. Sylvestre, D. C. Rockey. (2006) Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. Journal of Viral Hepatitis 13:5, 322-328
CrossRef1675
Robert E. Lanford, Bernadette Guerra, Helen Lee, Deborah Chavez, Kathleen M. Brasky, Catherine B. Bigger. (2006) Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics. Hepatology 43:5, 961-972
CrossRef1676
Andrew SH Lai, Kar Neng Lai. (2006) Viral nephropathy. Nature Clinical Practice Nephrology 2:5, 254-262
CrossRef1677
Gary L. Davis. (2006) Tailoring antiviral therapy in hepatitis C. Hepatology 43:5, 909-911
CrossRef1678
P PUGNALE, P LATORRE, C ROSSI, K CROVATTO, V PAZIENZA, A GOTTARDI, F NEGRO. (2006) Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells. Journal of Virological Methods 133:2, 195-204
CrossRef1679
Vijayan Balan, Marianne J. Rosati, Machiko H. Anderson, Jorge Rakela. (2006) Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy. Digestive Diseases and Sciences 51:5, 956-959
CrossRef1680
Andrés Ruiz-Sancho, Vicente Soriano. (2006) Coinfección por el VIH y el virus de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 24:5, 335-346
CrossRef1681
Andrew H. Talal, Ruy M. Ribeiro, Kimberly A. Powers, Michael Grace, Constance Cullen, Musaddeq Hussain, Marianthi Markatou, Alan S. Perelson. (2006) Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43:5, 943-953
CrossRef1682
Vijayan Balan. (2006) Albumin-interferon-α in the treatment of chronic hepatitis C. Future Virology 1:3, 269-278
CrossRef1683
S Hopkins, J Lambourne, G Farrell, L McCullagh, M Hennessy, S Clarke, F Mulcahy, C Bergin. (2006) Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals*. HIV Medicine 7:4, 248-254
CrossRef1684
Gil Weitzman, Ira Jacobson. (2006) Peginterferon α-2b in the treatment of hepatitis C. Future Virology 1:3, 279-292
CrossRef1685
R. S. Brown. (2006) Evaluating the evidence from clinical trials in chronic hepatitis C. Journal of Viral Hepatitis 13:s1, 15-25
CrossRef1686
Sanaa M. Kamal, Khairy N. Moustafa, Jason Chen, Jutta Fehr, Azza Abdel Moneim, Khalifa E. Khalifa, Leila A. El Gohary, Amr H. Ramy, Mohamed A. Madwar, Jens Rasenack, Nezam H. Afdhal. (2006) Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology 43:5, 923-931
CrossRef1687
Ricard Solà, Josep Antón Galeras, Silvia Montoliu, Cristina Tural, Lluis Force, Sandra Torra, Santiago Montull, Eduardo Rodríguez De Castro, Susanna Coll, Daniel Fuster, Pilar Barrufet, Guillem Sirera, Maria Dolors Giménez, Bonaventura Clotet, Ramón Planas. (2006) Poor Response to Hepatitis C Virus (HCV) Therapy in HIV- and HCV-Coinfected Patients Is Not Due to Lower Adherence to Treatment. AIDS Research and Human Retroviruses 22:5, 393-400
CrossRef1688
Susan L. Zickmund, Cindy L. Bryce, Julie A. Blasiole, Laura Shinkunas, Douglas R. LaBrecque, Robert M. Arnold. (2006) Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. European Journal of Gastroenterology & Hepatology 18:4, 381-388
CrossRef1689
J. D. Scott, B. J. McMahon, D. Bruden, D. Sullivan, C. Homan, C. Christensen, D. R. Gretch. (2006) High Rate of Spontaneous Negativity for Hepatitis C Virus RNA after Establishment of Chronic Infection in Alaska Natives. Clinical Infectious Diseases 42:7, 945-952
CrossRef1690
Robert J. Fontana. (2006) Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?. Gastroenterology 130:4, 1357-1362
CrossRef1691
Claire Wartelle-Bladou, Jean-Pierre Arpurt, Christophe Renou, Alexandre Pariente, Didier Pillon, Bernard Nalet, Magali Picon, André Glibert, Michel Chousterman, Denis Grasset, Thierry Morin, Pierre Bernard, Daniel Fischer, Mohamed Ramdani, Evelyne Lagier, Michel Rotily, Michel Rotily. (2006) High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 30:4, 525-532
CrossRef1692
Shiro Murashima, Masatoshi Tanaka, Makoto Haramaki, Shigeru Yutani, Yutaka Nakashima, Kazunori Harada, Tatsuya Ide, Ryukichi Kumashiro, Michio Sata. (2006) A Decrease in AFP Level Related to Administration of Interferon in Patients with Chronic Hepatitis C and a High Level of AFP. Digestive Diseases and Sciences 51:4, 808-812
CrossRef1693
Wulf O. Bocher, Marcus Schuchmann, Ralph Link, Heribert Hillenbrand, Fareed Rahman, Martin Sprinzl, Jonas Mudter, Hanns F. Lohr, Peter R. Galle. (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver International 26:3, 319-325
CrossRef1694
Eva Herrmann, Stefan Zeuzem. (2006) The kinetics of hepatitis C virus. European Journal of Gastroenterology & Hepatology 18:4, 339-342
CrossRef1695
Emma Paulon, Nikolai V. Naoumov. (2006) Individualization of antiviral treatment regimens for chronic hepatitis C. European Journal of Gastroenterology & Hepatology 18:4, 321-325
CrossRef1696
Gloria Taliani, Giulia Gemignani, Carlo Ferrari, Antonio Aceti, Dario Bartolozzi, Pier Luigi Blanc, Marco Capanni, Francesco Esperti, Paolo Forte, Vincenzo Guadagnino, Terenzio Mari, Nicoletta Marino, Stefano Milani, Caterina Pasquazzi, Floriano Rosina, Danilo Tacconi, Mario Toti, Anna Linda Zignego, Luca Messerini, Tommaso Stroffolini. (2006) Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients. Gastroenterology 130:4, 1098-1106
CrossRef1697
Gregory M. Asnis, Richard De La Garza. (2006) Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches. Journal of Clinical Gastroenterology 40:4, 322-335
CrossRef1698
M. Heydtmann, D. Freshwater, T. Dudley, V. Lai, S. Palmer, S. Hubscher, D. Mutimer. (2006) Pegylated Interferon Alpha-2b for Patients with HCV Recurrence and Graft Fibrosis Following Liver Transplantation. American Journal of Transplantation 6:4, 825-833
CrossRef1699
M. Friedrich-Rust, S. Zeuzem. (2006) Therapie der Hepatitis C. Der Gastroenterologe 1:2, 126-132
CrossRef1700
S. Chainuvati, S. K. Khalid, S. Kancir, M. Shea, J. Edwards, M. Sernyak, S. Wongcharatrawee, G. Garcia-Tsao. (2006) Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders+. Journal of Viral Hepatitis 13:4, 235-241
CrossRef1701
Francois H. T. Duong, Verena Christen, Magdalena Filipowicz, Markus H. Heim. (2006) S-adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology 43:4, 796-806
CrossRef1702
Miguel Santin, Evelyn Shaw, M. Jose Garcia, Antonio Delejido, Eduardo Rodriguez De Castro, Rosa Rota, Jordi Altés, Francisco Baguena, Silvia Valero, Montserrat Sala, Aurora Casanova. (2006) Efficacy and Safety of Pegylated Interferon- α 2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients. AIDS Research and Human Retroviruses 22:4, 315-320
CrossRef1703
A. Moghaddam, N. Reinton, O. Dalgard. (2006) A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a. Journal of Viral Hepatitis 13:4, 222-229
CrossRef1704
Chun-Jen Liu, Ming-Yang Lai, You-Chen Chao, Li-Ying Liao, Sien-Sing Yang, Tun-Jen Hsiao, Tsai-Yuan Hsieh, Chih-Lin Lin, Jui-Ting Hu, Chi-Ling Chen, Per-Jer Chen, Jia-Horng Kao, Ding-Shinn Chen. (2006) Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study. Hepatology 43:4, 742-749
CrossRef1705
Thomas Berg, Michael von Wagner, Samer Nasser, Christoph Sarrazin, Tobias Heintges, Tilman Gerlach, Peter Buggisch, Tobias Goeser, Jens Rasenack, Gerd R. Pape, Wolfgang E. Schmidt, Birgit Kallinowski, Hartwig Klinker, Ulrich Spengler, Peter Martus, Ulrich Alshuth, Stefan Zeuzem. (2006) Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology 130:4, 1086-1097
CrossRef1706
Lucy E. Wilson, Michael Torbenson, Jacquie Astemborski, Hawazin Faruki, Charles Spoler, Rudra Rai, Shruti Mehta, Gregory D. Kirk, Kenrad Nelson, Nezam Afdhal, David L. Thomas. (2006) Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 43:4, 788-795
CrossRef1707
W. L. Irving, S. Smith, R. Cater, S. Pugh, K. R. Neal, C. A. C. Coupland, S. D. Ryder, B. J. Thomson, M. Pringle, M. Bicknell, J. Hippisley-Cox. (2006) Clinical pathways for patients with newly diagnosed hepatitis C - What actually happens. Journal of Viral Hepatitis 13:4, 264-271
CrossRef1708
Adil Javed, Anthony T. Reder. (2006) Therapeutic role of beta-interferons in multiple sclerosis. Pharmacology & Therapeutics 110:1, 35-56
CrossRef1709
B BADINDEMONTJOYE, I FERRAND, P SOGNI, P PODEVIN. (2006) L’hépatologue, le psychiatre et les patients ayant une hépatite C. L'Encéphale 32:2, 198-203
CrossRef1710
Adrian M. Di Bisceglie, Xiaofeng Fan, Thomas Chambers, Janice Strinko. (2006) Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responder. Journal of Medical Virology 78:4, 446-451
CrossRef1711
U. MIHM, E. HERRMANN, C. SARRAZIN, S. ZEUZEM. (2006) Review article: predicting response in hepatitis C virus therapy. Alimentary Pharmacology and Therapeutics 23:8, 1043-1054
CrossRef1712
Jamie C. Mandac, Sonal Chaudhry, Kenneth E. Sherman, Yaron Tomer. (2006) The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology 43:4, 661-672
CrossRef1713
M. A. Rifai. (2006) Hepatitis C Screening and Treatment Outcomes in Patients With Substance Use/Dependence Disorders. Psychosomatics 47:2, 112-121
CrossRef1714
van der Eijk, Annemiek A., Vrolijk, Jan Maarten, Haagmans, Bart L., . (2006) Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C. New England Journal of Medicine 354:12, 1323-1324
Full Text1715
Furqaan Ahmed, Ira M. Jacobson. (2006) Treatment of Relapsers after Combination Therapy for Chronic Hepatitis C. Infectious Disease Clinics of North America 20:1, 137-153
CrossRef1716
Amrita Sethi, Mitchell L. Shiffman. (2006) Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response. Infectious Disease Clinics of North America 20:1, 115-135
CrossRef1717
María Luisa Montes-Ramírez, Manuel Rodríguez-Zapata. (2006) Alteraciones tiroideas tras el tratamiento con interferón pegilado y ribavirina: diferencias entre coinfectados y no coinfectados por el VIH. Enfermedades Infecciosas y Microbiología Clínica 24:3, 213-214
CrossRef1718
C. d'Arondel, M. Munteanu, J. Moussalli, V. Thibault, S. Naveau, A. Simon, D. Messous, R. Morra, C. Blot, T. Poynard. (2006) A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. Journal of Viral Hepatitis 13:3, 182-189
CrossRef1719
Iftihar Koksal. (2006) Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:3, 491-494
CrossRef1720
A. Kuo, N. A. Terrault. (2006) Management of Hepatitis C in Liver Transplant Recipients. American Journal of Transplantation 6:3, 449-458
CrossRef1721
H. Hagan, M. H. Latka, J. V. Campbell, E. T. Golub, R. S. Garfein, D. A. Thomas, F. Kapadia, S. A. Strathdee, . (2006) Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities. Clinical Infectious Diseases 42:5, 669-672
CrossRef1722
Michael R Beard, Brett E Jones. (2006) Hepatitis C virus and oxidative stress: a dangerous liaison. Future Virology 1:2, 223-232
CrossRef1723
Sangik Oh, Nezam H. Afdhal. (2006) Antiviral Therapy for Treatment Naïve Patients with Hepatitis C Virus. Infectious Disease Clinics of North America 20:1, 99-113
CrossRef1724
Sanaa M. Kamal, Amr E. Fouly, Refaat R. Kamel, Bridgette Hockenjos, Ahmed Al Tawil, Khalifa E. Khalifa, Qi He, Margaret J. Koziel, Khairy M. El Naggar, Jens Rasenack, Nezam H. Afdhal. (2006) Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response. Gastroenterology 130:3, 632-638
CrossRef1725
Anne Boulestin, Nassim Kamar, Karine Sandres-Sauné, Florence Legrand-Abravanel, Laurent Alric, Jean-Pierre Vinel, Lionel Rostaing, Jacques Izopet. (2006) Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. Journal of Medical Virology 78:3, 365-371
CrossRef1726
Norio Hayashi, Tetsuo Takehara. (2006) Antiviral therapy for chronic hepatitis C: past, present, and future. Journal of Gastroenterology 41:1, 17-27
CrossRef1727
Jean-Michel Pawlotsky. (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology 43:S1, S207-S220
CrossRef1728
Mitchell L. Shiffman. (2006) Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Current Gastroenterology Reports 8:1, 46-52
CrossRef1729
Robert P. Perrillo. (2006) Therapy of hepatitis B — Viral suppression or eradication?. Hepatology 43:S1, S182-S193
CrossRef1730
Omar M.E. Abdel-Salam. (2006) Antinociceptive and behavioral effects of ribavirin in mice. Pharmacology Biochemistry and Behavior 83:2, 230-238
CrossRef1731
L. Alric, S. Thebault, J.-M. Peron, P. Balard, S. Metivier, B. Pipy, J. Izopet, J.-P. Vinel. (2006) Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1. Journal of Viral Hepatitis 13:2, 139-144
CrossRef1732
Johannes Wiegand, Peter Buggisch, Wulf Boecher, Stefan Zeuzem, Cornelia M. Gelbmann, Thomas Berg, Wolfgang Kauffmann, Birgit Kallinowski, Markus Cornberg, Elmar Jaeckel, Heiner Wedemeyer, Michael P. Manns, . (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology 43:2, 250-256
CrossRef1733
Diana Sylvestre. (2006) Hepatitis C treatment in drug users: perception versus evidence. European Journal of Gastroenterology & Hepatology 18:2, 129-130
CrossRef1734
SANJEEV ARORA, CHRISTOPHER O'BRIEN, STEFAN ZEUZEM, MITCHELL L SHIFFMAN, MOISES DIAGO, ALBERT TRAN, PAUL J POCKROS, ROBERT W REINDOLLAR, EDWARD GANE, KAVITA PATEL, NEIL WINTFELD, JESSE GREEN. (2006) Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: Impact on health-related quality of life. Journal of Gastroenterology and Hepatology 21:2, 406-412
CrossRef1735
Mical S. Campbell. (2006) Hepatitis C: who should be treated?. Pharmacoepidemiology and Drug Safety 15:2, 77-79
CrossRef1736
E. FORMANN, P. STEINDL-MUNDA, H. HOFER, W. JESSNER, U. BERGHOLZ, C. GURGUTA, P. FERENCI. (2006) Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Alimentary Pharmacology and Therapeutics 23:4, 507-511
CrossRef1737
Jules L. Dienstag. (2006) Looking to the Future: New Agents for Chronic Hepatitis B. The American Journal of Gastroenterology 101:S1, S19-S25
CrossRef1738
C. Bradley Hare, Jonathan A. Morris, Alice Chu, Vincent Gotz, Jacqueline J. Loveland, David Hodes, Winslow Klaskala. (2006) Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. Pharmacoepidemiology and Drug Safety 15:2, 71-76
CrossRef1739
Yifei Liu, Christine Xu, Rongzi Yan, Charmaine Lim, Li-Tain Yeh, Chin-chung Lin. (2006) Sensitive and specific LC–MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. Journal of Chromatography B 832:1, 17-23
CrossRef1740
Philippe Halfon, Guillaume Pénaranda, Marc Bourlière, Hacène Khiri, Marie-France Masseyeff, Denis Ouzan. (2006) Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: Implications for clinical management of patients with chronic hepatitis C virus infection. Journal of Medical Virology 78:2, 208-215
CrossRef1741
Geert Robaeys, Hans Van Vlierberghe, Catharina Mathe??, Marc Van Ranst, Liesbeth Bruckers. (2006) Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. European Journal of Gastroenterology & Hepatology 18:2, 159-166
CrossRef1742
A. A. van der Eijk, H. G. M. Niesters, B. E. Hansen, R. A. Heijtink, H. L. A. Janssen, S. W. Schalm, R. A. de Man. (2006) Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. Journal of Viral Hepatitis 13:2, 96-103
CrossRef1743
S. S. LEE, V. G. BAIN, K. PELTEKIAN, M. KRAJDEN, E. M. YOSHIDA, M. DESCHENES, J. HEATHCOTE, R. J. BAILEY, S. SIMONYI, M. SHERMAN, . (2006) Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Alimentary Pharmacology and Therapeutics 23:3, 397-408
CrossRef1744
Camilla S Graham, Annalee Wells, Tun Liu, Kenneth E Sherman, Marion Peters, Raymond T Chung, Atul K Bhan, Janet Andersen, Margaret James Koziel. (2006) Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 20:3, 345-351
CrossRef1745
Ming-Lung Yu, Chia-Yen Dai, Zu-Yau Lin, Li-Po Lee, Nei-Jen Hou, Ming-Yen Hsieh, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang. (2006) A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver International 26:1, 73-81
CrossRef1746
KWONG-MING KEE, CHUAN-MO LEE, JING-HOUNG WANG, HUNG-DA TUNG, CHI-SIN CHANGCHIEN, SHENG-NAN LU, PEI-WEN WANG. (2006) Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis.. Journal of Gastroenterology and Hepatology 21:1p2, 319-326
CrossRef1747
Gamal Badra, Imam Waked, Carlo Selmi, Saleh M. Saleh, Ahmed El-Shaarawy, Mahmoud Lotfy. (2006) Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis. Clinical and Developmental Immunology 13:1, 11-15
CrossRef1748
Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minoru Tomita, Mitsuhiko Kawaguchi, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori. (2006) Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43:1, 54-63
CrossRef1749
Hirokazu Komeichi, Yasumi Katsuta. (2006) Current Treatment of Hepatitis C and Hepatocellular Carcinoma. Nihon Ika Daigaku Igakkai Zasshi 2:2, 108-114
CrossRef1750
E PEDONE, S BROCCHINI. (2006) Synthesis of two photolabile poly(ethylene glycol) derivatives for protein conjugation. Reactive and Functional Polymers 66:1, 167-176
CrossRef1751
Eva Martínez-Bauer, Javier Crespo, Manuel Romero-Gómez, Ricardo Moreno-Otero, Ricard Solá, Nancy Tesei, Fernando Pons, Xavier Forns, José M. Sánchez-Tapias. (2006) Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 43:1, 72-80
CrossRef1752
Chuan-Mo Lee, Chao-Hung Hung, Sheng-Nan Lu, Jing-Houng Wang, Hung-Da Tung, Wu-Shiung Huang, Chao-Long Chen, Wei-Jen Chen, Chi-Sin Changchien. (2006) Viral Etiology of Hepatocellular Carcinoma and HCV Genotypes in Taiwan. Intervirology 49:1-2, 76-81
CrossRef1753
Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Sachiyo Watahiki, Junko Sato, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2006) Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load. Journal of Medical Virology 78:1, 83-90
CrossRef1754
Tatsuya Fujino, Kazuto Goto, Eiichiro Arimura, Yumiko Sakiyama, Ryosuke Takemoto, Hidehiro Nishi, Toshihiko Miyahara, Kunitaka Fukuizumi, Hideki Saitsu, Hironori Sakai. (2006) An early prognosis for the treatment of Chronic Hepatitis C patients with Pegylated Interferon-.ALPHA.2b plus Ribavirin-Monitoring analysis by the serum HCV core antigen values-. Kanzo 47:7, 355-356
CrossRef1755
J. Wasem, G. Sroczynski, P. Aidelsburger, B. Buchberger, F. Hessel, A. Conrads-Frank, A. Peters-Blöchinger, B. M. Kurth, J. B. Wong, S. Rossol, U. Siebert. (2006) Gesundheitsökonomische Aspekte chronischer Infektionskrankheiten am Beispiel der chronischen Hepatitis C. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 49:1, 57-63
CrossRef1756
Sergio Neri, Davide Pulvirenti, Gaetano Bertino. (2006) Psychiatric Symptoms Induced by??Antiviral Therapy in Chronic??Hepatitis C. Clinical Drug Investigation 26:11, 655-662
CrossRef1757
Jie-Hyun Kim, Kwang-Hyub Han, Kwan Sik Lee, Young Nyun Park, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon. (2006) Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea. Yonsei Medical Journal 47:6, 793
CrossRef1758
Calogero Cammà, Savino Bruno, Vito Di Marco, Danilo Di Bona, Mariagrazia Rumi, Maria Vinci, Chiara Rebucci, Agostino Cividini, Giuseppe Pizzolanti, Ernesto Minola, Mario U. Mondelli, Massimo Colombo, Giovanbattista Pinzello, Antonio Craxfì. (2006) Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43:1, 64-71
CrossRef1759
Jeanne Serpaggi, Marie-Laure Chaix, Dominique Batisse, Caroline Dupont, Anaïs Vallet-Pichard, Hélène Fontaine, Jean-Paul Viard, Christophe Piketty, Elisabeth Rouveix, Christine Rouzioux, Laurence Weiss, Stanislas Pol. (2006) Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 20:2, 233-240
CrossRef1760
Wang-Long Chuang, Ming-Lung Yu, Chia-Yen Dai, Wen-Yu Chang. (2006) Treatment of Chronic Hepatitis C in Southern Taiwan. Intervirology 49:1-2, 99-106
CrossRef1761
Keith Nemergut, Edward C. Littlewood. 2006. Liver Diseases. , 151-201.
CrossRef1762
A. DE GOTTARDI, V. PAZIENZA, P. PUGNALE, F. BRUTTIN, L. RUBBIA-BRANDT, C. E. JUGE-AUBRY, C. A. MEIER, A. HADENGUE, F. NEGRO. (2006) Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Alimentary Pharmacology and Therapeutics 23:1, 107-114
CrossRef1763
Hiroshi Kohno, Shiomi Aimitsu, Mikiya Kitamoto, Yasuyuki Aisaka, Hiroiku Kawakami, Kazuaki Chayama. (2006) Prolonged Negative HCV-RNA Status Led to a Good Outcome in Chronic Hepatitis C Patients with Genotype 1b and Super-High Viral Load. Intervirology 49:6, 362-369
CrossRef1764
Annie Luetkemeyer, C Bradley Hare, John Stansell, Phyllis C Tien, Edwin Charlesbois, Paula Lum, Diane Havlir, Marion Peters. (2006) Clinical Presentation and Course of Acute Hepatitis C Infection in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:1, 31-36
CrossRef1765
Takashi Kumada, Hidenori Toyoda, Takashi Honda, Teiji Kuzuya, Yosiaki Katano, Isao Nakano, Hidemi Goto. (2006) Treatment of Chronic Hepatitis C with Interferon Alone or Combined with Ribavirin in Japan. Intervirology 49:1-2, 112-118
CrossRef1766
B. L. Pearlman. (2006) Hepatitis C Virus Infection in African Americans. Clinical Infectious Diseases 42:1, 82-91
CrossRef1767
Erik De Clercq. (2006) A guided tour through the antiviral drug field. Future Virology 1:1, 19-35
CrossRef1768
Ming-Yang Lai. (2006) Combined Interferon and Ribavirin Therapy for Chronic Hepatitis C in Taiwan. Intervirology 49:1-2, 91-95
CrossRef1769
E. Albanis, S. L. Friedman. (2006) Antifibrotic Agents for Liver Disease. American Journal of Transplantation 6:1, 12-19
CrossRef1770
Satoshi Shakado, Takashi Tanaka, Shinjiro Inomata, Akira Anan, Teruo Matsumoto, Takayuki Hanano, Syuichi Ueda, Daisuke Morihara, Shinya Nishizawa, Yasuaki Takeyama, Masanori Yokoyama, Makoto Irie, Kaoru Iwata, Tetsuro Sohda, Shotaro Sakisaka. (2006) Serum HCV core antigen level is a useful prediction marker of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin in patients with chronic hepatitis C. Kanzo 47:8, 411-412
CrossRef1771
Kwong-Ming Kee, Chuan-Mo Lee, Jing-Houng Wang, Hung-Da Tung, Chi-Sin Changchien, Sheng-Nan Lu, Pei-Wen Wang. (2006) Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. Journal of Gastroenterology and Hepatology 21:1, 319-326
CrossRef1772
C.Y. Eger, E.J. Giltay, J.H.W. Maasen. (2006) No carriers of hepatitis C among operating room personnel in a university hospital setting in The Netherlands. Journal of Hospital Infection 62:1, 114-115
CrossRef1773
Olav Dalgard, Alessandra Mangia. (2006) Short-Term Therapy for Patients with Hepatitis C Virus Genotype??2??or??3 Infection. Drugs 66:14, 1807-1815
CrossRef1774
Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Hiromasa Ishii, Kazuo Kashiwazaki, Jiro Nishida, Takeshi Yoshida, Shigeyuki Zeki, Hideo Yoshida, Yoshioka Masahiro, Yasutaka Inagaki, Naoki Kumagai, Toshifumi Hibi. (2006) Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. The Keio Journal of Medicine 55:3, 111-117
CrossRef1775
Kenji Ikeda, Yasuji Arase, Satoshi Saitoh, Masahiro Kobayashi, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada. (2006) Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center. Intervirology 49:1-2, 82-90
CrossRef1776
John B Wong. (2006) Hepatitis C. PharmacoEconomics 24:7, 661-672
CrossRef1777
Shintaro Abe, Ryoichi Narita, Takeshi Oto, Akinari Tabaru, Makoto Otsuki. (2006) Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:1, 308-312
CrossRef1778
Dragan Delic. (2006) Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection. Medicinski pregled 59:9-10, 415-419
CrossRef1779
Ivanko Bojic, Ljubisa Dokic, Svetlana Minic. (2006) Treatment options for chronic hepatitis C virus infection. Medicinski pregled 59:11-12, 560-566
CrossRef1780
F. Bani-Sadr, F. Carrat, E. Rosenthal, L. Piroth, P. Morand, F. Lunel-Fabiani, M. Bonarek, N. C. de Verdiere, G. Pialoux, P. Cacoub, S. Pol, C. Perronne, . (2005) Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. Clinical Infectious Diseases 41:12, 1806-1809
CrossRef1781
Isabelle Rosa, Laurent Costes, Valérie Garrait, Michel Chousterman. (2005) Efficacy of pegylated interferon alpha-2b for the treatment of chronic delta hepatitis in a patient co-infected with HIV. AIDS 19:18, 2177-2178
CrossRef1782
David C. Metz, Nimish Vakil, Emmet B. Keeffe, Gary R. Lichtenstein. (2005) Advances in Gastrointestinal Pharmacotherapy. Clinical Gastroenterology and Hepatology 3:12, 1167-1179
CrossRef1783
Vinod K Rustgi. (2005) Thymalfasin for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 3:6, 885-892
CrossRef1784
Juan Cristina. (2005) Genetic diversity and evolution of hepatitis C virus in the Latin American region. Journal of Clinical Virology 34, S1-S7
CrossRef1785
Vincent Soriano, Luz Martin-Carbonero, Ivana Maida, Javier Garcia-Samaniego, Marina Nuñez. (2005) New paradigms in the management of HIV and hepatitis C virus coinfection. Current Opinion in Infectious Diseases 18:6, 550-560
CrossRef1786
Stephanie A. Santos, Nickolas Kontorinis, Douglas T. Dieterich. (2005) Management of chronic Hepatitis C virus in patients with HIV. Current Treatment Options in Gastroenterology 8:6, 433-441
CrossRef1787
Amy Y-H. Wang, Ingrid J. Hickman, Ayanthi A. Richards, Jonathan P. Whitehead, Johannes B. Prins, Graeme A. MacDonald. (2005) High Molecular Weight Adiponectin Correlates with Insulin Sensitivity in Patients with Hepatitis C Genotype 3, But Not Genotype 1 Infection. The American Journal of Gastroenterology 100:12, 2717-2723
CrossRef1788
K. P. High, E.-L. Marcus, R. Tur-Kaspa. (2005) Chronic Hepatitis C Virus Infection in Older Adults. Clinical Infectious Diseases 41:11, 1606-1612
CrossRef1789
Jennifer E. Layden-Almer, Scott J. Cotler, Thomas J. Layden. (2005) HCV viral kinetics. Current Hepatitis Reports 4:4, 158-161
CrossRef1790
Vanessa Escuret, Vincent Aucagne, Nicolas Joubert, David Durantel, Kimberly L. Rapp, Raymond F. Schinazi, Fabien Zoulim, Luigi A. Agrofoglio. (2005) Synthesis of 5-haloethynyl- and 5-(1,2-dihalo)vinyluracil nucleosides: Antiviral activity and cellular toxicity. Bioorganic & Medicinal Chemistry 13:21, 6015-6024
CrossRef1791
L. Brant, H. E. Harris, M. E. Ramsay, R. Grieve, J. Roberts, . (2005) Pathways of care and resource utilization in a national cohort of patients with transfusion-acquired hepatitis C. Journal of Viral Hepatitis 12:6, 618-626
CrossRef1792
Arun Swaminath, Deanna L. Oliver, Andrew C. McNeil, Tarek I. Hassanein. (2005) The influence of hiv coinfection on the natural history of hcv infection. Current Hepatitis Reports 4:4, 131-137
CrossRef1793
N. Bouzgarrou, I. Fodha, S. Ben Othman, A. Achour, F. Grattard, A. Trabelsi, B. Pozzetto. (2005) Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. Journal of Medical Virology 77:4, 502-508
CrossRef1794
Jos?? R. Foruny, Javier Bl??zquez, Ana Moreno, Rafael B??rcena, Luis Gil-Grande, Carmen Quereda, Mar??a J. P??rez-El??as, Javier Moreno, Juan S??nchez, Alfonso Muriel, Miguel A. Rodriguez-Sagrado, Santiago Moreno. (2005) Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. European Journal of Gastroenterology & Hepatology 17:11, 1157-1164
CrossRef1795
K. E. Mayer, R. P. Myers, S. S. Lee. (2005) Silymarin treatment of viral hepatitis: a systematic review. Journal of Viral Hepatitis 12:6, 559-567
CrossRef1796
Ira M. Jacobson, Stevan A. Gonzalez, Furqaan Ahmed, Edward Lebovics, Albert D. Min, Henry C. Bodenheimer, Stephen P. Esposito, Robert S. Brown, Norbert Brau, Franklin M. Klion, Hillel Tobias, Edmund J. Bini, Neil Brodsky, Maurice A. Cerulli, Ayse Aytaman, Peter W. Gardner, Jane M. Geders, Julie E. Spivack, Michael G. Rahmin, David H. Berman, James Ehrlich, Mark W. Russo, Maxwell Chait, Deborah Rovner, Brian R. Edlin. (2005) A Randomized Trial of Pegylated Interferon alpha-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C. The American Journal of Gastroenterology 100:11, 2453-2462
CrossRef1797
Christoph Seeger. (2005) Salient molecular features of hepatitis C virus revealed. Trends in Microbiology 13:11, 528-534
CrossRef1798
Birger P??lsson, Hans Verbaan. (2005) Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 17:11, 1153-1155
CrossRef1799
&NA;. (2005) Pharmacological agents can ameliorate some of the neuropsychiatric adverse effects of interferon-?? treatment. Drugs & Therapy Perspectives 21:11, 18-22
CrossRef1800
Srikanta Dash, Salima Haque, Virendra Joshi, Ramesh Prabhu, Sidhartha Hazari, Cesar Fermin, Robert Garry. (2005) HCV-hepatocellular carcinoma: New findings and hope for effective treatment. Microscopy Research and Technique 68:3-4, 130-148
CrossRef1801
Jean Delwaide, Refaat El Saouda, Christiane G??rard, Jacques Bela??che. (2005) Hepatitis C infection: eligibility for antiviral therapies. European Journal of Gastroenterology & Hepatology 17:11, 1185-1189
CrossRef1802
V. RATZIU, A. HEURTIER, L. BONYHAY, T. POYNARD, P. GIRAL. (2005) Review article: an unexpected virus-host interaction - the hepatitis C virus-diabetes link. Alimentary Pharmacology and Therapeutics 22:s2, 56-60
CrossRef1803
K. E. Sherman, N. J. Shire, P. Cernohous, S. D. Rouster, J. H. Omachi, S. Brun, B. D. Silva. (2005) Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir. Clinical Infectious Diseases 41:8, 1186-1195
CrossRef1804
Mark S Sulkowski, David L Thomas. (2005) Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS 19:Suppl 3, S8-S12
CrossRef1805
A. Craxì. (2005) Response to letter from Professor Peter Ferenci. Digestive and Liver Disease 37:10, 808-809
CrossRef1806
P. Ferenci. (2005) Second thoughts about secondary analyses. Digestive and Liver Disease 37:10, 805-807
CrossRef1807
Kathryn J. Rolfe, Graeme J.M. Alexander, Tim G. Wreghitt, Surendra Parmar, Hamid Jalal, Martin D. Curran. (2005) A real-time Taqman method for hepatitis C virus genotyping. Journal of Clinical Virology 34:2, 115-121
CrossRef1808
Hua Tan, Jena Derrick, Jin Hong, Corneliu Sanda, William M. Grosse, Howard J. Edenberg, Milton Taylor, Scott Seiwert, Lawrence M. Blatt. (2005) Global Transcriptional Profiling Demonstrates the Combination of Type I and Type II Interferon Enhances Antiviral and Immune Responses at Clinically Relevant Doses. Journal of Interferon & Cytokine Research 25:10, 632-649
CrossRef1809
Harlan Wright, Philip Alex, Thuan Nguyen, Teddy Bader, Ahmet Gurakar, Anthony Sebastian, Liberty Gonzales, Gemma Wallis, Mark Naylor, Igor Dozmorov, Michael Centola, Bakr Nour. (2005) Multiplex Cytokine Profiling of Initial Therapeutic Response in Patients with Chronic Hepatitis C Virus Infection. Digestive Diseases and Sciences 50:10, 1793-1803
CrossRef1810
B TAKASE, A HAMABE, A UEHATA, T HUJIOKA, T KONDO, T MATSUI, F OHSUZU, M ISHIHARA. (2005) Recombinant interferon alpha treatment decreases heart rate variability indices and impairs exercise tolerance in patients with chronic hepatitis. Biomedecine & Pharmacotherapy 59, S163-S168
CrossRef1811
Antonio Aceti, Barbara Zechini, Tamara Griggi, Massimo Marangi, Caterina Pasquazzi, Giorgio Quaranta, Maurizio Sorice. (2005) Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy. Liver International 25:5, 987-993
CrossRef1812
SHI-MING LIN, CHIA-MING CHU. (2005) Secondary prevention of hepatitis C virus-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 20:10, 1475-1477
CrossRef1813
A. CHANG, K. SKOLE, M. GAUTAM, J. SCHMUTZ, M. BLACK, R. THOMAS, B. HORWITZ, F. K. FRIEDENBERG. (2005) The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 22:8, 701-706
CrossRef1814
Glenn J Wagner, Gery W Ryan. (2005) Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. AIDS 19:Suppl 3, S190-S198
CrossRef1815
R Peffault de Latour, T Asselah, V Lévy, C Scieux, A Devergie, P Ribaud, H Espérou, R Traineau, E Gluckman, D Valla, P Marcellin, G Socié. (2005) Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 36:8, 709-713
CrossRef1816
Janus P Ong, Rochelle Collantes, Angela Pitts, Lisa Martin, Michael Sheridan, Zobair M Younossi. (2005) High Rates of Uninsured Among HCV-Positive Individuals. Journal of Clinical Gastroenterology 39:9, 826-830
CrossRef1817
Erik De Clercq. (2005) Recent highlights in the development of new antiviral drugs. Current Opinion in Microbiology 8:5, 552-560
CrossRef1818
Eirini I. Rigopoulou, William G.H. Abbott, Philip Haigh, Nikolai V. Naoumov. (2005) Blocking of interleukin-10 receptor—a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clinical Immunology 117:1, 57-64
CrossRef1819
Nickolas Kontorinis, Kaushik Agarwal, Douglas T Dieterich. (2005) Treatment of hepatitis C virus in HIV patients: a review. AIDS 19:Suppl 3, S166-S173
CrossRef1820
(2005) Peginterferon Alfa-2b and Ribavirin for 12 versus 24 Weeks in HCV Infection. New England Journal of Medicine 353:11, 1182-1183
Full Text1821
J. J. Goedert, . (2005) Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. Haemophilia 11:5, 516-528
CrossRef1822
Yves Horsmans, Thomas Berg, Jean-Pierre Desager, Tobias Mueller, Eckart Schott, Simon P. Fletcher, Kevin R. Steffy, Lisa A. Bauman, Bradley M. Kerr, Devron R. Averett. (2005) Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42:3, 724-731
CrossRef1823
S. P. Savvas, J. Koskinas, C. Sinani, A. Hadziyannis, F. Spanou, S. J. Hadziyannis. (2005) Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. Journal of Viral Hepatitis 12:5, 551-557
CrossRef1824
Ernest C. Borden. (2005) Review: Milstein Award Lecture: Interferons and Cancer: Where from Here?. Journal of Interferon & Cytokine Research 25:9, 511-527
CrossRef1825
J. K. Lim, D. Wooten, R. Siegel, R. C. Cheung. (2005) Amantadine in treatment of chronic hepatitis C virus infection?. Journal of Viral Hepatitis 12:5, 445-455
CrossRef1826
Haizhen Zhu, David R. Nelson, James M. Crawford, Chen Liu. (2005) Defective Jak-Stat Activation in Hepatoma Cells Is Associated with Hepatitis C Viral IFN-α Resistance. Journal of Interferon & Cytokine Research 25:9, 528-539
CrossRef1827
M. S. Seyam, D. A. Freshwater, K. O'Donnell, D. J. Mutimer. (2005) Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. Journal of Viral Hepatitis 12:5, 531-535
CrossRef1828
Colin W Shepard, Lyn Finelli, Miriam J Alter. (2005) Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases 5:9, 558-567
CrossRef1829
Yvonne C Gilleece, Rita E Browne, David Asboe, Mark Atkins, Sundhiya Mandalia, Mark Bower, Brian G Gazzard, Mark R Nelson. (2005) Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:1, 41-46
CrossRef1830
F. Lodato, F. Azzaroli, S. Brillanti, A. Colecchia, M. R. Tame, M. Montagnani, R. Muratori, S. Giovanelli, V. Feletti, M. L. Bacchi Reggiani, E. Roda, G. Mazzella. (2005) Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. Journal of Viral Hepatitis 12:5, 536-542
CrossRef1831
Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Modoka Kohmoto, Daiki Habu, Hiroki Sakaguchi, Tadashi Takeda, Norifumi Kawada, Shuichi Seki, Susumu Shiomi. (2005) Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-α2b and ribavirin therapy in patients with genotype 1 and high viral loads. Journal of Medical Virology 77:1, 77-82
CrossRef1832
V. Sypsa, G. Touloumi, G. V. Papatheodoridis, N. C. Tassopoulos, I. Ketikoglou, I. Vafiadis, G. Hatzis, D. Tsantoulas, E. Akriviadis, S. Koutsounas, A. Hatzakis. (2005) Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. Journal of Viral Hepatitis 12:5, 543-550
CrossRef1833
T. Carlsson, O. Reichard, G. Norkrans, J. Blackberg, P. Sangfelt, E. Wallmark, O. Weiland. (2005) Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. Journal of Viral Hepatitis 12:5, 473-480
CrossRef1834
Firouz?? Bani-Sadr, Fabrice Carrat, Stanislas Pol, Ravy Hor, Eric Rosenthal, C??cile Goujard, Patrice Morand, Fran??oise Lunel-Fabiani, Dominique Salmon-Ceron, Lionel Piroth, Gilles Pialoux, Mich??le Bentata, Patrice Cacoub, Christian Perronne. (2005) Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:1, 47-52
CrossRef1835
N. A. Terrault, J-M. Pawlotsky, J. McHutchison, F. Anderson, M. Krajden, S. Gordon, I. Zitron, R. Perrillo, R. Gish, M. Holodniy, M. Friesenhahn. (2005) Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. Journal of Viral Hepatitis 12:5, 465-472
CrossRef1836
F. Legrand-Abravanel, F. Nicot, A. Boulestin, K. Sandres-Sauné, J.P. Vinel, L. Alric, Jacques Izopet. (2005) Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. Journal of Medical Virology 77:1, 66-69
CrossRef1837
V. Gonzalez, E. Padilla, M. Diago, M. D. Gimenez, R. Sola, L. Matas, S. Montoliu, R. M. Morillas, C. Perez, R. Planas. (2005) Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. Journal of Viral Hepatitis 12:5, 481-487
CrossRef1838
Donald M. Jensen, Patrick Marcellin. (2005) Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40???kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12???kDa) plus ribavirin. European Journal of Gastroenterology & Hepatology 17:9, 899-904
CrossRef1839
Jordan J. Feld, Jay H. Hoofnagle. (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:7053, 967-972
CrossRef1840
Bonnie Kolor. (2005) Patient Education and Treatment Strategies Implemented at a Pharmacist-Managed Hepatitis C Virus Clinic. Pharmacotherapy 25:9, 1230-1241
CrossRef1841
James A. Morrill, Melissa Shrestha, Richard W. Grant. (2005) Barriers to the Treatment of Hepatitis C. Patient, Provider, and System Factors. Journal of General Internal Medicine 20:8, 754-758
CrossRef1842
Ana Luc??a Rend??n, Marina N????ez, Miriam Romero, Pablo Barreiro, Luz Mart??n-Carbonero, Javier Garc??a-Samaniego, Inmaculada Jim??nez-N??cher, Juan Gonz??lez-Lahoz, Vincent Soriano. (2005) Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 39:4, 401-405
CrossRef1843
Norah J. Shire, Kenneth E. Sherman. (2005) Hepatitis C Virus in patients with inherited bleeding disorders. Current Hepatitis Reports 4:3, 87-91
CrossRef1844
Peter W. M. Dienhart, Richard K. Sterling. (2005) Management of hepatitis C virus in patients with porphyria cutanea tarda. Current Hepatitis Reports 4:3, 104-111
CrossRef1845
Jin-Ching Lee, Ming-Chen Yu, Tzu-Wen Lien, Ching-Fung Chang, John T.-A. Hsu. (2005) High-Throughput Cell-Based Screening for Hepatitis C Virus NS3/4A Protease Inhibitors. ASSAY and Drug Development Technologies 3:4, 385-392
CrossRef1846
Gregory T. Everson, James Trotter, Lisa Forman, Marcelo Kugelmas, Arthur Halprin, Barbara Fey, Catherine Ray. (2005) Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42:2, 255-262
CrossRef1847
Edmund J. Bini, Norbert Brau, Sue Currie, Hui Shen, Bhupinderjit S. Anand, Ke-Qin Hu, Lennox Jeffers, Samuel B. Ho, David Johnson, Warren N. Schmidt, Paul King, Ramsey Cheung, Timothy R. Morgan, Joseph Awad, Marcos Pedrosa, Kyong-Mi Chang, Ayse Aytaman, Franz Simon, Curt Hagedorn, Richard Moseley, Jawad Ahmad, Charles Mendenhall, Bradford Waters, Doris Strader, Anna W. Sasaki, Stephen Rossi, Teresa L. Wright. (2005) Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection. The American Journal of Gastroenterology 100:8, 1772-1779
CrossRef1848
Felice Marinosci, Carlo Bergamini, Emilia Fransvea, Nicola Napoli, Patrick Maurel, Pietro Dentico, Salvatore Antonaci, Gianluigi Giannelli. (2005) Clinical Role of Serum and Tissue Matrix Metalloprotease-9 Expression in Chronic HCV Patients Treated with Pegylated IFN-α2b and Ribavirin. Journal of Interferon & Cytokine Research 25:8, 453-458
CrossRef1849
Scott K Fung, Anna S. F Lok. (2005) Update on viral hepatitis in 2004. Current Opinion in Internal Medicine 4:4, 359-366
CrossRef1850
P. Michielsen, P. Damme, J. E. Steenbergen. (2005) Virale hepatitis. Bijblijven 21:8, 323-333
CrossRef1851
Gary L Davis, Karen L Lindsay. (2005) Treatment of chronic hepatitis C infection: one step at a time. The Lancet Infectious Diseases 5:8, 524-526
CrossRef1852
Adlette Inati, Ali Taher, Sandy Ghorra, Suzanne Koussa, Marwan Taha, Elie Aoun, Ala I. Sharara. (2005) Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. British Journal of Haematology 130:4, 644-646
CrossRef1853
Michael von Wagner, Miriam Huber, Thomas Berg, Holger Hinrichsen, Jens Rasenack, Tobias Heintges, Alexandra Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem. (2005) Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology 129:2, 522-527
CrossRef1854
Rena K. Fox, Sue L. Currie, Jennifer Evans, Teresa L. Wright, Leslie Tobler, Bruce Phelps, Michael P. Busch, Kimberly A. Page‐Shafer. (2005) Hepatitis C Virus Infection among Prisoners in the California State Correctional System. Clinical Infectious Diseases 41:2, 177-186
CrossRef1855
W Graham E Cooksley. (2005) Peginterferon-α 2a for the treatment of hepatitis B infection. Expert Opinion on Pharmacotherapy 6:8, 1373-1380
CrossRef1856
F. Marrache, Y. Consigny, M. P. Ripault, D. Cazals-Hatem, M. Martinot, N. Boyer, C. Degott, D. Valla, P. Marcellin. (2005) Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Journal of Viral Hepatitis 12:4, 421-428
CrossRef1857
C. Payan, F. Roudot-Thoraval, P. Marcellin, N. Bled, G. Duverlie, I. Fouchard-Hubert, P. Trimoulet, P. Couzigou, D. Cointe, C. Chaput, C. Henquell, A. Abergel, J. M. Pawlotsky, C. Hezode, M. Coude, A. Blanchi, S. Alain, V. Loustaud-Ratti, P. Chevallier, C. Trepo, V. Gerolami, I. Portal, P. Halfon, M. Bourliere, M. Bogard, E. Plouvier, C. Laffont, G. Agius, C. Silvain, V. Brodard, G. Thiefin, C. Buffet-Janvresse, G. Riachi, F. Grattard, T. Bourlet, F. Stoll-Keller, M. Doffoel, J. Izopet, K. Barange, M. Martinot-Peignoux, M. Branger, A. Rosenberg, P. Sogni, M. L. Chaix, S. Pol, V. Thibault, P. Opolon, A. Charrois, L. Serfaty, B. Fouqueray, J. D. Grange, J. J. Lefrere, F. Lunel-Fabiani. (2005) Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. Journal of Viral Hepatitis 12:4, 405-413
CrossRef1858
N. J. Shire, K. E. Sherman. (2005) Clinical Trials of Treatment for Hepatitis C Virus Infection in HIV-Infected Patients: Past, Present, and Future. Clinical Infectious Diseases 41:Supplement 1, S63-S68
CrossRef1859
Franz Porzsolt, Hana Kajnar, Aziz Awa, Margrit Fässler, Barbara Herzberger. (2005) Validity of original studies in health technology assessment reports: Significance of standardized assessment and reporting. International Journal of Technology Assessment in Health Care 21:03,
CrossRef1860
Uwe Weickert, Andrea Buttmann, Ralf Jakobs, Dieter Schilling, Axel Eickhoff, J??rgen Ferdinand Riemann. (2005) Diagnosis of Liver Cirrhosis. Journal of Clinical Gastroenterology 39:6, 529-532
CrossRef1861
Karen Weck. (2005) Molecular methods of hepatitis C genotyping. Expert Review of Molecular Diagnostics 5:4, 507-520
CrossRef1862
R. D'Souza, C. A. Sabin, G. R. Foster. (2005) Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy. The American Journal of Gastroenterology 100:7, 1509-1515
CrossRef1863
C. L. Cooper, D. W. Cameron. (2005) Effect of Alcohol Use and Highly Active Antiretroviral Therapy on Plasma Levels of Hepatitis C Virus (HCV) in Patients Coinfected with HIV and HCV. Clinical Infectious Diseases 41:Supplement 1, S105-S109
CrossRef1864
E. M. Tedaldi. (2005) New Drug Targets for HIV and Hepatitis C Virus Coinfection. Clinical Infectious Diseases 41:Supplement 1, S101-S104
CrossRef1865
D. L. Sylvestre. (2005) Approaching Treatment for Hepatitis C Virus Infection in Substance Users. Clinical Infectious Diseases 41:Supplement 1, S79-S82
CrossRef1866
M Nelson, G Matthews, MG Brook, J Main, . (2005) BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Medicine 6:S2, 96-106
CrossRef1867
Lau, George K.K., Piratvisuth, Teerha, Luo, Kang Xian, Marcellin, Patrick, Thongsawat, Satawat, Cooksley, Graham, Gane, Edward, Fried, Michael W., Chow, Wan Cheng, Paik, Seung Woon, Chang, Wen Yu, Berg, Thomas, Flisiak, Robert, McCloud, Philip, Pluck, Nigel, . (2005) Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine 352:26, 2682-2695
Full Text1868
Mangia, Alessandra, Santoro, Rosanna, Minerva, Nicola, Ricci, Giovanni L., Carretta, Vito, Persico, Marcello, Vinelli, Francesco, Scotto, Gaetano, Bacca, Donato, Annese, Mauro, Romano, Mario, Zechini, Franco, Sogari, Fernando, Spirito, Fulvio, Andriulli, Angelo, . (2005) Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine 352:25, 2609-2617
Full Text1869
David E. Kaplan, Kazushi Sugimoto, Fusao Ikeda, Jason Stadanlick, Mary Valiga, Kirti Shetty, K. Rajender Reddy, Kyong-Mi Chang. (2005) T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 41:6, 1365-1375
CrossRef1870
Stephan Brand, Kathrin Zitzmann, Julia Dambacher, Florian Beigel, Torsten Olszak, George Vlotides, Sören T. Eichhorst, Burkhard Göke, Helmut Diepolder, Christoph J. Auernhammer. (2005) SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-λs IL-28A and IL-29. Biochemical and Biophysical Research Communications 331:2, 543-548
CrossRef1871
Manuel Romero-Gómez. (2005) Reply. Gastroenterology 128:7, 2178-2179
CrossRef1872
Juan Julián González-García, Beatriz Mahillo, Susana Hernández, Raquel Pacheco, Sergio Diz, Paz García, Herminia Esteban, José Ramón Arribas, Carmen Quereda, Rafael Rubio, Jesús Díez, Santiago Moreno, Juan José Vázquez-Rodríguez. (2005) Estudio multicéntrico sobre prevalencia de las coinfecciones por virus de hepatitis, indicación de tratamiento de hepatitis crónica C y necesidad de trasplante hepático en pacientes infectados por el VIH en España. Estudio GESIDA 29/02-FIPSE 12185/01. Enfermedades Infecciosas y Microbiología Clínica 23:6, 340-348
CrossRef1873
Geert Leroux-Roels. (2005) Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Review of Vaccines 4:3, 351-371
CrossRef1874
Mandana Khalili, David Bernstein, Ellen Lentz, Christine Barylski, Margaret Hoffman-Terry. (2005) Pegylated Interferon α -2a With or Without Ribavirin in HCV/HIV Coinfection: Partially Blinded, Randomized Multicenter Trial. Digestive Diseases and Sciences 50:6, 1148-1155
CrossRef1875
Anastasia M. Rivkin, Sweta Chawla. (2005) Epoetin alfa for the Treatment of Combination Therapy–Induced Hemolytic Anemia in Patients Infected with Hepatitis C Virus. Pharmacotherapy 25:6, 862-875
CrossRef1876
Tami Daugherty, Maurizio Bonacini. (2005) Therapy of hepatitis C in patients with HIV infection. Expert Review of Anti-infective Therapy 3:3, 375-384
CrossRef1877
R. Todd Stravitz, Harold Chung, Richard K. Sterling, Velimir A. Luketic, Arun J. Sanyal, Angie S. Price, Amy Purrington, Mitchell L. Shiffman. (2005) Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C. The American Journal of Gastroenterology 100:6, 1415-1419
CrossRef1878
Shengyuan Luo, William Cassidy, Lennox Jeffers, K. Rajender Reddy, Christine Bruno, Charles D. Howell. (2005) Interferon-Stimulated Gene Expression in Black and White Hepatitis C Patients During Peginterferon Alfa-2a Combination Therapy. Clinical Gastroenterology and Hepatology 3:5, 499-506
CrossRef1879
Stefan Wirth, Heidrun Pieper-Boustani, Thomas Lang, Antje Ballauff, Ulrike Kullmer, Patrick Gerner, Philip Wintermeyer, Andreas Jenke. (2005) Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 41:5, 1013-1018
CrossRef1880
J. Heathcote, J. Main. (2005) Treatment of hepatitis C. Journal of Viral Hepatitis 12:3, 223-235
CrossRef1881
H Hofer, J B Neufeld, C Oesterreicher, P Grundtner, F Wrba, A Gangl, P Ferenci, C Gasche. (2005) Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. Genes and Immunity 6:3, 242-247
CrossRef1882
Furqaan Ahmed, Ira M. Jacobson. (2005) Management of hematologic side effects: Impact on compliance and efficacy. Current Hepatitis Reports 4:2, 56-60
CrossRef1883
Graham R. Foster, Abid R. Suddle. (2005) Treatment of HCV infection with pegylated interferons. Current Hepatitis Reports 4:2, 49-55
CrossRef1884
José Tomás Ramos, María Isabel de José, Rosa Polo, Claudia Fortuny, María José Mellado, María Ángeles Muñoz-Fernández, José Beceiro, José María Bertrán, Cristina Calvo, Lourdes Chamorro, Luis Ciria, Sara Guillén, Raúl González-Montero, María Isabel González-Tomé, María Dolores Gurbindo, Pablo Martín-Fontelos, Jorge Martínez-Pérez, David Moreno, María Carmen Muñoz-Almagro, Antonio Mur, María Luisa Navarro, Carmen Otero, Pablo Rojo, Bárbara Rubio, Jesús Saavedra. (2005) Recomendaciones CEVIHP/SEIP/AEP/PNS respecto al tratamiento antirretroviral en niños y adolescentes infectados por el VIH. Enfermedades Infecciosas y Microbiología Clínica 23:5, 279-312
CrossRef1885
Zobair M. Younossi, Arthur C. McCullough, David S. Barnes, Anthony Post, Janus P. Ong, Robert O’shea, Lisa M. Martin, Diane Bringman, Denise Farmer, Gavin Levinthal, Kevin D. Mullen, William D. Carey, Anthony S. Tavill, Roy Ferguson, Terry Gramlich. (2005) Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C. Digestive Diseases and Sciences 50:5, 970-975
CrossRef1886
Gregory T. Everson. (2005) Antiviral therapy in the liver transplant candidate and recipient. Current Hepatitis Reports 4:2, 75-82
CrossRef1887
D. Posthouwer, I. Plug, J. G. van der Bom, K. Fischer, F. R. Rosendaal, E. P. Mauser-Bunschoten. (2005) Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 11:3, 270-275
CrossRef1888
M. Zonneveld, H. J. Flink, E. Verhey, H. Senturk, S. Zeuzem, U. S. Akarca, Y. Cakaloglu, C. Simon, T. M. K. So, G. Gerken, R. A. Man, B. E. Hansen, S. W. Schalm, H. L. A. Janssen, . (2005) The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Alimentary Pharmacology and Therapeutics 21:9, 1163-1171
CrossRef1889
A. Mangia, G. L. Ricci, M. Persico, N. Minerva, V. Carretta, D. Bacca, M. Cela, M. Piattelli, M. Annese, G. Maio, D. Conte, V. Guadagnino, V. Pazienza, D. Festi, F. Spirito, A. Andriulli. (2005) A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. Journal of Viral Hepatitis 12:3, 292-299
CrossRef1890
S.-D. Lee, M.-L. Yu, P.-N. Cheng, M.-Y. Lai, Y.-C. Chao, S.-J. Hwang, W.-Y. Chang, T.-T. Chang, T.-Y. Hsieh, C.-J. Liu, D.-S. Chen. (2005) Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis 12:3, 283-291
CrossRef1891
Jesper Brok, Lise Lotte Gluud, Christian Gluud, Jesper Brok. 2005. Ribavirin plus interferon versus interferon for chronic hepatitis C. .
CrossRef1892
Holly Hagan, Shiela M. Strauss, Janetta M. Astone, Don C. Des Jarlais. (2005) Medical Examinations at Entry to Treatment for Drug Abuse as an Opportunity to Initiate Care for Hepatitis C Virus Infection. Clinical Infectious Diseases 40:s5, S297-S303
CrossRef1893
Gail Matthews, Ian J. Kronborg, Gregory J. Dore. (2005) Treatment for Hepatitis C Virus Infection among Current Injection Drug Users in Australia. Clinical Infectious Diseases 40:s5, S325-S329
CrossRef1894
Kathleen A. Clanon, Juergen Johannes Mueller, Michael Harank. (2005) Integrating Treatment for Hepatitis C Virus Infection into an HIV Clinic. Clinical Infectious Diseases 40:s5, S362-S366
CrossRef1895
Alain H. Litwin, Irene Soloway, Marc N. Gourevitch. (2005) Integrating Services for Injection Drug Users Infected with Hepatitis C Virus with Methadone Maintenance Treatment: Challenges and Opportunities. Clinical Infectious Diseases 40:s5, S339-S345
CrossRef1896
Marian Fireman, David W. Indest, Aaron Blackwell, Ashlee J. Whitehead, Peter Hauser. (2005) Addressing Tri‐Morbidity (Hepatitis C, Psychiatric Disorders, and Substance Use): The Importance of Routine Mental Health Screening as a Component of a Comanagement Model of Care. Clinical Infectious Diseases 40:s5, S286-S291
CrossRef1897
Anna Doab, Carla Treloar, Gregory J. Dore. (2005) Knowledge and Attitudes about Treatment for Hepatitis C Virus Infection and Barriers to Treatment among Current Injection Drug Users in Australia. Clinical Infectious Diseases 40:s5, S313-S320
CrossRef1898
Jens Reimer, Bernd Schulte, Xavier Castells, Ingo Schafer, Susanne Polywka, Dagmar Hedrich, Lucas Wiessing, Christian Haasen, Markus Backmund, Michael Krausz. (2005) Guidelines for the Treatment of Hepatitis C Virus Infection in Injection Drug Users: Status Quo in the European Union Countries. Clinical Infectious Diseases 40:s5, S373-S378
CrossRef1899
Diana L. Sylvestre. (2005) Treating Hepatitis C Virus Infection in Active Substance Users. Clinical Infectious Diseases 40:s5, S321-S324
CrossRef1900
M. Seydi, P. Morlat, F. Bonnet, J. Rambeloarisoa, N. Bernard, D. Lacoste, M. Bonarek, P. Trimoulet, R. Ramanampamonjy, M.-E. Lafon, M. Dramé, J. Beylot. (2005) Efficacité et tolérance de l'association interféron pégylé-ribavirine chez les patients co-infectés VIH-VHC en pratique clinique : étude observationnelle de 32 patients. La Revue de Médecine Interne 26:4, 280-287
CrossRef1901
Harel Dahari, Marian Major, Xinan Zhang, Kathleen Mihalik, Charles M. Rice, Alan S. Perelson, Stephen M. Feinstone, Avidan U. Neumann. (2005) Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology 128:4, 1056-1066
CrossRef1902
Markus Reiser, Holger Hinrichsen, Yves Benhamou, Henk W. Reesink, Heiner Wedemeyer, Cristina Avendano, Neus Riba, Chan-Loi Yong, Gerhard Nehmiz, Gerhard G. Steinmann. (2005) Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41:4, 832-835
CrossRef1903
PIERLUIGI TONIUTTO, CARLO FABRIS, ELISABETTA FUMO, LUCA APOLLONIO, MAYA CALDATO, CLAUDIO AVELLINI, ROSALBA MINISINI, MARIO PIRISI. (2005) Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. Journal of Gastroenterology and Hepatology 20:4, 577-582
CrossRef1904
RAKESH KUMAR, SUDHEER KUMAR, BARJESH CHANDER SHARMA, JAGDEEP SINGH, SHIV K SARIN. (2005) Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: Pilot study. Journal of Gastroenterology and Hepatology 20:4, 527-535
CrossRef1905
Akinari Tabaru, Ryoichi Narita, Masaaki Hiura, Shintaro Abe, Makoto Otsuki. (2005) Efficacy of Short-Term Interferon Therapy for Patients Infected with Hepatitis C Virus Genotype 2a. The American Journal of Gastroenterology 100:4, 862-867
CrossRef1906
Keith D. Tardif, Gulam Waris, Aleem Siddiqui. (2005) Hepatitis C virus, ER stress, and oxidative stress. Trends in Microbiology 13:4, 159-163
CrossRef1907
Steven K. Herrine, Robert S. Brown, David E. Bernstein, Michael S. Ondovik, Ellen Lentz, Helen Te. (2005) Peginterferon ?-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon ?-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety. Digestive Diseases and Sciences 50:4, 719-726
CrossRef1908
Maria H. Sjogren, Robert Sjogren, Kent Holtzmuller, Bradley Winston, Betty Butterfield, Stanley Drake, Amber Watts, Robin Howard, Milton Smith. (2005) Interferon Alfacon-1 and Ribavirin Versus Interferon ?-2b and Ribavirin in the Treatment of Chronic Hepatitis C. Digestive Diseases and Sciences 50:4, 727-732
CrossRef1909
Robert G. Gish, Nezam H. Afdhal, Douglas T. Dieterich, K. Rajender Reddy. (2005) Management of hepatitis C virus in special populations: Patient and treatment considerations. Clinical Gastroenterology and Hepatology 3:4, 311-318
CrossRef1910
Michael J Grace, David L Cutler, Ronald W Bordens. (2005) Pegylated IFNs for chronic hepatitis C: an update. Expert Opinion on Drug Delivery 2:2, 219-226
CrossRef1911
Manuel Romero-Gómez, Maria Del Mar Viloria, Raúl J. Andrade, Javier Salmerón, Moisés Diago, Conrado M. Fernández-Rodríguez, Raquel Corpas, Marina Cruz, Lourdes Grande, Luis Vázquez, Paloma Muñoz-de-Rueda, Pilar López-Serrano, Ana Gila, María L. Gutiérrez, Celia Pérez, Angela Ruiz-Extremera, Emilio Suárez, Jesús Castillo. (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:3, 636-641
CrossRef1912
Manuel Ramos-Casals, Juan Ma????, Norma Nardi, Pilar Brito-Zer??n, Antoni Xaubet, Jos?? Maria S??nchez-Tapias, Ricard Cervera, Josep Font. (2005) Sarcoidosis in Patients With Chronic Hepatitis C Virus Infection. Medicine 84:2, 69-80
CrossRef1913
B. J. Veldt, B. E. Hansen, M. J. C. Eijkemans, R. J. Knegt, T. Stijnen, J. D. F. Habbema, S. W. Schalm. (2005) Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C. Alimentary Pharmacology and Therapeutics 21:5, 539-547
CrossRef1914
Patrice Cacoub, David Saadoun, Nicolas Limal, Damien Sene, Olivier Lidove, Jean-Charles Piette. (2005) PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis & Rheumatism 52:3, 911-915
CrossRef1915
Axel Ulsenheimer, J. Tilman Gerlach, Maria-Christina Jung, Norbert Gruener, Martin W
CrossRef1916
Martine Neau-Cransac, Juliette Foucher, Victor De Ledinghen, Pierre-Henri Bernard, Elisabeth Legrand, Marie-Edith Lafon. (2005) Modifications of T-Lymphocyte Subsets before and during Interferon and Ribavirin Treatment for Chronic Hepatitis C Infection. Viral Immunology 18:1, 197-204
CrossRef1917
Samuel Daniel. (2005) Chronic Hepatitis C Treatment Patterns in African American Patients: An Update. The American Journal of Gastroenterology 100:3, 716-722
CrossRef1918
John Farley, Shawn Vasdev, Benedikt Fischer, Jürgen Rehm, Emma Haydon. (2005) Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. International Journal of Prisoner Health 1:1, 13-18
CrossRef1919
Calogero Cammà, Anna Licata, Giuseppe Cabibbo, Federica Latteri, Antonio Craxì. (2005) Treatment of hepatitis C: critical appraisal of the evidence. Expert Opinion on Pharmacotherapy 6:3, 399-408
CrossRef1920
Mark Sulkowski, Teresa Wright, Stephen Rossi, Sanjeev Arora, Matthew Lamb, Ka Wang, Jean-Michel Gries, Sreeni Yalamanchili. (2005) Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy*. Clinical Pharmacology & Therapeutics 77:3, 214-224
CrossRef1921
John K. Pratt, Pamela Donner, Keith F. McDaniel, Clarence J. Maring, Warren M. Kati, Hongmei Mo, Tim Middleton, Yaya Liu, Teresa Ng, Qinghua Xie, Rong Zhang, Debra Montgomery, Akhteruzzaman Molla, Dale J. Kempf, William Kohlbrenner. (2005) Inhibitors of HCV NS5B polymerase: synthesis and structure–activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines. Bioorganic & Medicinal Chemistry Letters 15:6, 1577-1582
CrossRef1922
J. S. Markowitz, E. M. Gutterman, D. Hodes, W. Klaskala. (2005) Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. Journal of Viral Hepatitis 12:2, 176-185
CrossRef1923
J. A. Chisholm, G. Williams, E. Spence, S. Parks, D. Keating, M. Gavin, P. R. Mills. (2005) Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Alimentary Pharmacology and Therapeutics 21:6, 723-732
CrossRef1924
Geoffrey Dusheiko, Mark Danta. (2005) Can Peg-IFN α-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?. Nature Clinical Practice Gastroenterology & Hepatology 2:3, 130-131
CrossRef1925
(2005) Purification and Characterization of HCV RNA-dependent RNA Polymerase from Korean Genotype 1b Isolate: Implications for Discovery of HCV Polymerase Inhibitors. Bulletin of the Korean Chemical Society 26:2, 285-291
CrossRef1926
P. Muratori, L. Muratori, M. Guidi, A. Granito, M. Susca, M. Lenzi, F. B. Bianchi. (2005) Clinical Impact of Non--Organ-Specific Autoantibodies on the Response to Combined Antiviral Treatment in Patients with Hepatitis C. Clinical Infectious Diseases 40:4, 501-507
CrossRef1927
Pratima Sharma, Jorge Rakela. (2005) Management of pre-liver transplantation patients?Part 1. Liver Transplantation 11:2, 124-133
CrossRef1928
Richard K. Sterling, Robert S. Brown, Charlotte M. Hofmann, Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal, Melissa J. Contos, A. Scott Mills, Vernon Smith, Mitchell L. Shiffman. (2005) The Spectrum of Chronic Hepatitis C Virus Infection in the Virginia Correctional System: Development of a Strategy for the Evaluation and Treatment of Inmates with HCV. The American Journal of Gastroenterology 100:2, 313-321
CrossRef1929
Rasa Bertuzis, Alison Hardie, Barbara Hottentraeger, Jacques Izopet, Wolfgang Jilg, Barbara Kaesdorf, Gregor Leckie, Jean Leete, Luc Perrin, Chunfu Qiu, Iris Ran, George Schneider, Peter Simmonds, John Robinson. (2005) Clinical performance of the LCx® HCV RNA quantitative assay. Journal of Virological Methods 123:2, 171-178
CrossRef1930
Wolf Peter Hofmann, Stefan Zeuzem, Christoph Sarrazin. (2005) Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy. Journal of Clinical Virology 32:2, 86-91
CrossRef1931
Konstantinos C. Thomopoulos, George J. Theocharis, Athanasios C. Tsamantas, Dimitrios Siagris, Dimitra Dimitropoulou, Charalambos A. Gogos, Chrysoula Labropoulou-Karatza. (2005) Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology 17:2, 149-153
CrossRef1932
Karin Lindahl, Lars Stahle, Annette Bruchfeld, Robert Schvarcz. (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41:2, 275-279
CrossRef1933
Kenneth E. Sherman, Norah J. Shire, Susan D. Rouster, Marion G. Peters, Margaret James Koziel, Raymond T. Chung, Paul S. Horn. (2005) Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 128:2, 313-327
CrossRef1934
C. Wiegard, A. W. Lohse. (2005) Leber und Rheuma. Zeitschrift f
CrossRef1935
A. Guilabert, X. Bosch, M. Julia, P. Iranzo, J.M. Mascaro. (2005) Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin. British Journal of Dermatology 152:2, 377-379
CrossRef1936
Glen Lutchman, Marc Ghany. (2005) Pushing the treatment envelope for chronic hepatitis C?is more necessarily better?. Hepatology 41:2, 234-236
CrossRef1937
Vijayan Balan, David Schwartz, George Y. Wu, Andrew J. Muir, Reem Ghalib, John Jackson, Emmet B. Keeffe, Lorenzo Rossaro, Alfreda Burnett, Betty L. Goon, Peter J. Bowers, Gerhard J. Leitz, . (2005) Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin. The American Journal of Gastroenterology 100:2, 299-307
CrossRef1938
Masao Honda, Takeo Shimazaki, Shuichi Kaneko. (2005) La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. Gastroenterology 128:2, 449-462
CrossRef1939
B. J. Thomson, R. G. Finch. (2005) Hepatitis C virus infection. Clinical Microbiology and Infection 11:2, 86-94
CrossRef1940
Naga Chalasani, Cosme Manzarbeitia, Peter Ferenci, Wolfgang Vogel, Robert J. Fontana, Michael Voigt, Caroline Riely, Paul Martin, Lewis Teperman, James Jiao, Juan Carlos Lopez-Talavera, . (2005) Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 41:2, 289-298
CrossRef1941
Gillian M Keating, Greg L Plosker. (2005) Peginterferon ??-2a (40KD) Plus Ribavirin. Drugs 65:4, 521-536
CrossRef1942
Andrew F. Angelino, Glenn J. Treisman. (2005) Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. International Review of Psychiatry 17:6, 471-476
CrossRef1943
(2005) Hepatitis C Virus (HCV). Transfusion Medicine and Hemotherapy 32:3-4, 184-195
CrossRef1944
Xavier Causse, Louis D’Alteroche, Si Nafa Si Ahmed, Bruno Giraudeau, Etienne-Henri Metman, Etienne-Henri Metman. (2005) Disposal of injection material used for the treatment of hepatitis C: comparison with insulin-dependent diabetes and thromboembolism. Gastroentérologie Clinique et Biologique 29:1, 64-69
CrossRef1945
Pratima Sharma, Hugo E. Vargas, Jorge Rakela. 2005. Monitoring and Care of the Patient Before Liver Transplantation. , 473-489.
CrossRef1946
R. D'Souza, J. Main, M. Crossey, W. Rosenberg, I. M. Murray-Lyon, C. Hayward, G. R. Foster. (2005) Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - patients' views of early cessation of therapy. Alimentary Pharmacology and Therapeutics 21:1, 43-47
CrossRef1947
Amandeep K. Shergill, Mandana Khalili, Stephanie Straley, Kathy Bollinger, John P. Roberts, Nancy A. Ascher, Norah A. Terrault. (2005) Applicability, Tolerability and Efficacy of Preemptive Antiviral Therapy in Hepatitis C-Infected Patients Undergoing Liver Transplantation. American Journal of Transplantation 5:1, 118-124
CrossRef1948
R. Moreno-Otero. (2005) Therapeutic modalities in hepatitis C: challenges and development. Journal of Viral Hepatitis 12:1, 10-19
CrossRef1949
G. Y. Minuk, A. Gutkin, S. G. Wong, K. D. E. Kaita. (2005) Patient concerns regarding chronic hepatitis C infections. Journal of Viral Hepatitis 12:1, 51-57
CrossRef1950
Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Sachiyo Watahiki, Junko Sato, Marie Matsuda, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2005) Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy. Intervirology 48:6, 372-380
CrossRef1951
Elif Doyuk Kartal, Hasan Colak, Ilhan Özgünes, Gaye Usluer. (2005) Exacerbation of Psoriasis due to Peginterferon alpha-2b plus Ribavirin Treatment of Chronic Active Hepatitis C. Chemotherapy 51:2-3, 167-169
CrossRef1952
Kris V Kowdley. (2005) Hematologic Side Effects of Interferon and Ribavirin Therapy. Journal of Clinical Gastroenterology 39:Supp 1, S3-S8
CrossRef1953
Uwe Siebert, Gaby Sroczynski, . (2005) Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security. International Journal of Technology Assessment in Health Care 21:01,
CrossRef1954
Jakub Svoboda, Charalambos Andreadis, Lisa H Downs, Wallace T Miller, Jr, Donald E Tsai, Stephen J Schuster. (2005) Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leukemia & Lymphoma 46:9, 1365-1368
CrossRef1955
Jonathan Shepherd, Håkan F. T. Brodin, Carolyn Backer Cave, Norman R. Waugh, Alison Price, John Gabbay. (2005) Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation. International Journal of Technology Assessment in Health Care 21:01,
CrossRef1956
Yoshihisa SATO, Naohiro KAWAMURA, Shuhei OKUYAMA, Kazuhisa NAKAMURA, Hiroyasu MATSUOKA, Noriyuki ASABA, Saeko NEZU, Hiroshi NAKAJIMA, Hitoshi ISHIDA, Shin-ichi TAKAHASHI. (2005) The Usefulness of Combination Treatment with Interferon .BETA. Administered Twice-daily Followed by Interferon .ALPHA.-2b plus Ribavirin in Chronic Hepatitis C. Kanzo 46:8, 498-505
CrossRef1957
Il Han Song. (2005) Antiviral Treatment of Chronic Hepatitis B and C : Current Update. Journal of the Korean Medical Association 48:5, 440
CrossRef1958
Bruce R. Bacon. (2005) Clinical trials report. Current Gastroenterology Reports 7:1, 9-10
CrossRef1959
Yasuhito TANAKA, Masashi MIZOKAMI. (2005) Genotype of hepatitis virus. 3. Hepatitis C virus.. Kanzo 46:8, 480-485
CrossRef1960
Girish Subba Rao, Jean Pappas Molleston. (2005) Children with hepatitis C. Current Gastroenterology Reports 7:1, 37-44
CrossRef1961
Maria Buti, Miguel A Casado, Leslie Fosbrook, Rafael Esteban. (2005) Financial Impact of Two Different Ways of Evaluating Early Virological Response to Peginterferon-??-2b Plus Ribavirin Therapy in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1. PharmacoEconomics 23:10, 1043-1055
CrossRef1962
Harry LA Janssen, Monika van Zonneveld, Hakan Senturk, Stefan Zeuzem, Ulus S Akarca, Yilmaz Cakaloglu, Christopher Simon, Thomas MK So, Guido Gerken, Robert A de Man, Hubert GM Niesters, Pieter Zondervan, Bettina Hansen, Solko W Schalm. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. The Lancet 365:9454, 123-129
CrossRef1963
Tae Hun Kim, Kyung A. Kim, Young Seok Lim, Geum-youn Gwak, Jung-Hwan Yoon, Gyeong Hoon Kang, Hyo-Suk Lee. (2005) Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy. Intervirology 48:4, 230-238
CrossRef1964
M. R. Kraus, A. Schafer, O. Al-Taie, M. Scheurlen. (2005) Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. Journal of Viral Hepatitis 12:1, 96-100
CrossRef1965
L Gallelli, M Ferraro, G F Mauro, G De Sarro. (2005) Generalised Dermatitis Induced by Pegylated Interferon-??-2b in a Patient Infected with Genotype-1 Hepatitis C Virus. Clinical Drug Investigation 25:4, 281-284
CrossRef1966
Dawn Sears, Gary L. Davis. 2005. Natural History of Hepatitis C. , 129-141.
CrossRef1967
Joji TOYOTA, Yosiyasu KARINO, Jun AKAIKE, Takumi OHMURA, Takahiro SATO, Katsu YAMAZAKI, Yasuaki KUWATA, Shiro IINO. (2005) Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy. Kanzo 46:3, 107-118
CrossRef1968
A. Restrepo, T. C. Johnson, D. Widjaja, L. Yarmus, K. Meyer, D. J. Clain, H. C. Bodenheimer, A. D. Min. (2005) The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. Journal of Viral Hepatitis 12:1, 86-90
CrossRef1969
R Todd Fredrick, Tarek I Hassanein. (2005) Role of Growth Factors in the Treatment of Patients With HIV/HCV Coinfection and Patients With Recurrent Hepatitis C Following Liver Transplantation. Journal of Clinical Gastroenterology 39:Supp 1, S14-S22
CrossRef1970
Charles L Raison, Marina Demetrashvili, Lucile Capuron, Andrew H Miller. (2005) Neuropsychiatric Adverse Effects of Interferon-??. CNS Drugs 19:2, 105-123
CrossRef1971
Santiago Moreno, Jes
CrossRef1972
A. A. Butt, M. Wagener, A. O. Shakil, J. Ahmad. (2005) Reasons for non-treatment of hepatitis C in veterans in care. Journal of Viral Hepatitis 12:1, 81-85
CrossRef1973
Rochelle S Collantes, Zobair M Younossi. (2005) The Use of Growth Factors to Manage the Hematologic Side Effects of PEG-Interferon Alfa and Ribavirin. Journal of Clinical Gastroenterology 39:Supp 1, S9-S13
CrossRef1974
Montse Laguno, José M.ª Sánchez-Tapias, Javier Murillas, Xavier Forns, José L. Blanco, Esteban Martínez, María Larrousse, Agathe León, Montse Loncá, Ana Milinkovic, José M. Miró, Felipe García, José M.ª Gatell, Josep Mallolas. (2005) Avances en el diagnóstico y tratamiento de la infección por el VHC en pacientes con y sin infección por el VIH. Enfermedades Infecciosas y Microbiología Clínica 23:1, 32-40
CrossRef1975
Jordan J. Feld, T. Jake Liang. (2005) HCV persistence: Cure is still a four letter word. Hepatology 41:1, 23-25
CrossRef1976
Curtis L Cooper. (2005) Therapies for HIV and viral hepatitis coinfection. Expert Review of Anti-infective Therapy 3:1, 81-89
CrossRef1977
K JEROME. (2005) The road to new antiviral therapies. Clinical and Applied Immunology Reviews 5:1, 65-76
CrossRef1978
T. Barry Kelleher, Nezam H. Afdhal. (2005) Maintenance therapy for chronic hepatitis C. Current Gastroenterology Reports 7:1, 50-53
CrossRef1979
M. Homoncik, A. Ferlitsch, P. Ferenci, E. Formann, B. Jilma, A. Gangl, S. Panzer, M. Peck-Radosavljevic. (2005) Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 21:1, 49-55
CrossRef1980
Bruno Raynard. (2005) Traitements catabolisants. Nutrition Clinique et Métabolisme 19:1, 25-29
CrossRef1981
Akihito Tsubota, Yasuji Arase, Takashi Someya, Yoshiyuki Suzuki, Fumitaka Suzuki, Satoshi Saitoh, Kenji Ikeda, Norio Akuta, Tetsuya Hosaka, Masahiro Kobayashi, Hiromitsu Kumada. (2005) Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for na
CrossRef1982
Narendra M. Dixit, Jennifer E. Layden-Almer, Thomas J. Layden, Alan S. Perelson. (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432:7019, 922-924
CrossRef1983
S. Norah, J. K. Margaret. (2004) Prediction of Relapse following Treatment for Hepatitis C: Is Whole Blood More than the Sum of Its Parts?. Clinical Infectious Diseases 39:12, 1761-1763
CrossRef1984
VINOD RUSTGI. (2004) Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. Journal of Gastroenterology and Hepatology 19:S6, S76-S78
CrossRef1985
Regino P. González-Peralta. (2004) Treatment of chronic hepatitis C in children. Pediatric Transplantation 8:6, 639-643
CrossRef1986
Olav Dalgard, Kristian Bj
CrossRef1987
Darius Moradpour, Hubert E. Blum. (2004) A primer on the molecular virology of hepatitis C. Liver International 24:6, 519-525
CrossRef1988
Amy L. Dunn, Thomas C. Abshire. (2004) Recent advances in the management of the child who has hemophilia. Hematology/Oncology Clinics of North America 18:6, 1249-1276
CrossRef1989
Eric J. Lawitz, Matthew J. Hepburn, Thomas J. Casey. (2004) A Pilot Study of Interleukin-11 in Subjects with Chronic Hepatitis C and Advanced Liver Disease Nonresponsive to Antiviral Therapy. The American Journal of Gastroenterology 99:12, 2359-2364
CrossRef1990
John McHutchison, Amany Zekry. (2004) Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. Nature Clinical Practice Gastroenterology & Hepatology 1:2, 70-71
CrossRef1991
MATTHIAS J BAHR, MICHAEL P MANNS. (2004) Treatment of chronic HCV infection in compensated and decompensated cirrhosis. Journal of Gastroenterology and Hepatology 19:s7, S94-S98
CrossRef1992
ZOBAIR M YOUNOSSI. (2004) Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. Journal of Gastroenterology and Hepatology 19:s7, S253-S257
CrossRef1993
Yoshiaki Iwasaki, Kouichi Takaguchi, Hiroshi Ikeda, Yasuhiro Makino, Yasuyuki Araki, Masaharu Ando, Haruhiko Kobashi, Toshitsugu Kobatake, Ryoji Tanaka, Minoru Tomita, Tomonori Senoh, Mitsuhiko Kawaguchi, Toshinari Shimoe, Koji Manabe, Keiji Kita, Junnosuke Shimamura, Kohsaku Sakaguchi, Yasushi Shiratori. (2004) Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver International 24:6, 603-610
CrossRef1994
A. Arizcorreta, F. Brun, C. Fernandez-Gutierrez, R. Garcia Juarez, F. Guerrero, E. Perez-Guzman, J. A. Giron-Gonzalez. (2004) Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. Clinical Microbiology and Infection 10:12, 1067-1074
CrossRef1995
Paul J. Pockros, Mitchell L. Shiffman, Eugene R. Schiff, Mark S. Sulkowski, Zobair Younossi, Douglas T. Dieterich, Teresa L. Wright, Samir H. Mody, K. Linda Tang, Betty L. Goon, Peter J. Bowers, Gerhard Leitz, Nezam H. Afdhal, . (2004) Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 40:6, 1450-1458
CrossRef1996
John B. Gross. (2004) Nonresponders to previous chronic hepatitis C treatment. Current Treatment Options in Gastroenterology 7:6, 469-475
CrossRef1997
CHLOE L THIO. (2004) Chronic hepatitis B or C in HIV-infected persons: pathogenesis and management. Journal of Gastroenterology and Hepatology 19:s7, S138-S144
CrossRef1998
WINITA HARDIKAR. (2004) Natural history and treatment of hepatitis C infection in children. Journal of Gastroenterology and Hepatology 19:s7, S379-S381
CrossRef1999
F. Z. Alfaleh, Q. Hadad, M. S. Khuroo, A. Aljumah, A. Algamedi, H. Alashgar, M. N. Al-Ahdal, I. Mayet, M. Q. Khan, G. Kessie. (2004) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International 24:6, 568-574
CrossRef2000
Amany Zekry, Keyur Patel, Andrew Muir, John G. McHutchison. (2004) Tinkering and tailoring with HCV therapy: Can we get away with less?. Hepatology 40:6, 1249-1251
CrossRef2001
CHRISTOPH SARRAZIN. (2004) Diagnosis of hepatitis C: update 2004. Journal of Gastroenterology and Hepatology 19:s7, S88-S93
CrossRef2002
Peter Ferenci. (2004) Current Treatment for chronic hepatitis C. Current Treatment Options in Gastroenterology 7:6, 491-499
CrossRef2003
Bernd Kronenberger, Eva Herrmann, Florence Micol, Michael von Wagner, Stefan Zeuzem. (2004) Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 40:6, 1442-1449
CrossRef2004
Stefan Zeuzem, Moisés Diago, Edward Gane, K. Rajender Reddy, Paul Pockros, Daniele Prati, Mitchell Shiffman, Patrizia Farci, Norman Gitlin, Christopher B. O’Brien, François Lamour, Pilar Lardelli. (2004) Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127:6, 1724-1732
CrossRef2005
Wan-Long Chuang, Chia-Yen Dai, Shinn-Cherng Chen, Li-Po Lee, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Ming-Lung Yu, Wen-Yu Chang. (2004) Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver International 24:6, 595-602
CrossRef2006
AYMAN A ABDO, SAMUEL S LEE. (2004) Management of hepatitis C virus genotype 4. Journal of Gastroenterology and Hepatology 19:11, 1233-1239
CrossRef2007
S. Saab, D. Cho, D. V. K. Quon, A. B. Ibrahim, P. Dong, V. Marder, L. Logan. (2004) Same day outpatient transjugular liver biopsies in haemophilia. Haemophilia 10:6, 727-731
CrossRef2008
Holger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, Markus Reiser, Roel E. Sentjens, José L. Calleja, Xavier Forns, Andreas Erhardt, Jens Crönlein, Ricardo L. Chaves, Chan-Loi Yong, Gerhard Nehmiz, Gerhard G. Steinmann. (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:5, 1347-1355
CrossRef2009
Dawn A Fishbein, Yungtai Lo, John F Reinus, Marc N Gourevitch, Robert S Klein. (2004) Factors Associated With Successful Referral For Clinical Care of Drug Users With Chronic Hepatitis C Who Have or Are At Risk For HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 37:3, 1367-1375
CrossRef2010
G. Fattovich, I. Zagni, M. L. Ribero, E. Castagnetti, E. Minola, L. Lomonaco, C. Scattolini, P. Fabris, S. Boccia, M. Giusti, G. Abbati, M. Felder, P. Rovere, A. Redaelli, A. Tonon, A. Tomba, R. Montanari, C. Paternoster, M. Distasi, G. Fornaciari, G. Tositti, C. Rizzo, S. Suppressa, M. Pantalena, F. Noventa, A. Tagger. (2004) A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. Journal of Viral Hepatitis 11:6, 543-551
CrossRef2011
D. Posthouwer, V. M. Wolters, K. Fischer, R. H. J. Houwen, H. M. Berg, E. P. Mauser-Bunschoten. (2004) Hepatitis C infection in children with haemophilia: a pilot study. Haemophilia 10:6, 722-726
CrossRef2012
Doris B. Strader. (2004) Hepatitis C virus among african-american persons. Current Hepatitis Reports 3:4, 129-135
CrossRef2013
Heiner Wedemeyer, Michael P Manns. (2004) Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. Nature Clinical Practice Gastroenterology & Hepatology 1:1, 24-25
CrossRef2014
A. Andriulli, M. Persico, A. Iacobellis, G. Maio, D. Di Salvo, A. Spadaccini, D. Bacca, G. Leandro, F. Ventrella, A. Mangia. (2004) Treatment of patients with HCV infection with or without liver biopsy. Journal of Viral Hepatitis 11:6, 536-542
CrossRef2015
Johannes Wiegand, Andrej Potthoff, Michael P. Manns, Heiner Wedemeyer. (2004) Acute hepatitis C infection: Can immunology teach us the right way to treat?. Current Hepatitis Reports 3:4, 148-156
CrossRef2016
David M. Asmuth, Hien H. Nguyen, Gregory P. Melcher, Stuart H. Cohen, Richard B. Pollard. (2004) Treatments for Hepatitis B. Clinical Infectious Diseases 39:9, 1353-1362
CrossRef2017
Haleh Bagheri, Atoussa Fouladi, Karl Barange, Maryse Lapeyre-Mestre, Jean-Louis Payen, Jean Louis Montastruc, Jean-Pierre Vinel. (2004) Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b–Ribavirin Therapy. Pharmacotherapy 24:11, 1546-1553
CrossRef2018
Lorna M Dove. (2004) Management of hepatitis C after transplantation. European Journal of Gastroenterology & Hepatology 16:11, 1131-1133
CrossRef2019
M.D. Tanamly, F. Tadros, S. Labeeb, H. Makld, M. Shehata, N. Mikhail, M. Abdel-Hamid, M. Shehata, L. Abu-Baki, A. Medhat, L.S. Magder, N.H. Afdhal, G.T. Strickland. (2004) Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Digestive and Liver Disease 36:11, 752-759
CrossRef2020
R. J. Aspinall, P. J. Pockros. (2004) The management of side-effects during therapy for hepatitis C. Alimentary Pharmacology and Therapeutics 20:9, 917-929
CrossRef2021
Gianluigi Giannelli, Graziana Guadagnino, Pietro Dentico, Guido Antonelli, Salvatore Antonaci. (2004) MxA and PKR Expression in Chronic Hepatitis C. Journal of Interferon & Cytokine Research 24:11, 659-663
CrossRef2022
HIDEYUKI NOMURA, HIRONORI TANIMOTO, EIJI KAJIWARA, JUNYA SHIMONO, TOSHIHIRO MARUYAMA, NOBUYUKI YAMASHITA, MASANORI NAGANO, MASASHI HIGASHI, TAMOTSU MUKAI, YUTAKA MATSUI, JUN HAYASHI, SEIZABURO KASHIWAGI, HIROMI ISHIBASHI. (2004) Factors contributing to ribavirin-induced anemia. Journal of Gastroenterology and Hepatology 19:11, 1312-1317
CrossRef2023
Mohammad S. Khuroo, Mehnaaz S. Khuroo, Salim T. Dahab. (2004) Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Alimentary Pharmacology and Therapeutics 20:9, 931-938
CrossRef2024
Erzsébet Bálint, Márta Bakay, Klára Ónody, F. Farkas, G. Horváth, Gy. Tolvaj, K. Dávid, Margit Horányi, Ilona Béládi. (2004) Therapy-Induced Antibodies Against the Antiviral and Antiproliferative Effects of Interferons in Patients with Chronic Hepatitis C Virus Infection. Acta Microbiologica et Immunologica Hungarica 51:3, 359-369
CrossRef2025
Sandrine Castelain, Véronique Descamps, Vincent Thibault, Catherine François, Dorine Bonte, Virginie Morel, Jacques Izopet, Dominique Capron, Patricia Zawadzki, Gilles Duverlie. (2004) TaqMan amplification system with an internal positive control for HCV RNA quantitation. Journal of Clinical Virology 31:3, 227-234
CrossRef2026
Emil Chuang, Alfred Del Vecchio, Steve Smolinski, Xiao-Yu Song, Robert T. Sarisky. (2004) Biomedicines to reduce inflammation but not viral load in chronic HCV – what's the sense?. Trends in Biotechnology 22:10, 517-523
CrossRef2027
Naglaa H. Shoukry, Andrew G. Cawthon, Christopher M. Walker. (2004) CELL-MEDIATED IMMUNITY AND THE OUTCOME OF HEPATITIS C VIRUS INFECTION. Annual Review of Microbiology 58:1, 391-424
CrossRef2028
Rui T. Marinho, Ruth M. Pinto, Maria L. Santos, Miguel Carneiro de Moura. (2004) Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. Liver International 24:5, 413-418
CrossRef2029
G. R. Foster. (2004) Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics 20:8, 825-830
CrossRef2030
Ewa Orlewska. (2004) Cost-effectiveness of pegylated IFN-α 2b and - 2a and ribavirin for chronic hepatitis C treatment. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, 495-504
CrossRef2031
A. Alberti, L. Benvegnù, S. Boccato, A. Ferrari, G. Sebastiani. (2004) Natural history of initially mild chronic hepatitis C. Digestive and Liver Disease 36:10, 646-654
CrossRef2032
Emma C Thomson, Janice Main. (2004) Advances in hepatitis B and C. Current Opinion in Infectious Diseases 17:5, 449-459
CrossRef2033
J. J. Goedert, D. L. Brown, K. Hoots, K. E. Sherman. (2004) Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 10:s4, 205-210
CrossRef2034
Jennifer M. Loftis, Peter Hauser. (2004) The phenomenology and treatment of interferon-induced depression. Journal of Affective Disorders 82:2, 175-190
CrossRef2035
James Gotto, Geoffrey M Dusheiko. (2004) Hepatitis C and treatment with pegylated interferon and ribavirin. The International Journal of Biochemistry & Cell Biology 36:10, 1874-1877
CrossRef2036
Marcellin, Patrick, Lau, George K.K., Bonino, Ferruccio, Farci, Patrizia, Hadziyannis, Stephanos, Jin, Rui, Lu, Zhi-Meng, Piratvisuth, Teerha, Germanidis, Georgios, Yurdaydin, Cihan, Diago, Moises, Gurel, Selim, Lai, Ming-Yang, Button, Peter, Pluck, Nigel, . (2004) Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine 351:12, 1206-1217
Full Text2037
Juan I. Arenas, Hugo E. Vargas. (2004) Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterology Clinics of North America 33:3, 549-562
CrossRef2038
I. Vuillermoz, E. Khattab, E. Sablon, I. Ottevaere, D. Durantel, C. Vieux, C. Trepo, Fabien Zoulim. (2004) Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. Journal of Medical Virology 74:1, 41-53
CrossRef2039
Michal R. Pijak, Frantisek Gazdik, Stefan Hrusovsky. (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 40:3, 760-761
CrossRef2040
Furqaan Ahmed, Ira M. Jacobson. (2004) Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterology Clinics of North America 33:3, 513-526
CrossRef2041
Mandana Khalili, Nicole Proietti. (2004) Treatment of the hepatitis C virus in patients coinfected with HIV. Gastroenterology Clinics of North America 33:3, 479-496
CrossRef2042
Montserrat Laguno, Javier Murillas, Jos?? Luis Blanco, Esteban Mart??nez, Rosa Miquel, Jos?? M S??nchez-Tapias, Xavier Bargallo, Angeles Garc??a-Criado, Elisa de Lazzari, Mar??a Larrousse, Agathe Le??n, Montserrat Lonc??, Ana Milinkovic, Josep M Gatell, Josep Mallolas. (2004) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18:13, 27-36
CrossRef2043
Bruce R. Bacon. (2004) Chronic Hepatitis C and Normal ALT: Considerations for Treatment. The American Journal of Gastroenterology 99:9, 1706-1707
CrossRef2044
J. Main, H. Thomas. (2004) How should we manage the patient?. Journal of Viral Hepatitis 11:s1, 19-22
CrossRef2045
Ira M. Jacobson, Furqaan Ahmed, Mark W Russo, Edward Lebovics, Douglas T. Dieterich, Stephen P. Esposito, Nancy Bach, Franklin Klion, Hillel Tobias, Louis Antignano, Robert S. Brown, David Gabbaizadeh, Jane Geders, Hulya Levendoglu. (2004) Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT. The American Journal of Gastroenterology 99:9, 1700-1705
CrossRef2046
Claire Farel, Daniel L Suzman, Mary McLaughlin, Colleen Campbell, Chad Koratich, Henry Masur, Julia A Metcalf, Michael R Robinson, Michael A Polis, Shyam Kottilil. (2004) Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS 18:13, 1805-1809
CrossRef2047
Stefan Mauss, William Valenti, Jean DePamphilis, Frank Duff, Lisa Cupelli, Sharon Passe, Jonathan Solsky, Francesca J Torriani, Douglas Dieterich, Dominique Larrey. (2004) Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 18:13, 21-25
CrossRef2048
Lorna M. Dove. (2004) A general approach to the management of chronic hepatitis C. Gastroenterology Clinics of North America 33:3, 463-477
CrossRef2049
Robert J. Fontana. (2004) Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Gastroenterology Clinics of North America 33:3, 527-547
CrossRef2050
Y. Getachew, J. D. Browning, M. Prebis, T. Rogers, G. R. Brown. (2004) Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation. Alimentary Pharmacology and Therapeutics 20:6, 629-636
CrossRef2051
Roberta Soffredini, Maria Grazia Rumi, Maria Luisa Parravicini, Guido Ronchi, Ersilio Del Ninno, Antonio Russo, Massimo Colombo. (2004) Serum Levels of Hepatitis C Virus Core Antigen as a Marker of Infection and Response to Therapy. The American Journal of Gastroenterology 99:9, 1738-1743
CrossRef2052
J. F. Dillon. (2004) What is the best treatment?. Journal of Viral Hepatitis 11:s1, 23-27
CrossRef2053
Sangik Oh, Nezam H. Afdhal. (2004) Antiviral therapy for treatment naı̈ve patients with hepatitis C virus. Gastroenterology Clinics of North America 33:3, 497-511
CrossRef2054
Martin Schaefer, Andreas Heinz, Markus Backmund. (2004) Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 99:9, 1167-1175
CrossRef2055
M. Enomoto, S. Nishiguchi, M. Kohmoto, A. Tamori, D. Habu, T. Takeda, S. Seki, S. Shiomi. (2004) Effects of ribavirin combined with interferon-alpha2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. Journal of Viral Hepatitis 11:5, 448-454
CrossRef2056
S. D. Sullivan, D. M. Jensen, D. E. Bernstein, T. I. Hassanein, G. R. Foster, S. S. Lee, H. Cheinquer, A. Craxi, Graham Cooksley, W. Klaskala, K. Pettit, K. K. Patel, J. Green. (2004) Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C. The American Journal of Gastroenterology 99:8, 1490-1496
CrossRef2057
Alexander Monto. (2004) Alcohol and hepatitis C: Implications for disease progression and treatment. Current Hepatitis Reports 3:3, 105-111
CrossRef2058
A. W. LIN, S. A. GONZALEZ, S. CUNNINGHAM-RUNDLES, G. DORANTE, S. MARSHALL, A. TIGNOR, C. HA, I. M. JACOBSON, A. H. TALAL. (2004) CD56 +dim and CD56 +bright cell activation and apoptosis in hepatitis C virus infection. Clinical & Experimental Immunology 137:2, 408-416
CrossRef2059
M. S. Campbell, K. R. Reddy. (2004) The evolving role of liver biopsy. Alimentary Pharmacology and Therapeutics 20:3, 249-259
CrossRef2060
Frederick L. Altice, R. Douglas Bruce. (2004) Hepatitis C virus infection in United States correctional institutions. Current Hepatitis Reports 3:3, 112-118
CrossRef2061
Geert Leroux-Roels, Erik Depla, Frank Hulstaert, Leen Tobback, Stéphanie Dincq, Jaques Desmet, Isabelle Desombere, Geert Maertens. (2004) A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22:23-24, 3080-3086
CrossRef2062
Hisashi Ishida, Kazuyoshi Ohkawa, Atsushi Hosui, Naoki Hiramatsu, Tatsuya Kanto, Keiji Ueda, Tetsuo Takehara, Norio Hayashi. (2004) Involvement of p38 signaling pathway in interferon-α-mediated antiviral activity toward hepatitis C virus. Biochemical and Biophysical Research Communications 321:3, 722-727
CrossRef2063
Jenny Heathcote, Alnoor Ramji. (2004) When to treat patients with chronic hepatitis C. Current Gastroenterology Reports 6:4, 261-263
CrossRef2064
Thomas Schussler, Catherine Staffeld-Coit, James Eason, Satheesh Nair. (2004) Severe Hepatitis C Infection in a Renal Transplant Recipient Following Hepatitis C Genotype Mismatch Transplant. American Journal of Transplantation 4:8, 1375-1378
CrossRef2065
Luca Lo Nigro, Paola Guardo, Milena La Spina, Elena Mirabile, Paola Pisana, Gino Schilir
CrossRef2066
T Stroffolini, A Mariano, G Iantosca. (2004) Reported risk factors are useless in detecting HCV-positive subjects in the general population. Digestive and Liver Disease 36:8, 547-550
CrossRef2067
Volker Brass, Hubert E Blum, Darius Moradpour. (2004) Recent developments in target identification against hepatitis C virus. Expert Opinion on Therapeutic Targets 8:4, 295-307
CrossRef2068
, Rudolf E Stauber, Harald Hofer, Franz Hackl, Kurt Schüze, Christian Datz, Karin Hegenbarth, Wolfgang Jessner, Petra Steindl-Munda, Peter Ferenci. (2004) Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wiener Klinische Wochenschrift 116:15-16, 530-535
CrossRef2069
Michael Stuart Forman, Alexandra Valsamakis. (2004) Increased Sensitivity of the Roche COBAS AMPLICOR HCV Test, Version 2.0, Using Modified Extraction Techniques. The Journal of Molecular Diagnostics 6:3, 225-230
CrossRef2070
Hariprasad S Trivedi, Madhuri Trivedi. (2004) Subnormal Rise of Erythropoietin in Patients Receiving Interferon and Ribavirin Combination Therapy for Hepatitis C. Journal of Clinical Gastroenterology 38:7, 595-598
CrossRef2071
Torriani, Francesca J., Rodriguez-Torres, Maribel, Rockstroh, Jürgen K., Lissen, Eduardo, Gonzalez-García, Juan, Lazzarin, Adriano, Carosi, Giampiero, Sasadeusz, Joseph, Katlama, Christine, Montaner, Julio, Sette, Hoel Jr., Passe, Sharon, De Pamphilis, Jean, Duff, Frank, Schrenk, Uschi Marion, Dieterich, Douglas T., . (2004) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients. New England Journal of Medicine 351:5, 438-450
Full Text2072
Chung, Raymond T., Andersen, Janet, Volberding, Paul, Robbins, Gregory K., Liu, Tun, Sherman, Kenneth E., Peters, Marion G., Koziel, Margaret J., Bhan, Atul K., Alston, Beverly, Colquhoun, Dodi, Nevin, Tom, Harb, George, van der Horst, Charles, . (2004) Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. New England Journal of Medicine 351:5, 451-459
Full Text2073
Johannes Wiegand, Elmar J
CrossRef2074
S.James Matthews, Christopher McCoy. (2004) Peginterferon alfa-2a: A review of approved and investigational uses. Clinical Therapeutics 26:7, 991-1025
CrossRef2075
Fareed Rahman, Theo Heller, Yuji Sobao, Eishiro Mizukoshi, Michelina Nascimbeni, Harvey Alter, Steven Herrine, Jay Hoofnagle, T. Jake Liang, Barbara Rehermann. (2004) Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 40:1, 87-97
CrossRef2076
Andrea De Luca, Simona Di Giambenedetto, Antonella Cingolani, Adriana Ammassari, Giuseppe Marasca, Mario Tumbarello, Massimo Fantoni, Enrica Tamburrini, Roberto Cauda. (2004) Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. AIDS 18:11, 1602-1604
CrossRef2077
Marc Lehmann, Manuela F. Meyer, Masyar Monazahian, Hans L. Tillmann, Michael P. Manns, Heiner Wedemeyer. (2004) High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. Journal of Medical Virology 73:3, 387-391
CrossRef2078
G. V. Papatheodoridis, E. Cholongitas. (2004) Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. Journal of Viral Hepatitis 11:4, 287-296
CrossRef2079
Pierre Pradat, Marianne Maynard, Maria Buti, Pascale Berthillon, Gaston Picchio, Hans L. Tillmann, Johannes Wiegand, Nicolas Voirin, Michael P. Manns, Juan-Ignacio Esteban, Mich
CrossRef2080
B. Kronenberger, C. Sarrazin, W. P. Hofmann, M. von Wagner, E. Herrmann, C. Welsch, R. Elez, B. Ruster, A. Piiper, S. Zeuzem. (2004) Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. Journal of Viral Hepatitis 11:4, 310-318
CrossRef2081
Paul J. Pockros, Robert Carithers, Paul Desmond, Daniel Dhumeaux, Michael W. Fried, Patrick Marcellin, Mitchell L. Shiffman, Gerald Minuk, K. Rajender Reddy, Robert W. Reindollar, Amy Lin, Michael J. Brunda, . (2004) Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial. The American Journal of Gastroenterology 99:7, 1298-1305
CrossRef2082
Stefan Mauss, Florian Berger, Joerg Goelz, Bernhard Jacob, G
CrossRef2083
J. M. Vrolijk, T. J. Tang, J. Kwekkeboom, B. L. Haagmans, A. J. Herscheid, J. G. Kusters, H. L. A. Janssen, J. T. Brouwer, S. W. Schalm. (2004) Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection. Journal of Viral Hepatitis 11:4, 342-348
CrossRef2084
Lennox J. Jeffers, William Cassidy, Charles D. Howell, Sylvia Hu, K. Rajender Reddy. (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:6, 1702-1708
CrossRef2085
Kuo-Hsiung Shu, Joung-Liang Lan, Ming-Ju Wu, Chi-Hung Cheng, Chen-Hsu Chen, Wen-Chin Lee, Horng-Rong Chang, Jong-Da Lian. (2004) ULTRALOW-DOSE ALPHA-INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF ACTIVE HEPATITIS C IN RENAL TRANSPLANT RECIPIENTS. Transplantation 77:12, 1894-1896
CrossRef2086
Sanaa M. Kamal, Alaa Ismail, Camilla S. Graham, Qi He, Jens W. Rasenack, Thomas Peters, Ahmed A. Tawil, Jutta J. Fehr, Khalifa El Sayed Khalifa, Mahmoud M. Madwar, Margaret James Koziel. (2004) Pegylated interferon ? therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39:6, 1721-1731
CrossRef2087
Itzhak Rosner, Michael Rozenbaum, Elias Toubi, Aharon Kessel, Jochanan E. Naschitz, Eli Zuckerman. (2004) The case for hepatitis C arthritis. Seminars in Arthritis and Rheumatism 33:6, 375-387
CrossRef2088
Natalie Stieltjes, Nadra Ounnoughene, Emilie Sava, Patricia Paugy, Valerie Roussel-Robert, Arielle R. Rosenberg, Benoit Terris, Dominique Salmon-Ceron, Philippe Sogni. (2004) Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus. British Journal of Haematology 125:6, 769-776
CrossRef2089
Mingjun Huang, Milind Deshpande. (2004) Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline. Expert Review of Anti-infective Therapy 2:3, 375-388
CrossRef2090
R.F.C. d'Souza. (2004) Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. QJM 97:6, 331-336
CrossRef2091
Muir, Andrew J., Bornstein, Jeffrey D., Killenberg, Paul G., . (2004) Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites. New England Journal of Medicine 350:22, 2265-2271
Full Text2092
Richard K. Sterling, Charlotte M. Hofmann, Velimir A. Luketic, Arun J. Sanyal, Melissa J. Contos, A. Scott Mills, Mitchell L. Shiffman. (2004) Treatment of Chronic Hepatitis C Virus in the Virginia Department of Corrections: Can Compliance Overcome Racial Differences to Response?. The American Journal of Gastroenterology 99:5, 866-872
CrossRef2093
M. Buti Ferret. (2004) Tratamiento de la infección por VHB y VHC. Medicine - Programa de Formación Médica Continuada Acreditado 9:11, 674-680
CrossRef2094
Emiliano Giostra, Gerd A. Kullak-Ublick, Walter Keller, Ronald Fried, Claire Vanlemmens, Stephan Kraehenbuhl, Sandrine Locher, Hans-Peter Egger, Pierre-Alain Clavien, Antoine Hadengue, Gilles Mentha, Philippe Morel, Francesco Negro. (2004) Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplant International 17:4, 169-176
CrossRef2095
Aijaz Ahmed, Emmet B Keeffe. (2004) Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 126:5, 1409-1415
CrossRef2096
R. T. Marinho, R. Pinto, M. L. Santos, I. V. Lobos, M. C. Moura. (2004) Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. Journal of Viral Hepatitis 11:3, 206-216
CrossRef2097
Ignazio Grattagliano, Stefan Russmann, Vincenzo O. Palmieri, Peter J
CrossRef2098
Nezam H. Afdhal, Douglas T. Dieterich, Paul J. Pockros, Eugene R. Schiff, Mitchell L. Shiffman, Mark S. Sulkowski, Teresa Wright, Zobair Younossi, Betty L. Goon, K.Linda Tang, Peter J. Bowers. (2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California.. Gastroenterology 126:5, 1302-1311
CrossRef2099
N. Kumagai, N. Takahashi, M. Kinoshita, S. Tsunematsu, K. Tsuchimoto, H. Saito, H. Ishii. (2004) Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study. Journal of Viral Hepatitis 11:3, 225-235
CrossRef2100
Hideyuki Nomura, Suketo Sou, Hironori Tanimoto, Takashi Nagahama, Yoichi Kimura, Jun Hayashi, Hiromi Ishibashi, Seizaburo Kashiwagi. (2004) Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial. Hepatology 39:5, 1213-1219
CrossRef2101
E. Santagostino, F. De Filippi, M. G. Rumi, M. Rivi, M. Colombo, P. M. Mannucci, . (2004) Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 44:5, 790-794
CrossRef2102
N. Brau. (2004) Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 11:3, 191-197
CrossRef2103
M. S. Sulkowski, R. Wasserman, L. Brooks, L. Ball, R. Gish. (2004) Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis 11:3, 243-250
CrossRef2104
T. Fehr. (2004) Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrology Dialysis Transplantation 19:5, 1049-1053
CrossRef2105
Laurent Alric, Emmanuelle Plaisier, Sophie Thébault, Jean-Marie Péron, Lionel Rostaing, Jacques Pourrat, Pierre Ronco, Jean-Charles Piette, Patrice Cacoub. (2004) Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. American Journal of Kidney Diseases 43:4, 617-623
CrossRef2106
Jacqueline O’Leary, Raymond T Chung. (2004) New antiviral therapies for hepatitis C. Expert Review of Anti-infective Therapy 2:2, 235-243
CrossRef2107
Doris B. Strader, Teresa Wright, David L. Thomas, Leonard B. Seeff. (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:4, 1147-1171
CrossRef2108
Mark S. Sulkowski. (2004) Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. Hepatology 39:4, 906-908
CrossRef2109
Mark S. Sulkowski, Franco Felizarta, Cheryl Smith, Jidah Slim, Ruth Berggren, Russell Goodman, Lisa Ball, Mandana Khalili, Douglas T. Dieterich. (2004) Daily Versus Thrice-Weekly Interferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Persons: A Multicenter Randomized Controlled Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 35:5, 464-472
CrossRef2110
Brian L. Pearlman. (2004) Hepatitis C Infection: A Clinical Review. Southern Medical Journal 97:4, 365-373
CrossRef2111
Norbert Bräu, Maribel Rodriguez-Torres, Dale Prokupek, Maurizio Bonacini, Carol A. Giffen, Jeffery J. Smith, Kevin R. Frost, Jay R. Kostman. (2004) Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 39:4, 989-998
CrossRef2112
Vincent Soriano, Mayte Pérez-Olmeda, Pilar Ríos, Marina Núñez, Javier García-Samaniego, Juan González-Lahoz. (2004) Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients. AIDS Research and Human Retroviruses 20:4, 351-353
CrossRef2113
Oluwatoyin M. Adeyemi, Donald Jensen, Bashir Attar, Rony Ghaoui, Maureen Gallagher, Deborah Wolen, Scott J. Cotler. (2004) Hepatitis C Treatment Eligibility in an Urban Population with and without HIV Coinfection. AIDS Patient Care and STDs 18:4, 239-245
CrossRef2114
Andrew S Ross, Atul K Bhan, Manuel Pascual, Michael Thiim, A Benedict Cosimi, Raymond T Chung. (2004) Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clinical Transplantation 18:2, 166-173
CrossRef2115
Alexander Neugebauer, Christian D.P. Klein, Rolf W. Hartmann. (2004) Protein-dynamics of the putative HCV receptor CD81 large extracellular loop. Bioorganic & Medicinal Chemistry Letters 14:7, 1765-1769
CrossRef2116
Susan Zickmund, Stephen L. Hillis, Mitchell J. Barnett, Laura Ippolito, Douglas R. LaBrecque. (2004) Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39:4, 999-1007
CrossRef2117
Robert G. Gish. (2004) Treating hepatitis C: the state of the art. Gastroenterology Clinics of North America 33:1, 1-9
CrossRef2118
Jean-Michel Pawlotsky, Harel Dahari, Avidan U. Neumann, Christophe Hezode, Georgios Germanidis, Isabelle Lonjon, Laurent Castera, Daniel Dhumeaux. (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:3, 703-714
CrossRef2119
Stephanos J. Hadziyannis, George V. Papatheodoridis. (2004) Recent peginterferon and ribavirin combination trials. Current Hepatitis Reports 3:1, 30-37
CrossRef2120
Paul J. Pockros. (2004) Current status of immunomodulatory therapies in HCV infection. Current Hepatitis Reports 3:1, 16-22
CrossRef2121
R. Perrillo, K. D. Rothstein, R. Rubin, I. Alam, J. Imperial, G. Harb, S. Hu, W. Klaskala. (2004) Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis 11:2, 157-165
CrossRef2122
Shiela M Strauss, Janetta M Astone, Don Des Jarlais, Holly Hagan. (2004) A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence 73:3, 227-236
CrossRef2123
Jordi Bruix, Loreto Boix, Margarita Sala, Josep M Llovet. (2004) Focus on hepatocellular carcinoma. Cancer Cell 5:3, 215-219
CrossRef2124
Michael P Manns. (2004) Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterology Clinics of North America 33:1, 11-24
CrossRef2125
Eva Herrmann, Stefan Zeuzem. (2004) Update on viral kinetics and hcv antiviral therapy. Current Hepatitis Reports 3:1, 5-9
CrossRef2126
W. G. Powderly. (2004) Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits. Clinical Infectious Diseases 38:Supplement 2, S109-S113
CrossRef2127
Robert J Fontana, Gregory T Everson, Sony Tuteja, Hugo E Vargas, Mitchell L Shiffman. (2004) Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology 2:3, 183-197
CrossRef2128
P. E. Golstein, M. L. Delforge, J. Deviere, P. Marcellin. (2004) Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. Journal of Viral Hepatitis 11:2, 183-186
CrossRef2129
Nezam H. Afdhal. (2004) Role of epoetin alfa in maintaining ribavirin dose. Gastroenterology Clinics of North America 33:1, 25-35
CrossRef2130
John G McHutchison, Anouk T Dev. (2004) Future trends in managing hepatitis C. Gastroenterology Clinics of North America 33:1, 51-61
CrossRef2131
Brett D. Kalmowitz, Nezam H. Afdhal. (2004) Maintenance therapies for hepatitis C. Current Hepatitis Reports 3:1, 23-29
CrossRef2132
A. Apolinario, M. Diago, O. Lo Iacono, R. Lorente, C. Perez, P. L. Majano, G. Clemente, C. Garcia-Monzon. (2004) Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. Alimentary Pharmacology and Therapeutics 19:5, 551-562
CrossRef2133
Jean-Michel Pawlotsky. (2004) Mechanisms of drug resistance to current and future antiviral therapies for hepatitis C virus infection. Current Hepatitis Reports 3:1, 38-43
CrossRef2134
Keyur Patel, Anouk T. Dev. (2004) Adherence to antiviral therapy in chronic hepatitis C. Current Hepatitis Reports 3:1, 10-15
CrossRef2135
J Lee. (2004) A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. Journal of Virological Methods 116:1, 27-33
CrossRef2136
Thomas R. OʼBrien, Gregory Kirk, Mingdong Zhang. (2004) Hepatocellular Carcinoma. The Cancer Journal 10:2, 67-73
CrossRef2137
Peter Hauser. (2004) Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNα-induced depression. Gastroenterology Clinics of North America 33:1, 37-50
CrossRef2138
Karan Emerick. (2004) TREATMENT OF HEPATITIS C IN CHILDREN. The Pediatric Infectious Disease Journal 23:3, 257-258
CrossRef2139
M. Angelico, M. Cepparulo, F. Angelico, S. Francioso, A. Barlattani, F. Di Candilo, R. Della Vecchia, L. Demelia, G. De Sanctis, S. Gentile, A. Grieco, G. Parruti, G. Sabusco, L. Tarquini, A. Tosti, S. Zaru, . (2004) A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology and Therapeutics 19:3, 339-347
CrossRef2140
Joseph Ahn, Steven Flamm. (2004) Peginterferon-α2b and ribavirin. Expert Review of Anti-infective Therapy 2:1, 17-25
CrossRef2141
Masao Omata, Haruhiko Yoshida. (2004) Prevention and treatment of hepatocellular carcinoma. Liver Transplantation 10:S2, S111-S114
CrossRef2142
Jean-Michel Pawlotsky, John G. McHutchison. (2004) Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 39:2, 554-567
CrossRef2143
Gregor Leckie, George Schneider, Klara Abravaya, Robert Hoenle, Julie Johanson, John Lampinen, Reuben Ofsaiof, Lisa Rundle, Shruti Shah, Andrea Frank, Dan Toolsie, Roy Vijesurier, Hong Wang, John Robinson. (2004) Performance attributes of the LCx® HCV RNA quantitative assay. Journal of Virological Methods 115:2, 207-215
CrossRef2144
Manal F. Abdelmalek, Roberto J. Firpi, Consuelo Soldevila-Pico, Alan I. Reed, Alan W. Hemming, Chen Liu, James M. Crawford, Gary L. Davis, David R. Nelson. (2004) Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 10:2, 199-207
CrossRef2145
Damien Lucidarme, Bernard Filoche. (2004) Hépatite aiguë C : traitement immédiat, précoce ou différé ?. Gastroentérologie Clinique et Biologique 28:2, 126-128
CrossRef2146
Ramó Bataller, Yong-han Paik, Jeffrey N. Lindquist, John J. Lemasters, David A. Brenner. (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126:2, 529-540
CrossRef2147
V. Soriano, J. M. Miro, J. Garcia-Samaniego, J. Torre-Cisneros, M. Nunez, J. del Romero, L. Martin-Carbonero, J. Castilla, J. A. Iribarren, C. Quereda, M. Santin, J. Gonzalez, J. R. Arribas, I. Santos, J. Hernandez-Quero, E. Ortega, V. Asensi, M. A. del Pozo, J. Berenguer, C. Tural, B. Clotet, M. Leal, J. Mallolas, J. M. Sanchez-Tapias, S. Moreno, J. M. Gatell, M. J. Tellez, R. Rubio, E. Ledesma, P. Domingo, P. Barreiro, J. Pedreira, M. Romero, J. Gonzalez-Lahoz, E. Lissen. (2004) Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. Journal of Viral Hepatitis 11:1, 2-17
CrossRef2148
Paolo Caliceti. (2004) Pharmacokinetics of pegylated interferons: What is misleading?. Digestive and Liver Disease 36, S334-S339
CrossRef2149
Will J. Fecht, Alex S. Befeler. (2004) Hepatocellular carcinoma: Updates in primary prevention. Current Gastroenterology Reports 6:1, 37-43
CrossRef2150
Thierry Poynard. (2004) Treatment of cirrhotic patients in the pegylated interferon era. Digestive and Liver Disease 36, S344-S348
CrossRef2151
J. T. Wilde. (2004) HIV and HCV coinfection in haemophilia. Haemophilia 10:1, 1-8
CrossRef2152
Luz Martin‐Carbonero, Yves Benhamou, Massimo Puoti, Juan Berenguer, Jose Mallolas, Carmen Quereda, Ana Arizcorreta, Antonio Gonzalez, Jurgen Rockstroh, Victor Asensi, Pilar Miralles, Montse Laguno, Leonor Moreno, Jose Antonio Giron, Martin Vogel, Javier Garcia‐Samaniego, Marina Nunez, Miriam Romero, Santiago Moreno, Juan Jose de la Cruz, Vincent Soriano. (2004) Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus–Infected Patients with Chronic Hepatitis C: A European Collaborative Study. Clinical Infectious Diseases 38:1, 128-133
CrossRef2153
Pascale Trimoulet, Victor de L
CrossRef2154
Antonio Craxi. (2004) Foreword. Digestive and Liver Disease 36, S333
CrossRef2155
Hector Rodriguez-Luna, Amer Khatib, Pratima Sharma, Giovanni De Petris, James W. Williams, Jose Ortiz, Kathleen Hansen, David Mulligan, Adyr Moss, David D. Douglas, Vijayan Balan, Jorge Rakela, Hugo E. Vargas. (2004) Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1. Transplantation 77:2, 190-194
CrossRef2156
Anouk Dev, Keyur Patel, John G. McHutchison. (2004) New therapies for chronic hepatitis C virus infection. Current Gastroenterology Reports 6:1, 77-86
CrossRef2157
K. Lindahl, R. Schvarcz, A. Bruchfeld, L. Stahle. (2004) Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. Journal of Viral Hepatitis 11:1, 84-87
CrossRef2158
Susan E Chan, Jonathan M Schwartz, Hugo R Rosen. (2004) Treatment of Hepatitis C in Solid Organ Transplantation. Drugs 64:5, 489-498
CrossRef2159
Sean D Sullivan, Antonio Craxi, Alfredo Alberti, Giovanni Giuliani, Claudio De Carli, Neil Wintfeld, Kavita K Patel, Jesse Green. (2004) Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. PharmacoEconomics 22:4, 257-265
CrossRef2160
Vincent Soriano, Massimo Puoti, Mark Sulkowski, Stefan Mauss, Patrice Cacoub, Antonietta Cargnel, Douglas Dieterich, Angelos Hatzakis, Jurgen Rockstroh. (2004) Care of patients with hepatitis C and HIV co-infection. AIDS 18:1, 1-12
CrossRef2161
Piero Luigi Almasio. (2004) Weight-based dosing: Which impact on efficacy and safety of therapy?. Digestive and Liver Disease 36, S349-S353
CrossRef2162
Ángel Luis Ballesteros, Sandra Franco, Daniel Fuster, Ramón Planas, Miguel Ángel Martínez, Lesly Acosta, Guillem Sirera, Anna Salas, Jordi Tor, Celestino Rey-Joly, Bonaventura Clotet, Cristina Tural. (2004) Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection. AIDS 18:1, 59-66
CrossRef2163
Vlad Ratziu, Jean-Baptiste Trabut, Thierry Poynard. (2004) Fat, diabetes, and liver injury in chronic hepatitis C. Current Gastroenterology Reports 6:1, 22-29
CrossRef2164
Leonor Moreno, Carmen Quereda, Ana Moreno, María J Perez-Elías, Antonio Antela, José L Casado, Fernando Dronda, Maria L Mateos, Rafael Bárcena, Santiago Moreno. (2004) Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 18:1, 67-73
CrossRef2165
Miriam Romero, Mayte P??rez-Olmeda, Javier Garc??a-Samaniego, Vicente Soriano. (2004) Management of Chronic Hepatitis C in Patients Co-Infected with HIV. Drug Safety 27:1, 7-24
CrossRef2166
Antonio Craxi. (2004) Early virologic response with pegylated interferons. Digestive and Liver Disease 36, S340-S343
CrossRef2167
Peter Ferenci. (2004) Treatment of chronic viral hepatitis. Best Practice & Research Clinical Gastroenterology 18, 113-120
CrossRef2168
Greg L Plosker, Gillian M Keating. (2004) Peginterferon-??-2a (40kD) Plus Ribavirin. Drugs 64:24, 2823-2843
CrossRef2169
Winston Lee, Douglas Dieterich. (2004) Challenges in the Management of HIV and Hepatitis C Virus Co-infection. Drugs 64:7, 693-700
CrossRef2170
Bruno C. Medeiros, Paul A. Seligman, Gregory T. Everson, Lisa M. Forman. (2004) Possible Autoimmune Thrombocytopenia Associated With Pegylated Interferon-??2a Plus Ribavarin Treatment For Hepatitis C. Journal of Clinical Gastroenterology 38:1, 84-86
CrossRef2171
Mark W. Russo, Michael W. Fried. (2004) Guidelines for stopping therapy in chronic hepatitis C. Current Gastroenterology Reports 6:1, 17-21
CrossRef2172
Steven Callens, Emmanuel Bottieau, Peter Michielsen, Robert Colebunders. (2004) Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 18:1, 131
CrossRef2173
Michelle M. Lipman, Scott J. Cotler. (2003) Antiviral therapy for hepatitis C. Current Treatment Options in Gastroenterology 6:6, 445-453
CrossRef2174
Edna Strauss, Hoel Sette Junior. (2003) Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration. Liver International 23:6, 410-412
CrossRef2175
Xavier Forns, Ramón Bataller. (2003) Can we identify liver fibrosis in HCV-infected patients without a liver biopsy?. Current Hepatitis Reports 2:4, 145-151
CrossRef2176
Thierry Poynard, Man-Fung Yuen, Vlad Ratzin, Ching Lung Lai. (2003) Viral hepatitis C. The Lancet 362:9401, 2095-2100
CrossRef2177
Jean-Michel Pawlotsky. (2003) The nature of interferon-?? resistance in hepatitis C virus infection. Current Opinion in Infectious Diseases 16:6, 587-592
CrossRef2178
Gail Matthews, Gregory Dore. (2003) Response to Soriano et al., ???Treatment of chronic hepatitis C virus infection. AIDS 17:18, 2665-2667
CrossRef2179
Sheng-Shun Yang, Ming-Yang Lai, Ding-Shinn Chen, Gran-Hum Chen, Jia-Horng Kao. (2003) Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver International 23:6, 426-433
CrossRef2180
Aijaz Ahmed, Emmet B. Keeffe. (2003) Upodate on chronic hepatitis C. Comprehensive Therapy 29:4, 224-232
CrossRef2181
Mayte Pérez-Olmeda, Vincent Soriano, Victor Asensi, Dolores Morales, Miriam Romero, Anna Ochoa, Fausto Sánchez-Montero, Miguel Santin, Josep Guardiola, Jesús Blanch, Marina Núñez, Inmaculada Jiménez-Nácher, Javier García-Samaniego, The HCV/HIV Spanish Study Group. (2003) Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin. AIDS Research and Human Retroviruses 19:12, 1083-1089
CrossRef2182
D MONEY. (2003) Antiviral and antiretroviral use in pregnancy. Obstetrics and Gynecology Clinics of North America 30:4, 731-749
CrossRef2183
Kyung-Ju Ryu, Seong-Wook Lee. (2003) Identification of the Most Accessible Sites to Ribozymes on the Hepatitis C Virus Internal Ribosome Entry Site. Journal of Biochemistry and molecular biology 36:6, 538-544
CrossRef2184
Douglas T. Dieterich, Ronald Wasserman, Norbert Brau, Tarek I. Hassanein, Edmund J. Bini, Peter J. Bowers, Mark S. Sulkowski. (2003) Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. The American Journal of Gastroenterology 98:11, 2491-2499
CrossRef2185
Lorraine Comanor, David Hendricks. (2003) Hepatitis C virus RNA tests: performance attributes and their impact on clinical utility. Expert Review of Molecular Diagnostics 3:6, 689-702
CrossRef2186
(2003) Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. The American Journal of Gastroenterology 98:11, 2344-2347
CrossRef2187
Michael Camilleri. (2003) GI clinical research 2002–2003: the year in review. Clinical Gastroenterology and Hepatology 1:6, 415-420
CrossRef2188
Rajnish S. Dave, Roger J. Pomerantz. (2003) RNA interference: on the road to an alternate therapeutic strategy!. Reviews in Medical Virology 13:6, 373-385
CrossRef2189
PD Griffiths. (2003) The end of the needle is in sight. Reviews in Medical Virology 13:6, 343-345
CrossRef2190
Jean-Baptiste Nousbaum, Jean-François Cadranel, Olivier Savary, Marie Christine Legrand, Patrice Dumouchel, Hervé Gouérou. (2003) Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients. Journal of Hepatology 39:4, 655-656
CrossRef2191
A. Zaman, M. B. Fennerty, E. B. Keeffe. (2003) Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Alimentary Pharmacology and Therapeutics 18:7, 661-670
CrossRef2192
Hisashi Moriguchi, Raymond T Chung, Ana Maria Contreras, Namiki Izumi, Takamoto Uemura, Makoto Kobayashi, Chifumi Sato. (2003) The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection. Gastroenterology 125:4, 1284-1286
CrossRef2193
MR Nelson, G Matthews, MG Brook, J Main, . (2003) BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. HIV Medicine 4:S1, 52-62
CrossRef2194
Catherine M Meyers, Leonard B Seeff, Catherine O Stehman-Breen, Jay H Hoofnagle. (2003) Hepatitis C and renal disease: an update 1 1Summary of a workshop held October 21 to 22, 2002, in the Lister Hill Auditorium, The National Institutes of Health, Bethesda, MD.. American Journal of Kidney Diseases 42:4, 631-657
CrossRef2195
Wolfgang Vogel. (2003) Peginterferon-α 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 1:3, 423-431
CrossRef2196
David Durantel, Vanessa Escuret, Fabien Zoulim. (2003) Current and emerging therapeutic approaches to hepatitis C infection. Expert Review of Anti-infective Therapy 1:3, 441-454
CrossRef2197
Alexander Monto. (2003) Alcohol and hepatitis C: Implications for disease progression and treatment. Current Hepatitis Reports 2:3, 125-131
CrossRef2198
P Ferenci. (2003) Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C. Digestive and Liver Disease 35:9, 601-606
CrossRef2199
D. M. DiMichele, G. Mirani, P. Wilfredo Canchis, D. W. Trost, A. H. Talal. (2003) Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 9:5, 613-618
CrossRef2200
Jagdeep J Vyas, Robert S Brown, Paul J Gaglio. (2003) Hepatitis C–HIV coinfection: current and future therapy. Expert Review of Anti-infective Therapy 1:3, 433-439
CrossRef2201
Edmund J. Bini. (2003) Hepatitis C in veterans. Current Hepatitis Reports 2:3, 108-115
CrossRef2202
Helen S. Yee, Teresa L. Wright. (2003) Hepatitis C antiviral treatment in special populations. Current Hepatitis Reports 2:3, 101-107
CrossRef2203
D. T. Dieterich, J. L. Spivak. (2003) Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management. Clinical Infectious Diseases 37:4, 533-541
CrossRef2204
Michelle P Walker, Nanhua Yao, Zhi Hong. (2003) Promising candidates for the treatment of chronic hepatitis C. Expert Opinion on Investigational Drugs 12:8, 1269-1280
CrossRef2205
B. McGovern, I. Bica. (2003) Should Treatment of Hepatitis C in HIV-Seropositive and HIV-Seronegative Patients with Hemophilia Include Induction Doses of Interferon?. Clinical Infectious Diseases 37:3, 463-464
CrossRef2206
Nassim Kamar, Karine Sandres-Saune, Janick Selves, David Ribes, Olivier Cointault, Dominique Durand, Jacques Izopet, Lionel Rostaing. (2003) Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. American Journal of Kidney Diseases 42:1, 184-192
CrossRef2207
E. Formann, W. Jessner, L. Bennett, P. Ferenci. (2003) Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. Journal of Viral Hepatitis 10:4, 271-276
CrossRef2208
James Versalovic. (2003) Diagnostic Molecular Microbiology: Nucleic Acid Probes and Microbes. Pathology Case Reviews 8:4, 137-144
CrossRef2209
D. Neau, P. Trimoulet, M. Winnock, A. Rullier, B. Le Bail, D. Lacoste, J.-M. Ragnaud, P. B. Sage, M.-E. Lafon, G. Chene, M. Dupon, . (2003) Comparison of 2 Regimens that Include Interferon- -2a plus Ribavirin for Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus--Coinfected Patients. Clinical Infectious Diseases 36:12, 1564-1571
CrossRef2210
Jean-Michel Pawlotsky. (2003) Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Research 59:1, 1-11
CrossRef2211
Herbert L. Bonkovsky, Richard W. Lambrecht, Ying Shan. (2003) Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 30:2, 137-144
CrossRef2212
Paolo Rossi, Tullio Bertani, Piero Baio, Roberta Caldara, Patrizia Luliri, Francesca Tengattini, Piermario Bellavita, Gianna Mazzucco, Rocco Misiani. (2003) Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney International 63:6, 2236-2241
CrossRef2213
John T. H. T. Yu, George K. K. Lau. (2003) Treatment of hepatitis B and C following nonliver organ transplants. Current Hepatitis Reports 2:2, 82-87
CrossRef2214
A. Scott Muerhoff, Hans L. Tillmann, Michael P. Manns, George J. Dawson, Suresh M. Desai. (2003) GB Virus C genotype determination in GB Virus-C/HIV co-infected individuals. Journal of Medical Virology 70:1, 141-149
CrossRef2215
W. Sievert, R. Batey, L. Mollison, S. Pianko, J. Mcdonald, G. Marinos, W. Reed, S. Warner, S. Bowden, R. De Solom, P. Bhathal, . (2003) Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone. Alimentary Pharmacology & Therapeutics 17:9, 1197-1204
CrossRef2216
F Fred Poordad, Tram Tran, Paul Martin. (2003) Developments in hepatitis C therapy during 2000 – 2002. Expert Opinion on Emerging Drugs 8:1, 9-25
CrossRef2217
Mayte Pérez-Olmeda, Marina Núñez, Miriam Romero, Juan González, Angeles Castro, José Ramón Arribas, José Pedreira, Pablo Barreiro, Javier García-Samaniego, Luz Martín-Carbonero, Inmaculada Jiménez-Nácher, Vincent Soriano. (2003) Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17:7, 1023-1028
CrossRef2218
Mark W. Russo, Michael W. Fried. (2003) Side effects of therapy for chronic hepatitis C. Gastroenterology 124:6, 1711-1719
CrossRef2219
Graham R Foster. (2003) Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opinion on Pharmacotherapy 4:5, 685-691
CrossRef2220
Patrick Marcellin, Nathalie Boyer. (2003) Chronic viral hepatitis. Best Practice & Research Clinical Gastroenterology 17:2, 259-275
CrossRef2221
Scott J. Cotler, Mary J. Morrissey, Thelma E. Wiley, Thomas J. Layden, Donald M. Jensen. (2003) A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients. Journal of Clinical Gastroenterology 36:4, 352-355
CrossRef2222
Paul Masci, Ronald M. Bukowski, Phillip A. Patten, Blaire L. Osborn, Ernest C. Borden. (2003) New and modified interferon alfas: Preclinical and clinical data. Current Oncology Reports 5:2, 108-113
CrossRef2223
Stephanos J Hadziyannis, George V Papatheodoridis. (2003) Peginterferon-α 2a (40 kDa) for chronic hepatitis C. Expert Opinion on Pharmacotherapy 4:4, 541-551
CrossRef2224
G. Fattovich, I. Zagni, G. Fornaciari, E. Minola, P. Fabris, S. Boccia, M. Giusti, G. Abbati, M. Felder, P. Rovere, A. Redaelli, A. Tonon, R. Montanari, C. Paternoster, M. Distasi, E. Castagnetti, G. Tositti, C. Rizzo, S. Suppressa, M. Pantalena, L. Lomonaco, C. Scattolini, A. Tagger. (2003) Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. Journal of Viral Hepatitis 10:2, 111-117
CrossRef2225
Vincent Soriano, Luz Martín-Carbonero, Javier García-Samaniego. (2003) Treatment of chronic hepatitis C virus infection. AIDS 17:5, 751-753
CrossRef2226
Tram T. Tran, Fred Poordad, Paul Martin. (2003) Treatment of hepatitis C. Current Hepatitis Reports 2:1, 3-8
CrossRef2227
Mitchell L. Shiffman. (2003) Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?. Current Hepatitis Reports 2:1, 17-23
CrossRef2228
Gary L. Davis. (2003) Treatment of chronic hepatitis C: Improved combination therapy. Current Hepatitis Reports 2:1, 40-46
CrossRef2229
Markus Cornberg, Heiner Wedemeyer, Michael P. Manns. (2003) Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. Current Hepatitis Reports 2:1, 24-31
CrossRef2230
CATHERINE CRONE, GEOFFREY M. GABRIEL. (2003) Comprehensive Review of Hepatitis C for Psychiatrists: Risks, Screening, Diagnosis, Treatment, and Interferon-Based Therapy Complications. Journal of Psychiatric Practice 9:2, 93-110
CrossRef2231
Mazen Alsatie, Paul Y. Kwo. (2003) Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy. Current Hepatitis Reports 2:1, 32-39
CrossRef2232
S. S. Lee. (2003) Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Alimentary Pharmacology and Therapeutics 17:5, 611-621
CrossRef2233
Anna Rita Gigliotti, Francesca Fioredda, Raffaella Giacchino. (2003) Hepatitis B and C Infection in Children Undergoing Chemotherapy or Bone Marrow Transplantation. Journal of Pediatric Hematology/Oncology 25:3, 184-192
CrossRef2234
(2003) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C. New England Journal of Medicine 348:3, 259-260
Full Text2235
P. J. Pockros, R. Reindollar, J. McHutchinson, R. Reddy, T. Wright, D.G. Boyd, L.B. Wilkes. (2003) The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients. Journal of Viral Hepatitis 10:1, 55-60
CrossRef2236
Bruce R. Bacon. (2003) Treatment for chronic hepatitis C. Current Gastroenterology Reports 5:1, 1-2
CrossRef2237
Gillian M Keating, Monique P Curran. (2003) Peginterferon-??-2a (40kD) Plus Ribavirin. Drugs 63:7, 701-730
CrossRef2238
Wen-Kai Weng, Shoshana Levy. (2003) Hepatitis C Virus (HCV) and Lymphomagenesis. Leukemia & Lymphoma 44:7, 1113-1120
CrossRef2239
Jan M. Vrolijk, Artur Kaul, Bettina E. Hansen, Volker Lohmann, Bart L. Haagmans, Solko W. Schalm, Ralf Bartenschlager. (2003) A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Journal of Virological Methods 110:2, 201
CrossRef2240
Khaled Greish, Jun Fang, Takao Inutsuka, Akinori Nagamitsu, Hiroshi Maeda. (2003) Macromolecular Therapeutics. Clinical Pharmacokinetics 42:13, 1089-1105
CrossRef2241
W. Jessner, R. Stauber, F. Hackl, C. Datz, T. Watkins-Riedel, H. Hofer, A. Gangl, H. Kessler, P. Ferenci. (2003) Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection*. Journal of Viral Hepatitis 10:1, 37-42
CrossRef2242
Andrew Bacon. (2002) Polymers – a synthetic or natural choice?
. Drug Discovery Today 7:24, 1202-1203
CrossRef2243
Christoph Sarrazin. (2002) Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. Journal of Clinical Virology 25, 23-29
CrossRef2244
Teresa L. Wright. (2002) Treatment of patients with hepatitis C and cirrhosis. Hepatology 36:S1, S185-S194
CrossRef2245
P ARNAUD. (2002) Les différents interférons : Pharmacologie, mécanismes d'action, tolérance et effets secondaires. La Revue de Médecine Interne 23, 449S-458S
CrossRef2246
Adrian M. Di Bisceglie, Jay H. Hoofnagle. (2002) Optimal therapy of hepatitis C. Hepatology 36:S1, S121-S127
CrossRef2247
Karen L. Lindsay. (2002) Introduction to therapy of hepatitis C. Hepatology 36:S1, S114-S120
CrossRef2248
Doris B. Strader. (2002) Understudied populations with hepatitis C. Hepatology 36:S1, S226-S236
CrossRef2249
Michael W. Fried. (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36:S1, S237-S244
CrossRef2250
Jay H. Hoofnagle. (2002) Course and outcome of hepatitis C. Hepatology 36:S1, S21-S29
CrossRef2251
Jean-Michel Pawlotsky. (2002) Use and interpretation of virological tests for hepatitis C. Hepatology 36:S1, S65-S73
CrossRef2252
Gary L. Davis. (2002) Monitoring of viral levels during therapy of hepatitis C. Hepatology 36:S1, S145-S151
CrossRef2253
Mitchell L. Shiffman. (2002) Retreatment of patients with chronic hepatitis C. Hepatology 36:S1, S128-S134
CrossRef2254
G DUSHEIKO. (2002) Hepatitis C. Medicine 30:11, 37-40
CrossRef
- Letters
